CA2430794A1 - Human genes and gene expression products isolated from human prostate - Google Patents

Abstract

This invention relates to novel human polynucleotides and variants thereof, their encoded polypeptides and variants thereof, to genes corresponding to these polynucleotides and to proteins expressed by the genes. The invention also relates to diagnostics and therapeutics comprising such novel human polynucleotides, their corresponding genes or gene products, including probes, antisense nucleotides, and antibodies. The polynucleotides of the invention correspond to a polynucleotide comprising the sequence information of at least one of SEQ ID NOS:1-1477. The polypeptides of the invention correspond to a polypeptide comprising the amino acid sequence information of at least one of SEQ ID NOS:1478-1568.

Description

ADMAN GENES AND GENE EXPRESSION PRODUCTS
ISOLATED FROM HUMAN PROSTATE
Cross-Reference to Related Application Ths application claims the benefit of earlier-filed U.S. provisional application serial no.
60/254,648 filed December 11, 2000, and of ealier-filed U.S. provisional application serial no.
60/275,688 filed March 13, 2001, which applications are incorporated herein by reference in their entirety.
Field of the Invention The present invention relates to polynucleotides of human origin, particularly in human prostate, and the encoded gene products.
Back ound of the Invention Identification of novel polynucleotides, particularly those that encode an expressed gene product, is important in the advancement of drug discovery, diagnostic technologies, and the understanding of the progression and nature of complex diseases such as cancer. Identification of genes expressed in different cell types isolated from sources that differ in disease state or stage, developmental stage, exposure to various environmental factors, the tissue of origin, the species from which the tissue was isolated, and the like is key to identifying the genetic factors that are responsible for the phenotypes associated with these various differences.
This invention provides novel human polynucleotides, the polypeptides encoded by these polynucleotides, and the genes and proteins corresponding to these novel polynucleotides.
Summary of the Invention This invention relates to novel human polynucleotides and variants thereof, their encoded polypeptides and variants thereof, to genes corresponding to these polynucleotides and to proteins expressed by the genes. The invention also relates to diagnostics and therapeutics comprising such novel human polynucleotides, their corresponding genes or gene products, including probes, antisense nucleotides, and antibodies. The polynucleotides of the invention correspond to a polynucleotide comprising the sequence information of at least one of SEQ ID NOS:1-1477. The polypeptides of the invention correspond to a polypeptide comprising the amino acid sequence information of at least one of SEQ ID NOS:1478-1568.
Various aspects and embodiments of the invention will be readily apparent to the ordinarily skilled artisan upon reading the description provided herein.
Detailed Description of the Invention Before the present invention is described, it is to be understood that this invention is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described.
All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.
It must be noted that as used herein and in the appended claims, the singular forms "a," "and,"
and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a polynucleotide" includes a plurality of such polynucleotides and reference to "the colon 1 S cancer cell" includes reference to one or more cells and equivalents thereof known to those skilled in the art, and so forth.
The publications and applications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.
Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.
Definitions The terms "polynucleotide" and "nucleic acid," used interchangeably herein, refer to a polymeric forms of nucleotides of any length, either ribonucleotides or deoxynucleotides. Thus, these terms include, but are not limited to, single-, double-, or multi-stranded DNA
or RNA, genomic DNA, cDNA, DNA-RNA hybrids, branched nucleic acid (see, e.g., U.S. Pat. Nos.
5,124,246; 5,710,264;
and 5,849,481) , or a polymer comprising purine and pyrimidine bases or other natural, chemically or biochemically modified, non-natural, or derivatized nucleotide bases. These terms furhter include, but are not limited to, mRNA or cDNA that comprise intronic sequences (see, e.g., Niwa et al. (1999) Cell 99(7):691-702). The backbone of the polynucleotide can comprise sugars and phosphate groups (as may typically be found in RNA or DNA), or modified or substituted sugar or phosphate groups.
Alternatively, the backbone of the polynucleotide can comprise a polymer of synthetic subunits such as phosphoramidites and thus can be an oligodeoxynucleoside phosphoramidate or a mixed phosphoramidate-phosphodiester oligomer. Peyrottes et al. (1996) Nucl. Acids Res. 24:1841-1848;
Chaturvedi et al. (1996) Nucl. Acids Res. 24:2318-2323. A polynuclotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs, uracyl, other sugars, and linking groups such as fluororibose and thioate, and nucleotide branches. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component. Other types of modifications included in this definition are caps, substitution of one or more of the naturally occurring nucleotides S with an analog, and introduction of means for attaching the polynucleotide to proteins, metal ions, labeling components, other polynucleotides, or a solid support.
The terms "polypeptide" and "protein," used interchangebly herein, refer to a polymeric form of amino acids of any length, which can include coded and non-coded amino acids, chemically or biochemically modified or derivatized amino acids, and polypeptides having modified peptide backbones. The term includes fusion proteins, including, but not limited to, fusion proteins with a heterologous amino acid sequence, fusions with heterologous and homologous leader sequences, with or without N-terminal methionine residues; immunologically tagged proteins;
and the like.
"Diagnosis" as used herein generally includes determination of a subject's susceptibility to a disease or disorder, determination as to whether a subject is presently affected by a disease or disorder, prognosis of a subject affected by a disease or disorder (e.g., identification of pre-metastatic or metastatic cancerous states, stages of cancer, or responsiveness of cancer to therapy), and therametrics (e.g., monitoring a subject's condition to provide information as to the effect or efficacy of therapy).
"Sample" or "biological sample" as used herein encompasses a variety of sample types, and are generally meant to refer to samples of biological fluids or tissues, particularly samples obtained from tissues, especially from cells of the type associated with a disease or condition for which a diagnostic application is designed (e.g., ductal adenocarcinoma), and the like. "Sample" or "biological sample" are meant to encompass blood and other liquid samples of biological origin, solid tissue samples, such as a biopsy specimen or tissue cultures or cells derived therefrom and the progeny thereof. These terms encompass samples that have been manipulated in any way after their procurement as well as derivatives and fractions of samples, where the samples may be maniuplated by, for example, treatment with reagents, solubilization, or enrichment for certain components. The terms also encompass clinical samples, and also includes cells in cell culture, cell supernatants, cell lysates, serum, plasma, biological fluids, and tissue samples. Where the sample is solid tissue, the cells of the tissue can be dissociated or tissue sections can be analyzed.
The terms "treatment," "treating," "treat" and the like are used herein to generally refer to obtaining a desired pharmacologic and/or physiologic effect. The effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and/or may be therapeutic in terms of a partial or complete stabilization or cure for a disease and/or adverse effect attributable to the disease. "Treatment" as used herein covers any treatment of a disease in a mammal, particularly a human, and includes: (a) preventing the disease or symptom from occurring in a subject which may be predisposed to the disease or symptom but has not yet been diagnosed as having it; (b) inhibiting the disease symptom, i.e., arresting its development; or relieving the disease symptom, i.e., causing regression of the disease or symptom.
The terms "individual," "subject," "host," and "patient," used interchangeably herein and refer to any mammalian subject for whom diagnosis, treatment, or therapy is desired, particularly humans.
Other subjects may include cattle, dogs, cats, guinea pigs, rabbits, rats, mice, horses, and so on.
As used herein the term "isolated" refers to a polynucleotide, a polypeptide, an antibody, or a host cell that is in an environment different from that in which the polynucleotide, the polypeptide, the antibody, or the host cell naturally occurs. A polynucleotide, a polypeptide, an antibody, or a host cell which is isolated is generally substantially purified. As used herein, the term "substantially purified"
refers to a compound (e.g., either a polynucleotide or a polypeptide or an antibody) that is removed from its natural environment and is at least 60% free, preferably 75% free, and most preferably 90%
free from other components with which it is naturally associated. Thus, for example, a composition containing A is "substantially free of B when at least 85% by weight of the total A+B in the composition is A. Preferably, A comprises at least about 90% by weight of the total of A+B in the composition, more preferably at least about 95% or even 99% by weight.
A "host cell," as used herein, refers to a microorganism or a eukaryotic cell or cell line cultured as a unicellular entity which can be, or has been, used as a recipient for a recombinant vector or other transfer polynucleotides, and include the progeny of the original cell which has been transfected. It is understood that the progeny of a single cell may not necessarily be completely identical in morphology or in genomic or total DNA complement as the original parent, due to natural, accidental, or deliberate mutation.
The terms "cancer," "neoplasm," "tumor," and "carcinoma," are used interchangeably herein to refer to cells which exhibit relatively autonomous growth, so that they exhibit an aberrant growth phenotype characterized by a significant loss of control of cell proliferation. In general, cells of interest for detection or treatment in the present application include precancerous (e.g., benign), malignant, metastatic, and non-metastatic cells. Detection of cancerous cell is of particular interest.
The use of "e", as in 10e-3, indicates that the number to the left of "e" is raised to the power of the number to the right of "e" (thus, 10e-3 is 10 3) The term "heterologous" as used herein in the context of, for example, heterologous nucleic acid or amino acid sequences, heterologous polypeptides, or heterologous nucleic acid, is meant to refer to material that originates from a source different from that with which it is joined or associated.
For example, two DNA sequences are heterologous to one another if the sequences are from different genes or from different species. A recombinant host cell containing a sequence that is heterologous to the host cell can be, for example, a bacterial cell containing a sequence encoding a human polypeptide.

The invention relates to polynucleotides comprising the disclosed nucleotide sequences, to full length cDNA, mRNA, genomic sequences, and genes corresponding to these sequences and degenerate variants thereof, and to polypeptides encoded by the polynucleotides of the invention and polypeptide variants. The following detailed description describes the polynucleotide compositions encompassed by the invention, methods for obtaining cDNA or genomic DNA
encoding a full-length gene product, expression of these polynucleotides and genes, identification of structural motifs of the polynucleotides and genes, identification of the function of a gene product encoded by a gene corresponding to a polynucleotide of the invention, use of the provided polynucleotides as probes and in mapping and in tissue profiling, use of the corresponding polypeptides and other gene products to raise antibodies, and use of the polynucleotides and their encoded gene products for therapeutic and diagnostic purposes.
Polynucleotide Compositions The scope of the invention with respect to polynucleotide compositions includes, but is not necessarily limited to, polynucleotides having a sequence set forth in any one of SEQ >I7 NOS:1-1477; polynucleotides obtained from the biological materials described herein or other biological sources (particularly human sources) by hybridization under stringent conditions (particularly conditions of high stringency); genes corresponding to the provided polynucleotides; variants of the provided polynucleotides and their corresponding genes, particularly those variants that retain a biological activity of the encoded gene product (e.g., a biological activity ascribed to a gene product corresponding to the provided polynucleotides as a result of the assignment of the gene product to a protein family(ies) and/or identification of a functional domain present in the gene product). Other nucleic acid compositions contemplated by and within the scope of the present invention will be readily apparent to one of ordinary skill in the art when provided with the disclosure here.
"Polynucleotide" and "nucleic acid" as used herein with reference to nucleic acids of the composition is not intended to be limiting as to the length or structure of the nucleic acid unless specifically indicated.
The invention features polynucleotides that are expressed in human tissue, especially human colon, prostate, breast, lung and/or endothelial tissue. Novel nucleic acid compositions of the invention of particular interest comprise a sequence set forth in any one of SEQ m NOS:1-1477 or an identifying sequence thereof. An "identifying sequence" is a contiguous sequence of residues at least about 10 nt to about 20 nt in length, usually at least about 50 nt to about 100 nt in length, that uniquely identifies a polynucleotide sequence, e.g., exhibits less than 90%, usually less than about 80% to about 85% sequence identity to any contiguous nucleotide sequence of more than about 20 nt.
Thus, the subject novel nucleic acid compositions include full length cDNAs or mRNAs that encompass an identifying sequence of contiguous nucleotides from any one of SEQ ~ NOS: 1-1477.

The polynucleotides of the invention also include polynucleotides having sequence similarity or sequence identity. Nucleic acids having sequence similarity are detected by hybridization under low stringency conditions, for example, at 50°C and lOXSSC (0.9 M
saline/0.09 M sodium citrate) and remain bound when subjected to washing at 55°C in 1XSSC. Sequence identity can be determined by hybridization under stringent conditions, for example, at 50°C or higher and O.1XSSC
(9 mM saline/0.9 mM sodium citrate). Hybridization methods and conditions are well lrnown in the art, see, e.g., USPN 5,707,829. Nucleic acids that are substantially identical to the provided polynucleotide sequences, e.g. allelic variants, genetically altered versions of the gene, etc., bind to the provided polynucleotide sequences ( SEQ m NOS:1-1477) under stringent hybridization conditions.
By using probes, particularly labeled probes of DNA sequences, one can isolate homologous or related genes. The source of homologous genes can be any species, e.g. primate species, particularly human;
rodents, such as rats and mice; canines, felines, bovines, ovines, equines, yeast, nematodes, etc.
Preferably, hybridization is performed using at least 15 contiguous nucleotides (nt) of at least one of SEQ m NOS:1-1477. That is, when at least 15 contiguous nt of one of the disclosed SEQ m NOS. is used as a probe, the probe will preferentially hybridize with a nucleic acid comprising the complementary sequence, allowing the identification and retrieval of the nucleic acids that uniquely hybridize to the selected probe. Probes from more than one SEQ m NO. can hybridize with the same nucleic acid if the cDNA from which they were derived corresponds to one mRNA.
Probes of more than 15 nt can be used, e.g., probes of from about 18 nt to about 100 nt, but 15 nt represents sufficient sequence for unique identification.
The polynucleotides of the invention also include naturally occurring variants of the nucleotide sequences (e.g:, degenerate variants, allelic variants, etc.).
Variants of the polynucleotides of the invention are identified by hybridization of putative variants with nucleotide sequences disclosed herein, preferably by hybridization under stringent conditions. For example, by using appropriate wash conditions, variants of the polynucleotides of the invention can be identified where the allelic variant exhibits at most about 25-30% base pair (bp) mismatches relative to the selected polynucleotide probe. In general, allelic variants contain 15-25% by mismatches, and can contain as little as even 5-15%, or 2-5%, or 1-2% by mismatches, as well as a single by mismatch.
The invention also encompasses homologs corresponding to the polynucleotides of SEQ m NOS:1-1477, where the source of homologous genes can be any mammalian species, e.g., primate species, particularly human; rodents, such as rats; canines, felines, bovines, ovines, equines, yeast, nematodes, etc. Between mammalian species, e.g., human and mouse, homologs generally have substantial sequence similarity, e.g., at least 75% sequence identity, usually at least 90%, more usually at least 95% between nucleotide sequences. Sequence similarity is calculated based on a reference sequence, which may be a subset of a larger sequence, such as a conserved motif, coding region, flanking region, etc. A reference sequence will usually be at least about 18 contiguous nt long, more usually at least about 30 nt long, and may extend to the complete sequence that is being compared.
Algorithms for sequence analysis are known in the art, such as gapped BLAST, described in Altschul, et al. Nucleic Acids Res. (1997) 25:3389-3402, or TeraBLAST available from TimeLogic Corp.
(Crystal Bay, Nevada).
In general, variants of the invention have a sequence identity greater than at least about 65%, preferably at least about 75%, more preferably at least about 85%, and can be greater than at least about 90% or more as determined by the Smith-Waterman homology search algorithm as implemented in MPSRCH program (Oxford Molecular). For the purposes of this invention, a preferred method of calculating percent identity is the Smith-Waterman algorithm, using the following. Global DNA
sequence identity must be greater than 65% as determined by the Smith-Waterman homology search algorithm as implemented in MPSRCH program (Oxford Molecular) using an affine gap search with the following search parameters: gap open penalty, 12; and gap extension penalty, 1.
The subject nucleic acids can be cDNAs or genomic DNAs, as well as fragments thereof, particularly fragments that encode a biologically active gene product and/or are useful in the methods disclosed herein (e.g., in diagnosis, as a unique identifier of a differentially expressed gene of interest, etc.). The term "cDNA" as used herein is intended to include all nucleic acids that share the arrangement of sequence elements found in native mature mRNA species, where sequence elements are exons and 3' and 5' non-coding regions. Normally mRNA species have contiguous exons, with the intervening introns, when present, being removed by nuclear RNA splicing, to create a continuous open reading frame encoding a polypeptide of the invention.
A genomic sequence of interest comprises the nucleic acid present between the initiation codon and the stop codon, as defined in the listed sequences, including all of the introns that are normally present in a native chromosome. It can further include the 3' and 5' untranslated regions found in the mature mRNA. It can further include specific transcriptional and translational regulatory sequences, such as promoters, enhancers, etc., including about 1 kb, but possibly more, of flanking genomic DNA at either the 5' and 3' end of the transcribed region. The genomic DNA can be isolated as a fragment of 100 kbp or smaller; and substantially free of flanking chromosomal sequence. The genomic DNA flanking the coding region, either 3' and 5', or internal regulatory sequences as sometimes found in introns, contains sequences required for proper tissue, stage-specific, or disease-state specific expression.
The nucleic acid compositions of the subject invention can encode all or a part of the subject polypeptides. Double or single stranded fragments can be obtained from the DNA
sequence by chemically synthesizing oligonucleotides in accordance with conventional methods, by restriction enzyme digestion, by PCR amplification, etc. Isolated polynucleotides and polynucleotide fragments of the invention comprise at least about 10, about 1 S, about 20, about 35, about 50, about 100, about 150 to about 200, about 250 to about 300, or about 350 contiguous nt selected from the polynucleotide sequences as shown in SEQ )D NOS:1-1477. For the most part, fragments will be of at least 15 nt, usually at least 18 nt or 25 nt, and up to at least about 50 contiguous nt in length or more. In a preferred embodiment, the polynucleotide molecules comprise a contiguous sequence of at least 12 nt selected from the group consisting of the polynucleotides shown in SEQ >D NOS:1-1477.
Probes specific to the polynucleotides of the invention can be generated using the polynucleotide sequences disclosed in SEQ m NOS:1-1477. The probes are preferably at least about 12, 1 S, 16, 18, 20, 22, 24, or 25 nt fragment of a corresponding contiguous sequence of SEQ D7 NOS:1-1477, and can be less than 10, 5, 2, 1, 0.5, 0.1, or 0.05 kb in length.
The probes can be synthesized chemically or can be generated from longer polynucleotides using restriction enzymes.
The probes can be labeled, for example, with a radioactive, biotinylated, or fluorescent tag.
Preferably, probes are designed based upon an identifying sequence of a polynucleotide of one of SEQ
m NOS:1-1477. More preferably, probes are designed based on a contiguous sequence of one of the subject polynucleotides that remain unmasked following application of a masking program for masking low complexity (e.g.,XBLAST, RepeatMasker, etc.) to the sequence., i.e., one would select an unmasked region, as indicated by the polynucleotides outside the poly-n stretches of the masked sequence produced by the masking program.
The polynucleotides of the subject invention are isolated and obtained in substantial purity, generally as other than an intact chromosome. Usually, the polynucleotides, either as DNA or RNA, will be obtained substantially free of other naturally-occurnng nucleic acid sequences, generally being at least about 50%, usually at least about 90% pure and are typically "recombinant," e.g., flanked by one or more nucleotides with which it is not normally associated on a naturally occurnng chromosome.
The polynucleotides of the invention can be provided as a linear molecule or within a circular molecule, and can be provided within autonomously replicating molecules (vectors) or within molecules without replication sequences. Expression of the polynucleotides can be regulated by their own or by other regulatory sequences known in the art. The polynucleotides of the invention can be introduced into suitable host cells using a variety of techniques available in the art, such as transferrin polycation-mediated DNA transfer, transfection with naked or encapsulated nucleic acids, liposome-mediated DNA transfer, intracellular transportation of DNA-coated latex beads, protoplast fusion, viral infection, electroporation, gene gun, calcium phosphate-mediated transfection, and the like.
The subject nucleic acid compositions can be used, for example, to produce polypeptides, as probes for the detection of mRNA of the invention in biological samples (e.g., extracts of human cells) to generate additional copies of the polynucleotides, to generate ribozymes or antisense oligonucleotides, and as single stranded DNA probes or as triple-strand forming oligonucleotides.
The probes described herein can be used to, for example, determine the presence or absence of the polynucleotide sequences as shown in SEQ 117 NOS:1-1477 or variants thereof in a sample. These and other uses are described in more detail below.
Use of Polynucleotides to Obtain Full-Length cDNA, Gene, and Promoter Region In one embodiment, the polynucleotides are useful as starting materials to construct larger molecules. In one example, the polynucleotides of the invention are used to construct polynucleotides that encode a larger polypeptide (e.g., up to the full-length native polypeptide as well as fusion proteins comprising all or a portion of the native polypeptide) or may be used to produce haptens of the polypeptide (e.g., polypeptides useful to generate antibodies).
In one particular example, the polynucleotides of the invention are used to make or isolate cDNA molecules encoding all or portion of a naturally-occuring polypeptide.
Full-length cDNA
molecules comprising the disclosed polynucleotides are obtained as follows. A
polynucleotide having a sequence of one of SEQ ID NOS:1-1477, or a portion thereof comprising at least 12, 15, 18, or 20 nt, is used as a hybridization probe to detect hybridizing members of a cDNA
library using probe design methods, cloning methods, and clone selection techniques such as those described in USPN
5,654,173. Libraries of cDNA are made from selected tissues, such as normal or tumor tissue, or from tissues of a mammal treated with, for example, a pharmaceutical agent.
Preferably, the tissue is the same as the tissue from which the polynucleotides of the invention were isolated, as both the polynucleotides described herein and the cDNA represent expressed genes. Most preferably, the cDNA library is made from the biological material described herein in the Examples. The choice of cell type for library construction can be made after the identity of the protein encoded by the gene corresponding to the polynucleotide of the invention is known. This will indicate which tissue and cell types are likely to express the related gene, and thus represent a suitable source for the mRNA for generating the cDNA. Where the provided polynucleotides are isolated from cDNA
libraries, the libraries are prepared from mRNA of human prostate cells, more preferably, human prostate cancer cells Techniques for producing and probing nucleic acid sequence libraries are described, for example, in Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., (1989) Cold Spring Harbor Press, Cold Spring Harbor, NY. The cDNA can be prepared by using primers based on polynucleotides comprising a sequence of SEQ ll~ NOS:1-1477. In one embodiment, the cDNA
library can be made from only poly-adenylated mRNA. Thus, poly-T primers can be used to prepare cDNA from the mRNA.
Members of the library that are larger than the provided polynucleotides, and preferably that encompass the complete coding sequence of the native message, are obtained. In order to confirm that the entire cDNA has been obtained, RNA protection experiments are performed as follows.
Hybridization of a full-length cDNA to an mRNA will protect the RNA from RNase degradation. If the cDNA is not full length, then the portions of the mRNA that are not hybridized will be subject to RNase degradation. This is assayed, as is known in the art, by changes in electrophoretie mobility on polyacrylamide gels, or by detection of released monoribonucleotides. Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., (1989) Cold Spring Harbor Press, Cold Spring Harbor, NY.
In order to obtain additional sequences 5' to the end of a partial cDNA, 5' RACE (PCR Protocols: A
S Guide to Methods and Applications, (1990) Academic Press, Inc.) can be performed.
Genomic DNA is isolated using the provided polynucleotides in a manner similar to the isolation of full-length cDNAs. Briefly, the provided polynucleotides, or portions thereof, are used as probes to libraries of genomie DNA. Preferably, the library is obtained from the cell type that was used to generate the polynucleotides of the invention, but this is not essential. Most preferably, the genomie DNA is obtained from the biological material described herein in the Examples. Such libraries can be in vectors suitable for carrying large segments of a genome, such as P1 or YAC, as described in detail in Sambrook et al., supra, 9.4-9.30. In addition, genomic sequences can be isolated from human BAC libraries, which are commercially available from Research Genetics, Inc., Huntsville, Alabama, USA, for example. In order to obtain additional 5' or 3' sequences, chromosome walking is performed, as described in Sambrook et al., such that adjacent and overlapping fragments of genomic DNA are isolated. These are mapped and pieced together, as is known in the art, using restriction digestion enzymes and DNA ligase.
Using the polynucleotide sequences of the invention, corresponding full-length genes can be isolated using both classical and PCR methods to construct and probe cDNA
libraries. Using either method, Northern blots, preferably, are performed on a number of cell types to determine which cell lines express the gene of interest at the highest level. Classical methods of constructing cDNA
libraries are taught in Sambrook et al., supra. With these methods, cDNA can be produced from mRNA and inserted into viral or expression vectors. Typically, libraries of mRNA comprising poly(A) tails can be produced with poly(T) primers. Similarly, cDNA libraries can be produced using the instant sequences as primers.
PCR methods are used to amplify the members of a cDNA library that comprise the desired insert. In this case, the desired insert will contain sequence from the full length cDNA that corresponds to the instant polynucleotides. Such PCR methods include gene trapping and RACE
methods. Gene trapping entails inserting a member of a cDNA library into a vector. The vector then is denatured to produce single stranded molecules. Next, a substrate-bound probe, such as a biotinylated oligo, is used to trap cDNA inserts of interest. Biotinylated probes can be linked to an avidin-bound solid substrate. PCR methods can be used to amplify the trapped eDNA. To trap sequences corresponding to the full length genes, the labeled probe sequence is based on the polynucleotide sequences of the invention. Random primers or primers specific to the library vector can be used to amplify the trapped cDNA. Such gene trapping techniques are described in Gruber et al., WO 95/04745 and Gruber et al., USPN 5,500,356. Kits are commercially available to perform gene trapping experiments from, for example, Life Technologies, Gaithersburg, Maryland, USA.
"Rapid amplification of cDNA ends," or RACE, is a PCR method of amplifying cDNAs from a number of different RNAs. The cDNAs are ligated to an oligonucleotide linker, and amplified by PCR using two primers. One primer is based on sequence from the instant polynucleotides, for which full length sequence is desired, and a second primer comprises sequence that hybridizes to the oligonucleotide linker to amplify the cDNA. A description of this method is reported in WO
97/19110. In preferred embodiments of RACE, a common primer is designed to anneal to an arbitrary adaptor sequence ligated to cDNA ends (Apte and Siebert, Biotechniques (1993) 15:890-893;
Edwards et al., Nuc. Acids Res. (1991) 19:5227-5232). When a single gene-specific RACE primer is paired with the common primer, preferential amplification of sequences between the single gene specific primer and the common primer occurs. Commercial cDNA pools modified for use in RACE
are available.
Another PCR-based method generates full-length cDNA library with anchored ends without needing specific knowledge of the cDNA sequence. The method uses lock-docking primers (I-VI), where one primer, poly TV (I-III) locks over the polyA tail of eukaryotic mRNA
producing first strand synthesis and a second primer, polyGH (IV-VI) locks onto the polyC tail added by terminal deoxynucleotidyl transferase (TdT)(see, e.g., WO 96/40998).
The promoter region of a gene generally is located 5' to the initiation site for RNA
polymerase II. Hundreds of promoter regions contain the "TATA" box, a sequence such as TATTA
or TATAA, which is sensitive to mutations. The promoter region can be obtained by performing 5' RACE using a primer from the coding region of the gene. Alternatively, the cDNA can be used as a probe for the genomic sequence, and the region S' to the coding region is identified by "walking up."
If the gene is highly expressed or differentially expressed, the promoter from the gene can be of use in a regulatory construct for a heterologous gene.
Once the full-length cDNA or gene is obtained, DNA encoding variants can be prepared by site-directed mutagenesis, described in detail in Sambrook et al., 15.3-15.63.
The choice of codon or nucleotide to be replaced can be based on disclosure herein on optional changes in amino acids to achieve altered protein structure and/or function.
As an alternative method to obtaining DNA or RNA from a biological material, nucleic acid comprising nucleotides having the sequence of one or more polynucleotides of the invention can be synthesized. Thus, the invention encompasses nucleic acid molecules ranging in length from 15 nt (corresponding to at least 15 contiguous nt of one of SEQ ID NOS:1-1477) up to a maximum length suitable for one or more biological manipulations, including replication and expression, of the nucleic acid molecule. The invention includes but is not limited to (a) nucleic acid having the size of a full gene, and comprising at least one of SEQ ID NOS:1-1477; (b) the nucleic acid of (a) also comprising at least one additional gene, operably linked to permit expression of a fusion protein; (c) an expression vector comprising (a) or (b); (d) a plasmid comprising (a) or (b); and (e) a recombinant viral particle comprising (a) or (b). Once provided with the polynucleotides disclosed herein, construction or preparation of (a) - (e) are well within the skill in the art.
The sequence of a nucleic acid comprising at least 15 contiguous nt of at least any one of SEQ
ID NOS:1-1477, preferably the entire sequence of at least any one of SEQ m NOS:1-1477, is not limited and can be any sequence of A, T, G, and/or C (for DNA) and A, U, G, and/or C (for RNA) or modified bases thereof, including inosine and pseudouridine. The choice of sequence will depend on the desired function and can be dictated by coding regions desired, the intron-like regions desired, and the regulatory regions desired. Where the entire sequence of any one of SEQ ID
NOS:1-1477 is within the nucleic acid, the nucleic acid obtained is referred to herein as a polynucleotide comprising the sequence of any one of SEQ B7 NOS:1-1477.
Expression of Polypeptide Encoded by Full-Length cDNA or Full-Len: h Gene The provided polynucleotides (e.g., a polynucleotide having a sequence of one of SEQ ID
NOS:1-1477), the corresponding cDNA, or the full-length gene is used to express a partial or complete gene product. Constructs of polynucleotides having sequences of SEQ
ID NOS:1-1477 can also be generated synthetically. Alternatively, single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides is described by, e.g., Stemmer et al., Gene (Amsterdam) (1995) 164(1):49-53. In this method, assembly PCR (the synthesis of long DNA
sequences from large numbers of oligodeoxyribonucleotides (oligos)) is described. The method is derived from DNA
shuffling (Stemmer, Nature (1994) 370:389-391), and does not rely on DNA
ligase, but instead relies on DNA polymerase to build increasingly longer DNA fragments during the assembly process.
Appropriate polynucleotide constructs are purified using standard recombinant DNA
techniques as described in, for example, Sambrook et al., Molecular Cloning.' A Laboratory Manual, 2nd Ed., (1989) Cold Spring Harbor Press, Cold Spring Harbor, NY, and under current regulations described in United States Dept. of HHS, National Institute of Health (NIFI) Guidelines for Recombinant DNA Research. The gene product encoded by a polynucleotide of the invention is expressed in any expression system, including, for example, bacterial, yeast, insect, amphibian and mammalian systems. Vectors, host cells and methods for obtaining expression in same are well known in the art. Suitable vectors and host cells are described in USPN
5,654,173.
Polynucleotide molecules comprising a polynucleotide sequence provided herein are generally propagated by placing the molecule in a vector. Viral and non-viral vectors are used, including plasmids. The choice of plasmid will depend on the type of cell in which propagation is desired and the purpose of propagation. Certain vectors are useful for amplifying and making large amounts of the desired DNA sequence. Other vectors are suitable for expression in cells in culture. Still other vectors are suitable for transfer and expression in cells in a whole animal or person. 'The choice of appropriate vector is well within the skill of the art. Many such vectors are available commercially.
Methods for preparation of vectors comprising a desired sequence are well known in the art.
The polynucleotides set forth in SEQ )D NOS:1-1477 or their corresponding full-length polynucleotides are linked to regulatory sequences as appropriate to obtain the desired expression properties. These can include promoters (attached either at the 5' end of the sense strand or at the 3' end of the antisense strand), enhancers, terminators, operators, repressors, and inducers. The promoters can be regulated or constitutive. In some situations it may be desirable to use conditionally active promoters, such as tissue-specific or developmental stage-specific promoters. These are linked to the desired nucleotide sequence using the techniques described above for linkage to vectors. Any techniques known in the art can be used.
When any of the above host cells, or other appropriate host cells or organisms, are used to replicate and/or express the polynucleotides or nucleic acids of the invention, the resulting replicated nucleic acid, RNA, expressed protein or polypeptide, is within the scope of the invention as a product of the host cell or organism. The product is recovered by any appropriate means known in the art.
Once the gene corresponding to a selected polynucleotide is identified, its expression can be regulated in the cell to which the gene is native. For example, an endogenous gene of a cell can be regulated by an exogenous regulatory sequence as disclosed in USPN 5,641,670.
Identification of Functional and Structural Motifs Translations of the nucleotide sequence of the provided polynucleotides, cDNAs or full genes can be aligned with individual known sequences. Similarity with individual sequences can be used to determine the activity of the polypeptides encoded by the polynucleotides of the invention. Also, sequences exhibiting similarity with more than one individual sequence can exhibit activities that are characteristic of either or both individual sequences.
The full length sequences and fragments of the polynucleotide sequences of the nearest neighbors as identified through, for example, BLAST-based searching,can be used as probes and primers to identify and isolate the full length sequence corresponding to provided polynucleotides.
The nearest neighbors can indicate a tissue or cell type to be used to construct a library for the full-length sequences corresponding to the provided polynucleotides.
Typically, a selected polynucleotide is translated in all six frames to determine the best alignment with the individual sequences. The sequences disclosed herein in the Sequence Listing are in a 5' to 3' orientation and translation in three frames can be sufficient (with a few specific exceptions as described in the Examples). These amino acid sequences are referred to, generally, as query sequences, which will be aligned with the individual sequences.
Databases with individual sequences are described in "Computer Methods for Macromolecular Sequence Analysis" Methods in Enrymology (1996) 266, Doolittle, Academic Press, Inc., a division of Harcourt Brace & Co., San Diego, California, USA. Databases include GenBank, EMBL, and DNA Database of Japan (DDBJ).

Query and individual sequences can be aligned using the methods and computer programs described above, and include BLAST 2.0, available over the world wide web at a site supported by the National Center for Biotechnology Information, which is supported by the National Library of Medicine and the National Institutes of Health, or TeraBLAST available from TimeLogic Corp.
(Crystal Bay, Nevada). See also Altschul, et al. Nucleic Acids Res. (1997) 25:3389-3402. Another alignment algorithm is Fasta, available in the Genetics Computing Group (GCG) package, Madison, Wisconsin, USA, a wholly owned subsidiary of Oxford Molecular Group, Inc.
Other techniques for alignment are described in Doolittle, supra. Preferably, an alignment program that permits gaps in the sequence is utilized to align the sequences. The Smith-Waterman is one type of algorithm that permits gaps in sequence alignments. See Meth. Mol. Biol. (1997) 70: 173-187. Also, the GAP program using the Needleman and Wunsch alignment method can be utilized to align sequences. An alternative search strategy uses MPSRCH software, which runs on a MASPAR
computer. MPSRCH
uses a Smith-Waterman algorithm to score sequences on a massively parallel computer. This approach improves ability to identify sequences that are distantly related matches, and is especially tolerant of small gaps and nucleotide sequence errors. Amino acid sequences encoded by the provided polynucleotides can be used to search both protein and DNA databases.
Incorporated herein by reference are all sequences that have been made public as of the filing date of this application by any of the DNA or protein sequence databases, including the patent databases (e.g., GeneSeq). Also incorporated by reference are those sequences that have been submitted to these databases as of the filing date of the present application but not made public until after the filing date of the present application.
Results of individual and query sequence alignments can be divided into three categories:
high similarity, weak similarity, and no similarity. Individual alignment results ranging from high similarity to weak similarity provide a basis for determining polypeptide activity and/or structure.
Parameters for categorizing individual results include: percentage of the alignment region length where the strongest alignment is found, percent sequence identity, and p value. The percentage of the alignment region length is calculated by counting the number of residues of the individual sequence found in the region of strongest alignment, e.g., contiguous region of the individual sequence that contains the greatest number of residues that are identical to the residues of the corresponding region of the aligned query sequence. This number is divided by the total residue length of the query sequence to calculate a percentage. For example, a query sequence of 20 amino acid residues might be aligned with a 20 amino acid region of an individual sequence. The individual sequence might be identical to amino acid residues 5, 9-15, and 17-19 of the query sequence. The region of strongest alignment is thus the region stretching from residue 9-19, an 11 amino acid stretch. The percentage of the alignment region length is: 11 (length of the region of strongest alignment) divided by (query sequence length) 20 or 55%.

Percent sequence identity is calculated by counting the number of amino acid matches between the query and individual sequence and dividing total number of matches by the number of residues of the individual sequences found in the region of strongest alignment. Thus, the percent identity in the example above would be 10 matches divided by 11 amino acids, or approximately, 90.9%
P value is the probability that the alignment was produced by chance. For a single alignment, the p value can be calculated according to Karlin et al., Proc. Natl. Acad.
Sci. (1990) 87:2264 and Karlin et al., Proc. Natl. Acad. Sci. (1993) 90. The p value of multiple alignments using the same query sequence can be calculated using an heuristic approach described in Altschul et al., Nat. Genet.
(1994) 6:119. Alignment programs, such as BLAST or TeraBLAST, can calculate the p value. See also Altschul et al., Nucleic Acids Res. (1997) 25:3389-3402.
Another factor to consider for determining identity or similarity is the location of the similarity or identity. Strong local alignment can indicate similarity even if the length of alignment is short. Sequence identity scattered throughout the length of the query sequence also can indicate a similarity between the query and profile sequences. The boundaries of the region where the sequences align can be determined according to Doolittle, supra; BLAST 2.0 (see, e.g., Altschul, et al. Nucleic Acids Res. (1997) 25:3389-3402), TeraBLAST (available from TimeLogic Corp., Crystal Bay, Nevada), or FAST programs; or by determining the area where sequence identity is highest.
High Similarity. In general, in alignment results considered to be of high similarity, the percent of the alignment region length is typically at least about SS% of total length query sequence;
more typically, at least about 58%; even more typically; at least about 60% of the total residue length of the query sequence. Usually, percent length of the alignment region can be as much as about 62%;
more usually, as much as about 64%; even more usually, as much as about 66%.
Further, for high similarity, the region of alignment, typically, exhibits at least about 75% of sequence identity; more typically, at least about 78%; even more typically; at least about 80%
sequence identity. Usually, percent sequence identity can be as much as about 82%; more usually, as much as about 84%; even more usually, as much as about 86%.
The p value is used in conjunction with these methods. If high similarity is found, the query sequence is considered to have high similarity with a profile sequence when the p value is less than or equal to about 10e-2; more usually; less than or equal to about 10e-3; even more usually; less than or equal to about 10e-4. More typically, the p value is no more than about 10e-5;
more typically; no more than or equal to about 10e-10; even more typically, no more than or equal to about 10e-15 for the query sequence to be considered high similarity.
Weak Similarity. In general, where alignment results considered to be of weak similarity, there is no minimum percent length of the alignment region nor minimum length of alignment. A
better showing of weak similarity is considered when the region of alignment is, typically, at least about 15 amino acid residues in length; more typically, at least about 20;
even more typically, at least about 25 amino acid residues in length. Usually, length of the alignment region can be as much as about 30 amino acid residues; more usually, as much as about 40; even more usually, as much as about 60 amino acid residues. Further, for weak similarity, the region of alignment, typically, exhibits at least about 35% of sequence identity; more typically, at least about 40%;
even more typically, at least about 45% sequence identity. Usually, percent sequence identity can be as much as about 50%;
more usually, as much as about 55%; even more usually, as much as about 60%.
If low similarity is found, the query sequence is considered to have weak similarity with a profile sequence when the p value is usually less than or equal to about 10e-2; more usually, less than or equal to about 10e-3; even more usually; less than or equal to about 10e-4.
More typically, the p value is no more than about 10e-5; more usually; no more than or equal to about 10e-10; even more usually, no more than or equal to about 10e-15 for the query sequence to be considered weak similarity.
Similarity Determined by Sequence Identity Alone. Sequence identity alone can be used to determine similarity of a query sequence to an individual sequence and can indicate the activity of the sequence. Such an alignment, preferably, permits gaps to align sequences.
Typically, the query sequence is related to the profile sequence if the sequence identity over the entire query sequence is at least about 15%; more typically, at least about 20%; even more typically, at least about 25%; even more typically, at least about 50%. Sequence identity alone as a measure of similarity is most useful when the query sequence is usually, at least 80 residues in length; more usually, at least 90 residues in length; even more usually, at least 95 amino acid residues in length. More typically, similarity can be concluded based on sequence identity alone when the query sequence is preferably 100 residues in length; more preferably, 120 residues in length; even more preferably, 150 amino acid residues in length.
Alignments with Profile and Multiple Aligned Sequences. Translations of the provided polynucleotides can be aligned with amino acid profiles that define either protein families or common motifs: Also, translations of the provided polynucleotides can be aligned to multiple sequence alignments (MSA) comprising the polypeptide sequences of members of protein families or motifs.
Similarity or identity with profile sequences or MSAs can be used to determine the activity of the gene products (e.g., polypeptides) encoded by the provided polynucleotides or corresponding cDNA or genes. For example, sequences that show an identity or similarity with a chemokine profile or MSA
can exhibit chemokine activities.
Profiles can be designed manually by (1) creating an MSA, which is an alignment of the amino acid sequence of members that belong to the family and (2) constructing a statistical representation of the alignment. Such methods are described, for example, in Birney et al., Nucl. Acid Res. (1996) 24(14): 2730-2739. MSAs of some protein families and motifs are publicly available.

For example, the Genome Sequencing Center at thw Washington University School of Medicine provides a web set (Pfam) which provides MSAs of 547 different families and motifs. These MSAs are described also in Sonnhammer et al., Proteins (1997) 28: 405-420. Other sources over the world wide web include the site supported by the European Molecular Biology Laboratories in Heidelberg, S Germany. A brief description of these MSAs is reported in Pascarella et al., Prot. Eng. (1996) 9(3):249-251. Techniques for building profiles from MSAs are described in Sonnhammer et al., supra;
Birney et al., supra; and "Computer Methods for Macromolecular Sequence Analysis," Methods in Enzymology (1996) 266, Doolittle, Academic Press, Inc., San Diego, California, USA.
Similarity between a query sequence and a protein family or motif can be determined by (a) comparing the query sequence against the profile and/or (b) aligning the query sequence with the members of the family or motif. Typically, a program such as Searchwise is used to compare the query sequence to the statistical representation of the multiple alignment, also known as a profile (see Birney et al., supra). Other techniques to compare the sequence and profile are described in Sonnhammer et al., supra and Doolittle, supra.
Next, methods described by Feng et al., J. Mol. Evol. (1987) 25:351 and Higgins et al., CABIOS (1989) 5:151 can be used align the query sequence with the members of a family or motif, also known as a MSA. Sequence alignments can be generated using any of a variety of software tools.
Examples include Pileup, which creates a multiple sequence alignment, and is described in Feng et al., J. Mol. Evol. (1987) 25:351. Another method, GAP, uses the alignment method of Needleman et al., J. Mol. Biol. (1970) 48:443. GAP is best suited for global alignment of sequences. A third method, BestFit, functions by inserting gaps to maximize the number of matches using the local homology algorithm of Smith et al., Adv. Appl. Math. (1981) 2:482. In general, the following factors are used to determine if a similarity between a query sequence and a profile or MSA exists: (1) number of conserved residues found in the query sequence, (2) percentage of conserved residues found in the query sequence, (3) number of frameshifts, and (4) spacing between conserved residues.
Some alignment programs that both translate and align sequences can make any number of frameshifts when translating the nucleotide sequence to produce the best alignment. The fewer frameshifts needed to produce an alignment, the stronger the similarity or identity between the query and profile or MSAs. For example, a weak similarity resulting from no frameshifts can be a better indication of activity or structure of a query sequence, than a strong similarity resulting from two frameshifts. Preferably, three or fewer frameshifts are found in an alignment;
more preferably two or fewer frameshifts; even more preferably, one or fewer frameshifts; even more preferably, no frameshifts are found in an alignment of query and profile or MSAs.
Conserved residues are those amino acids found at a particular position in all or some of the family or motif members. Alternatively, a position is considered conserved if only a certain class of amino acids is found in a particular position in all or some of the family members. For example, the N-terminal position can contain a positively charged amino acid, such as lysine, arginine, or histidine.
Typically, a residue of a polypeptide is conserved when a class of amino acids or a single amino acid is found at a particular position in at least about 40% of all class members; more typically, at least about 50%; even more typically, at least about 60% of the members.
Usually, a residue is conserved when a class or single amino acid is found in at least about 70% of the members of a family or motif; more usually, at least about 80%; even more usually, at least about 90%; even more usually, at least about 95%.
A residue is considered conserved when three unrelated amino acids are found at a particular position in some or all of the members; more usually, two unrelated amino acids. These residues are conserved when the unrelated amino acids are found at particular positions in at least about 40% of all class member; more typically, at least about 50%; even more typically, at least about 60% of the members. Usually, a residue is conserved when a class or single amino acid is found in at least about 70% of the members of a family or motif; more usually, at least about 80%;
even more usually, at least about 90%; even more usually, at least about 95%.
A query sequence has similarity to a profile or MSA when the query sequence comprises at least about 25% of the conserved residues of the profile or MSA; more usually, at least about 30%;
even more usually; at least about 40%. Typically, the query sequence has a stronger similarity to a profile sequence or MSA when the query sequence comprises at least about 45%
of the conserved residues of the profile or MSA; more typically, at least about 50%; even more typically, at least about 55%.
Identification of Secreted & Membrane-Bound Polypeutides. Both secreted and membrane-bound polypeptides of the present invention are of particular interest. For example, levels of secreted polypeptides can be assayed in body fluids that are convenient, such as blood, plasma, serum, and other body fluids such as urine, prostatic fluid and semen. Membrane-bound polypeptides are useful for constructing vaccine antigens or inducing an immune response. Such antigens would comprise all or part of the extracellular region of the membrane-bound polypeptides.
Because both secreted and membrane-bound polypeptides comprise a fragment of contiguous hydrophobic amino acids, hydrophobicity predicting algorithms can be used to identify such polypeptides.
A signal sequence is usually encoded by both secreted and membrane-bound polypeptide genes to direct a polypeptide to the surface of the cell. The signal sequence usually comprises a stretch of hydrophobic residues. Such signal sequences can fold into helical structures. Membrane-bound polypeptides typically comprise at least one transmembrane region that possesses a stretch of hydrophobic amino acids that can transverse the membrane. Some transmembrane regions also exhibit a helical structure. Hydrophobic fragments within a polypeptide can be identified by using computer algorithms. Such algorithms include Hopp & Woods, Proc. Natl. Acad.
Sci. USA (1981) 78:3824-3828; Kyte & Doolittle, J. Mol. Biol. (1982) 157: 105-132; and RADAR
algorithm, Degli Esposti et al., Eur. J. Biochem. (1990) 190: 207-219.
Another method of identifying secreted and membrane-bound polypeptides is to translate the polynucleotides of the invention in all six frames and determine if at least 8 contiguous hydrophobic S amino acids are present. Those translated polypeptides with at least 8; more typically, 10; even more typically, 12 contiguous hydrophobic amino acids are considered to be either a putative secreted or membrane bound polypeptide. Hydrophobic amino acids include alanine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, threonine, tryptophan, tyrosine, and valine Identification of the Function of an Expression Product of a Full-Length Gene Ribozymes, antisense constructs, and dominant negative mutants can be used to determine function of the expression product of a gene corresponding to a polynucleotide provided herein.
These methods and compositions are particularly useful where the provided novel polynucleotide exhibits no significant or substantial homology to a sequence encoding a gene of known function.
Antisense molecules and ribozymes can be constructed from synthetic polynucleotides. Typically, the phosphoramidite method of oligonucleotide synthesis is used. See Beaucage et al., Tet. Lett. (1981) 22:1859 and USPN 4,668,777. Automated devices for synthesis are available to create oligonucleotides using this chemistry. Examples of such devices include Biosearch 8600, Models 392 and 394 by Applied Biosystems, a division of Perkin-Elmer Corp., Foster City, California, USA; and Expedite by Perceptive Biosystems, Framingham, Massachusetts, USA. Synthetic RNA, phosphate analog oligonucleotides, and chemically derivatized oligonucleotides can also be produced, and can be covalently attached to other molecules. RNA oligonucleotides can be synthesized, for example, using RNA phosphoramidites. This method can be performed on an automated synthesizer, such as Applied Biosystems, Models 392 and 394, Foster City, California, USA.
Phosphorothioate oligonucleotides can also be synthesized for antisense construction. A
sulfurizing reagent, such as tetraethylthiruam disulfide (TETD) in acetonitrile can be used to convert the internucleotide cyanoethyl phosphite to the phosphorothioate triester within 15 minutes at room temperature. TETD replaces the iodine reagent, while all other reagents used for standard phosphoramidite chemistry remain the same. Such a synthesis method can be automated using Models 392 and 394 by Applied Biosystems, for example.
Oligonucleotides of up to 200 nt can be synthesized, more typically, 100 nt;
more typically 50 nt; even more typically, 30 to 40 nt. These synthetic fragments can be annealed and ligated together to construct larger fragments. See, for example, Sambrook et al., supra. Trans-cleaving catalytic RNAs (ribozymes) are RNA molecules possessing endoribonuclease activity. Ribozymes are specifically designed for a particular target, and the target message must contain a specific nucleotide sequence.
They are engineered to cleave any RNA species site-specifically in the background of cellular RNA.

The cleavage event renders the mRNA unstable and prevents protein expression.
Importantly, ribozymes can be used to inhibit expression of a gene of unknown function for the purpose of determining its function in an in vitro or in vivo context, by detecting the phenotypic effect. One commonly used ribozyme motif is the hammerhead, for which the substrate sequence requirements are minimal. Design of the hammerhead ribozyme, as well as therapeutic uses of ribozymes, are disclosed in Usman et al., Current Opin. Struct. Biol. (1996) 6:527. Methods for production of ribozymes, including hairpin structure ribozyme fragments, methods of increasing ribozyme specificity, and the like are known in the art.
The hybridizing region of the ribozyme can be modified or can be prepared as a branched structure as described in Hom and Urdea, Nucleic Acids Res. (1989) 17:6959.
The basic structure of the ribozymes can also be chemically altered in ways familiar to those skilled in the art, and chemically synthesized ribozymes can be administered as synthetic oligonucleotide derivatives modified by monomeric units. In a therapeutic context, liposome mediated delivery of ribozymes improves cellular uptake, as described in Birikh et al., Eur. J. Biochem.
(1997) 245:1.
Antisense nucleic acids are designed to specifically bind to RNA, resulting in the formation of RNA-DNA or RNA-RNA hybrids, with an arrest of DNA replication, reverse transcription or messenger RNA translation. Antisense polynucleotides based on a selected polynucleotide sequence can interfere with expression of the corresponding gene. Antisense polynucleotides are typically generated within the cell by expression from antisense constructs that contain the antisense strand as the transcribed strand. Antisense polynucleotides based on the disclosed polynucleotides will bind and/or interfere with the translation of mRNA comprising a sequence complementary to the antisense polynucleotide. The expression products of control cells and cells treated with the antisense construct are compared to detect the protein product of the gene corresponding to the polynucleotide upon which the antisense construct is based. The protein is isolated and identified using routine biochemical methods.
Given the extensive background literature and clinical experience in antisense therapy, one skilled in the art can use selected polynucleotides of the invention as additional potential therapeutics.
The choice of polynucleotide can be narrowed by first testing them for binding to "hot spot" regions of the genome of cancerous cells. If a polynucleotide is identified as binding to a "hot spot," testing the polynucleotide as an antisense compound in the corresponding cancer cells is warranted.
As an alternative method for identifying function of the gene corresponding to a polynucleotide disclosed herein, dominant negative mutations are readily generated for corresponding proteins that are active as homomultimers. A mutant polypeptide will interact with wild-type polypeptides (made from the other allele) and form a non-functional multimer.
Thus, a mutation is in a substrate-binding domain, a catalytic domain, or a cellular localization domain. Preferably, the mutant polypeptide will be overproduced. Point mutations are made that have such an effect. In addition, fusion of different polypeptides of various lengths to the terminus of a protein can yield dominant negative mutants. General strategies are available for making dominant negative mutants (see, e.g., Herskowitz, Nature (1987) 329:219). Such techniques can be used to create loss of function mutations, which are useful for determining protein function.
S Polypeptides and Variants Thereof The polypeptides of the invention include those encoded by the disclosed polynucleotides, as well as nucleic acids that, by virtue of the degeneracy of the genetic code, are not identical in sequence to the disclosed polynucleotides. Thus, the invention includes within its scope a polypeptide encoded by a polynucleotide having the sequence of any one of SEQ )D NOS:1-1477 or a variant thereof. Also included in the invention are the polypeptides comprising the amino acid sequences of SEQ )D
NOS:1478-1568.
In general, the term "polypeptide" as used herein refers to both the full length polypeptide encoded by the recited polynucleotide, the polypeptide encoded by the gene represented by the recited polynucleotide, as well as portions or fragments thereof. "Polypeptides" also includes variants of the naturally occurring proteins, where such variants are homologous or substantially similar to the naturally occurnng protein, and can be of an origin of the same or different species as the naturally occurring protein (e.g., human, murine, or some other species that naturally expresses the recited polypeptide, usually a mammalian species). In general, variant polypeptides have a sequence that has at least about 80%, usually at least about 90%, and more usually at least about 98% sequence identity with a differentially expressed polypeptide of the invention, as measured by BLAST 2.0 or TeraBLAST using the parameters described above. The variant polypeptides can be naturally or non-naturally glycosylated, i.e., the polypeptide has a glycosylation pattern that differs from the glycosylation pattern found in the corresponding naturally occurnng protein.
The invention also encompasses homologs of the disclosed polypeptides (or fragments thereof) where the homologs are isolated from other species, i.e. other animal or plant species, where such homologs, usually mammalian species, e.g. rodents, such as mice, rats;
domestic animals, e.g., horse, cow, dog, cat; and humans. By "homolog" is meant a polypeptide having at least about 35%, usually at least about 40% and more usually at least about 60% amino acid sequence identity to a particular differentially expressed protein as identified above, where sequence identity is determined using the BLAST 2.0 or TeraBLAST algorithm, with the parameters described supra.
In general, the polypeptides of the subject invention are provided in a non-naturally occurring environment, e.g. are separated from their naturally occurring environment. In certain embodiments, the subject protein is present in a composition that is enriched for the protein as compared to a control.
As such, purified polypeptide is provided, where by purified is meant that the protein is present in a composition that is substantially free of non-differentially expressed polypeptides, where by substantially free is meant that less than 90%, usually less than 60% and more usually less than 50%
of the composition is made up of non-differentially expressed polypeptides.
Also within the scope of the invention are variants; variants of polypeptides include mutants, fragments, and fusions. Mutants can include amino acid substitutions, additions or deletions. The amino acid substitutions can be conservative amino acid substitutions or substitutions to eliminate non-essential amino acids, such as to alter a glycosylation site, a phosphorylation site or an acetylation site, or to minimize misfolding by substitution or deletion of one or more cysteine residues that are not necessary for function. Conservative amino acid substitutions are those that preserve the general charge, hydrophobicity/ hydrophilicity, and/or steric bulk of the amino acid substituted. Variants can be designed so as to retain or have enhanced biological activity of a particular region of the protein (e.g., a functional domain and/or, where the polypeptide is a member of a protein family, a region associated with a consensus sequence). Selection of amino acid alterations for production of variants can be based upon the accessibility (interior vs. exterior) of the amino acid (see, e.g., Go et al, Int. J.
Peptide Protein Res. (1980) 15:211), the thermostability of the variant polypeptide (see, e.g., Querol et al., Prot. Eng. (1996) 9:265), desired glycosylation sites (see, e.g., Olsen and Thomsen, J. Gen.
Microbiol. (1991) 137:579), desired disulfide bridges (see, e.g., Clarke et al., Biochemistry (1993) 32:4322; and Wakarchuk et al., Protein Eng. (1994) 7:1379), desired metal binding sites (see, e.g., Toma et al., Biochemistry (1991) 30:97, and Haezerbrouck et al., Protein Eng.
(1993) 6:643), and desired substitutions within proline loops (see, e.g., Masul et al., Appl.
Env. Microbiol. (1994) 60:3579). Cysteine-depleted muteins can be produced as disclosed in USPN
4,959,314.
Variants also include fragments of the polypeptides disclosed herein, particularly haptens, biologically active fragments, and/or fragments corresponding to functional domains. Fragments of interest will typically be at least about 10 as to at least about 15 as in length, usually at least about 50 as in length, and can be as long as 300 as in length or longer, but will usually not exceed about 1000 as in length, where the fragment will have a stretch of amino acids that is identical to a polypeptide encoded by a polynucleotide having a sequence of any SEQ )D NOS:1-1477, a polypeptide comrpsing a sequence of at least one of SEQ >D NOS:1478-1568, or a homolog thereof. The protein variants described herein are encoded by polynucleotides that are within the scope of the invention. The genetic code can be used to select the appropriate codons to construct the corresponding variants.
Computer-Related Embodiments In general, a library of polynucleotides is a collection of sequence information, which information is provided in either biochemical form (e.g., as a collection of polynucleotide molecules), or in electronic form (e.g., as a collection of polynucleotide sequences stored in a computer-readable form, as in a computer system and/or as part of a computer program). The sequence information of the polynucleotides can be used in a variety of ways, e.g., as a resource for gene discovery, as a representation of sequences expressed in a selected cell type (e.g., cell type markers), and/or as markers of a given disease or disease state. In general, a disease marker is a representation of a gene product that is present in all cells affected by disease either at an increased or decreased level relative to a normal cell (e.g., a cell of the same or similar type that is not substantially affected by disease).
For example, a polynucleotide sequence in a library can be a polynucleotide that represents an mRNA, polypeptide, or other gene product encoded by the polynucleotide, that is either overexpressed or underexpressed in a breast ductal cell affected by cancer relative to a normal (i.e., substantially disease-free) breast cell.
The nucleotide sequence information of the library can be embodied in any suitable form, e.g., electronic or biochemical forms.' For example, a library of sequence information embodied in electronic form comprises an accessible computer data file (or, in biochemical form, a collection of nucleic acid molecules) that contains the representative nucleotide sequences of genes that are differentially expressed (e.g., overexpressed or underexpressed) as between, for example, i) a cancerous cell and a normal cell; ii) a cancerous cell and a dysplastic cell;
iii) a cancerous cell and a cell affected by a disease or condition other than cancer; iv) a metastatic cancerous cell and a normal cell and/or non-metastatic cancerous cell; v) a malignant cancerous cell and a non-malignant cancerous cell (or a normal cell) and/or vi) a dysplastic cell relative to a normal cell. Other combinations and comparisons of cells affected by various diseases or stages of disease will be readily apparent to the ordinarily skilled artisan. Biochemical embodiments of the library include a collection of nucleic acids that have the sequences of the genes in the library, where the nucleic acids can correspond to the entire gene in the library or to a fragment thereof, as described in greater detail below.
The polynucleotide libraries of the subject invention generally comprise sequence information of a plurality of polynucleotide sequences, where at least one of the polynucleotides has a sequence of any of SEQ >D NOS:1-1477. By plurality is meant at least 2, usually at least 3 and can include up to all of SEQ >D NOS:1-1477. The length and number of polynucleotides in the library will vary with the nature of the library, e.g., if the library is an oligonucleotide array, a cDNA array, a computer database of the sequence information, etc.
Where the library is an electronic library, the nucleic acid sequence information can be present in a variety of media. "Media" refers to a manufacture, other than an isolated nucleic acid molecule, that contains the sequence information of the present invention.
Such a manufacture provides the genome sequence or a subset thereof in a form that can be examined by means not directly applicable to the sequence as it exists in a nucleic acid. For example, the nucleotide sequence of the present invention, e.g. the nucleic acid sequences of any of the polynucleotides of SEQ >D
NOS:1-1477, can be recorded on computer readable media, e.g. any medium that can be read and accessed directly by a computer. Such media include, but are not limited to:
magnetic storage media, such as a floppy disc, a hard disc storage medium, and a magnetic tape;
optical storage media such as CD-ROM; electrical storage media such as RAM and ROM; and hybrids of these categories such as magnetic/optical storage media. One of skill in the art can readily appreciate how any of the presently known computer readable mediums can be used to create a manufacture comprising a recording of the present sequence information. "Recorded" refers to a process for storing information on computer readable medium, using any such methods as known in the art. Any convenient data storage structure can be chosen, based on the means used to access the stored information. A
variety of data processor programs and formats can be used for storage, e.g. word processing text file, database format, etc. In addition to the sequence information, electronic versions of the libraries of the invention can be provided in conjunction or connection with other computer-readable information and/or other types of computer-readable files (e.g., searchable files, executable files, etc, including, but not limited to, for example, search program software, etc.).
By providing the nucleotide sequence in computer readable form, the information can be accessed for a variety of purposes. Computer software to access sequence information is publicly available. For example, the gapped BLAST (Altschul et al. Nucleic Acids Res.
(1997) 25:3389-3402) and BLAZE (Brutlag et al. Comp. Chem. (1993) 17:203) search algorithms on a Sybase system, or the TeraBLAST (TimeLogic, Crystal Bay, Nevada) program optionally running on a specialized computer platform available from TimeLogic, can be used to identify open reading frames (ORFs) within the genome that contain homology to ORFs from other organisms.
As used herein, "a computer-based system" refers to the hardware means, software means, and data storage means used to analyze the nucleotide sequence information of the present invention. The minimum hardware of the computer-based systems of the present invention comprises a central processing unit (CPU), input means, output means, and data storage means. A
skilled artisan can readily appreciate that any one of the currently available computer-based system are suitable for use in the present invention. The data storage means can comprise any manufacture comprising a recording of the present sequence information as described above, or a memory access means that can access such a manufacture.
"Search means" refers to one or more programs implemented on the computer-based system, to compare a target sequence or target structural motif, or expression levels of a polynucleotide in a sample, with the stored sequence information. Search means can be used to identify fragments or regions of the genome that match a particular target sequence or target motif.
A variety of known algorithms are publicly known and commercially available, e.g. MacPattern (EMBL), BLASTN and BLASTX (NCB>7, TeraBLAST (TimeLogic, Crystal Bay, Nevada). A "target sequence"
can be any polynucleotide or amino acid sequence of six or more contiguous nucleotides or two or more amino acids, preferably from about 10 to 100 amino acids or from about 30 to 300 nt A variety of comparing means can be used to accomplish comparison of sequence information from a sample (e.g., to analyze target sequences, target motifs, or relative expression levels) with the data storage means. A skilled artisan can readily recognize that any one of the publicly available homology search programs can be used as the search means for the computer based systems of the present invention to accomplish comparison of target sequences and motifs. Computer programs to analyze expression levels in a sample and in controls are also known in the art.
A "target structural motif," or "target motif," refers to any rationally selected sequence or combination of sequences in which the sequences) are chosen based on a three-dimensional configuration that is formed upon the folding of the target motif, or on consensus sequences of regulatory or active sites. There are a variety of target motifs known in the art. Protein target motifs include, but arc not limited to, enzyme active sites and signal sequences.
Nucleic acid target motifs include, but are not limited to, hairpin structures, promoter sequences and other expression elements such as binding sites for transcription factors.
A variety of structural formats for the input and output means can be used to input and output the information in the computer-based systems of the present invention. One format for an output means ranks the relative expression levels of different polynucleotides. Such presentation provides a skilled artisan with a ranking of relative expression levels to determine a gene expression profile.
As discussed above, the "library" of the invention also encompasses biochemical libraries of the polynucleotides of SEQ >D NOS:1-1477 , e.g., collections of nucleic acids representing the provided polynucleotides. The biochemical libraries can take a variety of forms, e.g., a solution of cDNAs, a pattern of probe nucleic acids stably associated with a surface of a solid support (i.e., an array) and the like. Of particular interest are nucleic acid arrays in which one or more of SEQ >D
NOS:1-1477 is represented on the array. By array is meant a an article of manufacture that has at least a substrate with at least two distinct nucleic acid targets on one of its surfaces, where the number of distinct nucleic acids can be considerably higher, typically being at least 10, usually at least 20, and often at least 25 distinct nucleic acid molecules. A variety of different array formats have been developed and are known to those of skill in the art. The arrays of the subject invention find use in a variety of applications, including gene expression analysis, drug screening, mutation analysis and the like, as disclosed in the above-listed exemplary patent documents.
In addition to the above nucleic acid libraries, analogous libraries of polypeptides are also provided, where the polypeptides of the library will represent at least a portion of the polypeptides encoded by a gene corresponding to one or more of SEQ >D NOS:1-1477.
Utilities The polynucleotides of the invention are useful in a variety of applications.
Exemplary utilies of the polynucleotides of the invention are described below.
Construction of Larger Molecules: Recombinant DNAs and Nucleic Acid Multimers.
In one embodiment of particular interest, the polynucleotides described herein as useful as the building blocks for larger molecules. In one example, the polynucleotide is a component of a larger cDNA

molecule which in turn can be adapted for expression in a host cell (e.g., a bacterial or eukaryotic (e.g., yeast or mammalian) host cell). The cDNA can include, in addition to the polypeptide encoded by the starting material polynucleotide (i.e., a polynucleotide described herein), an amino acid sequence that is heterologous to the polypeptide encoded by the polynucleotide described herein (e.g., as in a sequence encoding a fusion protein). In some embodiments, the polynucleotides described herein is used as starting material polynucleotide for synthesizing all or a portion of the gene to which the described polynucleotide corresponds. For example, a DNA molecule encoding a full-length human polypeptide can be constructed using a polynucleotide described herein as starting material.
In another embodiment, the polynucleotides of the invention are used in nucleic acid multimers. Nucleic acid multimers can be linear or branched polymers of the same repeating single-stranded oligonucleotide unit or different single-stranded oligonucleotide units. Where the molecules are branched, the multimers are generally described as either "fork" or "comb"
structures. The oligonucleotide units of the multimer may be composed of RNA, DNA, modified nucleotides or combinations thereof. At least one of the units has a sequence, length, and composition that permits it to bind specifically to a first single-stranded nucleotide sequence of interest, typically analyte or an oligonucleotide bound to the analyte. In order to achieve such specificity and stability, this unit will normally be 15 to 50 nt, preferably 15 to 30 nt, in length and have a GC
content in the range of 40%
to 60%. In addition to such unit(s), the multimer includes a multiplicity of units that are capable of hybridizing specifically and stably to a second single-stranded nucleotide of interest, typically a labeled oligonucleotide or another multimer. These units will also normally be 15 to SO nt, preferably 15 to 30 nt, in length and have a GC content in the range of 40% to 60%. When a multimer is designed to be hybridized to another multimer, the first and second oligonucleotide units are heterogeneous (different). One or more of the polynucleotides described herein, or a portion of a polynucleotide described herein, can be used as a repeating unit of such nucleic acid multimers.
The total number of oligonucleotide units in the multimer will usually be in the range of 3 to 50, more usually 10 to 20. In multimers in which the unit that hybridizes to the nucleotide sequence of interest is different from the unit that hybridizes to the labeled oligonucleotide, the number ratio of the latter to the former will usually be 2:1 to 30:1, more usually 5:1 to 20:1, and-preferably 10:1 to 15:1.
The oligonucleotide units of the multimer may be covalently linked directly to each other through phosphodiester bonds or through interposed linking agents such as nucleic acid, amino acid, carbohydrate or polyol bridges, or through other cross-linking agents that are capable of cross-linking nucleic acid or modified nucleic acid strands. The sites) of linkage may be at the ends of the unit (in either normal 3,-5' orientation or randomly oriented) and/or at one or more internal nucleotides in the strand. In linear multimers the individual units are linked end-to-end to form a linear polymer. In one type of branched multimer three or more oligonucleotide units emanate from a point of origin to form a branched structure. The point of origin may be another oligonucleotide unit or a multifunctional molecule to which at least three units can be covalently bound. In another type, there is an oligonucleotide unit backbone with one or more pendant oligonucleotide units.
These latter-type multimers are "fork-like", "comb-like" or combination "fork-" and "comb-like"
in structure. The pendant units will normally depend from a modified nucleotide or other organic moiety having appropriate functional groups to which oligonucleotides may be conjugated or otherwise attached.
The multimer may be totally linear, totally branched, or a combination of linear and branched portions. Preferably there will be at least two branch points in the multimer, more preferably at least 3, preferably S to 10. The multimer may include one or more segments of double-stranded sequences.
Multimeric nucleic acid molecules are useful in amplifying the signal that results from hybridization of one the first sequence of the multimeric molecule to a target sequence. The amplification is theoretically proportional to the number of iterations of the second segment.
Without being held to theory, forked structures of greater than about eight branches exhibited steric hindrance which inhibited binding of labeled probes to the multimer. On the other hand, comb structures exhibit little or no steric problems and are thus a preferred type of branched multimer. For a description of branched nucleic acid multimers of both the fork and comb types, as well as methods of use and synthesis, see, e.g., U.S. Pat. Nos. 5,124,246 (fork-type structures);
5,710,264 (synthesis of comb structures); and 5,849,481.
Use of Polynucleotide Probes in Mapping, and in Tissue Profiling.
Polynucleotide probes, generally comprising at least 12 contiguous nt of a polynucleotide as shown in the Sequence Listing, are used for a variety of purposes, such as chromosome mapping of the polynucleotide and detection of transcription levels. Additional disclosure about preferred regions of the disclosed polynucleotide sequences is found in the Examples. A probe that hybridizes specifically to a polynucleotide disclosed herein should provide a detection signal at least 5-, 10-, or 20-fold higher than the background hybridization provided with other unrelated sequences.
Detection of Expression Levels. Nucleotide probes are used to detect expression of a gene corresponding to the provided polynucleotide. In Northern blots, mRNA is separated electrophoretically and contacted with a probe. A probe is detected as hybridizing to an mRNA
species of a particular size. The amount of hybridization is quantitated to determine relative amounts of expression, for example under a particular condition. Probes are used for in situ hybridization to cells to detect expression. Probes can also be used in vivo for diagnostic detection of hybridizing sequences. Probes are typically labeled with a radioactive isotope. Other types of detectable labels can be used such as chromophores, fluors, and enzymes. Other examples of nucleotide hybridization assays are described in W092/02526 and USPN 5,124,246.
Alternatively, the Polymerase Chain Reaction (PCR) is another means for detecting small amounts of target nucleic acids (see, e.g., Mullis et al., Meth. Enzymol.
(1987) 155:335; USPN

4,683,195; and USPN 4,683,202). Two primer polynucleotides nucleotides that hybridize with the target nucleic acids are used to prime the reaction. The primers can be composed of sequence within or 3' and 5' to the polynucleotides of the Sequence Listing. Alternatively, if the primers are 3' and 5' to these polynucleotides, they need not hybridize to them or the complements.
After amplification of the target with a thermostable polymerase, the amplified target nucleic acids can be detected by methods known in the art, e.g., Southern blot. mRNA or cDNA can also be detected by traditional blotting techniques (e.g., Southern blot, Northern blot, etc.) described in Sambrook et al., "Molecular Cloning:
A Laboratory Manual" (New York, Cold Spring Harbor Laboratory, 1989) (e.g., without PCR
amplification). In general, mRNA or cDNA generated from mRNA using a polymerase enzyme can be purified and separated using gel electrophoresis, and transferred to a solid support, such as nitrocellulose. The solid support is exposed to a labeled probe, washed to remove any unhybridized probe, and duplexes containing the labeled probe are detected.
Mapping. Polynucleotides of the present invention can be used to identify a chromosome on which the corresponding gene resides. Such mapping can be useful in identifying the function of the polynucleotide-related gene by its proximity to other genes with known function. Function can also be assigned to the polynucleotide-related gene when particular syndromes or diseases map to the same chromosome. For example, use of polynucleotide probes in identification and quantification of nucleic acid sequence aberrations is described in USPN 5,783,387. An exemplary mapping method is fluorescence in situ hybridization (FISH), which facilitates comparative genomic hybridization to allow total genome assessment of changes in relative copy number of DNA
sequences (see, e.g., Valdes et al., Methods in Molecular Biology (1997) 68:1). Polynucleotides can also be mapped to particular chromosomes using, for example, radiation hybrids or chromosome-specific hybrid panels.
See Leach et al., Advances in Genetics, (1995) 33:63-99; Walter et al., Nature Genetics (1994) 7:22;
Walter and Goodfellow, Trends in Genetics (1992) 9:352. Panels for radiation hybrid mapping are available from Research Genetics, Inc., Huntsville, Alabama, USA. Databases for markers using various panels are available via the world wide web at sites supported by the Stanford Human Genome Center (Stanford University) and the Whitehead Institute for Biomedical Research/MIT
Center for Genome Research. The statistical program RHMAP can be used to construct a map based on the data from radiation hybridization with a measure of the relative likelihood of one order versus another. RIIMAP is available via the world wide web at a site supported by the University of Michigan. In addition, commercial programs are available for identifying regions of chromosomes commonly associated with disease, such as cancer.
Tissue Typin. or Profiling. Expression of specific mRNA corresponding to the provided polynucleotides can vary in different cell types and can be tissue-specific.
This variation of mRNA
levels in different cell types can be exploited with nucleic acid probe assays to determine tissue types.
For example, PCR, branched DNA probe assays, or blotting techniques utilizing nucleic acid probes substantially identical or complementary to polynucleotides listed in the Sequence Listing can determine the presence or absence of the corresponding cDNA or mRNA.
Tissue typing can be used to identify the developmental organ or tissue source of a metastatic lesion by identifying the expression of a particular marker of that organ or tissue. If a polynucleotide is expressed only in a specific tissue type, and a metastatic lesion is found to express that polynucleotide, then the developmental source of the lesion has been identified. Expression of a particular polynucleotide can be assayed by detection of either the corresponding mRNA or the protein product. As would be readily apparent to any forensic scientist, the sequences disclosed herein are useful in differentiating human tissue from non-human tissue. In particular, these sequences are useful to differentiate human tissue from bird, reptile, and amphibian tissue, for example.
Use of Polymorphisms. A polynucleotide of the invention can be used in forensics, genetic analysis, mapping, and diagnostic applications where the corresponding region of a gene is polymorphic in the human population. Any means for detecting a polymorphism in a gene can be used, including, but not limited to electrophoresis of protein polymorphic variants, differential sensitivity to restriction enzyme cleavage, and hybridization to allele-specific probes.
Antibody Production. The present invention further provides antibodies, which may be isolated antibodies, that are specific for a polypeptide encoded by a polynucleotide described herein (e.g., a polypeptide encoded by a sequence corresponding to SEQ ID NOS:1-1477, a polypeptide comprising an amino acid sequence of SEQ 117 NOS:1478-1568). Antibodies can be provided in a composition comprising the antibody and a buffer and/or a pharmaceutically acceptable excipient.
Antibodies specific for a polypeptide associated with prostate cancer are useful in a variety of diagnostic and therapeutic methods, as discussed in detail herein.
Expression products of a polynucleotide of the invention, as well as the corresponding mRNA, cDNA, or complete gene, can be prepared and used for raising antibodies for experimental, diagnostic, and therapeutic purposes. For polynucleotides to which a corresponding gene has not been assigned, this provides an additional method of identifying the corresponding gene. The polynucleotide or related cDNA is expressed as described above, and antibodies are prepared. These antibodies are specific to an epitope on the polypeptide encoded by the polynucleotide, and can precipitate or bind to the corresponding native protein in a cell or tissue preparation or in a cell-free extract of an in vitro expression system.
Methods for production of antibodies that specifically bind a selected antigen are well known in the art. Immunogens for raising antibodies can be prepared by mixing a polypeptide encoded by a polynucleotide of the invention with an adjuvant, and/or by making fusion proteins with larger immunogenic proteins. Polypeptides can also be covalently linked to other larger immunogenic proteins, such as keyhole limpet hemocyanin. Immunogens are typically administered intradermally, subcutaneously, or intramuscularly to experimental animals such as rabbits, sheep, and mice, to generate antibodies. Monoclonal antibodies can be generated by isolating spleen cells and fusing myeloma cells to form hybridomas. Alternatively, the selected polynucleotide is administered directly, such as by intramuscular injection, and expressed in vivo. The expressed protein generates a variety of protein-specific immune responses, including production of antibodies, comparable to administration of the protein.
Preparations of polyclonal and monoclonal antibodies specific for polypeptides encoded by a selected polynucleotide are made using standard methods known in the art. The antibodies specifically bind to epitopes present in the polypeptides encoded by polynucleotides disclosed in the Sequence Listing. Typically, at least 6, 8, 10, or 12 contiguous amino acids are required to form an epitope. Epitopes that involve non-contiguous amino acids may require a longer polypeptide, e.g., at least 15, 25, or 50 amino acids. Antibodies that specifically bind to human polypeptides encoded by the provided polypeptides should provide a detection signal at least 5-, 10-, or 20-fold higher than a detection signal provided with other proteins when used in Western blots or other immunochemical assays. Preferably, antibodies that specifically bind polypeptides contemplated by the invention do not bind to other proteins in immunochemical assays at detectable levels and can immunoprecipitate the specific polypeptide from solution.
The invention also contemplates naturally occurring antibodies specific for a polypeptide of the invention. For example, serum antibodies to a polypeptide of the invention in a human population can be purified by methods well known in the art, e.g., by passing antiserum over a column to which the corresponding selected polypeptide or fusion protein is bound. The bound antibodies can then be eluted from the column, for example, using a buffer with a high salt concentration.
In addition to the antibodies discussed above, the invention also contemplates genetically engineered antibodies antibodies (e.g., chimeric antibodies, humanized antibodies, human antibodies produced by a transgenic animal (e.g., a transgenic mouse such as the XenomousTM), antibody derivatives (e.g., single chain antibodies, antibody fragments (e.g., Fab, etc.)), according to methods well known in the art.
The invention also contemplates other molecules that can specifically bind a polynucleotide or polypeptide of the invention. Examples of such molecules include, but are not necessarily limited to, single-chain binding proteins (e.g., mono- and mufti-valent single chain antigen binding proteins (see, e.g., U.S. Patent Nos. 4,704,692; 4,946,778; 4,946,778; 6,027,725;
6,121,424)), oligonucleotide-based synthetic antibodies (e.g., oligobodies (see, e.g., Radrizzani et al., Medicina (B Aires) (1999) 59:753-8; Radrizzani et al., Medicina (B Aires) (2000) 60(Suppl 2):55-60)), aptamers (see, e.g., Gening et al., Biotechniques (2001) 3:828, 830, 832, 834; Cox and Ellington, Bioorg. Med. Chem.
(2001) 9:2525-31), and the like.

Polynucleotides or Arrays for Diagnostics.
Polynucleotide arrays provide a high throughput technique that can assay a large number of polynucleotides in a sample. This technology can be used as a diagnostic and as tool to test for differential expression expression, e.g., to determine function of an encoded protein. A variety of methods of producing arrays, as well as variations of these methods, are known in the art and contemplated for use in the invention. For example, arrays can be created by spotting polynucleotide probes onto a substrate (e.g., glass, nitrocellulose, etc.) in a two-dimensional matrix or array having bound probes. The probes can be bound to the substrate by either covalent bonds or by non-specific interactions, such as hydrophobic interactions. Samples of polynucleotides can be detestably labeled (e.g., using radioactive or fluorescent labels) and then hybridized to the probes. Double stranded polynucleotides, comprising the labeled sample polynucleotides bound to probe polynucleotides, can be detected once the unbound portion of the sample is washed away.
Alternatively, the polynucleotides of the test sample can be immobilized on the array, and the probes detestably labeled.
Techniques for constructing arrays and methods of using these arrays are described in, for example, Schena et al. (1996) Proc Natl Acad Sci U S A. 93(20):10614-9; Schena et al.
(1995) Science 270(5235):467-70; Shalon et al. (1996) Genome Res. 6(7):639-45, USPN

5,807,522, EP 799 897;
WO 97/29212; WO 97/27317; EP 785 280; WO 97/02357; USPN 5,593,839; USPN
5,578,832; EP
728 520; USPN 5,599,695; EP 721 016; USPN 5,556,752; WO 95/22058; and USPN
5,631,734.
Arrays can be used to, for example, examine differential expression of genes and can be used to determine gene function. For example, arrays can be used to detect differential expression of a gene corresponding to a polynucleotide of the invention, where expression is compared between a test cell and control cell (e.g., cancer cells and normal cells). For example, high expression of a particular message in a cancer cell, which is not observed in a corresponding normal cell, can indicate a cancer specific gene product. Exemplary uses of arrays are further described in, for example, Pappalarado et al., Sem. Radiation Oncol. (1998) 8:217; and Ramsay Nature Biotechnol. (1998) 16:40. Furthermore, many variations on methods of detection using arrays are well within the skill in the art and within the scope of the present invention. For example, rather than immobilizing the probe to a solid support, the test sample can be immobilized on a solid support which is then contacted with the probe.
Differential Expression in Dia nosis The polynucleotides of the invention can also be used to detect differences in expression levels between two cells, e.g., as a method to identify abnormal or diseased tissue in a human. For polynucleotides corresponding to profiles of protein families, the choice of tissue can be selected according to the putative biological function. In general, the expression of a gene corresponding to a specific polynucleotide is compared between a first tissue that is suspected of being diseased and a second, normal tissue of the human. The tissue suspected of being abnormal or diseased can be derived from a different tissue type of the human, but preferably it is derived from the same tissue type; for example, an intestinal polyp or other abnormal growth should be compared with normal intestinal tissue. The normal tissue can be the same tissue as that of the test sample, or any normal tissue of the patient, especially those that express the polynucleotide-related gene of interest (e.g., brain, thymus, testis, heart, prostate, placenta, spleen, small intestine, skeletal muscle, pancreas, and the mucosal lining of the colon). A difference between the polynucleotide-related gene, mRNA, or protein in the two tissues which are compared, for example, in molecular weight, amino acid or nucleotide sequence, or relative abundance, indicates a change in the gene, or a gene which regulates it, in the tissue of the human that was suspected of being diseased. Examples of detection of differential expression and its use in diagnosis of cancer are described in USPNs 5,688,641 and 5,677,125.
A genetic predisposition to disease in a human can also be detected by comparing expression levels of an mRNA or protein corresponding to a polynucleotide of the invention in a fetal tissue with levels associated in normal fetal tissue. Fetal tissues that are used for this purpose include, but are not limited to, amniotic fluid, chorionic villi, blood, and the blastomere of an in vitro-fertilized embryo.
The comparable normal polynucleotide-related gene is obtained from any tissue.
The mRNA or protein is obtained from a normal tissue of a human in which the polynucleotide-related gene is expressed. Differences such as alterations in the nucleotide sequence or size of the same product of the fetal polynucleotide-related gene or mRNA, or alterations in the molecular weight, amino acid sequence, or relative abundance of fetal protein, can indicate a germline mutation in the polynucleotide-related gene of the fetus, which indicates a genetic predisposition to disease. In general, diagnostic, prognostic, and other methods of the invention based on differential expression involve detection of a level or amount of a gene product, particularly a differentially expressed gene product, in a test sample obtained from a patient suspected of having or being susceptible to a disease (e.g., breast cancer, lung cancer, colon cancer and/or metastatic forms thereofj, and comparing the detected levels to those levels found in normal cells (e.g., cells substantially unaffected by cancer) and/or other control cells (e.g., to differentiate a cancerous cell from a cell affected by dysplasia).
Furthermore, the severity of the disease can be assessed by comparing the detected levels of a differentially expressed gene product with those levels detected in samples representing the levels of differentially expressed gene product associated with varying degrees of severity of disease. It should be noted that use of the term "diagnostic" herein is not necessarily meant to exclude "prognostic" or "prognosis," but rather is used as a matter of convenience.
The term "differentially expressed gene" is generally intended to encompass a polynucleotide that can, for example, include an open reading frame encoding a gene product (e.g., a polypeptide), and/or introns of such genes and adjacent 5' and 3' non-coding nucleotide sequences involved in the regulation of expression, up to about 20 kb beyond the coding region, but possibly further in either direction. The gene can be introduced into an appropriate vector for extrachromosomal maintenance or for integration into a host genome. In general, a difference in expression level associated with a decrease in expression level of at least about 25%, usually at least about 50%
to 75%, more usually at least about 90% or more is indicative of a differentially expressed gene of interest, i.e., a gene that is underexpressed or down-regulated in the test sample relative to a control sample. Furthermore, a difference in expression level associated with an increase in expression of at least about 25%, usually at least about 50% to 75%, more usually at least about 90% and can be at least about 1'/z-fold, usually at least about 2-fold to about 10-fold, and can be about 100-fold to about 1,000-fold increase relative to a control sample is indicative of a differentially expressed gene of interest, i.e., an overexpressed or up-regulated gene.
"Differentially expressed polynucleotide" as used herein means a nucleic acid molecule (RNA
or DNA) comprising a sequence that represents a differentially expressed gene, e.g., the differentially expressed polynucleotide comprises a sequence (e.g., an open reading frame encoding a gene product) that uniquely identifies a differentially expressed gene so that detection of the differentially expressed polynucleotide in a sample is correlated with the presence of a differentially expressed gene in a sample. "Differentially expressed polynucleotide" is also meant to encompass fragments of the disclosed polynucleotides, e.g., fragments retaining biological activity, as well as nucleic acids homologous, substantially similar, or substantially identical (e.g., having about 90% sequence identity) to the disclosed polynucleotides.
Methods of the subject invention useful in diagnosis or prognosis typically involve comparison of the abundance of a selected differentially expressed gene product in a sample of interest with that of a control to determine any relative differences in the expression of the gene product, where the difference can be measured qualitatively and/or quantitatively. Quantitation can be accomplished, for example, by comparing the level of expression product detected in the sample with the amounts of product present in a standard curve. A comparison can be made visually; by using a technique such as densitometry, with or without computerized assistance; by preparing a representative library of cDNA clones of mRNA isolated from a test sample, sequencing the clones in the library to determine that number of cDNA clones corresponding to the same gene product, and analyzing the number of clones corresponding to that same gene product relative to the number of clones of the same gene product in a control sample; or by using an array to detect relative levels of hybridization to a selected sequence or set of sequences, and comparing the hybridization pattern to that of a control. The differences in expression are then correlated with the presence or absence of an abnormal expression pattern. A variety of different methods for determining the nucleic acid abundance in a sample are known to those of skill in the art (see, e.g., WO
97/27317).
In general, diagnostic assays of the invention involve detection of a gene product of a polynucleotide sequence (e.g., mRNA or polypeptide) that corresponds to a sequence of SEQ ID
NOS:1-1477. The patient from whom the sample is obtained can be apparently healthy, susceptible to disease (e.g., as determined by family history or exposure to certain environmental factors), or can already be identified as having a condition in which altered expression of a gene product of the invention is implicated.
Diagnosis can be determined based on detected gene product expression levels of a gene product encoded by at least one, preferably at least two or more, at least 3 or more, or at least 4 or more of the polynucleotides having a sequence set forth in SEQ ID NOS:1-1477, and can involve detection of expression of genes corresponding to all of SEQ ID NOS:1-1477 and/or additional sequences that can serve as additional diagnostic markers and/or reference sequences. Where the diagnostic method is designed to detect the presence or susceptibility of a patient to cancer, the assay preferably involves detection of a gene product encoded by a gene corresponding to a polynucleotide that is differentially expressed in cancer. Examples of such differentially expressed polynucleotides are described in the Examples below. Given the provided polynucleotides and information regarding their relative expression levels provided herein, assays using such polynucleotides and detection of their expression levels in diagnosis and prognosis will be readily apparent to the ordinarily skilled artisan.
Any of a variety of detectable labels can be used in connection with the various embodiments of the diagnostic methods of the invention. Suitable detectable labels include fluorochromes,(e.g.
fluorescein isothiocyanate (FITC), rhodamine, Texas Red, phycoerythrin, allophycocyanin, 6-carboxyfluorescein (6-FAM), 2',7'-dimethoxy-4',5'-dichloro-6-carboxyfluorescein, 6-carboxy-X-rhodamine (ROX), 6-carboxy-2',4',7',4,7-hexachlorofluorescein (HEX), 5-carboxyfluorescein (5-FAM) or N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA)), radioactive labels, (e.g. 32P, 35S, 3H, etc.), and the like. The detectable label can involve a two stage systems (e.g., biotin-avidin, hapten-anti-hapten antibody, etc.).
Reagents specific for the polynucleotides and polypeptides of the invention, such as antibodies and nucleotide probes, can be supplied in a kit for detecting the presence of an expression product in a biological sample. The kit can also contain buffers or labeling components, as well as instructions for using the reagents to detect and quantify expression products in the biological sample.
Exemplary embodiments of the diagnostic methods of the invention are described below in more detail.
Polypeptide detection in dia~,nosis. In one embodiment, the test sample is assayed for the level of a differentially expressed polypeptide, such as a polypeptide of a gene corresponding to SEQ
ID NOS:1-1477 and/or a polypeptide comprising a sequence of SEQ ID N0:1478-1568. Diagnosis can be accomplished using any of a number of methods to determine the absence or presence or altered amounts of the differentially expressed polypeptide in the test sample. For example, detection can utilize staining of cells or histological sections with labeled antibodies, performed in accordance with conventional methods. Cells can be permeabilized to stain cytoplasmic molecules. In general, antibodies that specifically bind a differentially expressed polypeptide of the invention are added to a sample, and incubated for a period of time sufficient to allow binding to the epitope, usually at least about 10 minutes. The antibody can be detectably labeled for direct detection (e.g., using radioisotopes, enzymes, fluorescers, chemiluminescers, and the like), or can be used in conjunction with a second stage antibody or reagent to detect binding (e.g., biotin with horseradish peroxidase-conjugated avidin, a secondary antibody conjugated to a fluorescent compound, e.g. fluorescein, rhodamine, Texas red, etc.). The absence or presence of antibody binding can be determined by various methods, including flow cytometry of dissociated cells, microscopy, radiography, scintillation counting, etc. Any suitable alternative methods of qualitative or quantitative detection of levels or amounts of differentially expressed polypeptide can be used, for example, ELISA, western blot, immunoprecipitation, radioimmunoassay, etc.
mRNA detection. The diagnostic methods of the invention can also or alternatively involve detection of mRNA encoded by a gene corresponding to a differentially expressed polynucleotide of the invention. Any suitable qualitative or quantitative methods known in the art for detecting specific mRNAs can be used. mRNA can be detected by, for example, in situ hybridization in tissue sections, by reverse transcriptase-PCR, or in Northern blots containing poly A+ mRNA.
One of skill in the art can readily use these methods to determine differences in the size or amount of mRNA transcripts between two samples. mRNA expression levels in a sample can also be determined by generation of a library of expressed sequence tags (ESTs) from the sample, where the EST
library is representative of sequences present in the sample (Adams, et al., (1991) Science 252:1651).
Enumeration ofthe relative representation of ESTs within the library can be used to approximate the relative representation of the gene transcript within the starting sample. The results of EST analysis of a test sample can then be compared to EST analysis of a reference sample to determine the relative expression levels of a selected polynucleotide, particularly a polynucleotide corresponding to one or more of the differentially expressed genes described herein. Alternatively, gene expression in a test sample can be performed using serial analysis of gene expression (SAGE) methodology (e.g., Velculescu et al., Science (1995) 270:484) or differential display (DD) methodology (see, e.g., USPN
5,776,683 and USPN 5,807,680).
Alternatively, gene expression can be analyzed using hybridization analysis.
Oligonucleotides or cDNA can be used to selectively identify or capture DNA or RNA of specific sequence composition, and the amount of RNA or cDNA hybridized to a known capture sequence determined qualitatively or quantitatively, to provide information about the relative representation of a particular message within the pool of cellular messages in a sample. Hybridization analysis can be designed to allow for concurrent screening of the relative expression of hundreds to thousands of genes by using, for example, array-based technologies having high density formats, including filters, microscope slides, or microchips, or solution-based technologies that use spectroscopic analysis (e.g., mass spectrometry). One exemplary use of arrays in the diagnostic methods of the invention is described below in more detail.
Use of a single gene in di Gnostic applications. The diagnostic methods of the invention can focus on the expression of a single differentially expressed gene. For example, the diagnostic method can involve detecting a differentially expressed gene, or a polymorphism of such a gene (e.g., a polymorphism in a coding region or control region), that is associated with disease. Disease-associated polymorphisms can include deletion or truncation of the gene, mutations that alter expression level and/or affect activity of the encoded protein, etc.
A number of methods are available for analyzing nucleic acids for the presence of a specific sequence, e.g. a disease associated polymorphism. Where large amounts of DNA
are available, genomic DNA is used directly. Alternatively, the region of interest is cloned into a suitable vector and grown in sufficient quantity for analysis. Cells that express a differentially expressed gene can be used as a source of mRNA, which can be assayed directly or reverse transcribed into cDNA for analysis. The nucleic acid can be amplified by conventional techniques, such as the polymerase chain reaction (PCR), to provide sufficient amounts for analysis, and a detectable label can be included in the amplification reaction (e.g., using a detestably labeled primer or detestably labeled oligonucleotides) to facilitate detection. Alternatively, various methods are also known in the art that utilize oligonucleotide ligation as a means of detecting polymorphisms, see, e.g., Riley et al., Nucl.
Acids Res. (1990) 18:2887; and Delahunty et al., Am. J. Hum. Genet. (1996) 58:1239.
The amplified or cloned sample nucleic acid can be analyzed by one of a number of methods known in the art. The nucleic acid can be sequenced by dideoxy or other methods, and the sequence of bases compared to a selected sequence, e.g., to a wild-type sequence.
Hybridization with the polymorphic or variant sequence can also be used to determine its presence in a sample (e.g., by Southern blot, dot blot, etc.). The hybridization pattern of a polymorphic or variant sequence and a control sequence to an array of oligonucleotide probes immobilized on a solid support, as described in US 5,445,934, or in WO 95/35505, can also be used as a means of identifying polymorphic or variant sequences associated with disease. Single strand conformational polymorphism (SSCP) analysis, denaturing gradient gel electrophoresis (DGGE), and heteroduplex analysis in gel matrices are used to detect conformational changes created by DNA sequence variation as alterations in electrophoretic mobility. Alternatively, where a polymorphism creates or destroys a recognition site for a restriction endonuclease, the. sample is digested with that endonuclease, and the products size fractionated to determine whether the fragment was digested. Fractionation is performed by gel or capillary electrophoresis, particularly acrylamide or agarose gels.
Screening for mutations in a gene can be based on the functional or antigenic characteristics of the protein. Protein truncation assays are useful in detecting deletions that can affect the biological activity of the protein. Various immunoassays designed to detect polymorphisms in proteins can be used in screening. Where many diverse genetic mutations lead to a particular disease phenotype, functional protein assays have proven to be effective screening tools. The activity of the encoded protein can be determined by comparison with the wild-type protein.
Diagnosis, Prognosis, Assessment of Therapy (Therametrics), and Management of Cancer The polynucleotides of the invention, as well as their gene products, are of particular interest as genetic or biochemical markers (e.g., in blood or tissues) that will detect the earliest changes along the carcinogenesis pathway and/or to monitor the efficacy of various therapies and preventive interventions. For example, the level of expression of certain polynucleotides can be indicative of a poorer prognosis, and therefore warrant more aggressive chemo- or radio-therapy for a patient or vice versa. The correlation of novel surrogate tumor specific features with response to treatment and outcome in patients can define prognostic indicators that allow the design of tailored therapy based on the molecular profile of the tumor. These therapies include antibody targeting, antagonists (e.g., small molecules), and gene therapy. Determining expression of certain polynucleotides and comparison of a patient's profile with known expression in normal tissue and variants of the disease allows a 1 S determination of the best possible treatment for a patient, both in terms of specificity of treatment and in terms of comfort level of the patient. Surrogate tumor markers, such as polynucleotide expression, can also be used to better classify, and thus diagnose and treat, different forms and disease states of cancer. Two classifications widely used in oncology that can benefit from identification of the expression levels of the genes corresponding to the polynucleotides of the invention are staging of the cancerous disorder, and grading the nature of the cancerous tissue.
The polynucleotides that correspond to differentially expressed genes, as well as their encoded gene products, can be useful to monitor patients having or susceptible to cancer to detect potentially malignant events at a molecular level before they are detectable at a gross morphological level. In addition, the polynucleotides of the invention, as well as the genes corresponding to such polynucleotides, can be useful as therametrics, e.g., to assess the effectiveness of therapy by using the polynucleotides or their encoded gene products, to assess, for example, tumor burden in the patient before, during, and after therapy.
Furthermore, a polynucleotide identified as corresponding to a gene that is differentially expressed in, and thus is important for, one type of cancer can also have implications for development or risk of development of other types of cancer, e.g., where a polynucleotide represents a gene differentially expressed across various cancer types. Thus, for example, expression of a polynucleotide corresponding to a gene that has clinical implications for metastatic colon cancer can also have clinical implications for stomach cancer or endometrial cancer.
Stamina. Staging is a process used by physicians to describe how advanced the cancerous state is in a patient. Staging assists the physician in determining a prognosis, planning treatment and evaluating the results of such treatment. Staging systems vary with the types of cancer, but generally involve the following "TNM" system: the type of tumor, indicated by T; whether the cancer has metastasized to nearby lymph nodes, indicated by N; and whether the cancer has metastasized to more distant parts of the body, indicated by M. Generally, if a cancer is only detectable in the area of the primary lesion without having spread to any lymph nodes it is called Stage I.
If it has spread only to the closest lymph nodes, it is called Stage II. In Stage III, the cancer has generally spread to the lymph nodes in near proximity to the site of the primary lesion. Cancers that have spread to a distant part of the body, such as the liver, bone, brain or other site, are Stage IV, the most advanced stage.
The polynucleotides of the invention can facilitate fine-tuning of the staging process by identifying markers for the aggresivity of a cancer, e.g., the metastatic potential, as well as the presence in different areas of the body. Thus, a Stage II cancer with a polynucleotide signifying a high metastatic potential cancer can be used to change a borderline Stage II
tumor to a Stage III tumor, justifying more aggressive therapy. Conversely, the presence of a polynucleotide signifying a lower metastatic potential allows more conservative staging of a tumor.
Grading of cancers. Grade is a term used to describe how closely a tumor resembles normal tissue of its same type. The microscopic appearance of a tumor is used to identify tumor grade based on parameters such as cell morphology, cellular organization, and other markers of differentiation. As a general rule, the grade of a tumor corresponds to its rate of growth or aggressiveness, with undifferentiated or high-grade tumors being more aggressive than well-differentiated or low-grade tumors. The following guidelines are generally used for grading tumors: 1) GX
Grade cannot be assessed; 2) G1 Well differentiated; 3) G2 Moderately well differentiated; 4) G3 Poorly differentiated;
5) G4 Undifferentiated. The polynucleotides of the invention can be especially valuable in determining the grade of the tumor, as they not only can aid in determining the differentiation status of the cells of a tumor, they can also identify factors other than differentiation that are valuable in determining the aggressiveness of a tumor, such as metastatic potential.
For prostate cancer, the Gleason Grading/Scoring system is most commonly used.
A prostate biopsy tissue sample is examined under a microscope and a grade is assigned to the tissue based on: 1) the appearance of the cells, and 2) the arrangement of the cells. Each parameter is assessed on a scale of one (cells are almost normal) to five (abnormal), and the individual Gleason Grades are presented separated by a "+" sign. Alternatively, the two grades are combined to give a Gleason Score of 2-10.
Thus, for a tissue sample that received a grade of 3 for each parameter, the Gleason Grade would be 3+3 and the Gleason Score would be 6. A lower Gleason Score indicates a well-differentiated tumor, while a higher Gleason Score indicates a poorly differentiated cancer that is more likely to spread.
The majority of biopsies in general are Gleason Scores 5, 6 and 7.

Gleason Score Gleason Score Gleason Score 2, 3, 4 5, 6 7 8, 9, 10 Low- rade tumor Medium- rade tumor Hi h- ade tumor Slow Growth Un redictable GrowthA ressive Growth Least dangerous. Intermediate cancersHigh-grade cancers may are usually behave like low-gradevery aggressive and or high- quick to Cells look most likegrade cancers. spread to the tissue normal prostate cells and surrounding the prostate.
are described as being "well-differentiated".The cells' behavior may depend on the volumeThese cancer cells of the look least Tends to be slow cancer and the PSA like normal prostate growing. level. cells and are usually described as This is the most "poorly-differentiated".
common rade of rostate cancer.

The polynucleotides of the Sequence Listing, and their corresponding genes and gene products, can be especially valuable in determining the grade of the tumor, as they not only can aid in determining the differentiation status of the cells of a tumor, they can also identify factors other than differentiation that are valuable in determining the aggressiveness of a tumor, such as metastatic potential. Detection of colon cancer. The polynucleotides corresponding to genes that exhibit the appropriate expression pattern can be used to detect colon cancer in a subject. Colorectal cancer is one of the most common neoplasms in humans and perhaps the most frequent form of hereditary neoplasia. Prevention and early detection are key factors in controlling and curing colorectal cancer.
Colorectal cancer begins as polyps, which are small, benign growths of cells that form on the inner lining of the colon. Over a period of several years, some of these polyps accumulate additional mutations and become cancerous. Multiple familial colorectal cancer disorders have been identified, which are summarized as follows: 1) Familial adenomatous polyposis (FAP); 2) Gardner's syndrome;
3) Hereditary nonpolyposis colon cancer (HNPCC); and 4) Familial colorectal cancer in Ashkenazi Jews. The expression of appropriate polynucleotides of the invention can be used in the diagnosis, prognosis and management of colorectal cancer. Detection of colon cancer can be determined using expression levels of any of these sequences alone or in combination with the levels of expression.
Determination of the aggressive nature and/or the metastatic potential of a colon cancer can be determined by comparing levels of one or more polynucleotides of the invention and comparing total levels of another sequence known to vary in cancerous tissue, e.g., expression of p53, DCC ras, for FAP (see, e.g., Fearon ER, et al., Cell (1990) 61(5):759; Hamilton SR et al., Cancer (1993) 72:957;
Bodmer W, et al., Nat Genet. (1994) 4(3):217; Fearon ER, Ann N Y Acad Sci.
(1995) 768:101). For example, development of colon cancer can be detected by examining the ratio of any of the polynucleotides of the invention to the levels of oncogenes (e.g., ras) or tumor suppressor genes (e.g., FAP or p53). Thus, expression of specific marker polynucleotides can be used to discriminate between normal and cancerous colon tissue, to discriminate between colon cancers with different cells of origin, to discriminate between colon cancers with different potential metastatic rates, etc. For a review of markers of cancer, see, e.g., Hanahan et al. (2000) Cell 100:57-70.
Detection of prostate cancer. The polynucleotides and their corresponding-genes and gene products exhibiting the appropriate differential expression pattern can be used to detect prostate cancer in a subject. Prostate cancer is quite common in humans, with one out of every six men at a lifetime risk for prostate cancer, and can be relatively harmless or extremely aggressive. Some prostate tumors are slow growing, causing few clinical symptoms, while aggressive tumors spread rapidly to the lymph nodes, other organs and especially bone. Over 95% of primary prostate cancers are adenocarcinomas. Signs and symptoms may include: frequent urination, especially at night;
inability to urinate; trouble starting or holding back urination; a weak or interrupted urine flow; and frequent pain or stiffness in the lower back, hips or upper thighs.
The prostate is divided into three areas - the peripheral zone, the transition zone, and the central zone - with a layer of tissue surrounding all three. Most prostate tumors form in the peripheral zone; the larger, glandular portion of the organ. Prostate cancer can also form in the tissue of the central zone. Surrounding the prostate is the prostate capsule, a tissue that separates the prostate from the rest of the body. When prostate cancer remains inside the prostate capsule, it is considered localized and treatable with surgery. Once the cancer punctures the capsule and spreads outside, treatment options are more limited. Prevention and early detection are key factors in controlling and curing prostate cancer.
While the Gleason Grade or Score of a prostate cancer can provide information useful in determining the appropriate treatment of a prostate cancer, the majority of prostate cancers are Gleason Scores 5, 6, and 7, which exhibit unpredictable behavior. These cancers may behave like less dangerous low-grade cancers or like extremely dangerous high-grade cancers. As a result, a patient living with a medium-grade prostate cancer is at constant risk of developing high-grade cancer.
The expression of appropriate polynucleotides can be used in the diagnosis, prognosis and management of prostate cancer. Detection of prostate cancer can be determined using expression levels of any of these sequences alone or in combination with the levels of expression of any other nucleotide sequences. Determination of the aggressive nature and/or the metastatic potential of a prostate cancer can be determined by comparing levels of one or more gene products of the genes corresponding to the polynucleotides described herein, and comparing total levels of another sequence known to vary in cancerous tissue, e.g., expression of p53, DCC, ras, FAP
(see, e.g., Fearon ER, et al., Cell (1990) 61 (5):759; Hamilton SR et al., Cancer (1993) 72:957; Bodmer W, et al., Nat Genet.
(1994) 4(3):217; Fearon ER, Ann N YAcad Sci. (1995) 768:101).
For example, development of prostate cancer can be detected by examining the level of expression of a gene corresponding to a polynucleotides described herein to the levels of oncogenes (e.g. ras) or tumor suppressor genes (e.g. FAP or p53). Thus expression of specific marker polynucleotides can be used to discriminate between normal and cancerous prostate tissue, to discriminate between prostate cancers with different cells of origin, to discriminate between prostate cancers with different potential metastatic rates, etc. For a review of markers of cancer, see, e.g., Hanahan et al. (2000) Cell 100:57-70.
In addition, many of the signs and symptoms of prostate cancer can be caused by a variety of other non-cancerous conditions. For example, one common cause of many of these signs and symptoms is a condition called benign prostatic hypertrophy, or BPH. In BPH, the prostate gets bigger and may block the flow of urine or interfere with sexual function. The methods and compositions of the invention can be used to distinguish between prostate cancer and such non-cancerous conditions.
The methods of the invention can be used in conjunction with conventional methods of diagnosis, e.g., digital rectal exam and/or detection of the level of prostate specific antigen (PSA), a substance produced and secreted by the prostate.
Detection of breast cancer. The majority of breast cancers are adenocarcinoma subtypes, which can be summarized as follows: 1) ductal carcinoma in situ (DCIS), including comedocarcinoma; 2) infiltrating (or invasive) ductal carcinoma (IDC); 3) lobular carcinoma in situ (LCIS); 4) infiltrating (or invasive) lobular carcinoma (ILC); 5) inflammatory breast cancer; 6) medullary carcinoma; 7) mucinous carcinoma; 8) Paget's disease of the nipple;
9) Phyllodes tumor;
and 10) tubular carcinoma;
The expression of polynucleotides of the invention can be used in the diagnosis and management of breast cancer, as well as to distinguish between types of breast cancer. Detection of breast cancer can be determined using expression levels of any of the appropriate polynucleotides of the invention, either alone or in combination. Determination of the aggressive nature and/or the metastatic potential of a breast cancer can also be determined by comparing levels of one or more polynucleotides of the invention and comparing levels of another sequence known to vary in cancerous tissue, e.g., ER expression. In addition, development of breast cancer can be detected by examining the ratio of expression of a differentially expressed polynucleotide to the levels of steroid hormones (e.g., testosterone or estrogen) or to other hormones (e.g., growth hormone, insulin). Thus, expression of specific marker polynucleotides can be used to discriminate between normal and cancerous breast tissue, to discriminate between breast cancers with different cells of origin, to discriminate between breast cancers with different potential metastatic rates, etc.
Detection of lung cancer. The polynucleotides of the invention can be used to detect lung cancer in a subject. Although there are more than a dozen different kinds of lung cancer, the two main types of lung cancer are small cell and nonsmall cell, which encompass about 90% of all lung cancer cases. Small cell carcinoma (also called oat cell carcinoma) usually starts in one of the larger bronchial tubes, grows fairly rapidly, and is likely to be large by the time of diagnosis. Nonsmall cell lung cancer (NSCLC) is made up of three general subtypes of lung cancer.
Epidermoid carcinoma (also called squamous cell carcinoma) usually starts in one of the larger bronchial tubes and grows relatively slowly. The size of these tumors can range from very small to quite large. Adenocarcinoma starts growing near the outside surface of the lung and can vary in both size and growth rate. Some slowly growing adenocarcinomas are described as alveolar cell cancer. Large cell carcinoma starts near the surface of the lung, grows rapidly, and the growth is usually fairly large when diagnosed.
Other less common forms of lung cancer are carcinoid, cylindroma, mucoepidermoid, and malignant mesothelioma.
The polynucleotides of the invention, e.g., polynucleotides differentially expressed in normal cells versus cancerous lung cells (e.g., tumor cells of high or low metastatic potential) or I O between types of cancerous lung cells (e.g., high metastatic versus low metastatic), can be used to distinguish types of lung cancer as well as identifying traits specific to a certain patient's cancer and selecting an appropriate therapy. For example, if the patient's biopsy expresses a polynucleotide that is associated with a low metastatic potential, it may justify leaving a larger portion of the patient's lung in surgery to remove the lesion. Alternatively, a smaller lesion with expression of a polynucleotide that is associated with high metastatic potential may justify a more radical removal of lung tissue and/or the surrounding lymph nodes, even if no metastasis can be identified through pathological examination.
Identification of Therapeutic Tar~Yts and Anti-Cancer Therapeutic Agents The present invention also encompasses methods for identification of agents having the ability to modulate activity of a differentially expressed gene product, as well as methods for identifying a differentially expressed gene product as a therapeutic target for treatment of cancer, especially prostate cancer.
Candidate agents Identification of compounds that modulate activity of a differentially expressed gene product can be accomplished using any of a variety of drug screening techniques. Such agents are candidates for development of cancer therapies. Of particular interest are screening assays for agents that have tolerable toxicity for normal, non-cancerous human cells. The screening assays of the invention are generally based upon the ability of the agent to modulate an activity of a differentially expressed gene product and/or to inhibit or suppress phenomenon associated with cancer (e.g., cell proliferation, colony formation, cell cycle arrest, metastasis, and the like).
The term "agent" as used herein describes any molecule, e.g. protein or pharmaceutical, with the capability of modulating a biological activity of a gene product of a differentially expressed gene.
Generally a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e. at zero concentration or below the level of detection.

Candidate agents encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 50 and less than about 2,500 daltons. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including, but not limited to:
peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof.
Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides and oligopeptides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts (including extracts from human tissue to identify endogenous factors affecting differentially expressed gene products) are available or readily produced.
Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means, and may be used to produce combinatorial libraries. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs.
Exemplary candidate agents of particular interest include, but are not limited to, antisense polynucleotides, and antibodies, soluble receptors, and the like. Antibodies and soluble receptors are of particular interest as candidate agents where the target differentially expressed gene product is secreted or accessible at the cell-surface (e.g., receptors and other molecule stably-associated with the outer cell membrane).
Screening of candidate agents Screening assays can be based upon any of a variety of techniques readily available and known to one of ordinary skill in the art. In general, the screening assays involve contacting a cancerous cell (preferably a cancerous prostate cell) with a candidate agent, and assessing the effect upon biological activity of a differentially expressed gene product. The effect upon a biological activity can be detected by, for example, detection of expression of a gene product of a differentially expressed gene (e.g., a decrease in mRNA or polypeptide levels, would in turn cause a decrease in biological activity of the gene product). Alternatively or in addition, the effect of the candidate agent can be assessed by examining the effect of the candidate agent in a functional assay. For example, where the differentially expressed gene product is an enzyme, then the effect upon biological activity can be assessed by detecting a level of enzymatic activity associated with the differentially expressed gene product. The functional assay will be selected according to the differentially expressed gene product. In general, where the differentially expressed gene is increased in expression in a cancerous cell, agents of interest are those that decrease activity of the differentially expressed gene product.
Assays described infra can be readily adapted in the screening assay embodiments of the invention. Exemplary assays useful in screening candidate agents include, but are not limited to, hybridization-based assays (e.g., use of nucleic acid probes or primers to assess expression levels), antibody-based assays (e.g., to assess levels of polypeptide gene products), binding assays (e.g., to detect interaction of a candidate agent with a differentially expressed polypeptide, which assays may be competitive assays where a natural or synthetic ligand for the polypeptide is available), and the like.
Additional exemplary assays include, but are not necessarily limited to, cell proliferation assays, antisense knockout assays, assays to detect inhibition of cell cycle, assays of induction of cell death/apoptosis, and the like. Generally such assays are conducted in vitro, but many assays can be adapted for in vivo analyses, e.g., in an animal model of the cancer.
Identification of therapeutic targets In another embodiment, the invention contemplates identification of differentially expressed genes and gene products as therapeutic targets. In some respects, this is the converse of the assays described above for identification of agents having activity in modulating (e.g., decreasing or increasing) activity of a differentially expressed gene product.
In this embodiment, therapeutic targets are identified by examining the effects) of an agent that can be demonstrated or has been demonstrated to modulate a cancerous phenotype (e.g., inhibit or suppress or prevent development of a cancerous phenotype). Such agents are generally referred to herein as an "anti-cancer agent", which agents encompass chemotherapeutic agents. For example, the agent can be an antisense oligonucleotide that is specific for a selected gene transcript. For example, the antisense oligonucleotide may have a sequence corresponding to a sequence of a differentially expressed gene described herein, e.g., a sequence of one of SEQ ID NOS:1-2164.
Assays for identification of therapeutic targets can be conducted in a variety of ways using methods that are well known to one of ordinary skill in the art. For example, a test cancerous cell that expresses or overexpresses a differentially expressed gene is contacted with an anti-cancer agent, the effect upon a cancerous phenotype and a biological activity of the candidate gene product assessed.
The biological activity of the candidate gene product can be assayed be examining, for example, modulation of expression of a gene encoding the candidate gene product (e.g., as detected by, for example, an increase or decrease in transcript levels or polypeptide levels), or modulation of an enzymatic or other activity of the gene product. The cancerous phenotype can be, for example, cellular proliferation, loss of contact inhibition of growth (e.g., colony formation), tumor growth (in vitro or in vivo), and the like. Alternatively or in addition, the effect of modulation of a biological activity of the candidate target gene upon cell death/apoptosis or cell cycle regulation can be assessed.
Inhibition or suppression of a cancerous phenotype, or an increase in cell/death apoptosis as a S result of modulation of biological activity of a candidate gene product indicates that the candidate gene product is a suitable target for cancer therapy. Assays described infra can be readily adapted in for assays for identification of therapeutic targets. Generally such assays are conducted in vitro, but many assays can be adapted for in vivo analyses, e.g., in an appropriate, art-accepted animal model of the cancer.
Use of Polynucleotides to Screen for Peptide Analo~,s and Antagonists Polypeptides encoded by the instant polynucleotides and corresponding full-length genes can be used to screen peptide libraries to identify binding partners, such as receptors, from among the encoded polypeptides. Peptide libraries can be synthesized according to methods known in the art (see, e.g., USPN 5,010,175 , and WO 91/17823).
1 S Agonists or antagonists of the polypeptides of the invention can be screened using any available method known in the art, such as signal transduction, antibody binding, receptor binding, mitogenic assays, chemotaxis assays, etc. The assay conditions ideally should resemble the conditions under which the native activity is exhibited in vivo, that is, under physiologic pH, temperature, and ionic strength. Suitable agonists or antagonists will exhibit strong inhibition or enhancement of the native activity at concentrations that do not cause toxic side effects in the subject. Agonists or antagonists that compete for binding to the native polypeptide can require concentrations equal to or greater than the native concentration, while inhibitors capable of binding irreversibly to the polypeptide can be added in concentrations on the order of the native concentration.
Such screening and experimentation can lead to identification of a novel polypeptide binding partner, such as a receptor, encoded by a gene or a cDNA corresponding to a polynucleotide of the invention, and at least one peptide agonist or antagonist of the novel binding partner. Such agonists and antagonists can be used to modulate, enhance, or inhibit receptor function in cells to which the receptor is native, or in cells that possess the receptor as a result of genetic engineering. Further, if the novel receptor shares biologically important characteristics with a known receptor, information about agonist/antagonist binding can facilitate development of improved agonists/antagonists of the known receptor.
Vaccines and Uses The differentially expressed nucleic acids and polypeptides produced by the nucleic acids of the invention can also be used to modulate primary immune response to prevent or treat cancer. Every immune response is a complex and intricately regulated sequence of events involving several cell types. It is triggered when an antigen enters the body and encounters a specialized class of cells called antigen-presenting cells (APCs). These APCs capture a minute amount of the antigen and display it in a form that can be recognized by antigen-specific helper T lymphocytes. The helper (Th) cells become activated and, in turn, promote the activation of other classes of lymphocytes, such as B cells or cytotoxic T cells. The activated lymphocytes then proliferate and carry out their specific effector functions, which in many cases successfully activate or eliminate the antigen.
Thus, activating the immune response to a particular antigen associated with a cancer cell can protect the patient from developing cancer or result in lymphocytes eliminating cancer cells expressing the antigen.
Gene products, including polypeptides, mRNA (particularly mRNAs having distinct secondary and/or tertiary structures), cDNA, or complete gene, can be prepared and used in vaccines for the treatment or prevention of hyperproliferative disorders and cancers.
The nucleic acids and polypeptides can be utilized to enhance the immune response, prevent tumor progression, prevent hyperproliferative cell growth, and the like. Methods for selecting nucleic acids and polypeptides that are capable of enhancing the immune response are known in the art. Preferably, the gene products for use in a vaccine are gene products which are present on the surface of a cell and are recognizable by 1 S lymphocytes and antibodies.
The gene products may be formulated with pharmaceutically acceptable carriers into pharmaceutical compositions by methods known in the art. The composition is useful as a vaccine to prevent or treat cancer. The composition may further comprise at least one co-immunostimulatory molecule, including but not limited to one or more major histocompatibility complex (MHC) molecules, such as a class I or class II molecule, preferably a class I
molecule. The composition may further comprise other stimulator molecules including B7.1, B7.2, ICAM-l, ICAM-2, LFA-1, LFA-3, CD72 and the like, immunostimulatory polynucleotides (which comprise an 5'-CG-3' wherein the cytosine is unmethylated), and cytokines which include but are not limited to IL-1 through IL-15, TNF-a, IFN-y, RANTES, G-CSF, M-CSF, IFN-a, CTAP III, ENA-78, GRO, I-309, PF-4, IP-10, LD-78, MGSA, MIP-la, MIP-1~3, or combination thereof, and the like for immunopotentiation. In one embodiment, the immunopotentiators of particular interest are those which facilitate a Thl immune response.
The gene products may also be prepared with a carrier that will protect the gene products against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, polylactic acid, and the like.
Methods for preparation of such formulations are known in the art.
In the methods of preventing or treating cancer, the gene products may be administered via one of several routes including but not limited to transdermal, transmucosal, intravenous, intramuscular, subcutaneous, intradermal, intraperitoneal, intrathecal, intrapleural, intrauterine, rectal, vaginal, topical, intratumor, and the like. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, administration bile salts and fusidic acid derivatives. In addition, detergents may be used to facilitate permeation. Transmucosal administration may be by nasal sprays or suppositories. For oral administration, the gene products are formulated into conventional oral administration form such as capsules, tablets and toxics.
The gene product is administered to a patient in an amount effective to prevent or treat cancer.
In general, it is desirable to provide the patient with a dosage of gene product of at least about 1 pg per Kg body weight, preferably at least about 1 ng per Kg body weight, more preferably at least about 1 pg or greater per Kg body weight of the recipient. A range of from about 1 ng per Kg body weight to about 100 mg per Kg body weight is preferred although a lower or higher dose may be administered. The dose is effective to prime, stimulate and/or cause the clonal expansion of antigen-specific T lymphocytes, preferably cytotoxic T lymphocytes, which in turn are capable of preventing or treating cancer in the recipient. The dose is administered at least once and may be provided as a bolus or a continuous administration. Multiple administrations of the dose over a period of several weeks to months may be preferable. Subsequent doses may be administered as indicated.
In another method of treatment, autologous cytotoxic lymphocytes or tumor infiltrating lymphocytes may be obtained from a patient with cancer. The lymphocytes are grown in culture, and antigen-specific lymphocytes are expanded by culturing in the presence of the specific gene products alone or in combination with at least one co-immunostimulatory molecule with cytokines. The antigen-specific lymphocytes are then infused back into the patient in an amount effective to reduce or eliminate the tumors in the patient. Cancer vaccines and their uses are further described in USPN
5,961,978; USPN 5,993,829; USPN 6,132,980; and WO 00/38706.
Pharmaceutical Compositions and Uses Pharmaceutical compositions can comprise polypeptides, receptors that specifically bind a polypeptide produced by a differentially expressed gene (e.g., antibodies, or polynucleotides (including antisense nucleotides and ribozymes) of the claimed invention in a therapeutically effective amount. The compositions can be used to treat primary tumors as well as metastases of primary tumors. In addition, the pharmaceutical compositions can be used in conjunction with conventional methods of cancer treatment, e.g., to sensitize tumors to radiation or conventional chemotherapy.
Where the pharmaceutical composition comprises a receptor (such as an antibody) that specifically binds to a gene product encoded by a differentially expressed gene, the receptor can be coupled to a drug for delivery to a treatment site or coupled to a detectable label to facilitate imaging of a site comprising colon cancer cells. Methods for coupling antibodies to drugs and detectable labels are well known in the art, as are methods for imaging using detectable labels.
The term "therapeutically effective amount" as used herein refers to an amount of a therapeutic agent to treat, ameliorate, or prevent a desired disease or condition, or to exhibit a detectable therapeutic or preventative effect. The effect can be detected by, for example, chemical markers or antigen levels. Therapeutic effects also include reduction in physical symptoms, such as decreased body temperature.
The precise effective amount for a subject will depend upon the subject's size and health, the nature and extent of the condition, and the therapeutics or combination of therapeutics selected for administration. Thus, it is not useful to specify an exact effective amount in advance. However, the effective amount for a given situation is determined by routine experimentation and is within the judgment of the clinician. For purposes of the present invention, an effective dose will generally be from about 0.01 mg/kg to 50 mg/kg or 0.05 mg/kg to about 10 mg/kg of the DNA
constructs in the individual to which it is administered.
A pharmaceutical composition can also contain a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" refers to a carrier for administration of a therapeutic agent, such as antibodies or a polypeptide, genes, and other therapeutic agents. The term refers to any pharmaceutical carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition, and which can be administered without undue toxicity. Suitable carriers can be large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles.
Such carriers are well known to those of ordinary skill in the art.
Pharmaceutically acceptable carriers in therapeutic compositions can include liquids such as water, saline, glycerol and ethanol. Auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, can also be present in such vehicles.
Typically, the therapeutic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection can also be prepared. Liposomes are included within the definition of a pharmaceutically acceptable carrier. Pharmaceutically acceptable salts can also be present in the pharmaceutical composition, e.g., mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. A thorough discussion of pharmaceutically acceptable excipients is available in Remington's Pharmaceutical Sciences (Mack Pub. Co., N.J. 1991).
Delivery Methods Once formulated, the compositions of the invention can be (1) administered directly to the subject (e.g., as polynucleotide or polypeptides); or (2) delivered ex vivo, to cells derived from the subject (e.g., as in ex vivo gene therapy). Direct delivery of the compositions will generally be accomplished by parenteral injection, e.g., subcutaneously, intraperitoneally, intravenously or intramuscularly, intratumorally or to the interstitial space of a tissue.
Other modes of administration include oral and pulmonary administration, suppositories, and transdermal applications, needles, and gene guns or hyposprays. Dosage treatment can be a single dose schedule or a multiple dose schedule.
Methods for the ex vivo delivery and reimplantation of transformed cells into a subject are known in the art and described in, e.g., WO 93/14778. Examples of cells useful in ex vivo applications include, for example, stem cells, particularly hematopoetic, lymph cells, macrophages, dendritic cells, or tumor cells. Generally, delivery of nucleic acids for both ex vivo and in vitro applications can be accomplished by, for example, dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei, all well known in the art.
Once differential expression of a gene corresponding to a polynucleotide of the invention has been found to correlate with a proliferative disorder, such as neoplasia, dysplasia, and hyperplasia, the disorder can be amenable to treatment by administration of a therapeutic agent based on the provided polynucleotide, corresponding polypeptide or other corresponding molecule (e.g., antisense, ribozyme, etc.). In other embodiments, the disorder can be amenable to treatment by administration of a small molecule drug that, for example, serves as an inhibitor (antagonist) of the function of the encoded gene product of a gene having increased expression in cancerous cells relative to normal cells or as an agonist for gene products that are decreased in expression in cancerous cells (e.g., to promote the activity of gene products that act as tumor suppressors).
The dose and the means of administration of the inventive pharmaceutical compositions are determined based on the specific qualities of the therapeutic composition, the condition, age, and weight of the patient, the progression of the disease, and other relevant factors. For example, administration of polynucleotide therapeutic composition agents of the invention includes local or systemic administration, including injection, oral administration, particle gun or catheterized administration, and topical administration. Preferably, the therapeutic polynucleotide composition contains an expression construct comprising a promoter operably linked to a polynucleotide of at least 12, 22, 25, 30, or 35 contiguous nt of the polynucleotide of the invention.
Various methods can be used to administer the therapeutic composition directly to a specific site in the body. For example, a small metastatic lesion is located and the therapeutic composition injected several times in several different locations within the body of tumor. Alternatively, arteries that serve a tumor are identified, and the therapeutic composition injected into such an artery, in order to deliver the composition directly into the tumor. A tumor that has a necrotic center is aspirated and the composition injected directly into the now empty center of the tumor. The antisense composition is directly administered to the surface of the tumor, for example, by topical application of the composition. X-ray imaging is used to assist in certain of the above delivery methods.

Targeted delivery of therapeutic compositions containing an antisense polynucleotide, subgenomic polynucleotides, or antibodies to specific tissues can also be used. Receptor-mediated DNA delivery techniques are described in, for example, Findeis et al., Trends Biotechnol. (1993) 11:202; Chiou et al., Gene Therapeutics: Methods And Applications Of Direct Gene Transfer (J.A.
Wolff, ed.) (1994); Wu et al., J. Biol. Chem. (1988) 263:621; Wu et al., J.
Biol. Chem. (1994) 269:542; Zenke et al., Proc. Natl. Acad. Sci. (LJSA) (1990) 87:3655; Wu et al., J. Biol. Chem. (1991) 266:338. Therapeutic compositions containing a polynucleotide are administered in a range of about 100 ng to about 200 mg of DNA for local administration in a gene therapy protocol. Concentration ranges of about 500 ng to about 50 mg, about 1 micrograms to about 2 mg, about 5 micrograms to about 500 micrograms, and about 20 micrograms to about 100 micrograms of DNA
can also be used during a gene therapy protocol. Factors such as method of action (e.g., for enhancing or inhibiting levels of the encoded gene product) and efficacy of transformation and expression are considerations which will affect the dosage required for ultimate efficacy of the antisense subgenomic polynucleotides.
Where greater expression is desired over a larger area of tissue, larger amounts of antisense subgenomic polynucleotides or the same amounts readministered in a successive protocol of administrations, or several administrations to different adjacent or close tissue portions of, for example, a tumor site, may be required to effect a positive therapeutic outcome. In all cases, routine experimentation in clinical trials will determine specific ranges for optimal therapeutic effect. For polynucleotide related genes encoding polypeptides or proteins with anti-inflammatory activity, suitable use, doses, and administration are described in USPN 5,654,173.
The therapeutic polynucleotides and polypeptides of the present invention can be delivered using gene delivery vehicles. The gene delivery vehicle can be of viral or non-viral origin (see generally, Jolly, Cancer Gene Therapy (1994) 1:51; Kimura, Human Gene Therapy (1994) 5:845;
Connelly, Human Gene Therapy (1995) 1:185; and Kaplitt, Nature Genetics (1994) 6:148).
Expression of such coding sequences can be induced using endogenous mammalian or heterologous promoters. Expression of the coding sequence can be either constitutive or regulated.
Viral-based vectors for delivery of a desired polynucleotide and expression in a desired cell are well known in the art. Exemplary viral-based vehicles include, but are not limited to, recombinant retroviruses (see, e.g., WO 90/07936; WO 94/03622; WO 93/25698; WO 93/25234;
USPN 5, 219,740; WO 93/11230; WO 93/10218; USPN 4,777,127; GB Patent No. 2,200,651; EP
0 345 242;
and WO 91/02805), alphavirus-based vectors (e.g., Sindbis virus vectors, Semliki forest virus (ATCC
VR-67; ATCC VR-1247), Ross River virus (ATCC VR-373; ATCC VR-1246) and Venezuelan equine encephalitis virus (ATCC VR-923; ATCC VR-1250; ATCC VR 1249; ATCC VR-532), and adeno-associated virus (AAV) vectors (see, e.g., WO 94/12649, WO 93/03769; WO
93/19191; WO

94/28938; WO 95/11984 and WO 95/00655). Administration of DNA linked to killed adenovirus, as described in Curiel, Hum. Gene Ther. (1992) 3:147, can also be employed.
Non-viral delivery vehicles and methods can also be employed, including, but not limited to, polycationic condensed DNA linked or unlinked to killed adenovirus alone (see, e.g., Curiel, Hum.
Gene Ther. (1992) 3:147); ligand-linked DNA (see, e.g., Wu, J. Biol. Chem.
(1989) 264:16985);
eukaryotic cell delivery vehicles cells (see, e.g., USPN 5,814,482; WO
95/07994; WO 96/17072;
WO 95/30763; and WO 97/42338) and nucleic charge neutralization or fusion with cell membranes.
Naked DNA can also be employed. Exemplary naked DNA introduction methods are described in WO 90/11092 and USPN 5,580,859. Liposomes that can act as gene delivery vehicles are described in USPN 5,422,120; WO 95/13796; WO 94/23697; WO 91/14445; and EP 0524968.
Additional approaches are described in Philip, Mol. Cell Biol. (1994) 14:2411, and in Woffendin, Proc. Natl.
Acad. Sci. (1994) 91:1581 Further non-viral delivery suitable for use includes mechanical delivery systems such as the approach described in Woffendin et al., Proc. Natl. Acad. Sci. USA (1994) 91(24):11581. Moreover, the coding sequence and the product of expression of such can be delivered through deposition of photopolymerized hydrogel materials or use of ionizing radiation (see, e.g., USPN 5,206,152 and WO
92/11033). Other conventional methods for gene delivery that can be used for delivery of the coding sequence include, for example, use of hand-held gene transfer particle gun (see, e.g., USPN
5,149,655); use of ionizing radiation for activating transferred gene (see, e.g., USPN 5,206,152 and WO 92/11033).
The present invention will now be illustrated by reference to the following examples which set forth particularly advantageous embodiments. However, it should be noted that these embodiments are illustrative and are not to be construed as restricting the invention in any way.
EXAMPLES
The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the present invention, and are not intended to limit the scope of what the inventors regard as their invention nor are they intended to represent that the experiments below are all or the only experiments performed. It will be readily apparent to those skilled in the art that the formulations, dosages, methods of administration, and other parameters of this invention may be further modified or substituted in various ways without departing from the spirit and scope of the invention. Efforts have been made to ensure accuracy with respect to numbers used (e.g. amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Centigrade, and pressure is at or near atmospheric.

Example l:Source of Biological Materials and Overview ofNovel Polynucleotides Ex rep ssed by the Biological Materials Candidate polynucleotides that may represent novel polynucleotides were obtained from cDNA libraries generated from selected cell lines and patient tissues. In order to obtain the candidate polynucleotides, mRNA was isolated from several selected cell lines and patient tissues, and used to construct cDNA libraries. The cells and tissues that served as sources for these cDNA libraries are summarized in Table 1 below.
Human colon cancer cell line Km12L4-A (Morikawa, et al., Cancer Research (1988) 48:6863) is derived from the KM12C cell line. The KM12C cell line (Morikawa et al. Cancer Res.
(1988) 48:1943-1948), which is poorly metastatic (low metastatic) was established in culture from a Dukes' stage B2 surgical specimen (Morikawa et al. Cancer Res. (1988) 48:6863). The KM12L4-A
is a highly metastatic subline derived from KM12C (Yeatman et al. Nucl. Acids.
Res. (1995) 23:4007;
Bao-Ling et al. Proc. Annu. Meet. Am. Assoc. Cancer. Res. (1995) 21:3269). The KM12C and KM12C-derived cell lines (e.g., KM12L4, KM12L4-A, etc.) are well-recognized in the art as a model cell line for the study of colon cancer (see, e.g., Moriakawa et al., supra;
Radinsky et al. Clin. Cancer Res. (1995) 1:19; Yeatman et al., (1995) supra; Yeatman et al. Clin. Exp.
Metastasis (1996) 14:246).
The MDA-MB-231 cell line (Brinkley et al. Cancer Res. (1980) 40:3118-3129) was originally isolated from pleural effusions (Cailleau, J. Natl. Cancer. Inst. (1974) 53:661), is of high metastatic potential, and forms poorly differentiated adenocarcinoma grade II in nude mice consistent with breast carcinoma. The MCF7 cell line was derived from a pleural effusion of a breast adenocarcinoma and is non-metastatic. The MV-522 cell line is derived from a human lung carcinoma and is of high metastatic potential. The UCP-3 cell line is a low metastatic human lung carcinoma cell line; the MV-522 is a high metastatic variant of UCP-3. These cell lines are well-recognized in the art as models for the study of human breast and lung cancer (see, e.g., Chandrasekaran et al., Cancer Res. (1979) 39:870 (MDA-MB-231 and MCF-7); Gastpar et al., J Med Chem (1998) 41:4965 (MDA-MB-231 and MCF-7); Ranson et al., Br J Cancer (1998) 77:1586 (MDA-MB-231 and MCF-7);
Kuang et al., Nucleic Acids Res (1998) 26:1116 (MDA-MB-231 and MCF-7); Varki et al., Int J
Cancer (1987) 40:46 (UCP-3); Varki et al., Tumour Biol. (1990) 11:327; (MV-522 and UCP-3);
Varki et al., Anticancer Res. (1990) 10:637; (MV-522); Kelner et al., Anticancer Res (1995) 15:867 (MV-522);
and Zhang et al., Anticancer Drugs (1997) 8:696 (MV522)).
The samples of libraries 15-20 are derived from two different patients (UC#2, and UC#3).
The bFGF-treated HMVEC were prepared by incubation with bFGF at l Ong/ml for 2 hrs; the VEGF-treated HMVEC were prepared by incubation with 20ng/ml VEGF for 2 hrs.
Following incubation with the respective growth factor, the cells were washed and lysis buffer added for RNA preparation.
GRRpz was derived from normal prostate epithelium. The WOca cell line is a Gleason Grade 4 cell line.

The source materials for generating the normalized prostate libraries of libraries 25 and 26 were cryopreserved prostate tumor tissue from a patient with Gleason grade 3+3 adenocarcinoma and matched normal prostate biopsies from a pool of at-risk subjects under medical surveillance. The source materials for generating the normalized prostate libraries of libraries 30 and 31 were cryopreserved prostate tumor tissue from a patient with Gleason grade 4+4 adenocarcinoma and matched normal prostate biopsies from a pool of at-risk subjects under medical surveillance.
The source materials for generating the normalized breast libraries of libraries 27, 28 and 29 were cryopreserved breast tissue from a primary breast tumor (infiltrating ductal carcinoma)(library 28), from a lymph node metastasis (library 29), or matched normal breast biopsies from a pool of at-risk subjects under medical surveillance. In each case, prostate or breast epithelia were harvested directly from frozen sections of tissue by laser capture microdissection (LCM, Arcturus Enginering Inc., Mountain View, CA), carried out according to methods well known in the art (see, Simone et al. Am J Pathol. 156(2):445-52 (2000)), to provide substantially homogenous cell samples.
Table 1. Description of cDNA Libraries LibraryDescription Number (lib#) of Clones in Libra 0 rtificial library composed of deselected 673 clones (clones with no associated variant or cluster 1 uman Colon Cell Line Kml2 L4: High Metastatic308731 Potential derived from Kml2C) 2 uman Colon Cell Line Kml2C: Low Metastatic284771 Potential 3 uman Breast Cancer Cell Line MDA-MB-231: 326937 High Metastatic otential; micro-mets in lung 4 uman Breast Cancer Cell Line MCF7: Non 318979 Metastatic 8 uman Lung Cancer Cell Line MV-522: Hi h 223620 Metastatic Potential 9 uman Lun Cancer Cell Line UCP-3: Low Metastatic312503 Potential 12 uman microvascular endothelial cells (HMEC)41938 - UNTREATED

PCR OligodT cDNA Libra 13 uman microvascular endothelial cells (HMEC)42100 - bFGF TREATED

(PCR Oli odT) cDNA Libra 14 uman microvascular endothelial cells (HMEC)42825 - VEGF TREATED

PCR Oli odT) cDNA Libra 15 ormal Colon - UC#2 Patient (MICRODISSECTED282722 PCR (OligodT) cDNA Libra 16 Colon Tumor - UC#2 Patient (MICRODISSECTED298831 PCR (OligodT) cDNA Libra 17 fiver Metastasis from Colon Tumor of UC#2 303467 Patient MICRODISSECTED PCR Oli odT cDNA Libra 18 ormal Colon - UC#3 Patient (MICRODISSECTED36216 PCR (OligodT) cDNA Libra 19 Colon Tumor - UC#3 Patient (MICRODISSECTED41388 PCR (OligodT) DNA Libra fiver Metastasis from Colon Tumor of UC#3 30956 Patient MICRODISSECTED PCR Oli odT cDNA libr LibraryDescription Number (lib#) of Clones in Libra 21 GRR z Cells derived from normal rostate 164801 a ithelium 22 Oca Cells derived from Gleason Grade 4 162088 prostate cancer a ithelium 23 ormal Lung Epithelium of Patient #1006 306198 (MICRODISSECTED
CR Oli odT cDNA libra 24 rimary tumor, Large Cell Carcinoma of Patient309349 #1006 MICRODISSECTED PCR Oli odT cDNA library 25 ormal Prostate E ithelium from Patient 279444 26 rostate Cancer E ithelium Gleason 3+3 Patient269406 27 ormal Breast E ithelium from Patient 515 239494 28 rim Breast tumor from Patient 515 259960 29 m h node metastasis from Patient 515 326786 30 ormal Prostate E ithelium from Chiron Patient298431 31 rostate Cancer Epithelium (Gleason 4+4) 331941 from Chiron Patient ID

Characterization of sequences in the libraries After using the software program Phred (ver 0.000925.c, Green and Weing" ~1993-2000) to select those polynucleotides having the best quality sequence, the polynucleotides were compared against the public databases to identify any homologous sequences. The sequences of the isolated polynucleotides were first masked to eliminate low complexity sequences using the RepeatMasker masking program, publicly available through a web site supported by the University of Washington (See also Smit, A.F.A. and Green, P., unpublished results). Generally, masking does not influence the final search results, except to eliminate sequences of relatively little interest due to their low complexity, and to eliminate multiple "hits" based on similarity to repetitive regions common to multiple sequences, e.g., Alu repeats.
The remaining sequences were then used in a homology search of the GenBank database using the TeraBLAST program (TimeLogic, Crystal Bay, Nevada). TeraBLAST is a version of the publicly available BLAST search algorithm developed by the National Center for Biotechnology, modified to operate at an accelerated speed with increased sensitivity on a specialized computer hardware platform. The program was run with the default parameters recommended by TimeLogic to provide the best sensitivity and speed for searching DNA and protein sequences. Sequences that exhibited greater than 70% overlap, 99% identity, and a p value of less than I
x 1 Oe-40 were discarded. Sequences from this search also were discarded if the inclusive parameters were met, but the sequence was ribosomal or vector-derived.
The resulting sequences from the previous search were classified into three groups (1, 2 and 3 below) and searched in a TeraBLASTX vs. NRP (non-redundant proteins) database search: (1) unknown (no hits in the GenBank search), (2) weak similarity (greater than 45%
identity and p value of less than 1 x I Oe-5), and (3) high similarity (greater than 60% overlap, greater than 80% identity, and p value less than 1 x 10e-5). Sequences having greater than 70% overlap, greater than 99%
identity, and p value of less than 1 x 10e-40 were discarded. ' The remaining sequences were classified as unknown (no hits), weak similarity, and high similarity (parameters as above). Two searches were performed on these sequences. First, a TeraBLAST vs. EST database search was performed and sequences with greater than 99% overlap, greater than 99% similarity and a p value of less than 1 x 10e-40 were discarded. Sequences with a p value of less than 1 x 1 Oe-65 when compared to a database sequence of human origin were also excluded. Second, a TeraBLASTN vs. Patent GeneSeq database was performed and sequences having greater than 99% identity, p value less than 1 x 10e-40, and greater than 99% overlap were discarded.
The remaining sequences were subjected to screening using other rules and redundancies in the dataset. Sequences with a p value of less than 1 x 10e-111 in relation to a database sequence of human origin were specifically excluded. The final result provided the sequences listed as SEQ B7 NOS:1-1267 in the accompanying Sequence Listing and summarized in Table 2 (inserted prior to claims). Each identified polynucleotide represents sequence from at least a partial mRNA transcript.
Summar~of polynucleotides of the invention Table 2 (inserted prior to claims) provides a summary of polynucleotides isolated as described. Specifically, Table 2 provides: 1) the SEQ ID NO ("SEQ ID") assigned to each sequence for use in the present specification; 2) theCluster Identification No.
("CLUSTER"); 3) the Sequence Name assigned to each sequence; 3) the sequence name ("SEQ NAME") used as an internal identifier of the sequence; 4) the orientation of the sequence ("ORIENT") (either forward (F) or reverse (R)); 5) the name assigned to the clone from which the sequence was isolated ("CLONE
ID"); and 6) the name of the library from which the sequence was isolated ("LIBRARY"). Because at least some of the provided polynucleotides represent partial mRNA transcripts, two or more polynucleotides may represent different regions of the same mRNA transcript and the same gene and/or may be contained within the same clone. Thus, for example, if two or more SEQ ID NOS: are identified as belonging to the same clone, then either sequence can be used to obtain the full-length mRNA or gene. Clones which comprise the sequences described herein were deposited as set out in the tables indicated below (see Example entitled "Deposit Information").
Example 2: Contig~Assembly The sequences of the polynucleotides provided in the present invention can be used to extend the sequence information of the gene to which the polynucleotides correspond (e.g., a gene, or mRNA
encoded by the gene, having a sequence of the polynucleotide described herein). This expanded sequence information can in turn be used to further characterize the corresponding gene, which in turn provides additional information about the nature of the gene product (e.g., the normal function of the gene product). The additional information can serve to provide additional evidence of the gene product's use as a therapeutic target, and provide further guidance as to the types of agents that can modulate its activity.
For example, a contig was assembled using the sequence of a polynucleotide described herein.
A "contig" is a contiguous sequence of nucleotides that is assembled from nucleic acid sequences having overlapping (e.g., shared or substantially similar) sequence information. The sequences of publicly-available ESTs (Expressed Sequence Tags) and the sequences of various of the above-described polynucleotides were used in the contig assembly. The contig was assembled using the software program Sequencher, version 4.05, according to the manufacturer's instructions. The sequence information obtained in the contig assembly was then used to obtain a consensus sequence derived from the contig using the Sequencher program. The resulting consensus sequence was used to search both the public databases as well as databases internal to the applicants to match the consensus polynucleotide with homology data and/or differential gene expressed data.
The final result provided the sequences listed as SEQ ID NOS: 1268-1385 in the accompanying Sequence Listing and summarized in Table 3 (inserted prior to claims). Table 3 provides a summary of the consensus sequences assembled as described.
Specifically, Table 3 provides: 1) the SEQ ID NO ("SEQ ID") assigned to each sequence for use in the present specification; 2) the consensus sequence name ("CONSENSUS SEQ NAME") used as an internal identifier of the sequence; and 3) the sequence name ("POLYNTD SEQ NAME") of a polynucleotide of SEQ ID NOS: 1-1267 used in assembly of the consensus sequence.
Example 3: Additional Gene Characterization Sequences of the polynucleotides of SEQ ID NOS: 1-1267 were used as a query sequence in a TeraBLASTN search of the DoubleTwist Human Genome Sequence Database (DoubleTwist, Inc., Oakland, CA), which contains all the human genomic sequences that have been assembled into a contiguous model of the human genome. Predicted cDNA and protein sequences were obtained where a polynucleotide of the invention was homologous to a predicted full-length gene sequence.
Alternatively, a sequence of a contig or consensus sequence described herein could be used directly as a query sequence in a TeraBLASTN search of the DoubleTwist Human Genome Sequence Database.
The final results of the search provided the predicted cDNA sequences listed as SEQ ID NOS:
1386-1477 in the accompanying Sequence Listing and summarized in Table 4 (inserted prior to claims), and the predicted protein sequences listed as SEQ ID NOS:1478-1568 in the accompanying Sequence Listing and summarized in Table 5 (inserted prior to claims).
Specifically, Table 4 provides: 1) the SEQ ID NO ("SEQ ID") assigned to each cDNA sequence for use in the present specification; 2) the cDNA sequence name ("cDNA SEQ NAME") used as an internal identifier of the sequence; 3) the sequence name ("POLYNTD SEQ NAME") of the polynucleotide of SEQ ID NOS:
1-1267 that maps to the cDNA; 4)The gene id number (GENE) of the DoubleTwist predicted gene ;
5) the chromosome ("CHROM") containing the gene corresponding to the cDNA
sequence; Table 5 provides: 1) the SEQ ID NO ("SEQ ID") assigned to each protein sequence for use in the present specification; 2) the protein sequence name ("PROTEIN SEQ NAME") used as an internal identifier of the sequence; 3) the sequence name ("POLYNTD SEQ NAME") of the polynucleotide of SEQ B7 NOS: 1-1267 that maps to the protein sequence; 4)The gene id number (GENE) of the DoubleTwist predicted gene ; 5) the chromosome ("CHROM") containing the gene corresponding to the cDNA
sequence.
A correlation between the polynucleotide used as a query sequence as described above and the corresponding predicted cDNA and protein sequences is contained in Table 6.
Specifically Table 6 provides: 1 ) the SEQ ID NO of the cDNA ("cDNA SEQ ID"); 2) the cDNA sequence name ("cDNA
SEQ NAME") used as an internal identifier of the sequence; 3) the SEQ ID NO of the protein ("PROTEIN SEQ ID") encoded by the cDNA sequence 4) the sequence name of the protein ("PROTEIN SEQ NAME") encoded by the cDNA sequence; 5) the SEQ ID NO of the polynucleotide ("POLYNTD SEQ ID") of SEQ ID NOS: 1-1267 that maps to the cDNA and protein;
and 6) the sequence name ("POLYNTD SEQ NAME") of the polynucleotide of SEQ ID NOS: I -1267 that maps to the cDNA and protein.
Through contig and consensus sequence assembly and the use of homology searching software programs, the sequence information provided herein can be readily extended to confirm, or confirm a predicted, gene having the sequence of the polynucleotides described in the present invention. Further the information obtained can be used to identify the function of the gene product of the gene corresponding to the polynucleotides described herein. While not necessary to the practice of the invention, identification of the function of the corresponding gene, can provide guidance in the design of therapeutics that target the gene to modulate its activity and modulate the cancerous phenotype (e.g., inhibit metastasis, proliferation, and the like).
Example 4:Results of Public Database Search to Identify Function of Gene Products SEQ ID NOS:1-1477 were translated in all three reading frames, and the nucleotide sequences and translated amino acid sequences used as query sequences to search for homologous sequences in the GenBank (nucleotide sequences) database. Query and individual sequences were aligned using the TeraBLAST program available from TimeLogic, Crystal Bay, Nevada. The sequences were masked to various extents to prevent searching of repetitive sequences or poly-A
sequences, using the RepeatMasker masking program for masking low complexity as described above.
Table 7 (inserted prior to claims) provides the alignment summaries having a p value of 1 x 1 Oe-2 or less indicating substantial homology between the sequences of the present invention and those of the indicated public databases. Specifically, Table 7 provides: 1 ) the SEQ ID NO ("SEQ
ID") of the query sequence; 2) the sequence name ("SEQ NAME") used as an internal identifier of the query sequence; 3) the accession number ("ACCESSION") of the GenBank database entry of the homologous sequence; 4) a description of the GenBank sequences ("GENBANK
DESCRIPTION");
and 5) the score of the similarity of the polynucleotide sequence and the GenBank sequence ("GENBANK SCORE"). The alignments provided in Table 7 are the best available alignment to a DNA sequence at a time just prior to filing of the present specification. Also incorporated by reference is all publicly available information regarding the sequence listed in Table 6 and their related sequences. The search program and database used for the alignment, as well as the calculation of the p value are also indicated. Full length sequences or fragments of the polynucleotide sequences can be used as probes and primers to identify and isolate the full length sequence of the corresponding polynucleotide.
Example S:Members of Protein Families SEQ ID NOS:1-1477 were used to conduct a profile search as described in the specification above. Several of the polynucleotides of the invention were found to encode polypeptides having characteristics of a polypeptide belonging to a known protein family (and thus represent members of these protein families) and/or comprising a known functional domain. Table 8 (inserted prior to 1 S claims) provides: 1 ) the SEQ ID NO ("SEQ ID") of the query polynucleotide sequence; 2) the sequence name ("SEQ NAME") used as an internal identifier of the query sequence; 3) the accession number ("PFAM ID") of the the protein family profile hit; 4) a brief description of the profile hit ("PFAM DESCRIPTION"); 5) the score ("SCORE") of the profile hit; 6) the starting nucleotide of the profile hit ("START"); and 7) the ending nucleotide of the profile hit ("END").
In addition, SEQ ID NOS:1478-1568 were also used to conduct a profile search as described above. Several of the polypeptides of the invention were found to have characteristics of a polypeptide belonging to a known protein family (and thus represent members of these protein families) and/or comprising a known functional domain. Table 9 (inserted prior to claims) provides:
I ) the SEQ ID NO ("SEQ ID") of the query protein sequence; 2) the sequence name ("PROTEIN
SEQ NAME") used as an internal identifier of the query sequence; 3) the accession number ("PFAM
ID") of the the protein family profile hit; 4) a brief description of the profile hit ("PFAM
DESCRIPTION"); 5) the score ("SCORE") of the profile hit; 6) the starting residue of the profile hit ("START"); and 7) the ending residue of the profile hit ("END").
Some SEQ ID NOS exhibited multiple profile hits where the query sequence contains overlapping profile regions, and/or where the sequence contains two different functional domains.
Each of the profile hits of Tables 8 and 9 is described in more detail below.
The acronyms for the profiles (provided in parentheses) are those used to identify the profile in the Pfam, Prosite, and InterPro databases. The Pfam database can be accessed through web sites supported by Genome Sequencing Center at the Washington University School of Medicine or by the European Molecular Biology Laboratories in Heidelberg, Germany. The Prosite database can be accessed at the ExPASy Molecular Biology Server on the Internet. The InterPro database can be accessed at a web site supported by the EMBL European Bioinformatics Institute. The public information available on the Pfam, Prosite, and InterPro databases regarding the various profiles, including but not limited to the activities, function, and consensus sequences of various proteins families and protein domains, is incorporated herein by reference.
Ank Repeats (ANK; Pfam Accession No. PF00231. SEQ ID NOS:482, 818, 914, 1216, 1484, 1537, and 1564 represent Ank repeat-containing proteins. The ankyrin motif is a 33 amino acid sequence named after the protein ankyrin which has 24 tandem 33-amino-acid motifs. Ank repeats were originally identified in the cell-cycle-control protein cdcl0 (Breeden et al., Nature (1987) 329:651 ). Proteins containing ankyrin repeats include ankyrin, myotropin, I-kappaB proteins, cell cycle protein cdcl0, the Notch receptor (Matsuno et al., Development (1997) 124(21):4265); G9a (or BAT8) of the class III region of the major histocompatibility complex (Biochem J. (1993) 290:811-818); FABP, GABP, 53BP2, Linl2, glp-1, SW14, and SW16. The functions of the ankyrin repeats are compatible with a role in protein-protein interactions (Bork, Proteins (1993) 17(4):363; Lambert and Bennet, Eur. J. Biochem. (1993) 211:1; Kerr et al., Current Op. Cell Biol.
(1992) 4:496; Bennet et al., J. Biol. Chem. (1980) 255:6424).
Epidermal Growth Factor (EGF: Pfam Accession No. PF00008). SEQ ID N0:967 represents a polynucleotide encoding a member of the EGF family of proteins. The distinguishing characteristic of this family is the presence of a sequence of about thirty to forty amino acid residues found in epidermal growth factor (EGF) which has been shown to be present, in a more or less conserved form, in a large number of other proteins (Davis, New Biol. (1990) 2:410-419;
Blomquist et al., Proc. Natl.
Acad. Sci. U.S.A. (1984) 81:7363-7367; Barkert et al., Protein Nucl. Acid Enz.
(1986) 29:54-86;
Doolittle et al., Nature. (1984) 307:558-560; Appella et al., FEBSLett. (1988) 231:1-4; Campbell and Bork, Curr. Opin. Struct. Biol. (1993) 3:385-392). A common feature of the domain is that the conserved pattern is generally found in the extracellular domain of membrane-bound proteins or in proteins known to be secreted. The EGF domain includes six cysteine residues which have been shown to be involved in disulfide bonds. The main structure is a two-stranded beta-sheet followed by a loop to a C-terminal short two-stranded sheet. Subdomains between the conserved cysteines strongly vary in length. These consensus patterns are used to identify members of this family: C-x-C-x(5)-G-x(2)-C and C-x-C-x(s)-[GP]-[FYW]-x(4,8)-C.
Zinc Finger C2H2 Tvne (Zincfing C2H2; Pfam Accession No. PF00096). SEQ ID
N0:521 corresponds to polynucleotides encoding members of the C2H2 type zinc finger protein family, which contain zinc finger domains that facilitate nucleic acid binding (Klug et al., Trends Biochem. Sci.
(1987) 12:464; Evans et al., Cell (1988) 52:1; Payre et al., FEBSLett. (1988) 234:245; Miller et al., EMBO.I. (1985) 4:1609; and Berg, Proc. Natl. Acad. Sci. USA (1988) 85:99). In addition to the conserved zinc ligand residues, a number of other positions are also important for the structural integrity of the C2H2 zinc fingers (Rosenfeld et al., J. Biomol. Struct. Dyn.
(1993) 11:557). The best conserved position, which is generally an aromatic or aliphatic residue, is located four residues after the second cysteine. The consensus pattern for C2H2 zinc fingers is: C-x(2,4)-C-x(3)-[LIVMFYWC]-x(8)-H-x(3,5)-H. The two C's and two H's are zinc ligands.
PDZ Domain (PDZ; Pfam Accession No. PF00595.) SEQ ID NOS:527, 1523, and 1551 correspond to genes comprising a PDZ domain (also known as DHR or GLGF
domain). PDZ
domains comprise 80-100 residue repeats, several of which interact with the C-terminal tetrapeptide motifs X-Ser/T'hr-X-Val-COO- of ion channels and/or receptors, and are found in mammalian proteins as well as in bacteria, yeast, and plants (Pontig et al. Protein Sci (1997) 6(2):464-8). Proteins comprising one or more PDZ domains are found in diverse membrane-associated proteins, including members of the MAGUK family of guanylate kinase homologues, several protein phosphatases and kinases, neuronal nitric oxide synthase, and several dystrophin-associated proteins, collectively known as syntrophins (Ponting et al. Bioessays (1997) 19(6):469-79). Many PDZ domain-containing proteins are localised to highly specialised submembranous sites, suggesting their participation in cellular junction formation, receptor or channel clustering, and intracellular signalling events. For example, PDZ domains of several MAGUKs interact with the C-terminal polypeptides of a subset of NMDA receptor subunits and/or with Shaker-type K+ channels. Other PDZ domains have been shown to bind similar ligands of other transmembrane receptors. In cell junction-associated proteins,the PDZ mediates the clustering of membrane ion channels by binding to their C-terminus.
The X-ray crystallographic structure of some proteins comrpising PDZ domains have been solved (see, e.g., Doyle et al. Cell (1996) 85(7):1067-76).
Zinc knuckle CCHC type (Zf CCHC; Pfam Accession No. PF00098). SEQ ID NOS:543 and 1069 correspond to a gene encoding a member of the family of CCHC zinc fingers. Because the prototype CCHC type zinc finger structure is from an HIV protein, this domain is also referred to as a retrovrial-type zinc finger domain. The family also contains proteins involved in eukaryotic gene regulation, such as C. elegans GLH-1. The structure is an 18-residue zinc finger; no examples of indels in the alignment. The motif that defines a CCHC type zinc finger domain is: C-X2-C-X4-H-X4-C (Summers J Cell Biochem 1991 Jan;45(1):41-8). The domain is found in, for example, HN-1 nucleocapsid protein, Moloney murine leukemia virus nucleocapsid protine NCplO
(De Rocquigny et al. Nucleic Acids Res. (1993) 21:823-9), and myelin transcription factor 1 (Myth (Kim et al. J.
Neurosci. Res. (1997) 50:272-90).
RNA Recognition Motif (rrm; Pfam Accession No. PF000761. SEQ ID NOS:514 and correspond to sequence encoding an RNA recognition motif, also known as an RRM, RBD, or RNP
domain. This domain, which is about 90 amino acids long, is contained in eukaryotic proteins that bind single-stranded RNA (Bandziulis et al. Genes Dev. (1989) 3:431-437;
Dreyfuss et al. Trends Biochem. Sci. (1988) 13:86-91). Two regions within the RNA-binding domain are highly conserved:
the first is a hydrophobic segment of six residues (which is called the RNP-2 motif, the second is an octapeptide motif (which is called RNP-1 or RNP-CS). The consensus pattern is:
[RK]-G-{EDRKHPCG}-[AGSCI]-[FY]-[LIVA]-x-[FYLM].
Metallothioneins (metalthio~ Pfam Accession No. PF00131). SEQ ID N0:335 corresponds to a polynucleotide encoding a member of the metallothionein (MT) protein family (Hamer Annu. Rev.
Biochem. (1986) 55:913-951; and Kagi et al. Biochemistry (1988) 27:8509-851 S), small proteins which bind heavy metals such as zinc, copper, cadmium, nickel, etc., through clusters of thiolate bonds. MT's occur throughout the animal kingdom and are also found in higher plants, fungi and some prokaryotes. On the basis of structural relationships MT's have been subdivided into three classes. Class I includes mammalian MT's as well as MT's from crustacean and molluscs, but with clearly related primary structure. Class II groups together MT's from various species such as sea urchins, fungi, insects and cyanobacteria which display none or only very distant correspondence to class I MT's. Class III MT's are atypical polypeptides containing gamma-glutamylcysteinyl units. The consensus pattern for this protein family is: C-x-C-[GSTAP]-x(2)-C-x-C-x(2)-C-x-C-x(2)-C-x-K.
Trypsin (tr~psin; Pfam Accession No. PF00089). SEQ ID NOS:422 and 1558 correspond to a novel serine protease of the trypsin family. The catalytic activity of the serine proteases from the trypsin family is provided by a charge relay system involving an aspartic acid residue hydrogen-bonded to a histidine, which itself is hydrogen-bonded to a serine. The sequences in the vicinity of the active site serine and histidine residues are well conserved in this family of proteases (Brenner S., Nature (1988) 334:528). The consensus patterns for this trypsin protein family are: 1) [LIVM]-[ST]-A-[STAG]-H-C, where H is the active site residue; and 2) [DNSTAGC]-[GSTAPIMVQH]-x(2)-G-[DE]-S-G-[GS]-[SAPHV]- [LIVMFYWH]-[LIVMFYSTANQH], where S is the active site residue.
All sequences known to belong to this family are detected by the above consensus sequences, except for 18 different proteases which have lost the first conserved glycine. If a protein includes both the serine and the histidine active site signatures, the probability of it being a trypsin family serine protease is 100%.
HSP70 protein (HSP70; Pfam Accession No. PF00012) SEQ ID NOS:952 and 1482 correspond to members of the family of ATP-binding heat shock proteins having an average molecular weight of 70kD (Pelham, Cell (1986) 46:959-961; Pelham, Nature (1988) 332:776-77; Craig, BioEssays (1989) 11:48-52). In most species, there are many proteins that belong to the hsp70 family, some of which are expressed under unstressed conditions. Hsp70 proteins can be found in different cellular compartments, including nuclear, cytosolic, mitochondrial, endoplasmic reticulum, etc. A
variety of functions have been postulated for hsp70 proteins. Some play an important role in the transport of proteins across membranes (Deshaies et al., Trends Biochem. Sci.
(1988) 13:384-388), while others are involved in protein folding and in the assembly/disassembly of protein complexes (Craig and Gross, Trends Biochem. Sci. (1991) 16:135-140).

There are three signature patterns for the hsp70 family of proteins. The first is centered on a conserved pentapeptide found in the N-terminal section of these proteins and the two others on conserved regions located in the central part of the sequence. The consensus patterns are: 1 ) [IV]-D-L-G-T-[ST]-x-[SC]; 2) [LIVMF]-[LIVMFY]-[DN]-[LIVMFS]-G-[GSH]-[GS]-[AST]-x(3)-[ST]-[LIVM]-[LIVMFC]; and 3) [LIVMY]-x-[LIVMF]-x-G-G-x-[ST]-x-[LIVM]-P-x-[LIVM]-x-[DEQKRSTA].
WD Domain (WD40) G-Beta Repeats (WD domain; Pfam Accession No. PF00400). SEQ
ID NOS: 1510 and 1536 represent members of the WD domain/G-beta repeat family.
Beta-transducin (G-beta) is one of the three subunits (alpha, beta, and gamma) of the guanine nucleotide-binding proteins (G proteins) which act as intermediaries in the transduction of signals generated by transmembrane receptors (Gilman, Annu. Rev. Biochem. (1987) 56:615). The alpha subunit binds to and hydrolyzes GTP; the beta and gamma subunits are required for the replacement of GDP by GTP
as well as for membrane anchoring and receptor recognition. In higher eukaryotes, G-beta exists as a small multigene family of highly conserved proteins of about 340 amino acid residues. Structurally, G-beta has eight tandem repeats of about 40 residues, each containing a central Trp-Asp motif (this type of repeat is sometimes called a WD-40 repeat). The consensus pattern for the WD domain/G-Beta repeat family is: [LIVMSTAC]-[LNMFYWSTAGC]-[L1MSTAG]-[LIVMSTAGC]-x(2)-[DN]-x(2)-[LIVMWSTAC]-x-[LIVMFSTAG]-W-[DEN]-[LIVMFSTAGCN].
Protein Kinase (protkinase; Pfam Accession No. PF00069). SEQ ID NO: 1540 represents a protein kinase. Protein kinases catalyze phosphorylation of proteins in a variety of pathways, and are implicated in cancer. Eukaryotic protein kinases (Hanks S.K., et al., FASEB J.
(1995) 9:576; Hunter T., Meth. Enzymol. (1991) 200:3; Hanks S.K., et al., Meth. Enrymol. (1991) 200:38; Hanks S.K., Curr. Opin. Struct. Biol. (1991) 1:369; Hanks S.K., et al., Science (1988) 241:42) are enzymes that belong to a very extensive family of proteins which share a conserved catalytic core common to both serine/threonine and tyrosine protein kinases. There are a number of conserved regions in the catalytic domain of protein kinases. The first region, which is located in the N-terminal extremity of the catalytic domain, is a glycine-rich stretch of residues in the vicinity of a lysine residue, which has been shown to be involved in ATP binding. The second region, which is located in the central part of the catalytic domain, contains a conserved aspartic acid residue which is important for the catalytic activity ofthe enzyme (Knighton D.R., et al., Science (1991) 253:407). The protein kinase profile includes two signature patterns for this second region: one specific for serine/threonine kinases and the other for tyrosine kinases. A third profile is based on the alignment in (Hanks S.K., et al., FASEB
J. (1995) 9:576) and covers the entire catalytic domain.
The consensus patterns are as follows: 1) [LIV]-G-{P}-G-{P}-[FYWMGSTNH]-[SGA]-{PW}-[LIVCAT]-{PD}-x-[GSTACLNMFY]-x(5,18)-[LIVMFYWCSTAR]-[AIVP]-[LIVMFAGCKR]-K, where K binds ATP; 2) [LIVMFYC]-x-[HY]-x-D-[LIVMFY]-K-x(2)-N-[LIVMFYCT](3), where D is an active site residue; and 3) [LIVMFYC]-x-[HY]-x-D-[LIVMFY]-[RSTAC]-x(2)-N-[LIVMFYC], where D is an active site residue.
If a protein analyzed includes the two of the above protein kinase signatures, the probability of it being a protein kinase is close to 100%. Eukaryotic-type protein kinases have also been found in prokaryotes such as Myxococcus xanthus (Munoz-Dorado J., et al., Cell (1991) 67:995) and Yersinia pseudotuberculosis. The patterns shown above has been updated since their publication in (Bairoch A., et al., Nature (1988) 331:22).
C2 domain (C2; Pfam Accession No. PF00168). SEQ ID NO: 1550 corresponds to a domain, which is involved in calcium-dependent phospholipid binding (Davletov J. Biol. Chem.
(1993) 268:26386-26390) or, in proteins that do not bind calcium, the domain may facilitate binding to inositol-1,3,4,5-tetraphosphate (Fukuda et al. J. Biol. Chem. (1994) 269:29206-29211; Sutton et al.
Cell (1995) 80:929-938). The consensus sequence is: [ACG]-x(2)-L-x(2,3)-D-x(1,2)-[NGSTLIF]-[GTMR]-x-[STAP]-D- [PA]-[FY].
Myosin head (motor domain) (m~ head; Pfam Accession No. PF00063). SEQ ID
NOS:189, 1548, and 1557 correspond to a myosin head domain, a glycine-rich region that typically forms a flexible loop between a beta-strand and an alpha-helix. This loop interacts with one of the phosphate groups of ATP or GTP in binding of a protein to the nucleotide. The myosin head sequence motif is generally referred to as the "A" consensus sequence (Walker et al., EMBO J. (1982) 1:945-951) or the "P-loop" (Saraste et al., Trends Biochem. Sci. (1990) 15:430-434). The consensus sequence is: [AG]-x(4)-G-K-[ST].
Su ar and other transporter (su ar tr; Pfam Accession No. PF00083). SEQ ID
NOS:334, 1244, and 1512 represent members of the sugar (and other) transporter family.
In mammalian cells the uptake of glucose is mediated by a family of closely related transport proteins which are called the glucose transporters (Silverman, Annu. Rev. Biochem. (1991) 60:757-794; Gould and Bell, Trends Biochem. Sci. (1990) 15:18-23; Baldwin, Biochim. Biophys. Acta (1993) 1154:17-49). At least seven of these transporters are currently known to exist and in Humans are encoded by the GLUT1 to GLUT7 genes. These integral membrane proteins are predicted to comprise twelve membrane spanning domains and show sequence similarities with a number of other sugar or metabolite transport proteins (Maiden et al., Nature (1987) 325:641-643; Henderson, Curr. Opin.
Struct. Biol. (1991) 1:590-601 ).
Two patterns have been developed to detect this family of proteins. The first pattern is based on the G-R-[KR] motif; but because this motif is too short to be specific to this family of proteins, a second pattern has been derived from a larger region centered on the second copy of this motif. The second pattern is based on a number of conserved residues which are located at the end of the fourth transmembrane segment and in the short loop region between the fourth and fifth segments. The two consensus sequences are: 1) [LIVMSTAG]-[LIVMFSAG]-x(2)-[LIVMSA]-[DE]-x-[LIVMFYWA]-G- R-[RK]-x(4,6)-[GSTA]; and 2) [LIVMF]-x-G-[LIVMFA]-x(2)-G-x(8)-[LIFY]-x(2)-[EQ]-x(6)-[RK].
HSP 90 protein (Pfam Accession No. PF00183). SEQ ID N0:1538 represents a polypeptide having a consensus sequence of a Hsp90 protein family member. Hsp90 proteins are proteins of an average molecular weight of approximately 90 kDa that respond to heat shock or other environmental stress by the induction of the synthesis of proteins collectively known as heat-shock proteins (hsp) (Lindquist et al. Annu. Rev. Genet. 22:631-677 (1988).
Proteins known to belong to this family include vertebrate hsp 90-alpha (hsp 86) and hsp 90-beta (hsp 84); Drosophila hsp 82 (hsp 83); and the endoplasmic reticulum protein'endoplasmin' (also known as Erp99 in mouse, GRP94 in hamster, and hsp 108 in chicken). Hsp90 proteins have been found associated with steroid hormone receptors, with tyrosine kinase oncogene products of several retroviruses, with eIF2alpha kinase, and with actin and tubulin. Without being held to theory, Hsp90 proteins are probable chaperonins that possess ATPase activity (Nadeau et al. J. Biol.
Chem. 268:1479-1487 (1993); Jakob et al. Trends Biochem Sci 19:205-211 (1994). Hsp90 family proteins have the following signature pattern, which represents a highly conserved region found in the N-terminal part of these proteins: Y-x-[NQH]-K-[DE]-[IVA]-F-[LM]-R-[ED]
KOW motif (Ribosomal protein L24 signature; Pfam Accession No. PF00467). SEQ
ID
N0:1553 represents a polypeptide having a KOW motif such as that found in the ribosomal protein L24, one of the proteins from the large ribosomal subunit. L24 belongs to a family of ribosomal proteins. In their mature form, these proteins have 103 to 150 amino-acid residues. As a signature pattern, The consensus sequence is based on a conserved stretch of 20 residues in the N-terminal section: [GDEN]-D-x-[IV]-x-[IV]-[LIVMA]-x-G-x(2)-[KRA]-[GNQ]- x(2,3)-[GA]-x-[IV].
TPR Domain (Pfam Accession No. PF00515). SEQ ID N0:1532 represents a polypeptide having at least one or more tetratricopeptide repeat (TPR) domains. The TPR is a degenerate 34 amino acid sequence identified in a wide variety of proteins, present in tandem arrays of 3-16 motifs, which form scaffolds to mediate protein-protein interactions and often the assembly of multiprotein complexes. TPR-containing proteins include the anaphase promoting complex (APC) subunits cdcl6, cde23 and cdc27, the NADPH oxidase subunit p67 phox, hsp90-binding immunophilins, transcription factors, the PKR protein kinase inhibitor, and peroxisomal and mitochondrial import proteins (see, e.g., Das et al. EMBO J;17(S):1192-9 (1998); and Lamb Trends Biochem Sci 20:257-259 (1995).
tRNA synthetase class II core domain (G, H, P, S and T~Pfam Accession No.
PF00587).
SEQ ID N0:1481 represents a polypeptide having a tRNA synthetase class II core domain.
Aminoacyl-tRNA synthetases (EC 6.1.1.-) (Schimmel Annu. Rev. Biochem. 56:125-158(1987)) are a group of enzymes which activate amino acids and transfer them to specific tRNA
molecules as the first step in protein biosynthesis. In prokaryotic organisms there are at least twenty different types of aminoacyl-tRNA synthetases, one for each different amino acid. In eukaryotes there are generally two aminoacyl-tRNA synthetases for each different amino acid: one cytosolic form and a mitochondria) form. While all these enzymes have a common function, they are widely diverse in terms of subunit size and of quaternary structure.
The synthetases specific for alanine, asparagine, aspartic acid, glycine, histidine, lysine, phenylalanine, proline, serine, and threonine are referred to as class-II
synthetases and probably have a common folding pattern in their catalytic domain for the binding of ATP and amino acid which is different to the Rossmann fold observed for the class I synthetases. Class-II
tRNA synthetases do not share a high degree of similarity, however at least three conserved regions are present (Delarue et al.
BioEssays 15:675-687(1993); Cusack et al. Nucleic Acids Res. 19:3489-3498(1991); Leveque et al.
Nucleic Acids Res. 18:305-312(1990)]. The consensus sequences are derived from these regions:
[FYH]-R-x-[DE]-x(4,12)-[RH]-x(3)-F-x(3)-[DE] (found in the majority of class-II tRNA synthetases with the exception of those specific for alanine, glycine as well as bacterial histidine); and [GSTALVF]-{DENQHRKP}-[GSTA]-[LIVMF]-[DE]-R-[LIVMF]-x- [LIVMSTAG]-[LIVMFY]
(found in the majority of class-II tRNA synthetases with the exception of those specific for serine and proline).
IQ calmodulin-bindin motif Pfam Accession No. PF00612). SEQ ID NOS:189 and represent polypeptides having an IQ calmodulin-binding motif. The IQ motif is an extremely basic unit of about 23 amino acids, whose conserved core usually fits the consensus A-x(3)-I-Q-x(2)-F-R-x(4)-K-K. The IQ motif, which can be present in one or more copies, serves as a binding site for different EF-hand proteins including the essential and regulatory myosin light chains, calmodulin (CaM), and CaM-like proteins (see, e.g., Cheney et al. Curr. Opin. Cell Biol.
4:27-35(1992); and Rhoads et al. FASEB J. 11:331-340(1997)). Many IQ motis are protein kinase C
(PKC) phosphorylation sites (Bawdier et al. J. Biol. Chem. 266:229-237(1991); and Chen et al. Biochemistry 32:1032-1039(1993)). Resolution of the 3D structure of scallop myosin has shown that the IQ motif forms a basic amphipathic helix (Xie et al. Nature 368:306-312(1994)).
Exemplary proteins containing an IQ motif include neuromodulin (GAP-43), neurogranin (NG/p17), sperm surface protein Spl7, and Ras GTPase-activating-like protein IQGAP1. IQGAP1 contains 4 IQ motifs.
Phophotyrosine interaction domain (PTB/PID) (Pfam Accession No. PF00640). SEQ
ID
N0:1523 represents a polypeptide having a phosphotyrosine interaction domain (PID or PI domain).
P1D is the second phosphotyrosine-binding domain found in the transforming protein Shc (Kavanaugh et al. Science 266:1862-1865(1994); Blaikie et al. J. Biol. Chem. 269:32031-32034(1994); and Bork et al. Cell 80:693-694(1995)). Shc couples activated growth factor receptors to a signaling pathway that regulates the proliferation of mammalian cells and it might participate in the transforming activity of oncogenic tyrosine kinases. The PID of Shc specifically binds to the Asn-Pro-Xaa-Tyr(P) motif found in many tyrosine-phosphorylated proteins including growth factor receptors. PID has also been found in, for example, human Shc-related protein Sck, mammalian protein X11 which is expressed prominently in the nervous system, rat FE65, a transcription-factor activator expressed preferentially in liver, mammalian regulator of G-protein signalling 12 (RGS12), and N-terminal insulinase-type domain. PID has an average length of about 160 amino acids. It is probably a globular domain with an antiparallel beta sheet. The function of this domain might be phosphotyrosine-binding. It is at least expected to be involved in regulatory protein/protein-binding (Bork et al. Cell 80:693-694(1995)).
~ntaxin (Pfam Accession No. PF00804). SEQ ID NOS:1039 and 1496 represent polypeptides having sequence similarity to syntaxin protein family. Members of the syntaxin family of proteins include, for example, epimorphin (or syntaxin 2), a mammalian mesenchymal protein which plays an essential role in epithelial morphogenesis; syntaxin 1A, syntaxin 1B, and syntaxin 4, which are synaptic proteins involved in docking of synaptic vesicles at presynaptic active zones;
syntaxin 3; syntaxin 5, which mediates endoplasmic reticulum to golgi transport; and syntaxin 6, which is involved in intracellular vesicle trafficking (Bennett et al. Cell 74:863-873(1993); Spring et al. Trends Biochem. Sci. 18:124-125(1993); Pelham et al. Cell 73:425-426(1993)). The syntaxin family of proteins each range in size from 30 Kd to 40 Kd; have a C-terminal extremity which is highly hydrophobic and is involved in anchoring the protein to the membrane; a central, well conserved region, which may be present in a coiled-coil conformation. The pattern specific for this family is based on the most conserved region of the coiled coil domain: [RQ]-x(3)-[LIVMA]-x(2)-[LIVM]-[ESH]-x(2)-[LIVMT]-x-[DEVM]- [LIVM]-x(2)-[LIVM]-[FS]-x(2)-[LIVM]-x(3)-[LIVT]-x(2)-Q- [GADEQ]-x(2)-[LIVM]-[DNQT]-x-[LIVMF]-[DESV]-x(2)-[LIVM].
Ribosomal L10 (Pfam Accession No. PF00826). SEQ ID NOS:759, 1207, and 1566 represents a polypeptide having sequence similarity to the ribosomal L10 protein family (see, e.g., Chan et al. Biochem. Biophys. Res. Commun. 225:952-956(1996)). The members of this family generally have 174 to 232 amino-acid residues and contain the following signature pattern (based on a conserved region located in the central section of the proten): A-D-R-x(3)-G-M-R-x-[SAP]-[FYW]-G-[KRVT]-[PA]-x-[GS]-x(2)- A-[KRLV]-[LIV]
GTP1/OBG FamilY~Pfam Accession No. PF01018). SEQ ID N0:126, 721, and 1518 represent polypeptides that have similarities to the members of the GTPI/OBG
family, a widespread family of GTP-binding proteins (Sazuka et al. Biochem. Biophys. Res. Commun.
189:363-370(1992);
Hudson et al. Gene 125:191-193(1993)). This family includes, for example, protein DRG (found in mouse, human, and xenopus), fission yeast protein gtpl, and Bacillus subtilis protein obg (which binds GTP). Family members are generally about 40 to 48 Kd and contain the five small sequence elements characteristic of GTP-binding proteins (Bourne et al. Nature 349:117-127(1991)). The signature pattern corresponds to the ATP/GTP B motif (also called G-3 in GTP-binding proteins): D-[LIVM]-P-G-[LIVM](2)-[DEY]-[GN]-A-x(2)-G-x-G

KRAB box (Pfam Accession No. PF01352). SEQ ID NOS:1556 and 349 represent polypeptides having a Krueppel-associated box (KRAB). A KRAB box is a domain of around 75 amino acids that is found in the N-terminal part of about one third of eukaryotic Krueppel-type C2H2 zinc finger proteins (ZFPs). It is enriched in charged amino acids and can be divided into subregions A and B, which are predicted to fold into two amphipathic alpha-helices. The KRAB A and B boxes can be separated by variable spacer segments and many KRAB proteins contain only the A box.
The KRAB domain functions as a transcriptional repressor when tethered to the template DNA by a DNA-binding domain. A sequence of 45 amino acids in the KRAB A
subdomain has been shown to be necessary and sufficient for transcriptional repression. The B box does not repress by itself but does potentiate the repression exerted by the KRAB A subdomain.
Gene silencing requires the binding of the KRAB domain to the RING-B box-coiled coil (RBCC) domain of the KAP-1/TIF1-beta corepressor. As KAP-1 binds to the heterochromatin proteins HP1, it has been proposed that the KRAB-ZFP-bound target gene could be silenced following recruitment to heterochromatin.
KRAB-ZFPs constitute one of the single largest class of transcription factors within the human genome, and appear to play important roles during cell differentiation and development. The KRAB domain is generally encoded by two exons. The regions coded by the two exons are known as KRAB-A and KRAB-B.
Small ribonucleoprotein (Sm protein; Pfam Accession No. PF01423). SEQ ID
N0:1495 represents a polypeptide having sequence similarity to small ribonucleoprotein (Sm protein). The U1, U2, U4/U6, and U5 small nuclear ribonucleoprotein particles (snRNPs) involved in pre-mRNA
splicing contain seven Sm proteins (8/B', D1, D2, D3, E, F and G) in common, which assemble around the Sm site present in four of the major spliceosomal small nuclear RNAs (Hermann et al.
EMBO J. 14: 2076-2088(1995)). The Sm proteins are essential for pre-mRNA
splicing and are implicated in the formation of stable, biologically active snRNP structures.
Cation efflux family (Pfam Accession No. PF01545). SEQ ID N0:563, 766, and represent polypeptides having sequence similarity to members of the canon efflux family. Members of this family are integral membrane proteins which increase tolerance to divalent metal ions such as cadmium, zinc, and cobalt. These proteins are efflux pumps that remove these ions from cells (Xiong et al. J. Bacteriol. 180: 4024-4029(1998); Kunito et al. Biosci. Biotechnol.
Biochem. 60: 699-704(1996)).
FG-GAP repeat (Pfam Accession No. PF01839). SEQ ID N0:1486 represents a polypeptide having an FG-GAP repeat. This family contains the extracellular repeat that is found in up to seven copies in alpha integrins. This repeat has been predicted to fold into a beta propeller structure (Springer et al. Proc Natl Acad Sci U S A 1997;94:65-72). The repeat is called the FG-GAP repeat after two conserved motifs in the repeat (Spring, ibid). The FG-GAP repeats are found in the N
terminus of integrin alpha chains, a region that has been shown to be important for ligand binding (Loftus et al. J Biol Chem 1994;269:25235-25238). A putative Ca2+ binding motif is found in some of the repeats.
Dilute (DIL) domain (Pfam Accession No. PF01843). SEQ ID N0:1548 represents a polypeptide having a DIL domain. Dilute encodes a type of myosin heavy chain, with a tail, or C-terminal, region that has elements of both type II (alpha-helical coiled-coil) and type I (non-coiled-coil) myosin heavy chains. The DIL non alpha-helical domain is found in dilute myosin heavy chain proteins and other myosins. In mouse the dilute protein plays a role in the elaboration, maintenance, or function of cellular processes of melanocytes and neurons (Mercer et al.
Nature 349(6311 ): 709-713(1991)). The DIL-containing MY02 protein of Saccharomyces cerevisiae is implicated in vectorial vesicle transport and is homologous to the dilute protein over practically its entire length (Johnston et al. J. Cell Biol. 113(3): 539-551(1991).
Ubiquinol-cytochrome C reductase complex l4kD subunit (Pfam Accession No.
PF022771).
SEQ ID NOS:419 and 1519 represent a polypeptide having sequence similarity to Ubiquinol-cytochrome C reductase complex l4kD subunit. The cytochrome bd type terminal oxidases catalyse quinol dependent, Na+ independent oxygen uptake. Members of this family are integral membrane proteins and contain a protoheame IX center B558. Cytochrome bd plays a role in microaerobic nitrogen fixation in the enteric bacterium Klebsiella pneumoniae, where it is expressed under all conditions that permit diazotrophy . The l4kD (or VI) subunit of the complex is not directly involved in electron transfer, but has a role in assembly of the complex (Braun et al Plant Physiol. 107(4):
1217-1223 ( 1995)).
Cytidylytransferase (Pfam Accession No. PF02348). SEQ ID NOS:109, 394, 569, 1128, and 1535 represent polypeptides having sequence similarity to the cytidylytransferase family of proteins, which are involved in lipopolysaccharide biosynthesis. This family consists of two main cytidylyltransferase activities: 1) 3-deoxy-manno-octulosonate cytidylyltransferase (Strohmaier et al. J
Bacteriol 1995;177:4488-4500.) EC:2.7.7.38 catalysing the reaction:- CTP + 3-deoxy-D-manno-octulosonate <_> diphosphate + CMP-3-deoxy-D-manno-octulosonate; and 2) acylneuraminate cytidylyltransferase EC:2.7.7.43 (Munster et al. Proc Natl Acad Sci U S A
1998;95:9140-9145;
Tullius et al. J Biol Chem 1996;271:15373-15380 ) catalysing the reaction:-CTP + N-acylneuraminate <_> diphosphate + CMP-N-acylneuraminate N-acetylneuraminic acid cytidylyltransferase (EC 2.7.7.43) (CMP-NeuAc synthetase) catalyzes the reaction of CTP and NeuAc to form CMP-NeuAc, which is the nucleotide sugar donor used by sialyltransferases. The outer membrane lipooligosaccharides of some microorganisms contain terminal sialic acid attached to N-acetyllactosamine; thus this modification may be important in pathogenesis.
Laminin G domain (Pfam Accession No. PF00054). SEQ ID N0:1521 represents a polypeptide having a laminin G domain, a homology domain first described in the long arm globular domain of laminin (Vuolteenaho et al. J. Biol. Chem. 265: 15611-15616(1990)).
Similar sequences also occurs in a large number of extracellular proteins. Laminin binds to heparin (Yurchenco et al. J.
Biol. Chem. 268(11): 8356-8365(1993); Sung et al. Eur. J. Biochem. 250(1): 138-143(1997)). The structure of the laminin-G domain has been predicted to resemble that of pentraxin (Beckmann et al. J.
Mol. Biol. 275: 725-730(1998)). Exemplary proteins having laminin-G domains include laminin, merosin, agrin, neurexins, vitamin K dependent protein S, and sex steroid binding protein SBP/SHBG.
4Fe-4S iron sulfur cluster binding_proteins, NifH/frxC family (Pfam Accession No.
PF00142 . SEQ ID NO:1100 represents a polypeptide having sequence similarity to the 4Fe-4S iron sulfur cluster binding proteins, NifH/frxC family. Nitrogen fixing bacteria possess a nitrogenase enzyme complex (EC 1.18.6.1) that comprises 2 components, which catalyse the reduction of molecular nitrogen to ammonia: component I (nitrogenase MoFe protein or dinitrogenase) contains 2 molecules each of 2 non-identical subunits; component II (nitrogenase Fe protein or dinitrogenase reductase) is a homodimer, the monomer being coded for by the niflI gene.
Component II has 2 ATP-binding domains and one 4Fe-4S cluster per homodimer: it supplies energy by ATP hydrolysis, and transfers electrons from reduced ferredoxin or flavodoxin to component I for the reduction of molecular nitrogen to ammonia. There are a number of conserved regions in the sequence of these proteins: in the N-terminal section there is an ATP-binding site motif'A' (P-loop) and in the central section there are two conserved cysteines which have been shown, in nifH, to be the ligands of the 4Fe-4S cluster.
Cyclophilin-type ~eptidyl-prolyl cis-trans isomerase (Pfam Accession No.
PF00160). SEQ ID
NOS:134, 259, 363, 1101, and 1267 represent polypeptides having sqeuence simlarity to the cyclophilin-type peptidyl-prolyl cis-trans isomerase protein family.
Cyclophilin (Stamnes et al. Trends Cell Biol. 2: 272-276(1992)) is the major high-affinity binding protein in vertebrates for the immunosuppressive drug cyclosporin A (CSA), but is also found in other organisms. It exhibits a peptidyl-prolyl cis-trans isomerase activity (EC 5.2.1.8) (PPIase or rotamase). PPIase is an enzyme that accelerates protein folding by catalyzing the cis-trans isomerization of proline imidic peptide bonds in oligopeptides (Fischer et al. Biochemistry 29: 2205-2212(1990)). It is probable that CSA
mediates some of its effects via an inhibitory action on PPIase. Cyclophilin A
is a cytosolic and highly abundant protein. The protein belongs to a family of isozymes, including cyclophilins B and C, and natural killer cell cyclophilin-related protein (Trandinh et al. FASEB J.
6: 3410-3420(1992);
Galat Eur. J. Biochem. 216: 689-707(1993); Hacker et al. Mol. Microbiol. 10:
445-456(1993)).
Major isoforms have been found throughout the cell, including the ER, and some are even secreted.
The sequences of the different forms of cyclophilin-type PPIases are well conserved.
Ubiquitin-conju~ating_enyme (Pfam Accession No. PF001791. SEQ ID N0:7 represents a polypeptide having sequence similarity to ubiquitin-conjugating enyme.
Ubiquitin-conjugating enzymes (EC 6.3.2.19) (IJBC or E2 enzymes) (Jentsch et al. Biochim. Biophys.
Acta 1089: 127-139(1991); Jentsch et al. Trends Biochem. Sci. 15: 195-198(1990); Hershko et al. Trends Biochem.
Sci. 16: 265-268(1991)). catalyze the covalent attachment of ubiquitin to target proteins. An activated ubiquitin moiety is transferred from an ubiquitin-activating enzyme (E1) to E2 which later ligates ubiquitin directly to substrate proteins with or without the assistance of N-end' recognizing proteins (E3). A cysteine residue is required for ubiquitin-thiolester formation. There is a single conserved cysteine in UBC's and the region around that residue is conserved in the sequence of known UBC isozymes. There are, however, exceptions, the breast cancer gene product TSG101 is one of several UBC homologues that lacks this active site cysteine (Ponting et al. J.
Mol. Med. 75: 467-469(1997); Koonin et al. Nat. Genet. 16: 330-331(1997)). In most species there are many forms of UBC which are implicated in diverse cellular functions.
NADH-ubiduinone/plastoguinone oxidoreductase chain 6 (Pfam Accession No.
PF00499).
SEQ ID NOS: 507 and 1002 represent polypeptides having sequence similarity with NADH-ubiquinone/plastoquinone oxidoreductase chain 6 protein family. In bacteria, the proton-translocating NADH-quinone oxidoreductase (NDH-1) is composed of 14 different subunits. The chain belonging to this family is a subunit that constitutes the membrane sector of the complex. It reduces ubiquinone to ubiquinol utilising NADH. In plants, chloroplastic NADH-plastoquinone oxidoreductase reduces plastoquinone to plastoquinol. Mitochondrial NADH-ubiquinone oxidoreductase from a variety of sources reduces ubiquinone to ubiquinol.
AP endonucleases family 1 (Pfam Accession No. PF00895). SEQ ID NO:10 and 1107 represent polypeptides having sequence similarity to members of the AP
endonucleases family 1.
DNA damaging agents such as the antitumor drugs bleomycin and neocarzinostatin or those that generate oxygen radicals produce a variety of lesions in DNA. Amongst these is base-loss which forms apurinic/apyrimidinic (AP) sites or strand breaks with atypical 3'termini. DNA repair at the AP
sites is initiated by specific endonuclease cleavage of the phosphodiester backbone. Such endonucleases are also generally capable of removing blocking groups from the 3'tenninus of DNA
strand breaks.
AP endonucleases can be classified into two families on the basis of sequence similarity. This family contains members of AP endonuclease family 1. Except for Rrpl and arp, these enzymes are proteins of about 300 amino-acid residues. Rrpl and arp both contain additional and unrelated sequences in their N-terminal section (about 400 residues for Rrpl and 270 for arp). The proteins contain glutamate which has been shown (Mol et al. Nature 374: 381-386(1995), in the Escherichia coli enzyme to bind a divalent metal ion such as magnesium or manganese.
Late Expression Factor 2 (lef 2; Pfam Accession No. PF03041). SEQ ID NO: 405 represents a polynucleotide encoding a member of the late expression factor 2 family of polypeptides. The lef 2 gene from baculovirus is required for expression of late genes and has been shown to be specifically required for expression from the vp39 and polh promoters (Passarelli and Miller, J. Virol. (1993) Apr;67(4):2149-58). Lef 2 has been found in both Lymantria dispar multicapsid nuclear polyhedrosis virus (LdMNPV) and Orgyia pseudotsugata multicapsid polyhedrosis virus (OpMNPV).
PaRillomavirus ES ~PaRilloma E5; Pfam Accession No. PF03025). SEQ ID NO: 1051 corresponds to a polynucleotide encoding a member of the papillomavirus ES
family of polypeptides.
The ES protein from papillomaviruses is about 80 amino acids long and contains three regions that have been predicted to be transmembrane alpha helices.
Male sterility protein (Sterile; Pfam Accession No. PF03015). SEQ ID NO: 391 encodes a member of the male sterility protein family. This family represents the C-terminal region of the male sterility protein in a number of organisms. One member of this family, the Arabidopsis thaliana male sterility 2 (MS2) protein, is involved in male gametogenesis. The MS2 protein shows sequence similarity to reductases in elongation/condensation complexes, such as jojoba protein (also a member of this group), an acyl CoA reductase that converts wax fatty acids to fatty alcohols. The MS2 protein may be a fatty acyl reductase involved in the formation of pollen wall substances (Harts et al., Plant.
J. (1997) Sep;l2(3):615-23).
Cytochrome C oxidase subunit II, transmembrane domain (COX2 TM: Pfam Accession No.
PF02790 . SEQ ID NO: 1183 corresponds to a gene comprising a cytochrome C
oxidase subunit II
transmembrane domain (COX2 TM). Cytochrome C oxidase is an oligomeric enzymatic complex which is a component of the respiratory chain and is involved in the transfer of electrons from cytochrome C to oxygen (Capaldi et al., Biochim. Biophys. Acta (1983) 726:135-148; Garcia-Horsman et al., J. Bacteriol. (1994) 176:5587-5600). In eukaryotes this enzyme complex is located in the mitochondria) inner membrane; in aerobic prokaryotes it is found in the plasma membrane. The enzyme complex consists of 3-4 subunits (prokaryotes) to up to 13 polypeptides (mammals).
Subunit 2 of cytochrome C oxidase (COX2 TM) transfers the electrons from cytochrome C to the catalytic subunit 1. It contains two adjacent transmembrane regions in its N-terminus and the major part of the protein is exposed to the periplasmic or to the mitochondria) intermembrane space, respectively. COX2 TM provides the substrate-binding site and contains a copper center called Cu(A), probably the primary acceptor in cytochrome C oxidase. Several bacterial COX2 TM have a C-terminal extension that contains a covalently bound heme c. The consensus pattern is: V-x-H-x(33,40)-C-x(3)-C-x(3)-H-x(2)-M, where the two C's and two H's are copper ligands.
Uncharacterized ACR YggU family COG1872 (DUF167; Pfam Accession No. PF02594).
SEQ ID NOS: 46, 813, 935, and 1225 correspond to a polynucleotide encoding a member of the uncharacterized ACR, YggU family COG1872 of proteins of E. coli. This protein in E. coli is a hypothetical 10.5 kDa protein in the GSHB-ANSB intergenic region.
Phosducin (Phosducin; Pfam Accession No. PF02114). SEQ ID NOS: 267 and 771 correspond to sequence encoding a Phosducin motif. The outer and inner segments of vertebrate rod photoreceptor cells contain phosducin, a soluble phosphoprotein that complexes with the beta/gamma-subunits of the GTP-binding protein, transducin (Lee et al., J. Biol. Chem.
(1990) 265:15867-15873).
Light-induced changes in cyclic nucleotide levels modulate the phosphorylation of phosducin by protein kinase A (Lee et al., J. Biol. Chem. (1990) 265:15867-15873). The protein is thought to participate in the regulation of visual phototransduction or in the integration of photo-receptor metabolism. Similar proteins have been isolated from the pineal gland (Abe et al., Gene (1990) 91:209-215): the 33kDa proteins have the same sequences and the same phosphorylation site, suggesting that the functional role of the protein is the same in both retina and pineal gland.
The Phosducin motif is an 8-element fingerprint that provides a signature for phosducins. The fingerprint was derived from an initial alignment of 7 sequences where the motifs were drawn from conserved regions spanning virtually the full alignment length. The sequences of the 8 elements are as follows: (1) EEDFEGQASHTGPKGVINDW; (2) DSVAHSKKEILRQMSSPQSR; (3) SRKMSVQEYELIHKDKEDE; (4) CLRKYRRQCMQDMHQKLSF; (5) GPRYGFVYELESGEQFLETIEKE; (6) YEDGIKGCDALNSSLICLAAEY; (7) DRFSSDVLPTLLVYKGGELLSNF; and (8) EQLAEEFFTGDVESFLNEYG.
Example 6' Detection of Differential Expression Using Arrays and source of patient tissue samples mRNA isolated from samples of cancerous and normal breast, colon, and prostate tissue obtained from patients were analyzed to identify genes differentially expressed in cancerous and normal cells. Normal and cancerous tissues were collected from patients using laser capture microdissection (LCM) techniques, which techniques are well known in the art (see, e.g., Ohyama et al. (2000) Biotechniques 29:530-6; Curran et al. (2000) Mol. Pathol. 53:64-8;
Suarez-Quian et al.
(1999) Biotechniques 26:328-35; Simone et al. (1998) Trends Genet 14:272-6;
Conia et al. (1997) J.
Clin. Lab. Anal. 11:28-38; Emmert-Buck et al. (1996) Science 274:998-1001).
Table 10 (inserted prior to claims) provides information about each patient from which colon tissue samples were isolated, including: the Patient ID ("PT ID") and Path ReportlD ("Path ID"), which are numbers assigned to the patient and the pathology reports for identification purposes; the group ("Grp")to which the patients have been assigned; the anatomical location of the tumor ("Anatom Loc"); the primary tumor size ("Size"); the primary tumor grade ("Grade"); the identification of the histopathological grade ("Histo Grade"); a description of local sites to which the tumor had invaded ("Local Invasion"); the presence of lymph node metastases ("Lymph Met"); the incidence of lymph node metastases (provided as a number of lymph nodes positive for metastasis over the number of lymph nodes examined) ("Lymph Met Incid"); the regional lymphnode grade ("Reg Lymph Grade"); the identification or detection of metastases to sites distant to the tumor and their location ("Dist Met & Loc"); the grade of distant metastasis ("Dist Met Grade"); and general comments about the patient or the tumor ("Comments"). Histophatology of all primary tumors incidated the tumor was adenocarcinmoa except for Patient ID Nos. 130 (for which no information was provided), 392 ( in which greater than 50% of the cells were mucinous carcinoma), and 784 (adenosquamous carcinoma). Extranodal extensions were described in three patients, Patient ID Nos.
784, 789, and 791. Lymphovascular invasion was described in Patient >l7 Nos.
128, 278, 517, 534, 784, 786, 789, 791, 890, and 892. Crohn's-like infiltrates were described in seven patients, Patient ID
Nos. 52, 264, 268, 392, 393, 784, and 791.
Table 11 below provides information about each patient from which the prostate tissue samples were isolated, including: 1 ) the "Patient ID", which is a number assigned to the patient for identification purposes; 2) the "Tissue Type"; and 3) the "Gleason Grade" of the tumor.
Histopathology of all primary tumors indicated the tumor was adenocarcinoma.
Table 11. Prostate patient data.
Gleason Gleason atient issue Type Grade atient issue Type Grade ID ID

93 Prostate +4 391 rostate Cancer+3 Cancer 94 rostate Cancer+3 20 Prostate +3 Cancer 95 rostate Cancer+3 25 rostate Cancer+3 96 Prostate +3 28 rostate Cancer+3 Cancer 97 rostate Cancer+2 31 Prostate +4 Cancer 100 rostate Cancer+3 92 rostate Cancer+3 101 Prostate +3 93 Prostate +4 Cancer Cancer 104 rostate Cancer+3 96 rostate Cancer+3 105 rostate Cancer+4 510 rostate Cancer+3 106 Prostate +3 511 rostate Cancer+3 Cancer 138 rostate Cancer+3 514 Prostate +3 Cancer 151 rostate Cancer+3 549 rostate Cancer+3 153 Prostate +3 552 rostate Cancer+3 Cancer 155 rostate Cancer+3 858 Prostate +4 Cancer 171 rostate Cancer+4 859 rostate Cancer+4 173 Prostate +4 864 Prostate +4 Cancer Cancer 31 rostate Cancer+4 883 rostate Cancer+4 32 rostate Cancer+3 895 rostate Cancer+3 51 Prostate +4 901 Prostate +3 Cancer Cancer 82 rostate Cancer+3 909 rostate Cancer+3 86 rostate Cancer+3 921 rostate Cancer+3 94 Prostate +4 923 Prostate +3 Cancer Cancer 51 rostate Cancer5+4 934 rostate Cancer+3 61 rostate Cancer+3 1134 rostate Cancer+4 62 Prostate +3 1135 Prostate +3 Cancer Cancer 65 rostate Cancer+2 1136 rostate Cancer+4 68 Prostate +3 1137 Prostate +3 Cancer Cancer 79 Prostate +4 1138 rostate Cancer+3 Cancer 88 rostate Cancer5+3 Table 12 provides information about each patient from which the breast tissue samples were isolated, including: 1 ) the "Pat Num", a number assigned to the patient for identification purposes; 2) the "Histology", which indicates whether the tumor was characterized as an intraductal carcinoma (IDC) or ductal carcinoma in situ (DCIS); 3) the incidence of lymph node metastases (LMF), represented as the number of lymph nodes positive to metastases out of the total number examined in the patient; 4) the "Tumor Size"; 5) "TNM Stage", which provides the tumor grade (T#), where the number indicates the grade and "p" indicates that the tumor grade is a pathological classification;
regional lymph node metastasis (N#), where "0" indicates no lymph node metastases were found, "1"
indicates lymph node metastases were found, and "X" means information not available and; the identification or detection of metastases to sites distant to the tumor and their location (M#), with "X"
indicating that no distant mesatses were reported; and the stage of the tumor ("Stage Grouping"). "nr"
indicates "no reported".
Table 12 Breast cancer patient data Pat umor Num istolo MF Size NM Sta to a Grou in a 280 r cm 2NXMX robable Sta IDC, a II
DCIS+D2 284 0/16 cm 2 NOMX Sta a II
1DC, DCIS

285 r .5 2NXMX robable Sta IDC, cm a II
DCIS

291 0/24 .5 2 NOMX Stage II
IDC, cm DCIS

302 r .2 2NXMX robable Sta IDC, cm a II
DCIS

375 r 1.5 1NXMX robable Sta IDC, cm a I
DCIS

408 0/23 .0 2 NOMX Sta a II
IDC cm 416 0/6 .3 2 NOMX Sta a II
IDC cm 421 r .5 2NXMX robable Stage IDC, cm II
DCIS

459 /5 .9 2 N1MX Sta a II
IDC cm 465 0/10 6.5 3 NOMX Sta a II
IDC cm 470 0/6 .S 2 NOMX Sta a II
IDC, cm DCIS

472 6/45 5.0+ 3 N1MX Sta a III
1DC, cm DCIS

474 0/18 6.0 3 NOMX Stage II
IDC cm 76 0/16 .4 2 NOMX Stage II
IDC cm OS 1/25 5.0 2 N1MX Stage II
IDC, cm DCIS

649 1 4.5 T2pN 1 Stage II
IDC, /29 cm MX
DCIS

Identification of differentially expressed genes cDNA probes were prepared from total RNA isolated from the patient cells described above.
Since LCM provides for the isolation of specific cell types to provide a substantially homogenous cell sample, this provided for a similarly pure RNA sample.
Total RNA was first reverse transcribed into cDNA using a primer containing a polymerase promoter, followed by second strand DNA synthesis. cDNA was then transcribed in vitro to produce antisense RNA using the T7 promoter-mediated expression (see, e.g., Luo et al. (1999) Nature Med 5:117-122), and the antisense RNA was then converted into cDNA. The second set of cDNAs were again transcribed in vitro, using the T7 promoter, to provide antisense RNA. Optionally, the RNA was again converted into cDNA, allowing for up to a third round of T7-mediated amplification to produce more antisense RNA. Thus the procedure provided for two or three rounds of in vitro transcription to produce the final RNA used for fluorescent labeling.
Fluorescent probes were generated by first adding control RNA to the antisense RNA mix, and producing fluorescently labeled cDNA from the RNA starting material.
Fluorescently labeled cDNAs prepared from the tumor RNA sample were compared to fluorescently labeled cDNAs prepared from normal cell RNA sample. For example, the cDNA probes from the normal cells were labeled with Cy3 fluorescent dye (green) and the cDNA probes prepared from the tumor cells were labeled with Cy5 fluorescent dye (red), and vice versa.
Each array used had an identical spatial layout and control spot set. Each microarray was divided into two areas, each area having an array with, on each half, twelve groupings of 32 x 12 spots, for a total of about 9,216 spots on each array. The two areas are spotted identically which provide for at least two duplicates of each clone per array.
Polynucleotides for use on the arrays were obtained from both publicly available sources and from cDNA libraries generated from selected cell lines and patient tissues.
PCR products of from about O.Skb to 2.0 kb amplified from these sources were spotted onto the array using a Molecular Dynamics Gen III spotter according to the manufacturer's recommendations. The first row of each of the 24 regions on the array had about 32 control spots, including 4 negative control spots and 8 test polynucleotides. The test polynucleotides were spiked into each sample before the labeling reaction with a range of concentrations from 2-600 pg/slide and ratios of 1:1. For each array design, two slides were hybridized with the test samples reverse-labeled in the labeling reaction. This provided for about four duplicate measurements for each clone, two of one color and two of the other, for each sample.
The differential expression assay was performed by mixing equal amounts of probes from tumor cells and normal cells of the same patient. The arrays were prehybridized by incubation for about 2 hrs at 60°C in SX SSC/0.2% SDS/1 mM EDTA, and then washed three times in water and twice in isopropanol. Following prehybridization of the array, the probe mixture was then hybridized to the array under conditions of high stringency (overnight at 42°C in 50% formamide, SX SSC, and 0.2% SDS. After hybridization, the array was washed at SS°C three times as follows: 1 ) first wash in 1X SSC/0.2% SDS; 2) second wash in O.1X SSC/0.2% SDS; and 3) third wash in O.1X SSC.
The arrays were then scanned for green and red fluorescence using a Molecular Dynamics Generation III dual color laser-scanner/detector. The images were processed using BioDiscovery Autogene software, and the data from each scan set normalized to provide for a ratio of expression relative to normal. Data from the microarray experiments was analyzed according to the algorithms described in U.S. application serial no. 60/252,358, filed November 20, 2000, by E.J. Moler, M.A.
Boyle, and F.M. Randazzo, and entitled "Precision and accuracy in cDNA
microarray data," which application is specifically incorporated herein by reference.

The experiment was repeated, this time labeling the two probes with the opposite color in order to perform the assay in both "color directions." Each experiment was sometimes repeated with two more slides (one in each color direction). The level fluorescence for each sequence on the array expressed as a ratio of the geometric mean of 8 replicate spots/genes from the four arrays or 4 replicate spots/gene from 2 arrays or some other permutation. The data were normalized using the spiked positive controls present in each duplicated area, and the precision of this normalization was included in the final determination of the significance of each differential. The fluorescent intensity of each spot was also compared to the negative controls in each duplicated area to determine which spots have detected significant expression levels in each sample.
A statistical analysis of the fluorescent intensities was applied to each set of duplicate spots to assess the precision and significance of each differential measurement, resulting in a p-value testing the null hypothesis that there is no differential in the expression level between the tumor and normal samples of each patient. During initial analysis of the microarrays, the hypothesis was accepted if p >
10-3, and the differential ratio was set to 1.000 for those spots. All other spots have a significant difference in expression between the tumor and normal sample. If the tumor sample has detectable expression and the normal does not, the ratio is truncated at 1000 since the value for expression in the normal sample would be zero, and the ratio would not be a mathematically useful value (e.g., infinity).
If the normal sample has detectable expression and the tumor does not, the ratio is truncated to 0.001, since the value for expression in the tumor sample would be zero and the ratio would not be a mathematically useful value. These latter two situations are referred to herein as "on/off." Database tables were populated using a 95% confidence level (p>0.05).
Table 13 (inserted prior to claims) provides the results for gene products expressed by at least 2-fold or greater in cancerous prostate, colon, or breast tissue samples relative to normal tissue samples in at least 20% of the patients tested. Table 12 includes: 1) the SEQ
ID NO ("SEQ ID") assigned to each sequence for use in the present specification; 2) the Cluster Identification No.
("CLUSTER"); 3) the percentage of patients tested in which expression levels (e.g., as message level) of the gene was at least 2-fold greater in cancerous breast tissue than in matched normal tissue ("BREAST PATIENTS >=2x"); 4) the percentage of patients tested in which expression levels (e.g., as message level) of the gene was less than or equal to %z of the expression level in matched normal breast cells ("BREAST PATIENTS <=halfx"); 5) the percentage of patients tested in which expression levels (e.g., as message level) of the gene was at least 2-fold greater in cancerous colon tissue than in matched normal tissue ("COLON PATIENTS >=2x"); 6) the percentage of patients tested in which expression levels (e.g., as message level) of the gene was less than or equal to %x of the expression level in matched normal colon cells ("COLON PATIENTS <=halfx"); 7) the percentage of patients tested in which expression levels (e.g., as message level) of the gene was at least 2-fold greater in cancerous prostate tissue than in matched normal tissue ("PROSTATE
PATIENTS >=2x");

and 8) the percentage of patients tested in which expression levels (e.g., as message level) of the gene was less than or equal to 'h of the expression level in matched normal prostate cells ("PROSTATE
PATIENTS <=halfx").
These data provide evidence that the genes represented by the polynucleotides having the indicated sequences are differentially expressed in breast cancer as compared to normal non-cancerous breast tissue, are differentially expressed in colon cancer as compared to normal non-cancerous colon tissue, and are differentially expressed in prostate cancer as compared to normal non-cancerous prostate tissue.
Example 7: Antisense Regulation of Gene Expression The expression of the differentially expressed genes represented by the polynucleotides in the cancerous cells can be further analyzed using antisense knockout technology to confirm the role and function of the gene product in tumorigenesis, e.g., in promoting a metastatic phenotype.
Methods for analysis using antisense technology are well known in the art. For example, a number of different oligonucleotides complementary to the mRNA generated by the differentially expressed genes identified herein can be designed as antisense oligonucleotides, and tested for their ability to suppress expression of the genes. Sets of antisense oligomers specific to each candidate target are designed using the sequences of the polynucleotides corresponding to a differentially expressed gene and the software program HYBsimulator Version 4 (available for Windows 95/Windows NT or for Power Macintosh, RNAture, Inc. 1003 Health Sciences Road, West, Irvine, CA 92612 USA). Factors considered when designing antisense oligonucleotides include: 1) the The expression of the differentially expressed genes represented by the polynucleotides in the cancerous cells can be analyzed using antisense knockout technology to confirm the role and function of the gene product in tumorigenesis, e.g., in promoting a metastatic phenotype.
A number of different oligonucleotides complementary to the mRNA generated by the differentially expressed genes identified herein can be designed as potential antisense oligonucleotides, and tested for their ability to suppress expression of the genes. Sets of antisense oligomers specific to each candidate target are designed using the sequences of the polynucleotides corresponding to a differentially expressed gene and the software program HYBsimulator Version 4 (available for Windows 95/Windows NT or for Power Macintosh, RNAture, Inc.
1003 Health Sciences Road, West, Irvine, CA 92612 USA). Factors that are considered when designing antisense oligonucleotides include: 1) the secondary structure of oligonucleotides; 2) the secondary structure of the target gene; 3) the specificity with no or minimum cross-hybridization to other expressed genes; 4) stability; 5) length and 6) terminal GC content. The antisense oligonucleotide is designed so that it will hybridize to its target sequence under conditions of high stringency at physiological temperatures (e.g., an optimal temperature for the cells in culture to provide for hybridization in the cell, e.g., about 37°C), but with minimal formation of homodimers.

Using the sets of oligomers and the HYBsimulator program, three to ten antisense oligonucleotides and their reverse controls are designed and synthesized for each candidate mRNA
transcript, which transcript is obtained from the gene corresponding to the target polynucleotide sequence of interest. Once synthesized and quantitated, the oligomers are screened for efficiency of a transcript knock-out in a panel of cancer cell lines. The efficiency of the knock-out is determined by analyzing mRNA levels using lightcycler quantification. The oligomers that resulted in the highest level of transcript knock-out, wherein the level was at least about SO%, preferably about 80-90%, up to 95% or more up to undetectable message, are selected for use in a cell-based proliferation assay, an anchorage independent growth assay, and an apoptosis assay.
The ability of each designed antisense oligonucleotide to inhibit gene expression is tested through transfection into LNCaP, PC3, 22Rv1, MDA-PCA-2b, or DU145 prostate carcinoma cells.
For each transfection mixture, a carrier molecule (such as a lipid, lipid derivative, lipid-like molecule, cholesterol, cholesterol derivative, or cholesterol-like molecule) is prepared to a working concentration of 0.5 mM in water, sonicated to yield a uniform solution, and filtered through a 0.45 pm PVDF
membrane. The antisense or control oligonucleotide is then prepared to a working concentration of 100 pM in sterile Millipore water. The oligonucleotide is further diluted in OptiMEMTM
(GibcoBRL), in a microfuge tube, to 2 pM, or approximately 20 pg oligo/ml of OptiMEMTM. In a separate microfuge tube, the carrier molecule, typically in the amount of about 1.5-2 nmol carrier/pg antisense oligonucleotide, is diluted into the same volume of OptiMEMTM used to dilute the oligonucleotide. The diluted antisense oligonucleotide is immediately added to the diluted carrier and mixed by pipetting up and down. Oligonucleotide is added to the cells to a final concentration of 30 nM.
The level of target mRNA that corresponds to a target gene of interest in the transfected cells is quantitated in the cancer cell lines using the Roche LightCyclerTM real-time PCR machine. Values for the target mRNA are normalized versus an internal control (e.g., beta-actin). For each 20 p l reaction, extracted RNA (generally 0.2-1 pg total) is placed into a sterile 0.5 or 1.5 ml microcentrifuge tube, and water is added to a total volume of 12.5 p1. To each tube is added 7.5 p1 of a buffer/enzyme mixture, prepared by mixing (in the order listed) 2.5 p1 HzO, 2.0 p1 IOX
reaction buffer, 10 p1 oligo dT (20 pmol), I.0 p1 dNTP mix (10 mM each), 0.5 p1 RNAsin~ (20u) (Ambion, Inc., Hialeah, FL), and 0.5 p1 MMLV reverse transcriptase (50u) (Ambion, Inc.). The contents are mixed by pipetting up and down, and the reaction mixture is incubated at 42°C for 1 hour. The contents of each tube are centrifuged prior to amplification.
An amplification mixture is prepared by mixing in the following order: 1 X PCR
buffer II, 3 mM MgClz, 140 pM each dNTP, 0.175 pmol each oligo, 1:50,000 dil of SYBR~
Green, 0.25 mg/ml BSA, 1 unit Taq polymerase, and H20 to 20 p1. (PCR buffer II is available in lOX concentration from Perkin-Elmer, Norwalk, CT). In IX concentration it contains 10 mM Tris pH 8.3 and 50 mM KC1.

SYBR~ Green (Molecular Probes, Eugene, OR) is a dye which fluoresces when bound to double stranded DNA. As double stranded PCR product is produced during amplification, the fluorescence from SYBR~ Green increases. To each 20 p1 aliquot of amplification mixture, 2 p1 of template RT is added, and amplification is carried out according to standard protocols. The results are expressed as the percent decrease in expression of the corresponding gene product relative to non-transfected cells, vehicle-only transfected (mock-transfected) cells, or cells transfected with reverse control oligonucleotides.
Example 8: Effect of Expression on Proliferation The effect of gene expression on the inhibition of cell proliferation can be assessed in metastatic breast cancer cell lines (MDA-MB-231 ("231 ")); SW620 colon colorectal carcinoma cells;
SKOV3 cells (a human ovarian carcinoma cell line); or LNCaP, PC3, 22Rv1, MDA-PCA-2b, or DU145 prostate cancer cells.
Cells are plated to approximately 60-80% confluency in 96-well dishes.
Antisense or reverse control oligonucleotide is diluted to 2 ~M in OptiMEMTM. The oligonucleotide-OptiMEMTM can then be added to a delivery vehicle, which delivery vehicle can be selected so as to be optimized for the particular cell type to be used in the assay. The oligo/delivery vehicle mixture is then further diluted into medium with serum on the cells. The final concentration of oligonucleotide for all experiments can be about 300 nM.
Antisense oligonucleotides are prepared as described above (see Example 3).
Cells are transfected overnight at 37°C and the transfection mixture is replaced with fresh medium the next morning. Transfection is carried out as described above in Example 8.
Those antisense oligonucleotides that result in inhibition of proliferation of SW620 cells indicate that the corresponding gene plays a role in production or maintenance of the cancerous phenotype in cancerous colon cells. Those antisense oligonucleotides that inhibit proliferation in SKOV3 cells represent genes that play a role in production or maintenance of the cancerous phenotype in cancerous breast cells. Those antisense oligonucleotides that result in inhibition of proliferation of MDA-MB-231 cells indicate that the corresponding gene plays a role in production or maintenance of the cancerous phenotype in cancerous ovarian cells. Those antisense oligonucleotides that inhibit proliferation in LNCaP, PC3, 22Rv1, MDA-PCA-2b, or DU145 cells represent genes that play a role in production or maintenance of the cancerous phenotype in cancerous prostate cells.
Example 9: Effect of Gene Expression on Cell Mi agr ton The effect of gene expression on the inhibition of cell migration can be assessed in LNCaP, PC3, 22Rv1, MDA-PCA-2b, or DU145 prostate cancer cells using static endothelial~cell binding assays, non-static endothelial cell binding assays, and transmigration assays.
For the static endothelial cell binding assay, antisense oligonucleotides are prepared as described above (see Example 8). Two days prior to use, prostate cancer cells (CaP) are plated and transfected with antisense oligonucleotide as described above (see Examples 3 and 4). On the day before use, the medium is replaced with fresh medium, and on the day of use, the medium is replaced with fresh medium containing 2 pM CellTracker green CMFDA (Molecular Probes, Inc.) and cells are incubated for 30 min. Following incubation, CaP medium is replaced with fresh medium (no CMFDA) and cells are incubated for an additional 30-60 min. CaP cells are detached using CMF
PBS/2.5 mM EDTA or trypsin, spun and resuspended in DMEM/1 % BSA/ 10 mM HEPES
pH 7Ø
Finally, CaP cells are counted and resuspended at a concentration of 1x106 cells/ml.
Endothelial cells (EC) are plated onto 96-well plates at 40-50% confluence 3 days prior to use. On the day of use, EC are washed 1X with PBS and 50~, DMDM/1%BSA/1 OmM
HEPES pH 7 is added to each well. To each well is then added 50K (5070 CaP cells in DMEM/1% BSA/ IOmM
HEPES pH 7. The plates are incubated for an additional 30 min and washed 5X
with PBS containing Cap and Mg++. After the final wash, 100 wL PBS is added to each well and fluorescence is read on a fluorescent plate reader (Ab492/Em 516 nm).
For the non-static endothelial cell binding assay, CaP are prepared as described above. EC
are plated onto 24-well plates at 30-40% confluence 3 days prior to use. On the day of use, a subset of EC are treated with cytokine for 6 hours then washed 2X with PBS. To each well is then added 150-200K CaP cells in DMEM/1 % BSA/ l OmM HEPES pH 7. Plates are placed on a rotating shaker (70 RPM) for 30 min and then washed 3X with PBS containing Ca~ and Mg++. After the final wash, 500 pL PBS is added to each well and fluorescence is read on a fluorescent plate reader (Ab492/Bm 516 nm).
For the transmigration assay, CaP are prepared as described above with the following changes. On the day of use, CaP medium is replaced with fresh medium containing 5 pM CellTracker green CMFDA (Molecular Probes, Inc.) and cells are incubated for 30 min.
Following incubation, CaP medium is replaced with fresh medium (no CMFDA) and cells are incubated for an additional 30-60 min. CaP cells are detached using CMF PBS/2.5 mM EDTA or trypsin, spun and resuspended in EGM-2-MV medium. Finally, CaP cells are counted and resuspended at a concentration of 1x106 cells/ml.
EC are plated onto FluorBlok transwells (BD Biosciences) at 30-40% confluence 5-7 days before use. Medium is replaced with fresh medium 3 days before use and on the day of use. To each transwell is then added 50K labeled CaP. 30 min prior to the first fluorescence reading, 10 pg of FITC-dextran (1 OK MW) is added to the EC plated filter. Fluorescence is then read at multiple time points on a fluorescent plate reader (Ab492/Em 516 nm).
Those antisense oligonucleotides that result in inhibition of binding of LNCaP, PC3, 22Rv1, MDA-PCA-2b, or DU145 prostate cancer cells to endothelial cells indicate that the corresponding gene plays a role in the production or maintenance of the cancerous phenotype in cancerous prostate cells. Those antisense oligonucleotides that result in inhibition of endothelial cell transmigration by LNCaP, PC3, 22Rv1, MDA-PCA-2b, or DU145 prostate cancer cells indicate that the corresponding gene plays a role in the production or maintenance of the cancerous phenotype in cancerous prostate cells.
Example 10' Effect of Gene Expression on Colony Formation The effect of gene expression upon colony formation of SW620 cells, SKOV3 cells, MD-MBA-231 cells, LNCaP cells, PC3 cells, 22Rv1 cells, MDA-PCA-2b cells, and DU145 cells can be tested in a soft agar assay. Soft agar assays are conducted by first establishing a bottom layer of 2 ml of 0.6% agar in media plated fresh within a few hours of layering on the cells. The cell layer is formed on the bottom layer by removing cells transfected as described above from plates using 0.05%
trypsin and washing twice in media. The cells are counted in a Coulter counter, and resuspended to 106 per ml in media. 10 p1 aliquots are placed with media in 96-well plates (to check counting with WST1), or diluted further for the soft agar assay. 2000 cells are plated in 800 p1 0.4% agar in duplicate wells above 0.6% agar bottom layer. After the cell layer agar solidifies, 2 ml of media is dribbled on top and antisense or reverse control oligo (produced as described in Example 8) is added without delivery vehicles. Fresh media and oligos are added every 3-4 days.
Colonies form in 10 days to 3 weeks. Fields of colonies are counted by eye. Wst-1 metabolism values can be used to compensate for small differences in starting cell number. Larger fields can be scanned for visual record of differences.
Those antisense oligonucleotides that result in inhibition of colony formation of SW620 cells indicate that the corresponding gene plays a role in production or maintenance of the cancerous - phenotype in cancerous colon cells. Those antisense oligonucleotides that inhibit colony formation in SKOV3 cells represent genes that play a role in production or maintenance of the cancerous phenotype in cancerous breast cells. Those antisense oligonucleotides that result in inhibition of colony formation of MDA-MB-231 cells indicate that the corresponding gene plays a role in production or maintenance of the cancerous phenotype in cancerous ovarian cells. Those antisense oligonucleotides that inhibit colony formation in LNCaP, PC3, 22Rv1, MDA-PCA-2b, or DU145 cells represent genes that play a role in production or maintenance of the cancerous phenotype in cancerous prostate cells.
Example 11 ~ Induction of Cell Death upon Depletion of Polypeptides by Depletion of mRNA
~"Antisense Knockout") In order to assess the effect of depletion of a target message upon cell death, LNCaP, PC3, 22Rv1, MDA-PCA-2b, or DU145 cells, or other cells derived from a cancer of interest, can be transfected for proliferation assays. For cytotoxic effect in the presence of cisplatin (cis), the same protocol is followed but cells are left in the presence of 2 pM drug. Each day, cytotoxicity is monitored by measuring the amount of LDH enzyme released in the medium due to membrane damage. The activity of LDH is measured using the Cytotoxicity Detection Kit from Roche Molecular Biochemicals. The data is provided as a ratio of LDH released in the medium vs. the total LDH
present in the well at the same time point and treatment (rLDH/tLDH). A
positive control using antisense and reverse control oligonucleotides for BCL2 (a known anti-apoptotic gene) is included;
loss of message for BCL2 leads to an increase in cell death compared with treatment with the control oligonueleotide (background cytotoxicity due to transfection).
Example 12' Functional Analysis of Gene Products Differentially Expressed in Cancer The gene products of sequences of a gene differentially expressed in cancerous cells can be further analyzed to confirm the role and function of the gene product in tumorigenesis, e.g., in promoting or inhibiting development of a metastatic phenotype. For example, the function of gene products corresponding to genes identified herein can be assessed by blocking function of the gene products in the cell. For example, where the gene product is secreted or associated with a cell surface membrane, blocking antibodies can be generated and added to cells to examine the effect upon the cell phenotype in the context of, for example, the transformation of the cell to a cancerous, particularly a metastatic, phenotype. In order to generate antibodies, a clone corresponding to a selected gene product is selected, and a sequence that represents a partial or complete coding sequence is obtained.
The resulting clone is expressed, the polypeptide produced isolated, and antibodies generated. The antibodies are then combined with cells and the effect upon tumorigenesis assessed.
Where the gene product of the differentially expressed genes identified herein exhibits sequence homology to a protein of known function (e.g., to a specific kinase or protease) and/or to a protein family of known function (e.g., contains a domain or other consensus sequence present in a protease family or in a kinase family), then the role of the gene product in tumorigenesis, as well as the activity of the gene product, can be examined using small molecules that inhibit or enhance function of the corresponding protein or protein family.
Additional functional assays include, but are not necessarily limited to, those that analyze the effect of expression of the corresponding gene upon cell cycle and cell migration. Methods for performing such assays are well known in the art.
Example 13: Deposit Information.
A deposit of the biological materials in the tables referenced below was made with the American Type Culture Collection, 10801 University Blvd., Manasas, VA 20110-2209, under the provisions of the Budapest Treaty, on or before the filing date of the present application. The accession number indicated is assigned after successful viability testing, and the requisite fees were paid. Access to said cultures will be available during pendency of the patent application to one determined by the Commissioner to be entitled to such under 37 C.F.R. ~ 1.14 and 35 U.S.C. ~ 122.
All restriction on availability of said cultures to the public will be irrevocably removed upon the granting of a patent based upon the application. Moreover, the designated deposits will be maintained for a period of thirty (30) years from the date of deposit, or for five (5) years after the last request for the deposit; or for the enforceable life of the U.S. patent, whichever is longer. Should a culture become nonviable or be inadvertently destroyed, or, in the case of plasmid-containing strains, lose its plasmid, it will be replaced with a viable cultures) of the same taxonomic description.
These deposits are provided merely as a convenience to those of skill in the art, and are not an admission that a deposit is required. A license may be required to make, use, or sell the deposited materials, and no such license is hereby granted. The deposit below was received by the ATCC on or before the filing date of the present application.
Table 14A. Cell Lines Deposited with ATCC
Cell De osit DateATCC AccessionCMCC Accession Line No. No.

KM12L4-AMarch 19, CRL-12496 11606 Kml2C Ma 15, 1998 CRL-12533 11611 MDA-MB- May 15, 1998CRL-12532 10583 MCF-7 October 9, CRL-12584 10377 In addition, pools of selected clones, as well as Ibranes containing specmc clones, were assigned an "ES" number (internal reference) and deposited with the ATCC.
Table 14 below provides the ATCC Accession Nos. of the clones deposited as a library named ES217. The deposit was made on January 18, 2001. Table 15 (inserted before the claims) provides the ATCC Accession Nos. of the clones deposited as libraries named ES210-ES216 on July 25, 2000.
Table 14B: Clones Deposited as Library No. E5217 with ATCC on or before January 18, 2001.
CloneID CMCC ATCC# CIoneID CMCC ATCC#

M00073094B:A015418 PTA-2918M00073425A:H125418 PTA-2918 M00073096B:A125418 PTA-2918M00073427B:E045418 PTA-2918 M00073412C:E075418 PTA-2918M00073408A:D065418 PTA-2918 M00073408C:F065418 PTA-2918M00073428D:H035418 PTA-2918 M00073435C:E065418 PTA-2918M00073435B:E115418 PTA-2918 M00073403B:F065418 PTA-2918M00074323D:F095418 PTA-2918 M00073412D:B075418 PTA-2918M00074333D:A115418 PTA-2918 M00073421C:B075418 PTA-2918M00074335A:H085418 PTA-2918 M00073429B:H105418 PTA-2918M00074337A:G085418 PTA-2918 M00073412D:E025418 PTA-2918M00074340B:D065418 PTA-2918 M00073097C:A035418 PTA-2918M00074343C:A035418 PTA-2918 M00073403C:C105418 PTA-2918M00074346A:H095418 PTA-2918 M00073425D:F085418 PTA-2918M00074347B:F115418 PTA-2918 M00073403C:E115418 PTA-2918M00074349A:E085418 PTA-2918 M00073431A:G025418 PTA-2918M00074355D:H065418 PTA-2918 M00073412A:C035418 PTA-2918M00074361C:B015418 PTA-2918 M00073424D:C035418 PTA-2918M00074365A:E095418 PTA-2918 M00073430C:A015418 PTA-2918M00074366A:D075418 PTA-2918 M00073407A:E125418 PTA-2918M00074366A:H075418 PTA-2918 M00073412A:H095418 PTA-2918M00074370D:G095418 PTA-2918 M00073418B:B095418 PTA-2918M00074375D:E055418 PTA-2918 M00073403C:H095418 PTA-2918M00074382D:F045418 PTA-2918 M00073416B:F015418 PTA-2918M00074384D:G075418 PTA-2918 M00073425A:G105418 PTA-2918M00074388B:E075418 PTA-2918 CIoneID CMCC ATCC# CIoneID CMCC ATCC#

M00073427B:C085418 PTA-2918M00074392C:D025418 PTA-2918 M00073430C:B025418 PTA-2918M00074405B:A045418 PTA-2918 M00073418B:H095418 PTA-2918M00074417D:F075418 PTA-2918 M00073423C:E015418 PTA-2918M00074392D:D015418 PTA-2918 M00074391B:D025418 PTA-2918M00074406B:F105418 PTA-2918 M00074390C:E045418 PTA-2918M00074430D:G095418 PTA-2918 M00074411B:G075418 PTA-2918M00074395A:B115418 PTA-2_918 M00074415B:A015418 PTA-2918M00074404B:H015418 PTA-2918 Retrieval of Individual Clones from Deposit of Pooled Clones. Where the ATCC
deposit is composed of a pool of cDNA clones or a library of cDNA clones, the deposit was prepared by first transfecting each of the clones into separate bacterial cells. The clones in the pool or library were then deposited as a pool of equal mixtures in the composite deposit. Particular clones can be obtained from the composite deposit using methods well known in the art. For example, a bacterial cell containing a particular clone can be identified by isolating single colonies, and identifying colonies containing the specific clone through standard colony hybridization techniques, using an oligonucleotide probe or probes designed to specifically hybridize to a sequence of the clone insert (e.g., a probe based upon unmasked sequence of the encoded polynucleotide having the indicated SEQ ID
NO). The probe should be designed to have a Tm of approximately 80°C (assuming 2°C for each A or T and 4°C for each G or C). Positive colonies can then be picked, grown in culture, and the recombinant clone isolated. Alternatively, probes designed in this manner can be used to PCR to isolate a nucleic acid molecule from the pooled clones according to methods well known in the art, e.g., by purifying the cDNA from the deposited culture pool, and using the probes in PCR reactions to produce an amplified product having the corresponding desired polynucleotide sequence.
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.
Those skilled in the art will recognize, or be able to ascertain, using not more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such specific embodiments and equivalents are intended to be encompassed by the following claims.

Table 2 ORIEN
s~ CLUSTERSEQNAME T CLONE ID LIBRARY

1 38838 504.A17.GZ43 F M00072942B:E02IF97-26811-NormBPHProstate 2 558959 2504.B06.GZ43 F M00072942D:F07IF97-26811-NormBPHProstate 3 19061 36581 F M00072943B:E04IF97-26811-NormBPHProstate 504.B11.GZ43 4 139979 504.B21.GZ43 F M00072944A:C07IF97-26811-NormBPHProstate 24540 504.B23.GZ43 F M00072944A:E06IF97-26811-NormBPHProstate 6 40164 2504.C08.GZ43 F M00072944C:C02IF97-26811-NormBPHProstate 7 53675 36584 F M00072944D:C08IF97-26811-NormBPHProstate 2504.C11.GZ43 8 119614 504.D09.GZ43 F M00072947B:G04IF97-26811-NormBPHProstate 9 918867 504.D16.GZ43 F M00072947D:G05IF97-26811-NormBPHProstate 823 2504.E23.GZ43 F M00072950A:A06IF97-26811-NormBPHProstate 11 604822 36590 F M00072961A:G04IF97-26811-NormBPHProstate 2504.F20.GZ43 12 343686 504.GO1.GZ43 F M00072961B:G10IF97-26811-NormBPHProstate 13 21554 504.G04.GZ43 F M00072961C:B06IF97-26811-NormBPHProstate 14 204211 504.G07.GZ43 F M00072962A:B05IF97-26811-NormBPHProstate 21567 36594 F M00072963B:G11IF97-26811-NormBPHProstate 504.H02.GZ43 16 956537 2504.I11.GZ43 F M00072967A:G07IF97-26811-NormBPHProstate 17 44238 2504.I13.GZ43 F M00072967B:G06IF97-26811-NormBPHProstate 18 56663 2504.I19.GZ43 F M00072968A:F08IF97-26811-NormBPHProstate 19 49884 366000 F M00072968D:A06IF97-26811-NormBPHProstate 2504.123.GZ43 402904 2504.J02.GZ43 F M00072968D:E05IF97-26811-NormBPHProstate 21 845171 2504.J11.GZ43 F M00072970C:B07IF97-26811-NormBPHProstate 22 471272 504.KOl.GZ43 F M00072971A:E04IF97-26811-NormBPHProstate 23 660842 36603 F M00072971A:F11IF97-26811-NormBPHProstate 504.K02.GZ43 24 764473 504.K07.GZ43 F M00072971C:B07IF97-26811-NormBPHProstate 406416 504.K14.GZ43 F M00072972A:C03IF97-26811-NormBPHProstate 26 842403 36604 F M00072974A:A11IF97-26811-NormBPHProstate 27 401809 2504.L16.GZ43 F M00072974D:B04IF97-26811-NormBPHProstate 504.M12.GZ43 28 28050 504.M18.GZ43 F M00072975A:D11IF97-26811-NormBPHProstate 29 37758 504.M19.GZ43 F M00072975A:E02IF97-26811-NormBPHProstate 85792 36609 F M00072977A:F06IF97-26811-NormBPHProstate 31 400258 504.009.GZ43 F M00072977B:C05IF97-26811-NormBPHProstate 504.012.GZ43 32 9934 505.B02.GZ43 F M00072980B:C05IF97-26811-NormBPHProstate 33 448503 2505.B05.GZ43 F M00072980B:G01IF97-26811-NormBPHProstate 34 731371 2505.B17.GZ43 F M00073001A:F07IF97-26811-NormBPHProstate 171148 36621 F M00073001B:E07IF97-26811-NormBPHProstate 2505.B18.GZ43 36 49090 2505.C06.GZ43 F M00073002B:BIF97-26811-NormBPHProstate 37 57638 2505.C17.GZ43 F M00073002D:B08IF97-26811-NormBPHProstate 38 523261 2505.C21.GZ43 F M00073003A:E06IF97-26811-NormBPHProstate 39 85192 36624 F M00073003B:E10IF97-26811-NormBPHProstate 505.DO1.GZ43 696086 505.D03.GZ43 F M00073003B:H01IF97-26811-NormBPHProstate 41 41455 505.D04.GZ43 F M00073003C:C05IF97-26811-NormBPHProstate 42 336576 2505.E09.GZ43 F M00073006A:H08IF97-26811-NormBPHProstate 43 36407 36627 F M00073006C:D07IF97-26811-NormBPHProstate 2505.E15.GZ43 44 397652 2505.F09.GZ43 F M00073007D:E05IF97-26811-NormBPHProstate 85792 505.G06.GZ43 F M00073009B:C08IF97-26811-NormBPHProstate 46 376516 505.G16.GZ43 F M00073009D:A02IF97-26811-NormBPHProstate 47 588996 36633 F M00073012A:C11IF97-26811-NormBPHProstate 505.H14.GZ43 48 8401 2505.I04.GZ43 F M00073013A:D10IF97-26811-NormBPHProstate 49 11561 2505.106.GZ43 F M00073013A:F10IF97-2681_1-NormBPHPro_state 726937 2505.I14.GZ43 F M00073013C:BIF97-26811-NormBPHProstate Table 2 1p CLUSTERSEQNAME ORTENCLONE ID LIBRARY

51 672233 2505.I16.GZ43 F M00073013C:G05IF97-26811-NormBPHProstate 52 31453 2505.J15.GZ43 F M00073014D:F01IF97-26811-NormBPHProstate 53 40330 366404 F M00073015A:E12IF97-26811-NormBPHProstate 2505.J20.GZ43 54 38454 2505.J22.GZ43 F M00073015A:H06IF97-26811-NormBPHProstate 55 666927 2505.J23.GZ43 F M00073015B:A05IF97-26811-NormBPHProstate 56 163500 505.K09.GZ43 F M00073015C:E10IF97-26811-NormBPHProstate 57 42034 36642 F M00073017A:D06IF97-26811-NormBPHProstate 2505.L07.GZ43 58 455662 2505.L09.GZ43 F M00073017A:F03IF97-26811-NormBPHProstate 59 985835 505.M09.GZ43 F M00073019A:H12IF97-26811-NormBPHProstate 60 502358 505.M10.GZ43 F M00073019B:B12IF97-26811-NormBPHProstate 61 189993 36647 F M00073020C:F07IF97-26811-NormBPHProstate 505.N19.GZ43 62 605923 505.N21.GZ43 F M00073020D:C06IF97-26811-NormBPHProstate 63 935908 505.009.GZ43 F M00073021C:E04IF97-26811-NormBPHProstate 64 568204 505.012.GZ43 F M00073021D:C03IF97-26811-NormBPHProstate 65 640970 366521 F M00073023A:D10IF97-26811-NormBPHProstate 66 558581 505.019.GZ43 F M00073025A:E11IF97-26811-NormBPHProstate 2505.P09.GZ43 67 823 2505.P23.GZ43 F M00073026B:F01IF97-26811-NormBPHProstate 68 195498 510.A11.GZ43 F M00073026D:G04IF97-26811-NormBPHProstate 69 7885 36903 F M00073027B:H12IF97-26811-NormBPHProstate 510.A19.GZ43 70 63363 2510.C06.GZ43 F M00073030A:G05IF97-26811-NormBPHProstate 71 558602 36907 F M00073030B:C02IF97-26811-NormBPHProstate 2510.C07.GZ43 72 38454 2510.C10.GZ43 F M00073030C:A02IF97-26811-NormBPHProstate 73 21546 369083 F M00073036C:H10IF97-26811-NormBPHProstate 2510.E13.GZ43 74 846506 2510.E16.GZ43 F M00073037A:C06IF97-26811-NormBPHProstate 75 62816 2510.F11.GZ43 F M00073037D:H02IF97-26811-NormBPHProstate 76 134226 369156 F M00073038C:C07IF97-26811-NormBPHProstate 77 63363 2510.F23.GZ43 F M00073038D:D12IF97-26811-NormBPHProstate 510.G05.GZ43 78 85192 510.G06.GZ43 F M00073038D:F10IF97-26811-NormBPHProstate 79 9048 510.G09.GZ43 F M00073039A:D09IF97-26811-NormBPHProstate 80 480019 510.G14.GZ43 F M00073039C:B10IF97-26811-NormBPHProstate 81 58429 36918 F M00073040A:B02IF97-26811-NormBPHProstate 510.G21.GZ43 82 115787 510.H03.GZ43 F M00073040D:F05IF97-26811-NormBPHProstate 83 42891 2510.108.GZ43 F M00073043B:C10IF97-26811-NormBPHProstate 84 469837 2510.I10.GZ43 F M00073043B:E08IF97-26811-NormBPHProstate 85 54634 369227 F M00073043C:F04IF97-26811-NormBPHProstate 2510.I16.GZ43 86 648899 2510.I23.GZ43 F M00073043D:H09IF97-26811-NormBPHProstate 87 778001 2510.J06.GZ43 F M00073044B:F08IF97-26811-NormBPHProstate 88 452714 2510.J10.GZ43 F M00073044C:C12IF97-26811-NormBPHProstate 89 142502 369251 F M00073044C:D08IF97-26811-NormBPHProstate 2510.J11.GZ43 90 668962 2510.J12.GZ43 F M00073044C:G12IF97-26811-NormBPHProstate 91 210229 2510.J14.GZ43 F M00073044D:F08IF97-26811-NormBPHProstate 92 483211 2510.J18.GZ43 F M00073045B:A03IF97-26811-NormBPHProstate 93 7307 369259 F M00073045B:D06IF97-26811-NormBPHProstate 2510.J22.GZ43 94 99399 510.K05.GZ43 F M00073045C:E06IF97-26811-NormBPHProstate 95 421869 510.K06.GZ43 F M00073045C:E07IF97-26811-NormBPHProstate 96 21827 510.K11.GZ43 F M00073045D:B04IF97-26811-NormBPHProstate 97 88462 510.K15.GZ43 F M00073046A:A05IF97-26811-NormBPHProstate 98 16176 510.K16.GZ43 F M00073046A:A06IF97-26811-NormBPHProstate 99 138646 369281 F M00073046B:A12IF97-26811-NormBPHProstate 510.K21.GZ43 100513744 2510.L10.GZ43 F M00073046D:F04IF97-26811-NormBPHProstate Table 2 S EN
OR

~ CLUSTERSEQNAME T CLONE ID LIBRARY

10115951 2510.L17.GZ4336930F M00073047B:E10IF97-26811-NormBPHProstate 10240270 2510.L21.GZ4336931F M00073047C:G01IF97-26811-NormBPHProstate 10373796 510.M14.GZ4336932F M00073048A:H05IF97-26811-NormBPHProstate 10418508 510.M20.GZ4336933F M00073048C:A11IF97-26811-NormBPHProstate 10518629 510.M21.GZ4336933F M00073048C:B01IF97-26811-NormBPHProstate 106405925 510.NOl.GZ4336933F M00073048C:E11IF97-26811-NormBPHProstate 107455862 510.N12.GZ4336934F M00073049A:H04IF97-26811-NormBPHProstate 108582134 510.N13.GZ4336935F M00073049B:B03IF97-26811-NormBPHProstate 109727966 510.N14.GZ43369351F M00073049B:B06IF97-26811-NormBPHProstate 110644299 510.N24.GZ4336936F M00073049C:C09IF97-26811-NormBPHProstate 111208449 510.007.GZ4336936F M00073049C:H07IF97-26811-NormBPHProstate 11244480 510.014.GZ4336937F M00073050A:D09IF97-26811-NormBPHProstate 113148227 510.021.GZ4336938F M00073051A:D07IF97-26811-NormBPHProstate 114197343 510.022.GZ4336938F M00073051A:F12IF97-26811-NormBPHProstate 11520571 510.023.GZ4336938F M00073051A:F07IF97-26811-NormBPHProstate 116724818 2510.P08.GZ43369393F M00073052B:H12IF97-26811-NormBPHProstate 1179051 365.A13.GZ4334523F M00073054A:A06IF97-26811-NormBPHProstate 11877849 365.A14.GZ4334524F M00073054A:C10IF97-26811-NormBPHProstate 1195823 365.A23.GZ4334524F M00073054B:E07IF97-26811-NormBPHProstate 12041430 365.B02.GZ4334525F M00073054C:E02IF97-26811-NormBPHProstate 12124115 365.B20.GZ4334527F M00073055D:E11IF97-26811-NormBPHProstate 122573764 2365.C10.GZ4334528F M00073056C:A09IF97-26811-NormBPHProstate 12344480 2365.C13.GZ4334528F M00073056C:C12IF97-26811-NormBPHProstate 12415604 2365.C20.GZ4334529F M00073057A:F09IF97-26811-NormBPHProstate 12554203 365.D03.GZ43345301F M00073057D:A12IF97-26811-NormBPHProstate 126756337 365.DIO.GZ4334530F M00073060B:C06IF97-26811-NormBPHProstate 12716852 2365.E03.GZ43345325F M00073061B:F10IF97-26811-NormBPHProstate 12859018 2365.E08.GZ4334533F M00073061C:G08IF97-26811-NormBPHProstate 12961166 2365.E11.GZ43345333F M00073062B:D09IF97-26811-NormBPHProstate 130119614 2365.E12.GZ4334533F M00073062C:D09IF97-26811-NormBPHProstate 131806992 2365.F07.GZ43345353F M00073064C:A11IF97-26811-NormBPHProstate 132659483 2365.F12.GZ43345358F M00073064C:H09IF97-26811-NormBPHProstate 13334077 2365.F13.GZ43345359F M00073064D:B11IF97-26811-NormBPHProstate 134404081 2365.F24.GZ43345370F M00073065D:D11IF97-26811-NormBPHProstate 135752623 365.G09.GZ4334537F M00073066B:G03IF97-26811-NormBPHProstate 136531505 365.G11.GZ43345381F M00073066C:D02IF97-26811-NormBPHProstate 137588059 365.G17.GZ4334538F M00073067A:E09IF97-26811-NormBPHProstate 138271456 365.G19.GZ4334538F M00073067B:D04IF97-26811-NormBPHProstate 1395791 365.G22.GZ4334539F M00073067D:B02IF97-26811-NormBPHProstate 140725987 2365.I04.GZ43 F M00073069D:G03IF97-26811-NormBPHProstate 14158218 2365.I06.GZ43 F M00073070A:B12IF97-26811-NormBPHProstate 142453526 2365.I11.GZ43 F M00073070B:B06IF97-26811-NormBPHProstate 143141010 2365.J14.GZ43345456F M00073071D:D02IF97-26811-NormBPHProstate 144558342 2365.J19.GZ43345461F M00073072A:A10IF97-26811-NormBPHProstate 145682065 2365.L07.GZ4334549F M00073074B:G04IF97-26811-NormBPHProstate 146466312 2365.L08.GZ4334549F M00073074D:A04IF97-26811-NormBPHProstate 147204211 2365.L23.GZ43345513F M00073078B:F08IF97-26811-NormBPHProstate 148158853 365.M03.GZ4334551F M00073080B:A07IF97-26811-NormBPHProstate 149633646 365.M09.GZ4334552F M0007308lA:F08IF97-26811-NormBPHProstate 150375488 ~365.M13.GZ4334552F ~M00073081D:C07IF97-26811-NormBPHProstate Table 2 S~ CLUSTERSEQNAME O~EN CLONE ID LIBRARY

151228149 365.M20.GZ43 F M00073084C:E02IF97-26811-NormBPHProstate 152599028 365.N12.GZ43 F M00073085D:B01IF97-26811-NormBPHProstate 153691653 365.N23.GZ43 F M00073086D:B05IF97-26811-NormBPHProstate 1548231 365.007.GZ43 F M00073088C:B04IF97-26811-NormBPHProstate 155397652 365.013.GZ43 F M00073088D:F07IF97-26811-NormBPHProstate 15620863 365.020.GZ43 F M00073091B:C04IF97-26811-NormBPHProstate 15711121 365.024.GZ43 F M00073091D:B06IF97-26811-NormBPHProstate 15833725 2365.P04.GZ43 F M00073092A:D03IF97-26811-NormBPHProstate 15937420 2365.P10.GZ43 F M00073092D:B03IF97-26811-NormBPHProstate 160236390 366.AO1.GZ43 F M00073094B:A01IF97-26811-NormBPHProstate 161831518 2366.F02.GZ43 F M00073412A:C03IF97-26811-NormBPHProstate 16289912 2366.E03.GZ43 F M00073408C:F06IF97-26811-NormBPHProstate 163853371 2366.J03.GZ43 F M00073424D:C03IF97-26811-NormBPHProstate 164401741 2366.C04.GZ43 F M00073403B:F06IF97-26811-NormBPHProstate 16550062 366.D04.GZ43 F M00073407A:E12IF97-26811-NormBPHProstate 166377367 2366.F04.GZ43 F M00073412A:H09IF97-26811-NormBPHProstate 1679741 2366.I04.GZ43 F M00073421C:B07IF97-26811-NormBPHProstate 16813951 366.H05.GZ43 F M00073416B:F01IF97-26811-NormBPHProstate 169497520 2366.J05.GZ43 F M00073425A:G10IF97-26811-NormBPHProstate 170136530 2366.J06.GZ43 F M00073425A:H12IF97-26811-NormBPHProstate 171403134 2366.C07.GZ43 F M00073403C:C10IF97-26811-NormBPHProstate 172379939 2366.L07.GZ43 F M00073428D:H03IF97-26811-NormBPHProstate 173128835 2366.C08.GZ43 F M00073403C:E11IF97-26811-NormBPHProstate 17434475 2366.P08.GZ43 F M00073435B:E11IF97-26811-NormBPHProstate 175427808 366.M09.GZ43 F M00073431A:G02IF97-26811-NormBPHProstate 176450472 2366.F10.GZ43 F M00073412C:E07IF97-26811-NormBPHProstate 17731060 2366.P11.GZ43 F M00073435C:E06IF97-26811-NormBPHProstate 178734776 2366.F12.GZ43 F M00073412D:B07IF97-26811-NormBPHProstate 17947789 2366.L12.GZ43 F M00073429B:H10IF97-26811-NormBPHProstate 180559440 2366.C13.GZ43 F M00073403C:H09IF97-26811-NormBPHProstate 181169728 2366.F13.GZ43 F M00073412D:E02IF97-26811-NormBPHProstate 182137023 366.K13.GZ43 F M00073427B:C08IF97-26811-NormBPHProstate 183732434 2366.I14.GZ43 F M00073423C:E01IF97-26811-NormBPHProstate 184529 366.K14.GZ43 F M00073427B:E04IF97-26811-NormBPHProstate 18532624 2366.J15.GZ43 F M00073425D:F08IF97-26811-NormBPHProstate 186378965 366.A17.GZ43 F M00073096B:A12IF97-26811-NormBPHProstate 18716009 2366.L19.GZ43 F M00073430C:A01IF97-26811-NormBPHProstate 188134637 366.H20.GZ43 F M00073418B:B09IF97-26811-NormBPHProstate 1891959 2366.L21.GZ43 F M00073430C:B02IF97-26811-NormBPHProstate 190805118 366.A22.GZ43 F M00073097C:A03IF97-26811-NormBPHProstate 191411952 366.H22.GZ43 F M00073418B:H09IF97-26811-NormBPHProstate 192887 366.D23.GZ43 F M00073408A:D06IF97-26811-NormBPHProstate 193172916 367.A21.GZ43 F M00073438A:A08IF97-26811-NormBPHProstate 194929222 367.A22.GZ43 F M00073438A:B02IF97-26811-NormBPHProstate 195968417 367.B10.GZ43 F M00073438D:G05IF97-26811-NormBPHProstate 196588996 2367.C06.GZ43 F M00073442A:F07IF97-26811-NormBPHProstate 197560612 2367.C08.GZ43 F M00073442B:D12IF97-26811-NormBPHProstate 19815307 2367.C12.GZ43 F M00073442D:E11IF97-26811-NormBPHProstate 19988462 367.D11.GZ43 F M00073446C:A03IF97-26811-NormBPHProstate 200923732 367.D18.GZ43 F M00073447B:A03IF97-26811-NormBPHProstate Table 2 S~ CLUSTERSEQNAME O~EN CLONE ID LIBRARY

201423085 367.D21.GZ43 F M00073447D:F01IF97-26811-NormBPHProstate 202483211 2367.E03.GZ43 F M00073448B:F11IF97-26811-NormBPHProstate 203465814 2367.E04.GZ43 F M00073448B:F07IF97-26811-NormBPHProstate 204244504 2367.E23.GZ43 F M00073453C:C09IF97-26811-NormBPHProstate 205395761 2367.F06.GZ43 F M00073455C:G09IF97-26811-NormBPHProstate 206514044 2367.F13.GZ43 F M00073457A:G09IF97-26811-NormBPHProstate 207227227 367.G11.GZ43 F M00073462C:H12IF97-26811-NormBPHProstate 208691653 367.G13.GZ43 F M00073462D:D12IF97-26811-NormBPHProstate 209416124 367.G17.GZ43 F M00073464B:E01IF97-26811-NormBPHProstate 210452486 367.G20.GZ43 F M00073464D:G12IF97-26811-NormBPHProstate 211486366 34615 F M00073465A:H08IF97-26811-NormBPHProstate 212417672 367.G22.GZ43 F M00073469B:A09IF97-26811-NormBPHProstate 2367.I09.GZ43 2134481 2367.I15.GZ43 F M00073469D:A06IF97-26811-NormBPHProstate 21411528 2367.I22.GZ43 F M00073470D:A01IF97-26811-NormBPHProstate 215552537 346208 F M00073474A:G11IF97-26811-NormBPHProstate 367.K06.GZ43 2161049007367.K13.GZ43 F M00073474C:F08IF97-26811-NormBPHProstate 21714533 367.K24.GZ43 F M00073475D:E05IF97-26811-NormBPHProstate 218192060 2367.L11.GZ43 F M00073478C:A07IF97-26811-NormBPHProstate 219571816 34626 F M00073483B:C07IF97-26811-NormBPHProstate 367.M06.GZ43 220660248 367.M14.GZ43 F M00073484B:A05IF97-26811-NormBPHProstate 221192060 367.M16.GZ43 F M00073484C:B04IF97-26811-NormBPHProstate 222606908 367.M19.GZ43 F M00073486A:A12IF97-26811-NormBPHProstate 223466749 34630 F M00073487A:C07IF97-26811-NormBPHProstate 367.N05.GZ43 224396325 367.N16.GZ43 F M00073489B:A07IF97-26811-NormBPHProstate 225400167 367.008.GZ43 F M00073493A:E12IF97-26811-NormBPHProstate 226446968 34633 F M00073493D:F05IF97-26811-NormBPHProstate 227160534 367.016.GZ43 F M00073495B:G11IF97-26811-NormBPHProstate 367.021.GZ43 228621397 2367.P12.GZ43 F M00073497C:D03IF97-26811-NormBPHProstate 229391679 368.A13.GZ43 F M00073504D:F03IF97-26811-NormBPHProstate 230605923 368.A23.GZ43 F M00073505D:F01IF97-26811-NormBPHProstate 231416124 346401 F M00073509B:B11IF97-26811-NormBPHProstate 368.B18.GZ43 232464200 368.B20.GZ43 F M00073509B:E03IF97-26811-NormBPHProstate 233640970 2368.C15.GZ43 F M00073513A:G07IF97-26811-NormBPHProstate 234858675 2368.C19.GZ43 F M00073513D:A11IF97-26811-NormBPHProstate 235467877 368.D08.GZ43 F M00073515A:F09IF97-26811-NormBPHProstate 236752831 368.D20.GZ43 F M00073517A:A06IF97-26811-NormBPHProstate 237423085 2368.E06.GZ43 F M00073517D:F11IF97-26811-NormBPHProstate 238474125 2368.F12.GZ43 F M00073520D:A04IF97-26811-NormBPHProstate 23970469 346510 F M00073524A:A03IF97-26811-NormBPHProstate 2368.F22.GZ43 24039999 368.GO1.GZ43 F M00073524A:G05IF97-26811-NormBPHProstate 241847088 368.H07.GZ43 F M00073529A:F03IF97-26811-NormBPHProstate 242510539 368.H12.GZ43 F M00073530B:A02IF97-26811-NormBPHProstate 243402167 34655 F M00073531B:H02IF97-26811-NormBPHProstate 368.H15.GZ43 244389538 368.H17.GZ43 F M00073531C:F12IF97-26811-NormBPHProstate 245858540 2368.I04.GZ43 F M00073537B:A12IF97-26811-NormBPHProstate 246113786 2368.I23.GZ43 F M00073539C:H05IF97-26811-NormBPHProstate 247468400 346593 F M00073541B:C10IF97-26811-NormBPHProstate 2368.J18.GZ43 248605923 368.K19.GZ43 F M00073547B:F04IF97-26811-NormBPHProstate 2491796 368.K21.GZ43 F M00073547C:D02IF97-26811-NormBPHProstate 25015951 2368.L06.GZ43 F M00073549B:B03IF97-26811-NormBPHProstate Table 2 ID CLUSTERSEQNAME ORTEN CLONE ID LIBRARY

25143907 2368.L24.GZ43 F M00073551B:E10IF97-26811-NormBPHProstate 25248738 368.M19.GZ43 F M00073552A:F06IF97-26811-NormBPHProstate 253597681 34668 F M00073554A:C01IF97-26811-NormBPHProstate 368.N03.GZ43 254821039 368.N05.GZ43 F M00073554A:G04IF97-26811-NormBPHProstate 255954391 368.N06.GZ43 F M00073554B:A08IF97-26811-NormBPHProstate 256404368 368.N08.GZ43 F M00073554B:D11IF97-26811-NormBPHProstate 257460493 34669 F M00073555A:B09IF97-26811-NormBPHProstate 368.N15.GZ43 258778001 368.N23.GZ43 F M00073555D:B04IF97-26811-NormBPHProstate 259404081 368.003.GZ43 F M00073557A:A05IF97-26811-NormBPHProstate 260368947 368.O11.GZ43 F M00073558A:A02IF97-26811-NormBPHProstate 261421869 2368.P13.GZ43 F M00073561C:A04IF97-26811-NormBPHProstate 262621573 535.A08.GZ43 F M00073565D:E05IF97-26811-NormBPHProstate 263640911 535.A10.GZ43 F M00073566A:G01IF97-26811-NormBPHProstate 264450754 535.B09.GZ43 F M00073568A:G06IF97-26811-NormBPHProstate 265455862 535.B12.GZ43 F M00073568C:G07IF97-26811-NormBPHProstate 26622339 535.B20.GZ43 F M00073569A:H02IF97-26811-NormBPHProstate 267372750 535.C23.GZ43 F M00073571A:F12IF97-26811-NormBPHProstate 268677530 2535.E22.GZ43 F M00073575B:H12IF97-26811-NormBPHProstate 269605923 370205 F M00073576B:E03IF97-26811-NormBPHProstate 2535.F05.GZ43 27035578 2535.F07.GZ43 F M00073576C:C11IF97-26811-NormBPHProstate 271568661 2535.F11.GZ43 F M00073577B:D12IF97-26811-NormBPHProstate 27264401 535.G02.GZ43 F M00073579B:A04IF97-26811-NormBPHProstate 27376555 37023 F M00073580A:D08IF97-26811-NormBPHProstate 535.G13.GZ43 27436568 2535.J20.GZ43 F M00073587D:E12IF97-26811-NormBPHProstate 275533888 535.KO1.GZ43 F M00073588B:H07IF97-26811-NormBPHProstate 27613301 2535.L03.GZ43 F M00073590C:F07IF97-26811-NormBPHProstate 27752735 2535.L18.GZ43 F M00073592B:D09IF97-26811-NormBPHProstate 27833508 535.M11.GZ43 F M00073594B:B11IF97-26811-NormBPHProstate 279436659 535.N06.GZ43 F M00073595D:A11IF97-26811-NormBPHProstate 280451707 535.007.GZ43 F M00073598D:E11IF97-26811-NormBPHProstate 281481445 37043 F M00073599C:E08IF97-26811-NormBPHProstate 535.013.GZ43 282135469 2535.P02.GZ43 F M00073601A:B06IF97-26811-NormBPHProstate 28336102 2535.P06.GZ43 F M00073601A:F07IF97-26811-NormBPHProstate 2846712 2535.P14.GZ43 F M00073601D:D08IF97-26811-NormBPHProstate 28587043 370461 F M00073603A:F04IF97-26811-NormBPHProstate 536.A06.GZ43 286375483 536.A07.GZ43 F M00073603B:C03IF97-26811-NormBPHProstate 287415500 536.A08.GZ43 F M00073603C:A11IF97-26811-NormBPHProstate 2887368 536.A09.GZ43 F M00073603C:C02IF97-26811-NormBPHProstate 289553460 536.A14.GZ43 F M00073603D:E07IF97-26811-NormBPHProstate 290210361 536.A19.GZ43 F M00073604B:B07IF97-26811-NormBPHProstate 291260521 536.A20.GZ43 F M00073604B:H06IF97-26811-NormBPHProstate 29270406 536.A22.GZ43 F M00073604C:H09IF97-26811-NormBPHProstate 29321817 536.B06.GZ43 F M00073605B:F10IF97-26811-NormBPHProstate 29462816 536.B07.GZ43 F M00073605B:F11IF97-26811-NormBPHProstate 29510376 536.B15.GZ43 F M00073606D:F12IF97-26811-NormBPHProstate 29635707 2536.C12.GZ43 F M00073610A:F06IF97-26811-NormBPHProstate 297738158 370531 F M00073614B:A12IF97-26811-NormBPHProstate 536.D17.GZ43 298974091 536.D20.GZ43 F M00073614B:G09IF97-26811-NormBPHProstate 299374280 536.D22.GZ43 F M00073614C:F06IF97-26811-NormBPHProstate 300375209 2536.E08.GZ43 F M00073615D:E03IF97-26811-NormBPHProstate Table 2 ID CLUSTERSEQNAME ORTENCLONE ID LIBRARY

301176266 2536.E11.GZ4337057F M00073616A:F06IF97-26811-NormBPHProstate 30231475 2536.E21.GZ4337058F M00073617A:H04IF97-26811-NormBPHProstate 303235423 536.G05.GZ4337062F M00073620A:G05IF97-26811-NormBPHProstate 30488462 536.G20.GZ4337063F M00073621D:A04IF97-26811-NormBPHProstate 305186007 536.G21.GZ4337063F M00073621D:D02IF97-26811-NormBPHProstate 30612346 536.G22.GZ4337063F M00073621D:H05IF97-26811-NormBPHProstate 30798685 536.H08.GZ4337064F M00073623D:H10IF97-26811-NormBPHProstate 308861172 536.H20.GZ4337065F M00073625C:D09IF97-26811-NormBPHProstate 309164426 2536.I05.GZ43370668F M00073626D:A01IF97-26811-NormBPHProstate 310428727 2536.I15.GZ43370678F M00073628A:E03IF97-26811-NormBPHProstate 311573 2536.J05.GZ43370692F M00073630A:C03IF97-26811-NormBPHProstate 312883034 2536.J09.GZ43370696F M00073630B:E09IF97-26811-NormBPHProstate 313856743 2536.J11.GZ43370698F M00073630C:D02IF97-26811-NormBPHProstate 31460888 536.K12.GZ4337072F M00073632A:B12IF97-26811-NormBPHProstate 315207397 536.K21.GZ4337073F M00073632C:A03IF97-26811-NormBPHProstate 316177456 2536.L18.GZ43370753F M00073633D:A04IF97-26811-NormBPHProstate 31747454 2536.L22.GZ4337075F M00073633D:G04IF97-26811-NormBPHProstate 31833967 536.M10.GZ4337076F M00073634C:H08IF97-26811-NormBPHProstate 319402043 536.N05.GZ4337078F M00073635D:C10IF97-26811-NormBPHProstate 320831101 536.N20.GZ4337080F M00073636C:F03IF97-26811-NormBPHProstate 321736938 536.012.GZ4337081F M00073637C:B01IF97-26811-NormBPHProstate 32240144 536.014.GZ43370821F M00073637C:E04IF97-26811-NormBPHProstate 32313473 536.022.GZ4337082F M00073638A:A12IF97-26811-NormBPHProstate 32423951 2536.P14.GZ43370845F M00073638D:D10IF97-26811-NormBPHProstate 32572334 2536.P17.GZ43370848F M00073639A:G08IF97-26811-NormBPHProstate 326140322 2536.P22.GZ43370853F M00073639B:F02IF97-26811-NormBPHProstate 32742714 536.M04.GZ4337076F M00073634B:C121F97-26811-NormBPHProstate 32825714 537.A21.GZ4337087F M00073640B:G08IF97-26811-NormBPHProstate 329177456 537.A23.GZ4337087F M00073640C:A03IF97-26811-NormBPHProstate 3307546 2537.B07.GZ4337088F M00073640D:A11IF97-26811-NormBPHProstate 33121102 2537.B14.GZ4337089F M00073640D:G07IF97-26811-NormBPHProstate 332375856 2537.C10.GZ43370913F M00073641B:G07IF97-26811-NormBPHProstate 33315080 2537.C18.GZ43370921F M00073641C:E04IF97-26811-NormBPHProstate 33444198 537.D11.GZ4337093F M00073643B:E11IF97-26811-NormBPHProstate 335598913 537.D20.GZ4337094F M00073644A:G12IF97-26811-NormBPHProstate 336374952 2537.FO1.GZ43370976F M00073646A:C01IF97-26811-NormBPHProstate 337374839 2537.F18.GZ43370993F M00073647B:H07IF97-26811-NormBPHProstate 33821817 537.G05.GZ4337100F M00073649A:A03IF97-26811-NormBPHProstate 3393211 537.G09.GZ4337100F M00073649A:G08IF97-26811-NormBPHProstate 340397144 537.H24.GZ4337104F M00073651C:F06IF97-26811-NormBPHProstate 341379025 2537.I03.GZ43371050F M00073651C:H07IF97-26811-NormBPHProstate 3427368 2537.I08.GZ43371055F M00073652D:B11IF97-26811-NormBPHProstate 343350 2537.J07.GZ43371078F M00073655B:A04IF97-26811-NormBPHProstate 34455140 2537.J23.GZ43371094F M00073657B:D05IF97-26811-NormBPHProstate 3454031 537.K17.GZ4337111F M00073659C:D03IF97-26811-NormBPHProstate 34648711 2537.L23.GZ4337114F M00073663A:E02IF97-26811-NormBPHProstate 347744278 537.M11.GZ4337115F M00073663D:G06IF97-26811-NormBPHProstate 348436755 537.M14.GZ4337115F M00073664A:E03IF97-26811-NormBPHProstate 349148227 537.N12.GZ4337117F M00073666B:B01IF97-26811-NormBPHProstate 350402325 537.N23.GZ4337119F M00073668A:H03IF97-26811-NormBPHProstate Table 2 ID CLUSTERSEQNAME ORTENCLONE ID LIBRARY

35114002 537.N24.GZ43 F M00073668B:A08IF97-26811-NormBPHProstate 352714906 537.005.GZ43 F M00073668D:D10IF97-26811-NormBPHProstate 353557739 37119 F M00073669A:F04IF97-26811-NormBPHProstate 537.O10.GZ43 354296 537.013.GZ43 F M00073669B:E12IF97-26811-NormBPHProstate 355373515 537.021.GZ43 F M00073669D:G10IF97-26811-NormBPHProstate 356455443 2537.P14.GZ43 F M00073671B:D09IF97-26811-NormBPHProstate 35712272 2538.F24.GZ43 F M00073687A:D11IF97-26811-NormBPHProstate 358380624 538.M23.GZ43 F M00073699C:E02IF97-26811-NormBPHProstate 3594442 538.N23.GZ43 F M00073701D:G10IF97-26811-NormBPHProstate 360556517 538.A08.GZ43 F M00073672D:B07IF97-26811-NormBPHProstate 361530582 37124 F M00073672D:E09IF97-26811-NormBPHProstate 538.A10.GZ43 3628126 538.A12.GZ43 F M00073673A:D11IF97-26811-NormBPHProstate 363733673 2538.B03.GZ43 F M00073673D:H03IF97-26811-NormBPHProstate 364446 538.B15.GZ43 F M00073674D:F10IF97-26811-NormBPHProstate 365449576 37127 F M00073676A:G08IF97-26811-NormBPHProstate 538.B20.GZ43 366555630 2538.C07.GZ43 F M00073676D:H04IF97-26811-NormBPHProstate 36719627 2538.C14.GZ43 F M00073677B:F01IF97-26811-NormBPHProstate 368401402 538.D03.GZ43 F M00073678B:E08IF97-26811-NormBPHProstate 369296 37131 F M00073678B:H02IF97-26811-NormBPHProstate 538.D04.GZ43 3703843 538.D11.GZ43 F M00073679A:D06IF97-26811-NormBPHProstate 3711239 2538.EO1.GZ43 F M00073680D:F11IF97-26811-NormBPHProstate 372676448 37133 F M00073681A:F12IF97-26811-NormBPHProstate 373423064 2538.E05.GZ43 F M00073684B:F10IF97-26811-NormBPHProstate 2538.E22.GZ43 374449749 2538.F03.GZ43 F M00073685A:F07IF97-26811-NormBPHProstate 37572417 371362 F M00073688C:A12IF97-26811-NormBPHProstate 538.H02.GZ43 3764650 538.H08.GZ43 F M00073688D:C11IF97-26811-NormBPHProstate 377673484 37141 F M00073689C:C09IF97-26811-NormBPHProstate 538.H19.GZ43 378134226 2538.I06.GZ43 F M00073690B:G04IF97-26811-NormBPHProstate 3799516 2538.I17.GZ43 F M00073691A:G02IF97-26811-NormBPHProstate 380400463 2538.J10.GZ43 F M00073692D:H02IF97-26811-NormBPHProstate 38148289 371465 F M00073695C:D11IF97-26811-NormBPHProstate 538.K17.GZ43 38235380 2538.L09.GZ43 F M00073696C:D11IF97-26811-NormBPHProstate 383375810 2538.L11.GZ43 F M00073696D:A08IF97-26811-NormBPHProstate 384640911 37151 F M00073697C:F11IF97-26811-NormBPHProstate 385374382 2538.L20.GZ43 F M00073699B:D02IF97-26811-NormBPHProstate 538.M16.GZ43 386448604 538.M17.GZ43 F M00073699B:D09IF97-26811-NormBPHProstate 387447798 538.N06.GZ43 F M00073700A:C09IF97-26811-NormBPHProstate 388452289 538.N11.GZ43 F M00073700B:D12IF97-26811-NormBPHProstate 389518084 37156 F M00073707B:G08IF97-26811-NormBPHProstate 2538.P16.GZ43 390706359 554.A04.GZ43 F M00073708D:E10IF97-26811-NormBPHProstate 391901160 554.A06.GZ43 F M00073708D:F03IF97-26811-NormBPHProstate 392510479 554.A12.GZ43 F M00073709B:F01IF97-26811-NormBPHProstate 393149529 37585 F M00073709C:A01IF97-26811-NormBPHProstate 554.A15.GZ43 394727966 554.A16.GZ43 F M00073709C:A02IF97-26811-NormBPHProstate 395398682 554.A23.GZ43 F M00073710B:A09IF97-26811-NormBPHProstate 39657638 554.B12.GZ43 F M00073710D:G06IF97-26811-NormBPHProstate 3978956 37588 F M00073711C:E12IF97-26811-NormBPHProstate 554.B17.GZ43 398599028 554.D02.GZ43 F M00073713D:E07IF97-26811-NormBPHProstate 399497138 554.D09.GZ43 F M00073715A:F05IF97-26811-NormBPH
37592 Prostate 400735042 554.D12.GZ43 F M00073715B:B06_ 375931 IF97-26811-NormBPHProstate Table 2 ~ CLUSTERSEQNAME O~EN CLONE ID LIBRARY

401 42867 2554.E10.GZ43375953F M00073717C:A12IF97-26811-NormBPHProstate 402 29906 2554.E17.GZ43 F M00073718A:F11IF97-26811-NormBPHProstate 403 560612 37596 F M00073720D:H11IF97-26811-NormBPHProstate 2554.F20.GZ43 404 980 554.G22.GZ4337601F M00073724D:F04IF97-26811-NormBPHProstate 405 642041 2554.I10.GZ43376049F M00073732C:B09IF97-26811-NormBPHProstate 406 163500 2554.I15.GZ43 F M00073733A:A05IF97-26811-NormBPHProstate 407 1522 376054 F M00073733A:E03IF97-26811-NormBPHProstate 2554.I18.GZ43 408 573764 2554.J15.GZ43376078F M00073735C:E04IF97-26811-NormBPHProstate 409 40330 554.K08.GZ43 F M00073737A:C12IF97-26811-NormBPHProstate 410 525011 2554.L09.GZ4337612F M00073739D:B04IF97-26811-NormBPHProstate 411 847088 2554.L18.GZ4337612F M00073740B:F08IF97-26811-NormBPHProstate 412 36174 554.M14.GZ4337614F M00073741C:D05IF97-26811-NormBPHProstate 413 455254 554.N09.GZ4337616F M00073743C:F03IF97-26811-NormBPHProstate 414 89912 554.017.GZ4337620F M00073746A:H03IF97-26811-NormBPHProstate 415 451707 2554.P16.GZ43376223F M00073748A:F09IF97-26811-NormBPHProstate 416 43900 2554.P17.GZ4337622F M00073748B:A12IF97-26811-NormBPHProstate 417 752831 2554.P23.GZ4337623F M00073748B:F07IF97-26811-NormBPHProstate 418 558581 565.B13.GZ4339813F M00073750A:E08IF97-26811-NormBPHProstate 419 7307 565.B15.GZ43398171F M00073750A:H08IF97-26811-NormBPHProstate 420 403109 565.B18.GZ4339821F M00073750B:D05IF97-26811-NormBPHProstate 421 60809 2565.C02.GZ4339796F M00073750C:G06IF97-26811-NormBPHProstate 422 375711 2565.C17.GZ43 F M00073751D:A06IF97-26811-NormBPHProstate 423 1371 39820 F M00073753B:B05IF97-26811-NormBPHProstate 565.D06.GZ43 424 402399 565.D22.GZ43 F M00073754B:D05IF97-26811-NormBPHProstate 425 18508 2565.E03.GZ43 F M00073754B:H02IF97-26811-NormBPHProstate 426 617 2565.E05.GZ4339801F M00073754C:C01IF97-26811-NormBPHProstate 427 147634 2565.F18.GZ43398223F M00073758C:G03IF97-26811-NormBPHProstate 428 10334 565.G20.GZ4339825F M00073760B:BIF97-26811-NormBPHProstate 429 1530 565.HO1.GZ4339795F M00073760D:F04IF97-26811-NormBPHProstate 430 373261 565.H12.GZ4339812F M00073762A:B09IF97-26811-NormBPHProstate 431 18746 565.H21.GZ4339827F M00073762D:C02IF97-26811-NormBPHProstate 432 524083 565.H24.GZ4339832F M00073763A:D06IF97-26811-NormBPHProstate 433 724819 2565.122.GZ43398290F M00073764B:B09IF97-26811-NormBPHProstate 434 401809 2565.J08.GZ43 F M00073764D:A07IF97-26811-NormBPHProstate 435 424776 398067 F M00073764D:B12IF97-26811-NormBPHProstate 436 648899 2565.J09.GZ43 F M00073765A:E02IF97-26811-NormBPHProstate 2565.J13.GZ43 437 752623 2565.J19.GZ43398243F M00073765C:B01IF97-26811-NormBPHProstate 438 193333 565.K04.GZ4339800F M00073766A:B07IF97-26811-NormBPHProstate 439 493811 565.K07.GZ4339805F M00073766B:B07IF97-26811-NormBPHProstate 440 46581 565.K09.GZ4339808F M00073766B:C04IF97-26811-NormBPHProstate 441 19736 2565.L21.GZ4339827F M00073769D:G10IF97-26811-NormBPHProstate 442 449073 565.M14.GZ4339816F M00073772B:E07IF97-26811-NormBPHProstate 443 42891 565.M24.GZ4339832F M00073773A:F05IF97-26811-NormBPHProstate 444 456043 565.N02.GZ4339797F M00073773A:G04IF97-26811-NormBPHProstate 445 70411 565.N03.GZ43397991F M00073773B:A09IF97-26811-NormBPHProstate 446 174228 565.N20.GZ4339826F M00073774C:G12IF97-26811-NormBPHProstate 447 448795 565.007.GZ4339805F M00073776C:F11IF97-26811-NormBPHProstate 448 452714 565.012.GZ4339813F M00073777A:A01IF97-26811-NormBPHProstate 449 70908 565.016.GZ4339820F M00073777A:H03IF97-26811-NormBPHProstate 450 562386 2565.P08.GZ43398073F M00073779B:B11IF97-26811-NormBPHProstate Table 2 ID CLUSTERSEQNAME ORTENCLONE ID LIBRARY

451 21817 2565.P24.GZ43 F M00073784A:A12IF97-26811-NormBPHProstate 452 696086 540.A24.GZ43 F M00073785C:A05IF97-26811-NormBPHProstate 453 36174 372031 F M00073785D:D01IF97-26811-NormBPHProstate 454 481445 540.B02.GZ43 F M00073787D:H12IF97-26811-NormBPHProstate 540.C04.GZ43 455 552537 2540.C10.GZ43 F M00073788C:A10IF97-26811-NormBPHProstate 456 507628 540.D02.GZ43 F M00073790C:E07IF97-26811-NormBPHProstate 457 113786 37208 F M00073793C:E09IF97-26811-NormBPHProstate 2540.E09.GZ43 458 454796 2540.F03.GZ43 F M00073795A:F03IF97-26811-NormBPHProstate 459 134637 2540.F05.GZ43 F M00073795B:B05IF97-26811-NormBPHProstate 460 450227 2540.F06.GZ43 F M00073795B:B09IF97-26811-NormBPHProstate 461 23300 372133 F M00073796A:C03IF97-26811-NormBPHProstate 2540.F13.GZ43 462 57350 540.G11.GZ43 F M00073798A:H03IF97-26811-NormBPHProstate 463 633752 37216 F M00073800D:F08IF97-26811-NormBPHProstate 540.H07.GZ43 464 516985 540.H13.GZ43 F M00073801B:A10IF97-26811-NormBPHProstate 465 376272 37218 F M00073802D:B11IF97-26811-NormBPHProstate 2540.IIO.GZ43 466 39862 540.K12.GZ43 F M00073806D:C09IF97-26811-NormBPHProstate 467 525801 540.M05.GZ43 F M00073809C:E09IF97-26811-NormBPHProstate 468 830453 37230 F M00073810C:F05IF97-26811-NormBPHProstate 469 454796 540.M22.GZ43 F M00073813D:B06IF97-26811-NormBPHProstate 2540.P02.GZ43 470 572170 2540.P13.GZ43 F M00073814C:B04IF97-26811-NormBPHProstate 471 44044 540.B15.GZ43 F M00073786D:B03IF97-26811-NormBPHProstate 472 553297 2540.C19.GZ43 F M00073789C:B06IF97-26811-NormBPHProstate 473 402167 37207 F M00073790A:A12IF97-26811-NormBPHProstate 2540.C21.GZ43 474 38334 540.D19.GZ43 F M00073792B:A03IF97-26811-NormBPHProstate 475 477271 37209 F M00073794B:G09IF97-26811-NormBPHProstate 2540.E17.GZ43 476 519354 2540.FO1.GZ43 F M00073794D:G07IF97-26811-NormBPHProstate 477 528957 372128 F M00073796A:D08IF97-26811-NormBPHProstate 2540.F15.GZ43 478 89912 2540.F17.GZ43 F M00073796B:A03IF97-26811-NormBPHProstate 479 495563 540.G16.GZ43 F M00073799A:A09IF97-26811-NormBPHProstate 480 626993 37216 F M00073799A:G02IF97-26811-NormBPHProstate 481 429609 540.G19.GZ43 F M00073799D:G04IF97-26811-NormBPHProstate 540.HO1.GZ43 482 932437 2540.I17.GZ43 F M00073803B:B03IF97-26811-NormBPHProstate 483 427559 2540.I20.GZ43 F M00073803B:C06IF97-26811-NormBPHProstate 484 14214 540.M15.GZ43 F M00073810B:G10IF97-26811-NormBPHProstate 485 379689 37231 F M00073810C:A06IF97-26811-NormBPHProstate 540.M18.GZ43 486 552374 540.016.GZ43 F M00073813A:E06IF97-26811-NormBPHProstate 487 743053 540.019.GZ43 F M00073813B:A01IF97-26811-NormBPHProstate 488 474125 541.A06.GZ43 F M00073815D:E02IF97-26811-NormBPHProstate 489 498886 37239 F M00073818A:A06IF97-26811-NormBPHProstate 541.B15.GZ43 490 993554 541.D03.GZ43 F M00073819D:C11IF97-26811-NormBPHProstate 491 7170 541.D14.GZ43 F M00073821A:B10IF97-26811-NormBPHProstate 492 36866 541.D21.GZ43 F M00073821B:H03IF97-26811-NormBPHProstate 493 451707 2541.E16.GZ43 F M00073822C:E02IF97-26811-NormBPHProstate 494 948383 2541.F05.GZ43 F M00073824A:C04IF97-26811-NormBPHProstate 495 454796 2541.F18.GZ43 F M00073826B:C01IF97-26811-NormBPHProstate 496 821039 2541.I08.GZ43 F M00073831B:H09IF97-26811-NormBPHProstate 497 568204 372591 F M00073832A:A06IF97-26811-NormBPHProstate 498 652099 2541.I17.GZ43 F M00073832A:G01IF97-26811-NormBPHProstate 2541.I23.GZ43 499 723822 2541.I24.GZ43 F M00073832B:B05IF97-26811-NormBPHProstate 500 207018 2541.J17.GZ43 F M00073834A:H10IF97-26811-NormBPHProstate Table 2 ID CLUSTERSEQNAME ORTENCLONE ID LIBRARY

501 2745 2541.J23.GZ43 F M00073834D:E07IF97-26811-NormBPHProstate 502 1049007541.K02.GZ43 F M00073834D:H06IF97-26811-NormBPHProstate 503 558463541.K15.GZ43 F M00073836D:E05IF97-26811-NormBPHProstate 504 20052 541.K18.GZ43 F M00073837B:D12IF97-26811-NormBPHProstate 505 2084492541.L02.GZ43 F M00073838A:H07IF97-26811-NormBPHProstate 506 8533712541.L06.GZ43 F M00073838B:F09IF97-26811-NormBPHProstate 507 398682372661 F M00073838B:H06IF97-26811-NormBPHProstate 2541.L08.GZ43 508 40241 2541.L12.GZ43 F M00073838D:E01IF97-26811-NormBPHProstate 509 4230852541.L21.GZ43 F M00073839A:D05IF97-26811-NormBPHProstate 510 640911541.M24.GZ43 F M00073840D:C08IF97-26811-NormBPHProstate 511 52037037270 F M00073841A:A03IF97-26811-NormBPHProstate 541.NO1.GZ43 512 6438282541.P14.GZ43 F M00073845D:F05IF97-26811-NormBPHProstate 513 3847762506.C08.GZ43 F M00073850A:H09IF97-26811-NormBPHProstate 514 765 2506.C15.GZ43 F M00073850D:G04IF97-26811-NormBPHProstate 515 3188 36662 F M00073851A:C05IF97-26811-NormBPHProstate 2506.C18.GZ43 516 20818 2506.C20.GZ43 F M00073851A:E04IF97-26811-NormBPHProstate 517 4010672506.EO1.GZ43 F M00073853C:A01IF97-26811-NormBPHProstate 518 382 2506.E12.GZ43 F M00073854B:B04IF97-26811-NormBPHProstate 519 237334366665 F M00073854C:F08IF97-26811-NormBPHProstate 2506.E18.GZ43 520 379913506.GO1.GZ43 F M00073857A:B12IF97-26811-NormBPHProstate 521 663109506.G24.GZ43 F M00073859A:C09IF97-26811-NormBPHProstate 522 702885506.H20.GZ43 F M00073860B:F12IF97-26811-NormBPHProstate 523 37416436674 F M00073861D:A09IF97-26811-NormBPHProstate 2506.I12.GZ43 524 4023252506.I14.GZ43 F M00073861D:D08IF97-26811-NormBPHProstate 525 2660 2506.I24.GZ43 F M00073862B:D11IF97-26811-NormBPHProstate 526 3735782506.J12.GZ43 F M00073862D:F06IF97-26811-NormBPHProstate 527 403773366785 F M00073863B:G09IF97-26811-NormBPHProstate 2506.J20.GZ43 528 4290 2506.J22.GZ43 F M00073863C:D04IF97-26811-NormBPHProstate 529 117060506.K20.GZ43 F M00073865B:G04IF97-26811-NormBPHProstate 530 42794 2506.L08.GZ43 F M00073866A:G07IF97-26811-NormBPHProstate 531 40541 36682 F M00073867B:E01IF97-26811-NormBPHProstate 506.M05.GZ43 532 401013506.M13.GZ43 F M00073867D:F10IF97-26811-NormBPHProstate 533 374406506.O11.GZ43 F M00073871B:C12IF97-26811-NormBPHProstate 534 40094 2506.P07.GZ43 F M00073872C:B09IF97-26811-NormBPHProstate 535 37428036692 F M00073872D:B01IF97-26811-NormBPHProstate 2506.P11.GZ43 536 3760542506.P13.GZ43 F M00073872D:E10IF97-26811-NormBPHProstate 537 1724742506.P19.GZ43 F M00073873C:A06IF97-26811-NormBPHProstate 538 8159 542.A15.GZ43 F M00073875A:B03IF97-26811-NormBPHProstate 539 51272 37279 F M00073875C:G02IF97-26811-NormBPHProstate 542.BO1.GZ43 540 7097962542.C20.GZ43 F M00073878C:A03IF97-26811-NormBPHProstate 541 380482542.D09.GZ43 F M00073879D:B08IF97-26811-NormBPHProstate 542 573764542.D18.GZ43 F M00073880B:B02IF97-26811-NormBPHProstate 543 5105 37286 F M00073880B:B09IF97-26811-NormBPHProstate 542.D19.GZ43 544 5513792542.F05.GZ43 F M00073883B:D03IF97-26811-NormBPHProstate 545 6159992542.F08.GZ43 F M00073883B:H03IF97-26811-NormBPHProstate 546 464200542.H02.GZ43 F M00073886C:C12IF97-26811-NormBPHProstate 547 74305337294 F M00073889B:G08IF97-26811-NormBPHProstate 2542.I14.GZ43 548 4832112542.J12.GZ43 F M00073891A:A06IF97-26811-NormBPHProstate 549 519354542.K05.GZ43 F M00073892A:E02IF97-26811-NormBPHProstate 550 595883542.K08.GZ43 F M00073892B:F12IF97-26811-NormBPHProstate Table 2 ORIEN
S~ CLUSTERSEQNAME T CLONE ID LIBRARY

551 374817 2542.L03.GZ43 37304M00073893D:A04IF97-26811-NormBPHProstate F

552 604822 542.MOS.GZ43 37306 M00073895C:F02IF97-26811-NormBPHProstate F

553 454509 542.M09.GZ43 37307 M00073896A:F07IF97-26811-NormBPHProstate F

554 184489 542.005.GZ43 37311 M00073899C:E12IF97-26811-NormBPHProstate F

555 565709 2542.P02.GZ43 37313M00073905B:A03IF97-26811-NormBPHProstate F

556 13301 2542.P08.GZ43 373143M00073905D:C11IF97-26811-NormBPHProstate 557 723485 F M00073907B:B06IF97-26811-NormBPHProstate 2542.P19.GZ43 37315 F

558 418723 2542.F24.GZ43 372919M00073884D:B06IF97-26811-NormBPHProstate F

559 847088 542.H23.GZ43 37296 M00073888C:C10IF97-26811-NormBPHProstate F

560 534076 2542.J21.GZ43 373012M00073891C:A12IF97-26811-NormBPHProstate 561 240 F M00073893B:C08IF97-26811-NormBPHProstate 542.K21.GZ43 37303 F

562 58218 542.M24.GZ43 37308 M00073897B:B11IF97-26811-NormBPHProstate F

563 641662 542.N21.GZ43 37310 M00073899A:C02IF97-26811-NormBPHProstate F

564 398642 542.N22.GZ43 37310 M00073899A:D06IF97-26811-NormBPHProstate 565 452289 F M00073911B:G10IF97-26811-NormBPHProstate 555.B08.GZ43 373191 F

566 621397 555.B20.GZ43 37320 M00073912B:C04IF97-26811-NormBPHProstate F

567 641662 555.D22.GZ43 37325 M00073916A:B07IF97-26811-NormBPHProstate F

568 13903 2555.E20.GZ43 373275M00073917B:B07IF97-26811-NormBPHProstate 569 727966 F M00073918C:B03IF97-26811-NormBPHProstate 2555.F16.GZ43 373295 F

570 702885 555.H18.GZ43 37334 M00073921B:H12IF97-26811-NormBPHProstate F

571 525801 2555.I05.GZ43 373356M00073922C:E02IF97-26811-NormBPHProstate F

572 11561 2555.I21.GZ43 373372M00073923C:A04IF97-26811-NormBPHProstate 573 602052 F M00073924B:H03IF97-26811-NormBPHProstate 2555.J07.GZ43 373382 F

574 453398 S55.K17.GZ43 37341 M00073927D:E09IF97-26811-NormBPHProstate 575 528957 F M00073931D:E02IF97-26811-NormBPHProstate 555.M18.GZ43 37346 F

576 652099 555.N05.GZ43 37347 M00073932D:G05IF97-26811-NormBPHProstate 577 16641 F M00073936D:E05IF97-26811-NormBPHProstate 2555.POS.GZ43 37352 F

578 517481 2555.P22.GZ43 373541M00073938B:D11IF97-26811-NormBPHProstate F

579 411128 555.A11.GZ43 37317 M00073908C:D09IF97-26811-NormBPHProstate F

580 558342 2555.E11.GZ43 37326M00073916C:H11IF97-26811-NormBPHProstate 581 692282 F M00073918A:F07IF97-26811-NormBPHProstate 2555.F09.GZ43 373288 F

582 520370 2555.F10.GZ43 373289M00073918A:G12IF97-26811-NormBPHProstate F

583 271 555.G11.GZ43 37331 M00073919C:B04IF97-26811-NormBPHProstate F

584 525801 555.H12.GZ43 37333 M00073920D:F08IF97-26811-NormBPHProstate 585 467877 F M00073922D:G04IF97-26811-NormBPHProstate 2555.I12.GZ43 373363 F

586 502358 2555.J10.GZ43 373385M00073924C:G05IF97-26811-NormBPHProstate F

587 15935 555.K10.GZ43 37340 M00073927C:B07IF97-26811-NormBPHProstate F

588 451821 555.N09.GZ43 37348 M00073933B:B12IF97-26811-NormBPHProstate F

589 604822 556.A02.GZ43 37354 M00073938B:F09IF97-26811-NormBPHProstate F

590 50391 556.B22.GZ43 37358 M00073941B:A06IF97-26811-NormBPHProstate F

591 139789 2556.C11.GZ43 37360M00073941D:H09IF97-26811-NormBPHProstate F

592 649670 2556.C19.GZ43 37361M00073942B:C01IF97-26811-NormBPHProstate 593 20563 F M00073942C:E04IF97-26811-NormBPHProstate 556.D02.GZ43 37361 F

594 113786 556.D06.GZ43 373621M00073942D:D09IF97-26811-NormBPHProstate F

595 420371 556.D09.GZ43 37362 M00073942D:G05IF97-26811-NormBPHProstate F

596 1607 2556.E07.GZ43 37364M00073944A:E10IF97-26811-NormBPHProstate F

597 60888 2556.E11.GZ43 37365M00073944A:H05IF97-26811-NormBPHProstate F

598 472262 2556.F11.GZ43 37367M00073944C:H07IF97-26811-NormBPHProstate F

599 171595 2556.F14.GZ43 373677M00073944D:A07IF97-26811-NormBPHProstate F

600 17855 2556.F15.GZ43 373678M00073944D:E12IF97-26811-NormBPHProstate F

Table 2 ID CLUSTERSEQNAME O~EN CLONE ID LIBRARY

601 842551 556.G19.GZ43 F M00073946D:F07IF97-26811-NormBPHProstate 602 87051 556.H15.GZ4337372F M00073947C:B01IF97-26811-NormBPHProstate 603 297358 556.H19.GZ4337373F M00073947C:E09IF97-26811-NormBPHProstate 604 22884 2556.I05.GZ43373740F M00073948A:G05IF97-26811-NormBPHProstate 605 48896 2556.J03.GZ43373762F M00073949A:C09IF97-26811-NormBPHProstate 606 9047 2556.J15.GZ43373774F M00073949D:C11IF97-26811-NormBPHProstate 607 1409 2556.J18.GZ43373777F M00073950C:A05IF97-26811-NormBPHProstate 608 63551 556.K03.GZ4337378F M00073950D:H12IF97-26811-NormBPHProstate 609 13629 556.K07.GZ4337379F M00073952A:G04IF97-26811-NormBPHProstate 610 850377 2556.L21.GZ43373828F M00073956D:F02IF97-26811-NormBPHProstate 611 448319 556.M11.GZ4337384F M00073960A:B12IF97-26811-NormBPHProstate 612 582134 556.M16.GZ4337384F M00073960B:A09IF97-26811-NormBPHProstate 613 946181 556.N05.GZ4337386F M00073961B:G01IF97-26811-NormBPHProstate 614 782981 556.005.GZ4337388F M00073962D:E04IF97-26811-NormBPHProstate 615 43910 556.O11.GZ4337389F M00073963A:G08IF97-26811-NormBPHProstate 616 154120 556.016.GZ4337389F M00073963B:F04IF97-26811-NormBPHProstate 617 550104 2556.P03.GZ4337390F M00073964B:H07IF97-26811-NormBPHProstate 618 471364 557.B09.GZ4337396F M00073967A:A10IF97-26811-NormBPHProstate 619 398642 557.B11.GZ4337396F M00073967C:A01IF97-26811-NormBPHProstate 620 572170 557.B22.GZ43373973F M00073968B:B06IF97-26811-NormBPHProstate 621 780111 2557.C11.GZ4337398F M00073968D:F11IF97-26811-NormBPHProstate 622 472262 557.D14.GZ43 F M00073970B:G01IF97-26811-NormBPHProstate 623 40330 37401 F M00073977D:B10IF97-26811-NormBPHProstate 557.G10.GZ43 624 218375 557.G20.GZ43374091F M00073978D:A02IF97-26811-NormBPHProstate 625 520370 557.H11.GZ4337410F M00073979C:G07IF97-26811-NormBPHProstate 626 621573 2557.I17.GZ43374136F M00073981C:F08IF97-26811-NormBPHProstate 627 551744 2557.J14.GZ43374157F M00073983B:D03IF97-26811-NormBPHProstate 628 35049 2557.J16.GZ43374159F M00073983C:C07IF97-26811-NormBPHProstate 629 8268 2557.J21.GZ43374164F M00073984B:D04IF97-26811-NormBPHProstate 630 697955 2557.J22.GZ43374165F M00073984B:E01IF97-26811-NormBPHProstate 631 727968 557.K11.GZ4337417F M00073985C:A05IF97-26811-NormBPHProstate 632 839437 2557.L12.GZ43374203F M00073987B:A09IF97-26811-NormBPHProstate 633 533888 2557.L23.GZ4337421F M00073988B:C08IF97-26811-NormBPHProstate 634 555867 557.M10.GZ4337422F M00073988D:F09IF97-26811-NormBPHProstate 635 709796 557.N14.GZ4337425F M00073993A:A05IF97-26811-NormBPHProstate 636 736938 557.A03.GZ4337393F M00073965D:A12IF97-26811-NormBPHProstate 637 867511 2557.BO1.GZ4337395F M00073966C:F08IF97-26811-NormBPHProstate 638 531505 2557.C04.GZ43 F M00073968C:C09IF97-26811-NormBPHProstate 639 401809 37397 F M00073968C:F02IF97-26811-NormBPHProstate 2557.C05.GZ43 640 796532 2557.F03.GZ43374050F M00073975A:A12IF97-26811-NormBPHProstate 641 572170 557.H03.GZ4337409F M00073979B:B05IF97-26811-NormBPHProstate 642 644299 557.H05.GZ4337410F M00073979C:B01IF97-26811-NormBPHProstate 643 633646 2557.J06.GZ43374149F M00073982B:H01IF97-26811-NormBPHProstate 644 558581 2557.LO1.GZ43 F M00073986C:D07IF97-26811-NormBPHProstate 645 558579 557.M06.GZ4337422F M00073988C:G08IF97-26811-NormBPHProstate 646 448604 558.A07.GZ43 F M00074000C:D06IF97-26811-NormBPHProstate 647 404482 37431 F M00074003C:H06IF97-26811-NormBPHProstate 558.B13.GZ43 648 847088 558.B24.GZ43 F M00074004A:H01IF97-26811-NormBPHProstate 649 451981 2558.C04.GZ43 F M00074004C:F03IF97-26811-No_rmBPHProstate 650 660842 2558.C18.GZ43 F M00074006C:B12IF97-26811-NormBPHProstate Table 2 ID CLUSTERSEQNAME ORTEN CLONE ID LIBRARY

651 558569 558.D03.GZ43 37438 M00074007B:A02IF97-26811-NormBPHProstate F

652 640319 2558.E21.GZ43 37442M00074010B:D07IF97-26811-NormBPHProstate 653 556827 F M00074011A:F08IF97-26811-NormBPHProstate 2558.E24.GZ43 374431 F

654 10354 2558.F06.GZ43 374437M00074011D:C05IF97-26811-NormBPHProstate F

655 993554 2558.F19.GZ43 374450M00074013B:F07IF97-26811-NormBPHProstate F

656 643828 2558.F21.GZ43 374452M00074013C:C09IF97-26811-NormBPHProstate 657 48289 F M00074014A:G03IF97-26811-NormBPHProstate 558.G07.GZ43 37446 F

658 682 558.G13.GZ43 37446 M00074014D:F04IF97-26811-NormBPHProstate F

659 132559 558.G17.GZ43 37447 M00074015A:C03IF97-26811-NormBPHProstate F

660 23300 558.H13.GZ43 37449 M00074017B:G10IF97-26811-NormBPHProstate 661 510539 F M00074017D:C01IF97-26811-NormBPHProstate 558.H17.GZ43 37449 F

662 388450 2558.JO1.GZ43 374528M00074019D:H05IF97-26811-NormBPHProstate F

663 50661 2558.J03.GZ43 374530M00074020B:G11IF97-26811-NormBPHProstate F

664 715752 2558.J04.GZ43 374531M00074020C:A05IF97-26811-NormBPHProstate 665 752831 F M00074020D:G10IF97-26811-NormBPHProstate 2558.J09.GZ43 374536 F

666 505984 558.K02.GZ43 37455 M00074021C:H07IF97-26811-NormBPHProstate F

667 672233 558.K08.GZ43 37455 M00074022A:C06IF97-26811-NormBPHProstate F

668 733132 2558.L15.GZ43 37459M00074024B:G07IF97-26811-NormBPHProstate 669 1037152F M00074025A:F06IF97-26811-NormBPHProstate 2558.L19.GZ43 37459 F

670 8268 2558.L21.GZ43 37459M00074025B:A12IF97-26811-NormBPHProstate F

671 918867 558.M11.GZ43 37461 M00074026C:H09IF97-26811-NormBPHProstate F

672 64589 558.M18.GZ43 37461 M00074027D:B03IF97-26811-NormBPHProstate 673 217122 F M00074030D:A12IF97-26811-NormBPHProstate 558.N22.GZ43 37464 F

674 559336 558.009.GZ43 37465 M00074032B:H08IF97-26811-NormBPHProstate F

675 535996 558.O10.GZ43 37465 M00074032C:E02IF97-26811-NormBPHProstate F

676 553342 558.O11.GZ43 37465 M00074032C:H07IF97-26811-NormBPHProstate 677 404368 F M00074036B:C08IF97-26811-NormBPHProstate 2558.P16.GZ43 37468 F

678 823296 2558.P20.GZ43 374691M00074036D:B05IF97-26811-NormBPHProstate F

679 48738 559.AO1.GZ43 37469 M00074037A:B03IF97-26811-NormBPHProstate F

680 948383 559.A09.GZ43 37470 M00074038A:G08IF97-26811-NormBPHProstate 681 738784 F M00074038C:B08IF97-26811-NormBPHProstate 559.A13.GZ43 37470 F

682 588996 559.B05.GZ43 37472 M00074040A:B06IF97-26811-NormBPHProstate F

683 5013 559.D05.GZ43 37477 M00074043C:A05IF97-26811-NormBPHProstate F

684 954558 559.G18.GZ43 37485 M00074050B:H07IF97-26811-NormBPHProstate 685 424776 F M00074051C:F05IF97-26811-NormBPHProstate 559.H08.GZ43 374871 F

686 519176 559.H20.GZ43 37488 M00074052C:E03IF97-26811-NormBPHProstate F

687 448221 2559.I12.GZ43 374899M00074053C:E05IF97-26811-NormBPHProstate F

688 184489 2559.I13.GZ43 374900M00074053C:G11IF97-26811-NormBPHProstate 689 404482 F M00074053D:D05IF97-26811-NormBPHProstate 2559.I17.GZ43 374904 F

690 13903 2559.J02.GZ43 374913M00074054C:B04IF97-26811-NormBPHProstate F

691 204255 2559.J13.GZ43 374924M00074055A:G08IF97-26811-NormBPHProstate F

692 551744 559.K12.GZ43 37494 M00074057A:B12IF97-26811-NormBPHProstate 693 395953 F M00074058A:H02IF97-26811-NormBPHProstate 2559.L08.GZ43 37496 F

694 63891 2559.L09.GZ43 374968M00074058B:A10IF97-26811-NormBPHProstate F

695 406961 559.M02.GZ43 37498 M00074059B:G10IF97-26811-NormBPHProstate F

696 23951 559.M21.GZ43 37500 M00074060D:A10IF97-26811-NormBPHProstate 697 34391 F M00074061B:E01IF97-26811-NormBPHProstate 559.N05.GZ43 37501 F

698 16978 559.N13.GZ43 37502 M00074063A:B03IF97-26811-NormBPHProstate F

699 13565 559.N15.GZ43 37502 M00074063A:D09IF97-26811-NormBPHProstate F

700 402267 559.N18.GZ43 37502 M00074063B:B12IF97-26811-NormBPHProstate F

Table 2 701 35578 2559.P19.GZ43 37507M00074069D:C11IF97-26811-NormBPHProstate F

702 459865 560.A08.GZ43 37508 M00074070D:G05IF97-26811-NormBPHProstate 703 37848 F M00074075B:A091F97-26811-NormBPHProstate 560.B11.GZ43 37511 F

704 66923 560.B15.GZ43 37511 M00074075C:H04IF97-26811-NormBPHProstate F

705 400258 560.B20.GZ43 37512 M00074076B:F04IF97-26811-NormBPHProstate F

706 404368 2560.C15.GZ43 37514M00074079A:E07IF97-26811-NormBPHProstate 707 333093 F M00074084C:E01IF97-26811-NormBPHProstate 2560.E19.GZ43 37519 F

708 676448 2560.E22.GZ43 37519M00074084D:B04IF97-26811-NormBPHProstate F

709 554127 2560.F07.GZ43 375206M00074085A:H10IF97-26811-NormBPHProstate F

710 171148 2560.F10.GZ43 375209M00074085B:E06IF97-26811-NormBPHProstate 711 946181 F M00074085D:E08IF97-26811-NormBPHProstate 2560.F16.GZ43 375215 F

712 697955 560.G13.GZ43 37523 M00074087B:C09IF97-26811-NormBPHProstate F

713 453476 560.G18.GZ43 37524 M00074087C:G05IF97-26811-NormBPHProstate F

714 833580 560.HO1.GZ43 37524 M00074088B:A03IF97-26811-NormBPHProstate 715 531583 F M00074088C:E07IF97-26811-NormBPHProstate 560.H12.GZ43 37525 F

716 558342 560.H21.GZ43 37526 M00074089A:B09IF97-26811-NormBPHProstate F

717 455862 2560.I09.GZ43 375280M00074089D:E03IF97-26811-NormBPHProstate F

718 19627 2560.I16.GZ43 375287M00074090A:E09IF97-26811-NormBPHProstate 719 9134 F M00074093A:A06IF97-26811-NormBPHProstate 720 41346 560.K02.GZ43 375321M00074093B:A03IF97-26811-NormBPHProstate F
560.K08.GZ43 37532 F

721 756337 560.K10.GZ43 37532 M00074093B:C07IF97-26811-NormBPHProstate F

722 397115 560.K18.GZ43 37533 M00074094B:F10IF97-26811-NormBPHProstate 723 805118 F M00074096D:G12IF97-26811-NormBPHProstate 2560.L14.GZ43 37535 F

724 456113 2560.L15.GZ43 37535M00074097A:F10IF97-26811-NormBPHProstate F

725 677530 2560.L22.GZ43 375365M00074097C:B09IF97-26811-NormBPHProstate F

726 697955 560.M11.GZ43 37537 M00074098C:B09IF97-26811-NormBPHProstate 727 493811 F M00074099C:B09IF97-26811-NormBPHProstate 560.M23.GZ43 37539 F

728 127471 560.N09.GZ43 37540 M00074100B:E01IF97-26811-NormBPHProstate F

729 559267 560.008.GZ43 37542 M00074101D:D07IF97-26811-NormBPHProstate F

730 691653 560.012.GZ43 37542 M00074102A:C04IF97-26811-NormBPHProstate 731 966599 F M00074105A:D02IF97-26811-NormBPHProstate 2560.P24.GZ43 375463 F

732 139979 561.B03.GZ43 37625 M00074106C:E03IF97-26811-NormBPHProstate F

733 668962 561.B12.GZ43 37626 M00074107C:C08IF97-26811-NormBPHProstate F

734 217122 2561.C13.GZ43 37629M00074111C:B02IF97-26811-NormBPHProstate 735 70908 F M00074111C:G11IF97-26811-NormBPHProstate 2561.C15.GZ43 37629 F

736 557771 561.D14.GZ43 37631 M00074116C:A03IF97-26811-NormBPHProstate F

737 629125 2561.E10.GZ43 37633M00074120A:A12IF97-26811-NormBPHProstate F

738 626993 2561.F09.GZ43 376360M00074123B:A03IF97-26811-NormBPHProstate 739 69779 F M00074123B:G07IF97-26811-NormBPHProstate 2561.F13.GZ43 376364 F

740 752623 2561.I07.GZ43 376430M00074130B:F06IF97-26811-NormBPHProstate F

741 692282 2561.I11.GZ43 376434M00074131A:H09IF97-26811-NormBPHProstate F

742 685244 2561.JO1.GZ43 376448M00074132C:F10IF97-26811-NormBPHProstate 743 597681 F M00074135A:G09IF97-26811-NormBPHProstate 561.K03.GZ43 37647 F

744 1037152561.K10.GZ43 376481M00074135C:E09IF97-26811-NormBPHProstate F

745 533888 2561.L02.GZ43 37649M00074137C:E05IF97-26811-NormBPHProstate F

746 378561 2561.L13.GZ43 37650M00074138D:A01IF97-26811-NormBPHProstate F

747 415520 2561.L14.GZ43 37650M00074138D:A08IF97-26811-NormBPHProstate F

748 415520 2561.L15.GZ43 37651M00074138D:B07IF97-26811-NormBPHProstate F

749 455254 561.M03.GZ43 37652 M00074142B:C11IF97-26811-NormBPHProstate F

750 315533 561.M09.GZ43 37652 M00074142D:A10IF97-26811-NormBPHProstate F

Table 2 ID CLUSTERSEQNAME ORTENCLONE ID LIBRARY

75110585 561.OIO.GZ43 F M00074148B:D09IF97-26811-NormBPHProstate 75220052 561.B18.GZ43 F M00074108B:C04IF97-26811-NormBPHProstate 753558602 376273 F M00074122A:B02IF97-26811-NormBPHProstate 2561.E22.GZ43 754559336 561.G20.GZ43 F M00074126B:E12IF97-26811-NormBPHProstate 755163602 561.H17.GZ43 F M00074128D:C09IF97-26811-NormBPHProstate 756756337 2561.I19.GZ43 F M00074132A:E11IF97-26811-NormBPHProstate 757452194 376442 F M00074132B:B07IF97-26811-NormBPHProstate 2561.I24.GZ43 75831453 2561.J18.GZ43 F M00074134A:G11IF97-26811-NormBPHProstate 759220845 561.017.GZ43 F M00074149A:B10IF97-26811-NormBPHProstate 7601022935561.019.GZ43 F M00074149A:F12IF97-26811-NormBPHProstate 761396325 37658 F M00074153A:E07IF97-26811-NormBPHProstate 2561.P16.GZ43 762835488 2561.P19.GZ43 F M00074153D:A05IF97-26811-NormBPHProstate 763119614 2561.P23.GZ43 F M00074154A:D03IF97-26811-NormBPHProstate 764400258 456.A08.GZ43 F M00074155B:G09IF97-26811-NormBPHProstate 765165378 35583 F M00074157C:G08IF97-26811-NormBPHProstate 766641662 456.B09.GZ43 F M00074157D:G05IF97-26811-NormBPHProstate 456.B12.GZ43 767648899 456.B17.GZ43 F M00074158C:F12IF97-26811-NormBPHProstate 768128596 456.B18.GZ43 F M00074158C:H10IF97-26811-NormBPHProstate 769452194 35587 F M00074159C:A05IF97-26811-NormBPHProstate 2456.CO1.GZ43 770534076 2456.C05.GZ43 F M00074160A:D12IF97-26811-NormBPHProstate 771372750 456.D04.GZ43 F M00074161C:F04IF97-26811-NormBPHProstate 772391508 456.D05.GZ43 F M00074162A:B03IF97-26811-NormBPHProstate 7737105 35590 F M00074165D:A11IF97-26811-NormBPHProstate 2456.E17.GZ43 774177808 2456.F16.GZ43 F M00074170A:D09IF97-26811-NormBPHProstate 775516526 2456.F23.GZ43 F M00074170D:F05IF97-26811-NormBPHProstate 776372710 456.G10.GZ43 F M00074172B:D12IF97-26811-NormBPHProstate 777540142 35598 F M00074174A:C02IF97-26811-NormBPHProstate 456.H02.GZ43 7781041923456.H07.GZ43 F M00074174C:C03IF97-26811-NormBPHProstate 779136276 2456.I05.GZ43 F M00074175D:E04IF97-26811-NormBPHProstate 780568661 2456.I09.GZ43 F M00074176A:A06IF97-26811-NormBPHProstate 781403242 356029 F M00074176A:B10IF97-26811-NormBPHProstate 2456.I10.GZ43 78241455 2456.J06.GZ43 F M00074177B:H08IF97-26811-NormBPHProstate 783853431 2456.J18.GZ43 F M00074178B:G07IF97-26811-NormBPHProstate 784423303 2456.J24.GZ43 F M00074179A:A01IF97-26811-NormBPHProstate 78541455 356068 F M00074179C:B01IF97-26811-NormBPHProstate 456.K07.GZ43 786568204 456.M05.GZ43 F M00074184D:A04IF97-26811-NormBPHProstate 787642041 456.M06.GZ43 F M00074184D:B01IF97-26811-NormBPHProstate 788427449 456.N23.GZ43 F M00074190B:F09IF97-26811-NormBPHProstate 789565709 35616 F M00074191C:D08IF97-26811-NormBPHProstate 456.O10.GZ43 790676448 456.018.GZ43 F M00074192C:C10IF97-26811-NormBPHProstate 79199399 2456.P23.GZ43 F M00074195D:B09IF97-26811-NormBPHProstate 792222887 457.A21.GZ43 F M00074197C:A12IF97-26811-NormBPHProstate 793778001 35623 F M00074198C:A12IF97-26811-NormBPHProstate 457.B07.GZ43 794806992 457.B10.GZ43 F M00074198D:D10IF97-26811-NormBPHProstate 795217122 457.B13.GZ43 F M00074199A:C10IF97-26811-NormBPHProstate 796733673 457.C19.GZ43 F M00074201A:F03IF97-26811-NormBPHProstate 79737375 35627 F M00074201C:E12IF97-26811-NormBPHProstate 457.C23.GZ43 79841702 457.D05.GZ43 F M00074202A:A05IF97-26811-NormBPHProstate 79913903 457.D12.GZ43 F M00074202B:D03IF97-26811-NormBPHProstate 800626993 2457.E05.GZ43 F M00074203D:F01IF97-26811-NormBPHProstate Table 2 ID CLUSTERSEQNAME ORTENCLONE 1~ LIBRARY

801 474125 2457.E23.GZ43 F M00074206A:G02IF97-26811-NormBPHProstate 802 552374 2457.E24.GZ43 F M00074206A:H12IF97-26811-NormBPHProstate 803 220576 2457.F02.GZ43 F M00074206B:F04IF97-26811-NormBPHProstate 804 450754 2457.F17.GZ43 F M00074207D:E07IF97-26811-NormBPHProstate 805 732950 2457.F20.GZ43 F M00074208B:B05IF97-26811-NormBPHProstate 806 948383 2457.F23.GZ43 F M00074208B:F09IF97-26811-NormBPHProstate 807 218833 457.G03.GZ43 F M00074208D:E08IF97-26811-NormBPHProstate 808 192830 457.G13.GZ43 F M00074209D:H11IF97-26811-NormBPHProstate 809 1017557457.G17.GZ43 F M00074210B:G12IF97-26811-NormBPHProstate 810 557507 457.H17.GZ43 F M00074213A:C06IF97-26811-NormBPHProstate 811 551338 35639 F M00074215A:F09IF97-26811-NormBPHProstate 2457.I12.GZ43 812 839437 2457.J13.GZ43 F M00074216C:C11IF97-26811-NormBPHProstate 813 376516 2457.J23.GZ43 F M00074216D:H03IF97-26811-NormBPHProstate 814 397140 457.K03.GZ43 F M00074217A:H01IF97-26811-NormBPHProstate 815 28050 35645 F M00074217C:B04IF97-26811-NormBPHProstate 457.K07.GZ43 816 640582 457.K08.GZ43 F M00074217C:C09IF97-26811-NormBPHProstate 817 993554 2457.L04.GZ43 F M00074219D:F03IF97-26811-NormBPHProstate 818 465446 2457.L21.GZ43 F M00074221B:F12IF97-26811-NormBPHProstate 819 429609 35649 F M00074223B:D12IF97-26811-NormBPHProstate 457.M11.GZ43 820 449482 457.M20.GZ43 F M00074224A:G06IF97-26811-NormBPHProstate 821 31453 457.N07.GZ43 F M00074225A:H12IF97-26811-NormBPHProstate 822 16641 457.002.GZ43 F M00074226C:E06IF97-26811-NormBPHProstate 823 130924 35655 F M00074230D:B05IF97-26811-NormBPHProstate 458.A10.GZ43 824 184653 458.A13.GZ43 F M00074231A:D10IF97-26811-NormBPHProstate 825 20858 458.A24.GZ43 F M00074231D:G11IF97-26811-NormBPHProstate 826 140585 458.B08.GZ43 F M00074232B:G06IF97-26811-NormBPHProstate 827 547023 35664 F M00074234A:C05IF97-26811-NormBPHProstate 458.B23.GZ43 828 53675 458.B24.GZ43 F M00074234A:E07IF97-26811-NormBPHProstate 829 498886 2458.C06.GZ43 F M00074234B:F07IF97-26811-NormBPHProstate 830 10354 2458.C12.GZ43 F M00074234D:F12IF97-26811-NormBPHProstate 831 12906 35666 F M00074235C:D06IF97-26811-NormBPHProstate 2458.C23.GZ43 832 184489 458.D06.GZ43 F M00074236B:E06IF97-26811-NormBPHProstate 833 37634 458.D07.GZ43 F M00074236C:E11IF97-26811-NormBPHProstate 834 72628 2458.FO1.GZ43 F M00074242D:F09IF97-26811-NormBPHProstate 835 23957 356729 F M00074243A:H08IF97-26811-NormBPHProstate 2458.F06.GZ43 836 29906 458.GO1.GZ43 F M00074244C:B11IF97-26811-NormBPHProstate 837 453526 458.G20.GZ43 F M00074247B:G11IF97-26811-NormBPHProstate 838 18644 458.G21.GZ43 F M00074247C:E02IF97-26811-NormBPHProstate 839 8956 35677 F M00074248C:E12IF97-26811-NormBPHProstate 458.H07.GZ43 840 9710 458.H16.GZ43 F M00074249C:B11IF97-26811-NormBPHProstate 841 390274 458.H20.GZ43 F M00074249C:H08IF97-26811-NormBPHProstate 842 112224 2458.109.GZ43 F M00074250D:E06IF97-26811-NormBPHProstate 843 20915 2458.I10.GZ43 F M00074250D:F06IF97-26811-NormBPHProstate 844 77670 2458.I15.GZ43 F M00074251B:F08IF97-26811-NormBPHProstate 845 32366 2458.I17.GZ43 F M00074251C:B061F97-26811-NormBPHProstate 846 11031 2458.I20.GZ43 F M00074251C:E03IF97-26811-NormBPHProstate 847 112224 2458.I21.GZ43 F M00074251D:E03IF97-26811-NormBPHProstate 848 40164 2458.J03.GZ43 F M00074252C:E02IF97-26811-NormBPHProstate 849 72825 2458.J21.GZ43 F M00074253C:F03IF97-26811-NormBPHPro_state 850 36407 458.K07.GZ43 F M00074255B:A01IF97-26811-NormBPHProstate Table 2 ORIEN
CLUSTERSEQNAME T CLONE ID LIBRARY

851 63902 2458.L06.GZ43356878F M00074258A:H12IF97-26811-NormBPHProstate 852 954558 2458.L07.GZ4335687F M00074258A:H09IF97-26811-NormBPHProstate 853 447270 2458.L23.GZ43356895F M00074259C:G08IF97-26811-NormBPHProstate 854 16174 458.M05.GZ4335690F M00074260B:A11IF97-26811-NormBPHProstate 855 139173 458.N06.GZ4335692F M00074265B:C07IF97-26811-NormBPHProstate 856 217122 458.N10.GZ4335693F M00074266A:D01IF97-26811-NormBPHProstate 857 497138 458.N19.GZ4335693F M00074267A:B04IF97-26811-NormBPHProstate 858 559336 458.009.GZ4335695F M00074268A:D08IF97-26811-NormBPHProstate 859 507628 458.017.GZ43356961F M00074268C:G03IF97-26811-NormBPHProstate 860 14453 2458.P06.GZ4335697F M00074270B:A01IF97-26811-NormBPHProstate 861 858675 2458.P18.GZ43356986F M00074271B:E11IF97-26811-NormBPHProstate 862 597681 459.A04.GZ4335699F M00074273B:B03IF97-26811-NormBPHProstate 863 715752 459.A24.GZ4335701F M00074275A:B04IF97-26811-NormBPHProstate 864 14049 459.B10.GZ4335702F M00074276A:A12IF97-26811-NormBPHProstate 865 830453 459.B11.GZ4335702F M00074276A:E02IF97-26811-NormBPHProstate 866 63551 2459.C05.GZ4335704F M00074278B:D07IF97-26811-NormBPHProstate 867 456211 2459.C09.GZ4335704F M00074278D:E07IF97-26811-NormBPHProstate 868 682065 2459.C16.GZ4335705F M00074279C:C11IF97-26811-NormBPHProstate 869 1049007459.D07.GZ43357071F M00074280D:H03IF97-26811-NormBPHProstate 870 415520 2459.E11.GZ4335709F M00074284B:B03IF97-26811-NormBPHProstate 871 136276 2459.E16.GZ4335710F M00074284C:B06IF97-26811-NormBPHProstate 872 532090 2459.E19.GZ4335710F M00074284C:E12IF97-26811-NormBPHProstate 873 165378 2459.F20.GZ43357132F M00074288A:F11IF97-26811-NormBPHProstate 874 523261 459.GO1.GZ4335713F M00074290A:G10IF97-26811-NormBPHProstate 875 22351 459.G07.GZ4335714F M00074290C:B05IF97-26811-NormBPHProstate 876 573764 459.G23.GZ4335715F M00074292D:B04IF97-26811-NormBPHProstate 877 552996 459.H09.GZ4335716F M00074293D:B05IF97-26811-NormBPHProstate 878 923732 459.H10.GZ4335717F M00074293D:H07IF97-26811-NormBPHProstate 879 375712 2459.I10.GZ43357194F M00074296C:G09IF97-26811-NormBPHProstate 880 8342 2459.J12.GZ43357220F M00074299B:F01IF97-26811-NormBPHProstate 881 446975 459.K15.GZ4335724F M00074302D:G10IF97-26811-NormBPHProstate 882 747429 2459.L07.GZ43357263F M00074304B:C09IF97-26811-NormBPHProstate 883 697955 2459.L13.GZ4335726F M00074304D:D07IF97-26811-NormBPHProstate 884 2594 2459.L18.GZ4335727F M00074306A:B09IF97-26811-NormBPHProstate 885 19812 2459.L23.GZ4335727F M00074306B:H01IF97-26811-NormBPHProstate 886 38435 459.N09.GZ4335731F M00074310D:D02IF97-26811-NormBPHProstate 887 4526 459.012.GZ4335734F M00074314A:C06IF97-26811-NormBPHProstate 888 61211 459.023.GZ43357351F M00074315B:A03IF97-26811-NormBPHProstate 889 558789 2459.P24.GZ43357376F M00074317C:C01IF97-26811-NormBPHProstate 890 676448 464.BOl.GZ4335770F M00074319C:H03IF97-26811-NormBPHProstate 891 18780 2464.C08.GZ4335773F M00074832B:E05IF97-26811-NormBPHProstate 892 35553 464.D18.GZ4335777F M00074835A:H10IF97-26811-NormBPHProstate 893 797055 464.D23.GZ4335777F M00074835B:F12IF97-26811-NormBPHProstate 894 595523 2464.E21.GZ4335779F M00074837A:B06IF97-26811-NormBPHProstate 895 97523 2464.E23.GZ4335779F M00074837A:E01IF97-26811-NormBPHProstate 896 22970 2464.F12.GZ43357812F M00074838B:E11IF97-26811-NormBPHProstate 897 743862 2464.F19.GZ43357819F M00074838D:B06IF97-26811-NormBPHProstate 898 551338 464.G18.GZ43357.84F M00074843A:C06IF97-26811-NormBPHProstate 899 524917 464.H05.GZ4335785F M00074843D:D02IF97-26811-NormBPHProstate 900 10663 464.H07.GZ4335785F M00074844B:B02IF97-26811-NormBPHProstate Table 2 CLUSTERSEQNAME ORTENCLONE ID LIBRARY

ID

901 453526 464.H14.GZ43 F M00074844D:F09IF97-26811-NormBPHProstate 902 459310 464.H17.GZ43 F M00074845A:D12IF97-26811-NormBPHProstate 903 215935 464.H22.GZ43 F M00074845B:F07IF97-26811-NormBPHProstate 904 158853 2464.I04.GZ43 F M00074845D:D07IF97-26811-NormBPHProstate 905 465814 2464.I20.GZ43 F M00074847B:G03IF97-26811-NormBPHProstate 906 558463 2464.I23.GZ43 F M00074847D:E07IF97-26811-NormBPHProstate 907 323112 2464.J17.GZ43 F M00074849C:A04IF97-26811-NormBPHProstate 908 813848 464.K14.GZ43 F M00074852A:B01IF97-26811-NormBPHProstate 909 517954 464.K18.GZ43 F M00074852B:A02IF97-26811-NormBPHProstate 910 532090 2464.L02.GZ43 F M00074852D:D08IF97-26811-NormBPHProstate 911 365634 2464.L06.GZ43 F M00074853A:D05IF97-26811-NormBPHProstate 912 560612 2464.L15.GZ43 F M00074854A:C11IF97-26811-NormBPHProstate 913 419172 464.M02.GZ43 F M00074855B:A05IF97-26811-NormBPHProstate 914 932437 464.N05.GZ43 F M00074857D:B02IF97-26811-NormBPHProstate 915 411524 464.N06.GZ43 F M00074858B:E05IF97-26811-NormBPHProstate 916 558959 464.015.GZ43 F M00074861 IF97-26811-NormBPHProstate 358031 D:DO1 917 528957 2464.P10.GZ43 F M00074863D:F07IF97-26811-NormBPHProstate 918 85702 2464.P17.GZ43 F M00074864C:B09IF97-26811-NormBPHProstate 919 88413 464.A05.GZ43 F M00074317D:B08IF97-26811-NormBPHProstate 920 549017 464.B11.GZ43 F M00074320C:A06IF97-26811-NormBPHProstate 921 582134 465.A03.GZ43 F M00074865A:F05IF97-26811-NormBPHProstate 922 482747 465.B11.GZ43 F M00074869C:D04IF97-26811-NormBPHProstate 923 545694 2465.CO1.GZ43 F M00074871C:G05IF97-26811-NormBPHProstate 924 853085 2465.C24.GZ43 F M00074874A:G07IF97-26811-NormBPHProstate 925 146695 465.D10.GZ43 F M00074875B:E08IF97-26811-NormBPHProstate 926 935908 2465.E03.GZ43 F M00074879A:A02IF97-26811-NormBPHProstate 927 726585 2465.E08.GZ43 F M00074879C:D02IF97-26811-NormBPHProstate 928 647607 2465.F11.GZ43 F M00074884C:F10IF97-26811-NormBPHProstate 929 464200 465.G06.GZ43 F M00074887A:F03IF97-26811-NormBPHProstate 930 672079 465.H11.GZ43 F M00074890A:E03IF97-26811-NormBPHProstate 931 498886 2465.I12.GZ43 F M00074895D:H12IF97-26811-NormBPHProstate 932 542693 2465.I17.GZ43 F M00074898B:B01IF97-26811-NormBPHProstate 933 447795 2465.J11.GZ43 F M00074900C:E10IF97-26811-NormBPHProstate 934 725257 2465.J19.GZ43 F M00074901C:E05IF97-26811-NormBPHProstate 935 376516 465.K20.GZ43 F M00074903D:C04IF97-26811-NormBPHProstate 936 659483 2465.L02.GZ43 F M00074904A:E11IF97-26811-NormBPHProstate 937 41346 2465.L06.GZ43 F M00074904B:B07IF97-26811-NormBPHProstate 938 498886 2465.L22.GZ43 F M00074905D:A01IF97-26811-NormBPHProstate 939 447525 465.M11.GZ43 F M00074906B:H12IF97-26811-NormBPHProstate 940 672079 465.M18.GZ43 F M00074906D:G02IF97-26811-NormBPHProstate 941 738784 2465.P14.GZ43 F M00074912B:A10IF97-26811-NormBPHProstate 942 402167 466.A02.GZ43 F M00074912D:H08IF97-26811-NormBPHProstate 943 11686 466.B02.GZ43 F M00074916A:H03IF97-26811-NormBPHProstate 944 709796 2466.C15.GZ43 F M00074919C:A08IF97-26811-NormBPHProstate 945 553629 466.D19.GZ43 F M00074921C:E05IF97-26811-NormBPHProstate 946 627263 466.D20.GZ43 F M00074922A:D06IF97-26811-NormBPHProstate 947 20975 2466.F16.GZ43 F M00074927A:D02IF97-26811-NormBPHProstate 948 861172 2466.F19.GZ43 F M00074927B:G08IF97-26811-NormBPHProstate 949 588996 466.G06.GZ43 F M00074927D:G09IF97-26811-NormBPHProstate 950 993554 466.H07.GZ43 F M00074929D:D04IF97-26811-NormBPHProstate Table 2 ID CLUSTERSEQNAME ORTEN CLONE ID LIBRARY

951 652099 466.H19.GZ43 36026 M00074930C:D11IF97-26811-NormBPHProstate F

952 281 2466.I08.GZ43 360281M00074933A:D04IF97-26811-NonnBPHProstate 953 407944 F M00074935A:C01IF97-26811-NormBPHProstate 2466.JO1.GZ43 360298 F

954 644299 2466.J24.GZ43 360321M00074936B:E10IF97-26811-NormBPHProstate F

955 374829 2466.L07.GZ43 36035M00074939B:A06IE97-26811-NonnBPHProstate F

956 12885 466.M02.GZ43 36037 M00074940C:H08IF97-26811-NormBPHProstate 957 123563 F M00074950A:D01IF97-26811-Nor;nBPHProstate 2466.P11.GZ43 36045 F

958 540142 467.B24.GZ43 36051 M00074958D:H10IF97-26811-NormBPHProstate F

959 806992 467.D20.GZ43 36055 M00074966D:E08IF97-26811-NormBPHProstate F

960 61211 467.D23.GZ43 36056 M00074967B:A11IF97-26811-NormBPHProstate 961 682065 F M00074968D:A02IF97-26811-NonnBPHProstate 2467.E19.GZ43 36058 F

962 449521 467.G19.GZ43 36062 M00074974C:E11IF97-26811-NormBPHProstate F

963 19342 467.H18.GZ43 36065 M00074980D:E07IF97-26811-NormBPHProstate F

964 373888 467.A03.GZ43 36046 M00074954A:H06IF97-26811-NormBPHProstate 965 417672 F M00074954B:E03IF97-26811-NormBPHProstate 467.A05.GZ43 36047 F

966 376630 2467.B11.GZ43 36050M00074957D:F11IF97-26811-NormBPHProstate F

967 733132 467.D10.GZ43 36054 M00074962B:F08IF97-26811-NormBPHProstate F

968 189951 2467.E12.GZ43 360573M00074968A:D09IF97-26811-NormBPHProstate 969 59884 F M00074973A:H03IF97-26811-NormBPHProstate 467.GO1.GZ43 36061 F

970 16011 467.K17.GZ43 36072 M00072987B:A03IF97-26811-ProstateCancer3+3 F

971 2081 467.N22.GZ43 36079 M00072997B:H03IF97-26811-ProstateCancer3+3 972 377134 F M00072951C:C11IF97-26811-ProstateCancer3+3 973 3581 2467.I02.GZ43 360659M00072953B:G03IF97-26811-ProstateCancer3+3 F
2467.112.GZ43 360669 F

974 21702 2467.J09.GZ43 360690M00072982D:B03IF97-26811-ProstateCancer3+3 F

975 1409 467.K03.GZ43 36070 M00072985A:C12IF97-26811-ProstateCancer3+3 F

976 36814 467.K08.GZ43 36071 M00072985B:D03IF97-26811-ProstateCancer3+3 977 448841 F M00072986A:C03IF97-26811-ProstateCancer3+3 467.K14.GZ43 36071 F

978 568661 467.M07.GZ43 36076 M00072993B:D06IF97-26811-ProstateCancer3+3 F

979 388450 467.N03.GZ43 36078 M00072995C:D07IF97-26811-ProstateCancer3+3 F

980 129409 467.N07.GZ43 36078 M00072995D:C09IF97-26811-ProstateCancer3+3 981 14464 F M00072996B:A10IF97-26811-ProstateCancer3+3 467.N09.GZ43 36078 F

982 1005804467.N12.GZ43 36078 M00072996C:C04IF97-26811-ProstateCancer3+3 F

983 470032 467.004.GZ43 36080 M00072997D:F08IF97-26811-ProstateCancer3+3 F

984 10354 467.005.GZ43 36080 M00072997D:H06IF97-26811-ProstateCancer3+3 985 376972 F M00074323D:F09IF97-26811-ProstateCancer3+3 472.A03.GZ43 36085 F

986 18338 2472.C18.GZ43 36091M00074333D:A11IF97-26811-ProstateCancer3+3 F

987 378269 472.D06.GZ43 36092 M00074335A:H08IF97-26811-ProstateCancer3+3 988 385300 F M00074337A:G08IF97-26811-ProstateCancer3+3 989 571 472.D16.GZ43 36093 M00074340B:D06IF97-26811-ProstateCancer3+3 F
2472.E02.GZ43 36094 F

990 377667 2472.E22.GZ43 36096M00074343C:A03IF97-26811-ProstateCancer3+3 F

991 450657 2472.F22.GZ43 360991M00074346A:H09IF97-26811-ProstateCancer3+3 F

992 15619 472.G03.GZ43 36099 M00074347B:F11IF97-26811-ProstateCancer3+3 993 185791 F M00074349A:E08IF97-26811-ProstateCancer3+3 472.G13.GZ43 36100 F

994 193306 2472.I14.GZ43 361055M00074355D:H06IF97-26811-ProstateCancer3+3 F

995 377967 472.K13.GZ43 36110 M00074361C:B01IF97-26811-ProstateCancer3+3 F

996 373149 2472.L11.GZ43 36112M00074365A:E09IF97-26811-ProstateCancer3+3 F

997 612171 2472.L15.GZ43 361128M00074366A:D07IF97-26811-ProstateCancer3+3 F

998 560365 2472.L16.GZ43 36112M00074366A:H07IF97-26811-ProstateCancer3+3 F

999 21747 472.M22.GZ43 36115 M00074370D:G09IF97-26811-ProstateCancer3+3 1000_ 472.004.GZ43 36118 M00074375D:E05IF97-26811-ProstateCancer3+3 Table 2 SI CLUSTERSEQNAME ORTENCLONE ID LIBRARY
Q

1001374588 2472.P14.GZ43361223F M00074382D:F04IF97-26811-ProstateCancer3+3 100215692 2472.P22.GZ43361231F M00074384D:G07IF97-26811-ProstateCancer3+3 1003378507 473.AOI.GZ4336123F M00074388B:E07IF97-26811-ProstateCancer3+3 1004374382 2473.C03.GZ4336128F M00074392C:D02IF97-26811-ProstateCancer3+3 1005372993 2473.F08.GZ43361361F M00074405B:A04IF97-26811-ProstateCancer3+3 1006235268 2473.F14.GZ43361367F M00074417D:F07IF97-26811-ProstateCancer3+3 1007387530 473.G03.GZ4336138F M00074392D:D01IF97-26811-ProstateCancer3+3 1008375786 473.G09.GZ4336138F M00074406B:F10IF97-26811-ProstateCancer3+3 1009401120 473.H18.GZ4336141F M00074430D:G09IF97-26811-ProstateCancer3+3 10104885 2473.I04.GZ43 F M00074395A:BIF97-26811-ProstateCancer3+3 10115810 361429 F 11 IF97-26811-ProstateCancer3+3 2473.I08.GZ43 M00074404B:H01 1012556192 473.K02.GZ4336147F M00074391B:D02IF97-26811-ProstateCancer3+3 1013392161 2473.LO1.GZ43361498F M00074390C:E04IF97-26811-ProstateCancer3+3 1014971463 2473.L11.GZ4336150F M00074411B:G07IF97-26811-ProstateCancer3+3 10151338 473.013.GZ4336158F M00074415B:A01IF97-26811-ProstateCancer3+3 1016470032 2474.CO1.GZ4336166F M00074453B:H03IF97-26811-ProstateCancer3+3 1017565709 2474.C04.GZ4336166F M00074453C:E09IF97-26811-ProstateCancer3+3 1018966482 2474.C08.GZ4336167F M00074454A:D08IF97-26811-ProstateCancer3+3 1019549017 2474.E09.GZ4336172F M00074461D:E04IF97-26811-ProstateCancer3+3 102032016 2474.E18.GZ43361731F M00074463B:C03IF97-26811-ProstateCancer3+3 1021477010 474.G17.GZ4336177F M00074468B:C03IF97-26811-ProstateCancer3+3 1022837214 2474.I02.GZ43361811F M00074473D:H09IF97-26811-ProstateCancer3+3 1023861902 2474.106.GZ43361815F M00074474B:F02IF97-26811-ProstateCancer3+3 102410843072474.J18.GZ43361851F M00074488C:C10IF97-26811-ProstateCancer3+3 1025715573 2474.J19.GZ43361852F M00074488C:C08IF97-26811-ProstateCancer3+3 1026402167 474.K20.GZ4336187F M00074492A:F11IF97-26811-ProstateCancer3+3 1027287803 474.M19.GZ4336192F M00074501A:G07IF97-26811-ProstateCancer3+3 1028421298 474.NO1.GZ4336193F M00074502C:B08IF97-26811-ProstateCancer3+3 1029558463 2474.P19.GZ4336199F M00074515A:E02IF97-26811-ProstateCancer3+3 1030187860 2474.P22.GZ4336199F M00074515C:A11IF97-26811-ProstateCancer3+3 1031474947 475.A05.GZ4336200F M00074516B:H03IF97-26811-ProstateCancer3+3 1032161012 2475.C18.GZ4336206F M00074525A:B05IF97-26811-ProstateCancer3+3 1033823296 2475.E18.GZ4336211F M00074533A:D07IF97-26811-ProstateCancer3+3 1034176266 475.G16.GZ4336216F M00074539D:A10IF97-26811-ProstateCancer3+3 1035385843 475.H06.GZ4336217F M00074540B:H07IF97-26811-ProstateCancer3+3 10361009284475.H13.GZ4336218F M00074541D:E07IF97-26811-ProstateCancer3+3 1037428883 2475.J15.GZ43362232F M00074549B:A06IF97-26811-ProstateCancer3+3 1038732950 2475.L17.GZ4336228F M00074557A:G08IF97-26811-ProstateCancer3+3 1039387530 475.N08.GZ43362321F M00074561D:D12IF97-26811-ProstateCancer3+3 104027991 475.O11.GZ4336234F M00074566B:A04IF97-26811-ProstateCancer3+3 1041485653 2475.P12.GZ43362373F M00074569D:D04IF97-26811-ProstateCancer3+3 1042540379 475.B20.GZ4336204F M00074521D:F01IF97-26811-ProstateCancer3+3 1043732950 2475.J19.GZ43362236F M00074549C:H08IF97-26811-ProstateCancer3+3 1044187860 475.K24.GZ4336226F M00074555A:E10IF97-26811-ProstateCancer3+3 1045570804 475.M20.GZ4336230F M00074561A:B09IF97-26811-ProstateCancer3+3 1046449889 475.N21.GZ4336233F M00074565A:D08IF97-26811-ProstateCancer3+3 1047724905 480.A13.GZ4335851F M00074571D:F02IF97-26811-ProstateCancer3+3 104821702 480.A20.GZ4335852F M00074573A:H02IF97-26811-ProstateCancer3+3 104983576 480.B22.GZ4335854F M00074577B:B12IF97-2681_1-ProstateCancer3+3 1050649404 2480.CO1.GZ4335855F M00074577C:A05IF97-26811-ProstateCancer3+3 ' Table 2 ID CLUSTERSEQNAME ORTENCLONE ID LIBRARY

1051635332 480.D13.GZ43 F M00074582C:C02IF97-26811-ProstateCancer3+3 1052805118 480.D16.GZ43 F M00074582D:B09IF97-26811-ProstateCancer3+3 1053549507 2480.E19.GZ43 F M00074584D:C01IF97-26811-ProstateCancer3+3 1054838155 480.G04.GZ43 F M00074588C:H06IF97-26811-ProstateCancer3+3 1055529381 480.G11.GZ43 F M00074589A:E10IF97-26811-ProstateCancer3+3 105629273 480.H06.GZ43 F M00074593A:F05IF97-26811-ProstateCancer3+3 1057963580 35867 F M00074596D:B12IF97-26811-ProstateCancer3+3 2480.I08.GZ43 1058104204 480.K20.GZ43 F M00074606C:G02IF97-26811-ProstateCancer3+3 105920580 2480.L02.GZ43 F M00074607D:A12IF97-26811-ProstateCancer3+3 1060899126 480.M15.GZ43 F M00074613D:F01IF97-26811-ProstateCancer3+3 106114214 480.M20.GZ43 F M00074614B:D10IF97-26811-ProstateCancer3+3 106247888 2480.P07.GZ43 F M00074625A:C12IF97-26811-ProstateCancer3+3 1063486512 2480.P22.GZ43 F M00074628C:C11IF97-26811-ProstateCancer3+3 1064597201 2480.P23.GZ43 F M00074628C:D03IF97-26811-ProstateCancer3+3 1065134597 35888 F M00074633A:B09IF97-26811-ProstateCancer3+3 481.B06.GZ43 1066933128 2481.C22.GZ43 F M00074636D:C01IF97-26811-ProstateCancer3+3 10678997 481.D04.GZ43 F M00074637A:C02IF97-26811-ProstateCancer3+3 106820863 481.D10.GZ43 F M00074638D:C12IF97-26811-ProstateCancer3+3 106958496 35896 F M00074639A:C08IF97-26811-ProstateCancer3+3 481.D13.GZ43 1070372993 2481.E03.GZ43 F M00074640D:F07IF97-26811-ProstateCancer3+3 1071558581 2481.F24.GZ43 F M00074645C:B07IF97-26811-ProstateCancer3+3 1072471364 2481.I05.GZ43 F M00074654D:B05IF97-26811-ProstateCancer3+3 1073234423 359084 F M00074662B:A05IF97-26811-ProstateCancer3+3 2481.J23.GZ43 1074469837 2481.J24.GZ43 F M00074662D:D01IF97-26811-ProstateCancer3+3 1075449749 481.K12.GZ43 F M00074664C:G09IF97-26811-ProstateCancer3+3 107635578 2481.L13.GZ43 F M00074668D:D04IF97-26811-ProstateCancer3+3 1077464200 35916 F M00074674D:D02IF97-26811-ProstateCancer3+3 481.N10.GZ43 1078555867 481.005.GZ43 F M00074676D:H07IF97-26811-ProstateCancer3+3 1079218833 482.A05.GZ43 F M00074681C:G11IF97-26811-ProstateCancer3+3 1080782981 482.A06.GZ43 F M00074681D:A02IF97-26811-ProstateCancer3+3 1081475054 35927 F M00074687B:E01IF97-26811-ProstateCancer3+3 482.B22.GZ43 1082468400 2482.E07.GZ43 F M00074699B:C03IF97-26811-ProstateCancer3+3 108316641 2482.E17.GZ43 F M00074701D:H09IF97-26811-ProstateCancer3+3 1084460493 2482.E20.GZ43 F M00074702B:F12IF97-26811-ProstateCancer3+3 1085922 35938 F M00074702D:H05IF97-26811-ProstateCancer3+3 2482.FO1.GZ43 108610371522482.I05.GZ43 F M00074713B:F02IF97-26811-ProstateCancer3+3 1087540379 2482.J06.GZ43 F M00074716C:H07IF97-26811-ProstateCancer3+3 1088475054 2482.L14.GZ43 F M00074723D:C06IF97-26811-ProstateCancer3+3 1089452194 35954 F M00074723D:D05IF97-26811-ProstateCancer3+3 2482.L15.GZ43 10907292 482.NO1.GZ43 F M00074728C:B08IF97-26811-ProstateCancer3+3 1091375712 482.N09.GZ43 F M00074730B:A04IF97-26811-ProstateCancer3+3 1092450119 483.A13.GZ43 F M00074740B:F06IF97-26811-ProstateCancer3+3 1093549507 35966 F M00074744B:B12IF97-26811-ProstateCancer3+3 483.B23.GZ43 1094448319 483.D03.GZ43 F M00074748C:G02IF97-26811-ProstateCancer3+3 1095402591 2483.E11.GZ43 F M00074752A:D08IF97-26811-ProstateCancer3+3 1096654181 2483.F04.GZ43 F M00074753C:E10IF97-26811-ProstateCancer3+3 1097379774 359779 F M00074755A:B10IF97-26811-ProstateCancer3+3 2483.F14.GZ43 1098587168 2483.F15.GZ43 F M00074755A:E07IF97-26811-ProstateCancer3+3 1099187860 2483.I21.GZ43 F M00074765D:F06IF97-26811-ProstateCancer3+3 1100437748 2483.J07.GZ43 F M00074766C:F12IF97-26811-ProstateCancer3+3 Table 2 ORIEN
~ CLUSTERSEQNAME T CLONE ID LIBRARY

1101404081 483.K02.GZ43 F M00074768C:A05IF97-26811-ProstateCancer3+3 1102545694 2483.L15.GZ43 F M00074773C:G03IF97-26811-ProstateCancer3+3 1103474947 2483.L22.GZ43 F M00074774A:D03IF97-26811-ProstateCancer3+3 1104528957 483.M09.GZ43 F M00074777A:E01IF97-26811-ProstateCancer3+3 1105597201 483.N15.GZ43 F M00074780C:C02IF97-26811-ProstateCancer3+3 1106460493 483.007.GZ43 F M00074782A:E04IF97-26811-ProstateCancer3+3 1107135899 35999 F M00074808B:H02IF97-26811-ProstateCancer3+3 488.B07.GZ43 1108839006 2488.C19.GZ43 F M00074996C:D07IF97-26811-ProstateCancer3+3 11091022081488.D15.GZ43 F M00074981C:C09IF97-26811-ProstateCancer3+3 1110423303 2488.E20.GZ43 F M00075000A:D06IF97-26811-ProstateCancer3+3 1111387530 36256 F M00074805A:C12IF97-26811-ProstateCancer3+3 2488.F06.GZ43 1112667872 2488.F15.GZ43 F M00074981D:A03IF97-26811-ProstateCancer3+3 111322334 488.G02.GZ43 F M00074794C:H02IF97-26811-ProstateCancer3+3 1114524917 488.G05.GZ43 F M00074801C:E06IF97-26811-ProstateCancer3+3 1115453981 36259 F M00074821B:B03IF97-26811-ProstateCancer3+3 488.G12.GZ43 1116423664 488.H12.GZ43 F M00074823A:E03IF97-26811-ProstateCancer3+3 11171009284488.K04.GZ43 F M00074800B:H01IF97-26811-ProstateCancer3+3 111810092842488.L04.GZ43 F M00074800D:G09IF97-26811-ProstateCancer3+3 1119597201 36271 F M00074812A:F03IF97-26811-ProstateCancer3+3 488.N08.GZ43 _ 1120724818 488.N13.GZ43 F M00074825C:E06IF97-26811-ProstateCancer3+3 1121534076 2488.PO1.GZ43 F M00074794A:G10IF97-26811-ProstateCancer3+3 1122901160 489.A03.GZ43 F M00075018A:G04IF97-26811-ProstateCancer3+3 1123448680 362831 F M00075020D:B04IF97-26811-ProstateCancer3+3 489.A04.GZ43 112413903 489.A13.GZ43 F M00075049A:C09IF97-26811-ProstateCancer3+3 1125214762 489.B07.GZ43 F M00075032A:F02IF97-26811-ProstateCancer3+3 112621662 489.D06.GZ43 F M00075029B:E03IF97-26811-ProstateCancer3+3 1127379301 36290 F M00075069C:C01IF97-26811-ProstateCancer3+3 489.D18.GZ43 1128727966 2489.F09.GZ43 F M00075039A:E01IF97-26811-ProstateCancer3+3 112913071 489.G05.GZ43 F M00075024C:G05IF97-26811-ProstateCancer3+3 113060089 489.G20.GZ43 F M00075074D:G11IF97-26811-ProstateCancer3+3 113113091 36299 F M00075011A:C11IF97-26811-ProstateCancer3+3 489.G24.GZ43 113232367 489.H15.GZ43 F M00075061A:B03IF97-26811-ProstateCancer3+3 11331135 2489.I11.GZ43 F M00075043B:H05IF97-26811-ProstateCancer3+3 1134779428 2489.J08.GZ43 F M00075035C:C09IF97-26811-ProstateCancer3+3 1135560612 363052 F M00075045D:H03IF97-26811-ProstateCancer3+3 2489.J11.GZ43 1136726937 2489.J21.GZ43 F M00075078C:A07IF97-26811-ProstateCancer3+3 113713182 489.K20.GZ43 F M00075075A:D12IF97-26811-ProstateCancer3+3 11381037152489.K21.GZ43 F M00075077C:F09IF97-26811-ProstateCancer3+3 1139782981 36308 F M00075026A:D11IF97-26811-ProstateCancer3+3 2489.L05.GZ43 114020975 489.M11.GZ43 F M00075044A:C10IF97-26811-ProstateCancer3+3 11411097678489.M20.GZ43 F M00075075A:E09IF97-26811-ProstateCancer3+3 114222208 489.N03.GZ43 F M00075020C:D12IF97-26811-ProstateCancer3+3 1143625055 36314 F M00075117B:B06IF97-26811-ProstateCancer3+3 490.A07.GZ43 11446544 490.B06.GZ43 F M00075114C:G11IF97-26811-ProstateCancer3+3 114519627 490.B20.GZ43 F M00075153C:C11IF97-26811-ProstateCancer3+3 1146779428 2490.C23.GZ43 F M00075161A:E05IF97-26811-ProstateCancer3+3 1147395603 36328 F M00075126B:A06IF97-26811-ProstateCancer3+3 490.D10.GZ43 114843907 2490.E11.GZ43 F M00075126D:H07IF97-26811-ProstateCancer3+3 1149782981 2490.FO1.GZ43 F M00075092C:F04IF97-26811-ProstateCancer3+3 1150428699 490.H05.GZ43 F M00075110C:B03'', IF97-26811-ProstateCancer3+3 Table 2 S~ CLUSTERSEQNAME ORTENCLONE ID LIBRARY

11511005804490.H12.GZ4336339F M00075132C:A03IF97-26811-ProstateCancer3+3 115272334 2490.I20.GZ43363424F M00075152D:C06IF97-26811-ProstateCancer3+3 115340517 2490.J09.GZ43363437F M00075125B:C07IF97-26811-ProstateCancer3+3 115413495 2490.J12.GZ43363440F M00075132C:E07IF97-26811-ProstateCancer3+3 115510092842490.J22.GZ43363450F M00075160A:E04IF97-26811-ProstateCancer3+3 115660866 2490.L17.GZ43363493F M00075149B:A01IF97-26811-ProstateCancer3+3 115714453 490.M08.GZ4336350F M00075120C:H04IF97-26811-ProstateCancer3+3 1158659483 490.NO1.GZ4336352F M00075093B:F10IF97-26811-ProstateCancer3+3 1159792 490.N03.GZ4336352F M00075102A:D02IF97-26811-ProstateCancer3+3 1160380136 490.N24.GZ43 F M00075090D:B07IF97-26811-ProstateCancer3+3 116162319 36354 F M00075161D:G06IF97-26811-ProstateCancer3+3 490.023.GZ43 1162842403 491.A04.GZ43 F M00075165B:D04IF97-26811-ProstateCancer3+3 1163779428 2491.C13.GZ43 F M00075174D:D06IF97-26811-ProstateCancer3+3 1164697943 491.D12.GZ4336368F M00075180D:F05IF97-26811-ProstateCancer3+3 116535486 491.D19.GZ4336368F M00075181D:G10IF97-26811-ProstateCancer3+3 1166311745 2491.F16.GZ43 F M00075189C:G05IF97-26811-ProstateCancer3+3 1167640911 491.H09.GZ4336377F M00075199D:D11IF97-26811-ProstateCancer3+3 1168470032 491.H23.GZ43 F M00075201D:A05IF97-26811-ProstateCancer3+3 1169853371 36378 F M00075203A:G06IF97-26811-ProstateCancer3+3 2491.I06.GZ43 117056899 2491.J14.GZ43363826F M00075211D:F09IF97-26811-ProstateCancer3+3 1171414887 2491.L20.GZ43 F M00075221C:E02IF97-26811-ProstateCancer3+3 1172540379 491.002.GZ4336393F M00075228D:G09IF97-26811-ProstateCancer3+3 1173558579 2491.P07.GZ43363963F M00075232C:A06IF97-26811-ProstateCancer3+3 1174467877 2491.P10.GZ4336396F M00075232D:C06IF97-26811-ProstateCancer3+3 1175379077 2491.P20.GZ4336397F M00075234C:E06IF97-26811-ProstateCancer3+3 1176209378 496.B09.GZ43 F M00075239C:D06IF97-26811-ProstateCancer3+3 117716204 36411 F M00075242A:G04IF97-26811-ProstateCancer3+3 2496.C08.GZ43 1178137552 496.C18.GZ4336414F M00075243D:F04IF97-26811-ProstateCancer3+3 1179625055 496.D03.GZ4336415F M00075245A:A06IF97-26811-ProstateCancer3+3 118029921 2496.E14.GZ43364193F M00075249A:B08IF97-26811-ProstateCancer3+3 1181831469 2496.F14.GZ43364217F M00075252B:F10IF97-26811-ProstateCancer3+3 1182649404 496.G15.GZ4336424F M00075255A:G11IF97-26811-ProstateCancer3+3 1183129139 2496.I06.GZ43364281F M00075259C:G02IF97-26811-ProstateCancer3+3 118472712 496.K15.GZ43 F M00075270D:A02IF97-26811-ProstateCancer3+3 118583576 36433 F M00075273C:E01IF97-26811-ProstateCancer3+3 2496.L09.GZ43 1186452194 2496.L17.GZ4336436F M00075274B:F06IF97-26811-ProstateCancer3+3 1187625055 2496.L22.GZ4336436F M00075275B:H07IF97-26811-ProstateCancer3+3 1188400152 496.M22.GZ43 F M00075279C:E08IF97-26811-ProstateCancer3+3 1189558463 36439 F M00075283A:F04IF97-26811-ProstateCancer3+3 496.N15.GZ43 1190411524 2497.C11.GZ4336452F M00075302B:C07IF97-26811-ProstateCancer3+3 1191715573 497.DI1.GZ43 F M00075305C:C07IF97-26811-ProstateCancer3+3 119223000 2497.E09.GZ4336457F M00075309C:A06IF97-26811-ProstateCancer3+3 11939386 2497.I15.GZ43364674F M00075323B:B12IF97-26811-ProstateCancer3+3 119461725 2497.I21.GZ43364680F M00075324B:C10IF97-26811-ProstateCancer3+3 1195142924 2497.J05.GZ43364688F M00075324D:E02IF97-26811-ProstateCancer3+3 1196160424 2497.J23.GZ43364706F M00075326C:B01IF97-26811-ProstateCancer3+3 1197741521 497.K02.GZ4336470F M00075326D:A09IF97-26811-ProstateCancer3+3 1198175903 497.K22.GZ4336472F M00075329B:E10IF97-26811-ProstateCancer3+3 1199388450 2497.L05.GZ4336473F M00075330D:F11IF97-26811-ProstateCancer3+3 120031500 2497.L21.GZ4336475F M00075333D:B07IF97-26811-ProstateCancer3+3 Table 2 S CLUSTERSEQNAME ORTENCLONE ID LIBRARY
DQ

120152245 2497.L22.GZ43 F M00075333D:D10IF97-26811-ProstateCancer3+3 120218761 497.M17.GZ43 F M00075336B:B04IF97-26811-ProstateCancer3+3 1203449839 36477 F M00075344D:A08IF97-26811-ProstateCancer3+3 497.009.GZ43 1204715573 2497.P04.GZ43 F M00075347D:D01IF97-26811-ProstateCancer3+3 1205212364 2562.B05.GZ43 F M00075354A:D11IF97-26811-ProstateCancer3+3 12061024470562.B06.GZ43 F M00075354A:G12IF97-26811-ProstateCancer3+3 120740517 37549 F M00075354C:B12IF97-26811-ProstateCancer3+3 562.B09.GZ43 120813585 562.D02.GZ43 F M00075360D:D04IF97-26811-ProstateCancer3+3 1209598388 2562.E03.GZ43 F M00075365B:B06IF97-26811-ProstateCancer3+3 1210185903 37556 F M00075384A:B03IF97-26811-ProstateCancer3+3 1211475054 2562.IO1.GZ43 F M00075389B:C06IF97-26811-ProstateCancer3+3 2562.J02.GZ43 12126136 562.K03.GZ43 F M00075391D:D07IF97-26811-ProstateCancer3+3 121360741 37570 F M00075402A:F01IF97-26811-ProstateCancer3+3 562.N02.GZ43 1214218833 562.OO1.GZ43 F M00075405B:C07IF97-26811-ProstateCancer3+3 1215372710 37580 F M00075405D:A10IF97-26811-ProstateCancer3+3 562.006.GZ43 1216465446 2562.E14.GZ43 F M00075365D:B08IF97-26811-ProstateCancer3+3 1217130289 562.H11.GZ43 F M00075380D:F06IF97-26811-ProstateCancer3+3 121865337 562.B24.GZ43 F M00075356D:C03IF97-26811-ProstateCancer3+3 1219743053 375511 F M00075352D:F09IF97-26811-ProstateCancer3+3 1220733229 562.A22.GZ43 F M00075359D:E09IF97-26811-ProstateCancer3+3 2562.C18.GZ43 1221185886 2562.E16.GZ43 F M00075365D:H01IF97-26811-ProstateCancer3+3 122211035 2562.F17.GZ43 F M00075373C:B09IF97-26811-ProstateCancer3+3 1223135008 375600 F M00075378B:C07IF97-26811-ProstateCancer3+3 562.G19.GZ43 1224715573 562.G21.GZ43 F M00075379A:E07IF97-26811-ProstateCancer3+3 1225376516 37562 F M00075383A:B11IF97-26811-ProstateCancer3+3 562.H18.GZ43 1226154672 562.020.GZ43 F M00075407A:B05IF97-26811-ProstateCancer3+3 1227550132 37581 F M00075409A:E04IF97-26811-ProstateCancer3+3 2562.P16.GZ43 1228452806 2562.P18.GZ43 F M00075409B:G12IF97-26811-ProstateCancer3+3 122934977 498.A02.GZ43 F M00075416C:B02IF97-26811-ProstateCancer3+3 12301759 36485 F M00075458B:F09IF97-26811-ProstateCancer3+3 1231743862 498.A19.GZ43 F M00075464C:A07IF97-26811-ProstateCancer3+3 498.B22.GZ43 1232180990 2498.C19.GZ43 F M00075458C:F01IF97-26811-ProstateCancer3+3 1233137835 2498.C22.GZ43 F M00075463C:E07IF97-26811-ProstateCancer3+3 1234396148 498.D22.GZ43 F M00075464C:C04IF97-26811-ProstateCancer3+3 1235442923 36494 F M00075448B:G11IF97-26811-ProstateCancer3+3 498.G15.GZ43 1236480410 498.H08.GZ43 F M00075434A:D06IF97-26811-ProstateCancer3+3 1237395603 36502 F M00075457C:A06IF97-26811-ProstateCancer3+3 498.H18.GZ43 1238821859 2498.I17.GZ43 F M00075454C:D06IF97-26811-ProstateCancer3+3 12391082121365060 F M00075460C:B06IF97-26811-ProstateCancer3+3 498.K20.GZ43 124096136 498.M19.GZ43 F M00075459A:C02IF97-26811-ProstateCancer3+3 124120460 498.OO1.GZ43 F M00075414A:D10IF97-26811-ProstateCancer3+3 12426305 2498.P07.GZ43 F M00075433A:C06IF97-26811-ProstateCancer3+3 124328050 365218 F M00075505B:A04IF97-26811-ProstateCancer3+3 507.B18.GZ43 1244436755 2507.C03.GZ43 F M00075474D:B07IF97-26811-ProstateCancer3+3 1245691653 2507.C18.GZ43 F M00075504B:A10IF97-26811-ProstateCancer3+3 1246839006 507.H02.GZ43 F M00075473C:E08IF97-26811-ProstateCancer3+3 1247187223 367111 F M00075499A:H02IF97-26811-ProstateCancer3+3 2507.J14.GZ43 1248966599 2507.L12.GZ43 F M00075495D:D11IF97-26811-ProstateCancer3+3 1249961781 507.M13.GZ43 F M00075496D:G05IF97-26811-ProstateCancer3+3 36724_ 1250726937 507.N22.GZ43 F M00075514A:G12IF97-26811-ProstateCancer3+3 Table 2 NAME ORTENCLONE ID LIBRARY
SE

ID CLUSTERQ

1251379470 507.012.GZ43 F M00075495B:C12IF97-26811-ProstateCancer3+3 125237881 2507.P13.GZ43 F M00075497D:H03IF97-26811-ProstateCancer3+3 1253855568 511.A03.GZ43 F M00075529A:A02IF97-26811-ProstateCancer3+3 1254625055 511.A07.GZ43 F M00075538C:E03IF97-26811-ProstateCancer3+3 1255720671 511.H08.GZ43 F M00075544A:C03IF97-26811-ProstateCancer3+3 1256375488 511.D23.GZ43 F M00075598B:A09IF97-26811-ProstateCancer3+3 1257958 511.D24.GZ43 F M00075521B:E11IF97-26811-ProstateCancer3+3 125820614 2511.I23.GZ43 F M00075597C:G01IF97-26811-ProstateCancer3+3 1259217230 2511.) 18.GZ43F M00075584D:B05IF97-26811-ProstateCancer3+3 126051189 511.N20.GZ43 F M00075590B:G04IF97-26811-ProstateCancer3+3 1261377044 499.A22.GZ43 F M00075603D:D09IF97-26811-ProstateCancer3+3 12624655 499.B16.GZ43 F M00075607B:D05IF97-26811-ProstateCancer3+3 1263395761 2499.C09.GZ43 F M00075609A:H06IF97-26811-ProstateCancer3+3 1264135675 499.D16.GZ43 F M00075613D:F01IF97-26811-ProstateCancer3+3 1265779428 2499.E18.GZ43 F M00075619C:D08IF97-26811-ProstateCancer3+3 1266224580 2499.F08.GZ43 F M00075621A:F06IF97-26811-ProstateCancer3+3 126713182 2499.I09.GZ43 F M00075639A:D12IF97-26811-ProstateCancer3+3 Table 3 SEQ ID CONSENSUS SEQ POLYNTD SEQ NAME
NAME

1268 C1u1009284.1 2490.J22.GZ43 363450 1269 C1u1022935.2 2561.019.GZ43 376586 1270 C1u1037152.1 2558.L19.GZ43 374594 1271 C1u13903.1 2489.A13.GZ43 362841 1272 C1u139979.2 2504.B21.GZ43 365834 1273 C1u163602.2 2561.H17.GZ43 376416 1274 CIu187860.2 2474.P22.GZ43 361999 1275 CIu189993.1 2505.N19.GZ43 366504 1276 CIu20975.1 2466.F16.GZ43 360217 1277 C1u217122.1 2458.N10.GZ43 356930 1278 C1u218833.1 2562.OO1.GZ43 375800 1279 C1u244504.2 2367.E23.GZ43 346113 1280 C1u271456.1 2365.G19.GZ43 345389 1281 C1u376516.1 2457.J23.GZ43 356451 1282 CIu376630.1 2467.B11.GZ43 360500 1283 C1u377044.2 2499.A22.GZ43 365257 1284 C1u379689.1 2540.M18.GZ43 372313 1285 C1u380482.2 2542.D09.GZ43 372856 1286 C1u387530.4 2475.N08.GZ43 362321 1287 CIu388450.2 2497.L05.GZ43 364736 1288 C1u396325.1 2561.P16.GZ43 376607 1289 C1u397115.3 2560.K18.GZ43 375337 1290 C1u398642.2 2542.N22.GZ43 373109 1291 C1u400258.1 2504.012.GZ43 366137 1292 C1u402167.1 2540.C21.GZ43 372076 1293 C1u402591.3 2483.E11.GZ43 359762 1294 C1u402904.1 2504.J02.GZ43 366007 1295 C1u404081.2 2483.K02.GZ43 359897 1296 C1u411524.1 2497.C11.GZ43 364526 1297 C1u41346.1 2560.K08.GZ43 375327 1298 C1u415520.1 2561.L14.GZ43 376509 1299 C1u416124.1 2367.G17.GZ43 346155 1300 C1u417672.1 2367.I09.GZ43 346195 1301 C1u423664.1 2488.H12.GZ43 362624 1302 C1u429609.1 2457.M11.GZ43 356511 1303 C1u442923.3 2498.G15.GZ43 365010 1304 C1u446975.1 2459.K15.GZ43 357247 1305 C1u449839.2 2497.009.GZ43 364812 1306 C1u449889.1 2475.N21.GZ43 362334 1307 CIu451707.2 2554.P16.GZ43 376223 1308 CIu454509.3 2542.M09.GZ43 373072 1309 C1u454796.1 2540.P02.GZ43 372369 1310 C1u455862.1 2560.I09.GZ43 375280 1311 CIu460493.1 2483.007.GZ43 359998 1312 C1u464200.1 2465.G06.GZ43 358214 1313 C1u465446.2 2457.L21.GZ43 356497 1314 C1u470032.1 2474.CO1.GZ43 361666 1315 C1u474125.1 2457.E23.GZ43 356331 1316 C1u474125.2 2541.A06.GZ43 372397 1317 C1u477271.1 2540.E17.GZ43 372120 1318 CIu480410.1 2498.H08.GZ43 365027 1319 CIu483211.2 2510.J18.GZ43 369259 1320 C1u497138.1 2458.N19.GZ43 356939 Table 3 SEQ ID CONSENSUS SEQ POLYNTD SEQ NAME
NAME

1321 C1u498886.1 2465.L22.GZ43 358350 1322 C1u498886.2 2541.B 15.GZ43 372430 1323 CIu5013.2 2559.D05.GZ43 374772 1324 CIu5105.2 2542.D19.GZ43 372866 1325 C1u510539.2 2558.H17.GZ43 374496 1326 C1u514044.1 2367.F13.GZ43 346127 1327 CIu516526.1 2456.F23.GZ43 355971 1328 C1u519176.2 2559.H20.GZ43 374883 1329 C1u520370.1 2541.NO1.GZ43 372704 1330 C1u524917.1 2464.H05.GZ43 357853 1331 C1u528957.1 2540.F15.GZ43 372142 1332 C1u533888.1 2557.L23.GZ43 374214 1333 C1u534076.1 2456.C05.GZ43 355881 1334 C1u540142.2 2456.H02.GZ43 355998 1335 C1u540379.2 2491.002.GZ43 363934 1336 C1u549507.1 2483.B23.GZ43 359702 1337 C1u551338.3 2457.I12.GZ43 356416 1338 C1u552537.2 2540.C10.GZ43 372065 1339 C1u556827.3 2558.E24.GZ43 374431 1340 C1u558569.2 2558.D03.GZ43 374386 1341 C1u565709.1 2542.P02.GZ43 373137 1342 C1u568204.1 2456.M05.GZ43 356121 1343 C1u570804.1 2475.M20.GZ43 362309 1344 C1u572170.2 2557.H03.GZ43 374098 1345 CIu573764.1 2365.C10.GZ43 345284 1346 C1u587168.1 2483.F15.GZ43 359790 1347 C1u588996.1 2466.G06.GZ43 360231 1348 CIu597681.1 2459.A04.GZ43 356996 1349 C1u598388.1 2562.E03.GZ43 375562 1350 C1u604822.2 2504.F20.GZ43 365929 1351 C1u621573.1 2535.A08.GZ43 370095 1352 C1u625055.1 2511.A07.GZ43 369416 1353 C1u627263.1 2466.D20.GZ43 360173 1354 C1u635332.1 2480.D13.GZ43 358588 1355 C1u640911.2 2541.M24.GZ43 372703 1356 CIu641662.2 2555.D22.GZ43 373253 1357 CIu659483.1 2365.F12.GZ43 345358 1358 C1u6712.1 2535.P14.GZ43 370461 1359 C1u676448.3 2464.BO1.GZ43 357705 1360 C1u682065.2 2467.E19.GZ43 360580 1361 C1u685244.2 2561.JO1.GZ43 376448 1362 C1u691653.1 2560.012.GZ43 375427 1363 C1u692282.1 2561.I11.GZ43 376434 1364 C1u697955.1 2557.J22.GZ43 374165 1365 C1u702885.3 2555.H18.GZ43 373345 1366 C1u70908.1 2561.C15.GZ43 376294 1367 C1u709796.2 2542.C20.GZ43 372843 1368 C1u715752.1 2459.A24.GZ43 357016 1369 C1u727966.1 2489.F09.GZ43 362957 1370 C1u732950.2 2475.L17.GZ43 362282 1371 CIu752623.2 2561.I07.GZ43 376430 1372 C1u756337.1 2561.I19.GZ43 376442 1373 CIu782981.1 2489.L05.GZ43 363097 Table 3 SEQ ID CONSENSUS SEQ POLYNTD SEQ NAME
NAME

1374 C1u805118.3 2480.D16.GZ43 358591 1375 C1u806992.2 2467.D20.GZ43 360557 1376 CIu823296.3 2558.P20.GZ43 374691 1377 C1u830453.2 2540.M22.GZ43 372317 1378 C1u839006.1 2507.H02.GZ43 367111 1379 C1u847088.1 2542.H23.GZ43 372966 1380 C1u853371.2 2491.I06.GZ43 363794 1381 C1u88462.1 2510.K15.GZ43 369280 1382 C1u935908.2 2505.009.GZ43 366518 1383 C1u948383.1 2541.F05.GZ43 372516 1384 C1u966599.3 2507.L12.GZ43 367217 1385 C1u993554.1 2558.F19.GZ43 374450 Table 4 SEQ cDNA SEQ POLYNTD SEQ GENE CHROM
ID NAME NAME

1386 DTT00087024.12467.H18.GZ43 DTG00087008.11 1387 DTT00089020.12367.I15.GZ43 DTG00089002.11 1388 DTT00171014.12473.F14.GZ43 DTG00171001.11 1389 DTT00514029.12488.G02.GZ43 DTG00514005.11 1390 DTT00740010.1362590 DTG00740003.11 2466.I08.GZ43 1391 DTT00945030.12466.D19.GZ43 DTG00945008.11 1392 DTT01169022.12464.N05.GZ43 DTG01169003.1.2 1393 DTT01178009.12510.021.GZ43 DTG01178002.12 1394 DTT01315010.1369382 DTG01315001.12 2496.F14.GZ43 1395 DTT01503016.12538.M17.GZ43 DTG01503005.12 1396 DTT01555018.12538.C07.GZ43 DTG01555002.12 1397 DTT01685047.12496.C08.GZ43 DTG01685007.12 1398 DTT01764019.1364139 DTG01764003.12 2535.C23.GZ43 1399 DTT01890015.12482.J06.GZ43 DTG01890004.12 1400 DTT02243008.12474.J19.GZ43 DTG02243002.13 1401 DTT02367007.1361852 DTG02367002.13 1402 DTT02671007.12366.P08.GZ43 DTG02671002.13 2464.H22.GZ43 1403 DTT02737017.12538.M16.GZ43 DTG02737001.13 1404 DTT02850005.1371543 DTG02850001.13 2472.G03.GZ43 1405 DTT02966016.12510.M14.GZ43 DTG02966003.14 1406 DTT03037029.1369327 DTG03037005.14 2504.D16.GZ43 1407 DTT03150008.12491.P10.GZ43 DTG03150002.14 1408 DTT03367008.12542.P19.GZ43 DTG03367003.14 1409 DTT03630013.12510.022.GZ43 DTG03630002.14 1410 DTT03881017.1369383 DTG03881007.15 2507.012.GZ43 1411 DTT03913023.12459.P24.GZ43 DTG03913005.15 1412 DTT03978010.12367.G22.GZ43 DTG03978001.15 1413 DTT04070014.12540.H07.GZ43 DTG04070007.15 1414 DTT04084010.1372182 DTG04084001.15 2542.D19.GZ43 1415 DTT04160007.12472.M22.GZ43 DTG04160003.15 1416 DTT04302021.12483.007.GZ43 DTG04302002.15 1417 DTT04378009.12368.O11.GZ43 DTG04378001.15 1418 DTT04403013.1346725 DTG04403003.15 2506.M05.GZ43 1419 DTT04414015.12368.D20.GZ43 DTG04414005.15 1420 DTT04660017.12507.C03.GZ43 DTG04660003.16 1421 DTT04956054.12538.t17.GZ43 DTG04956020.16 1422 DTT04970018.1371448 DTG04970007.16 2365.F24.GZ43 1423 DTT05205007.12459.J12.GZ43 DTG05205001.16 1424 DTT05571010.12555.J10.GZ43 DTG05571004.17 1425 DTT05650008.12557.LO1.GZ43 DTG05650003.17 1426 DTT05742029.1374192 DTG05742002.17 2560.K10.GZ43 1427 DTT06137030.12565.B15.GZ43 DTG06137001.18 1428 DTT06161014.12367.F06.GZ43 DTG06161007.18 1429 DTT06706019.12467.D10.GZ43 DTG06706003.19 1430 DTT06837021.1360547 DTG06837002.19 2540.I10.GZ43 1431 DTT07040015.12504.E23.GZ43 DTG07040006.19 1432 DTT07088009.12565.HO1.GZ43 DTG07088001.19 1433 DTT07182014.12536.G22.GZ43 DTG07182006.110 1434 DTT07405044.1370637 DTG07405010.110 2560.B11.GZ43 1435 DTT07408020.12466.M02.GZ43 DTG07408005.110 1436 DTT07498014.12506.K20.GZ43 DTG07498002.110 1437 DTT07600010.12464.H17.GZ43 DTG07600001.110 Table 4 SEQ cDNA SEQ POLYNTD GENE CHROM
ID NAME SEQ NAME

1438 DTT08005024.12475.N21.GZ43362334DTG08005009.111 1439 DTT08098020.12540.M18.GZ43372313DTG08098001.111 1440 DTT08167018.12542.F05.GZ43372900DTG08167002.111 1441 DTT08249022.12498.G15.GZ43365010DTG08249008.111 1442 DTT08499022.12540.A24.GZ43372031DTG08499009.112 1443 DTT08514022.12541.L12.GZ43372667DTG08514006.112 1444 DTT08527013.12489.F09.GZ43362957DTG08527005.112 1445 DTT08595020.12554.N09.GZ43376168DTG08595003.112 1446 DTT08711019.12540.C19.GZ43372074DTG08711001.112 1447 DTT08773020.12559.I12.GZ43374899DTG08773008.112 1448 DTT08874012.12537.P14.GZ43371229DTG08874001.112 1449 DTT09387018.12561.P19.GZ43376610DTG09387001.114 1450 DTT09396022.12489.M11.GZ43363127DTG09396001.114 1451 DTT09553027.12505.J22.GZ43366411DTG09553007.114 1452 DTT09604016.12483.J07.GZ43359878DTG09604006.114 1453 DTT09705033.12536.022.GZ43370829DTG09705006.114 1454 DTT09742009.12542.N21.GZ43373108DTG09742002.115 1455 DTT09753017.12464.L02.GZ43357946DTG09753002.115 1456 DTT09793019.12464.I04.GZ43357876DTG09793004.115 1457 DTT09796028.12366.L21.GZ43345942DTG09796002.115 1458 DTT10221016.12556.C19.GZ43373610DTG10221004.116 1459 DTT10360040.12475.M20.GZ43362309DTG10360016.116 1460 DTT10539016.12506.J20.GZ43366793DTG10539005.117 1461 DTT10564022.12475.H06.GZ43362175DTG10564006.117 1462 DTT10683041.12542.K21.GZ43373036DTG10683007.117 1463 DTT10819011.12474.I06.GZ43361815DTG10819003.117 1464 DTT11363027.12542.C20.GZ43372843DTG11363008.119 1465 DTT11479018.12506.G24.GZ43366725DTG11479007.119 1466 DTT11483012.12459.H09.GZ43357169DTG11483001.119 1467 DTT11548015.12565.C17.GZ43398204DTG11548002.119 1468 DTT11730017.12535.B09.GZ43370120DTG11730004.120 1469 DTT11791010.12506.E12.GZ43366665DTG11791003.120 1470 DTT11864036.12456.H07.GZ43356003DTG11864011.121 1471 DTT11902028.12490.B06.GZ43363242DTG11902009.121 1472 DTT11915017.12474.G17.GZ43361778DTG11915002.121 1473 DTT11966040.12457.L21.GZ43356497DTG11966014.122 1474 DTT12042027.12459.GO1.GZ43357137DTG12042005.122 1475 DTT12201062.12562.B09.GZ43375496DTG12201018.1X

1476 DTT12470020.12489.A13.GZ43362841DTG12470004.1X

1477 DTT12550009.12504.GO1.GZ43365934DTG12550003.1~ X

Table 5 SEQ PROTEIN DBL TWIST
ID SEQ POLYNTD SEQ NAMEGENE CHROM LOCUS ID
NAME

1478 DTP00087033.12467.H18.GZ43 DTG00087008.11 DTL00087012.1 1479 DTP00089029.12367.I15.GZ43 DTG00089002.11 DTL00089002.1 1480 DTP00171023.1346201 DTG00171001.11 DTL00171013.1 1481 DTP00514038.12473.F14.GZ43 DTG00514005.11 DTL00514023.1 2488.G02.GZ43 1482 DTP00740019.12466.I08.GZ43 DTG00740003.11 DTL00740006.1 1483 DTP00945039.12466.D19.GZ43 DTG00945008.11 1484 DTP01169031.1360172 DTG01169003.12 DTL01169014.1 2464.N05.GZ43 1485 DTP01178018.12510.021.GZ43 DTG01178002.12 DTL01178007.1 1486 DTP01315019.12496.F14.GZ43 DTG01315001.12 DTL01315004.1 1487 DTP01503025.12538.M17.GZ43 DTG01503005.12 DTL01503007.1 1488 DTP01555027.1371544 DTG01555002.12 DTL01555003.1 2538.C07.GZ43 1489 DTP01685056.12496.C08.GZ43 DTG01685007.12 DTL01685004.1 1490 DTP01764028.12535.C23.GZ43 DTG01764003.12 DTL01764005.1 1491 DTP01890024.12482.J06.GZ43 DTG01890004.12 DTL01890001.1 1492 DTP02243017.1359493 DTG02243002.13 DTL02243002.1 1493 DTP02367016.12474.J19.GZ43 DTG02367002.13 DTL02367004.1 1494 DTP02671016.1361852 DTG02671002.13 DTL02671002.1 2366.P08.GZ43 2464.H22.GZ43 1495 DTP02737026.12538.M16.GZ43 DTG02737001.13 DTL02737012.1 1496 DTP02850014.1371543 DTG02850001.13 ~ DTL02850004.1 2472.G03.GZ43 1497 DTP02966025.12510.M14.GZ43 DTG02966003.14 DTL02966001.1 1498 DTP03037038.12504.D16.GZ43 DTG03037005.14 DTL03037004.1 1499 DTP03150017.12491.P10.GZ43 DTG03150002.14 DTL03149001.1 1500 DTP03367017.1363966 DTG03367003.14 DTL03367005.1 2542.P19.GZ43 1501 DTP03630022.12510.022.GZ43 DTG03630002.14 DTL03630006.1 1502 DTP03881026.12507.012.GZ43 DTG03881007.15 DTL03881006.1 1503 DTP03913032.1367289 DTG03913005.15 DTL03913012.1 1504 DTP03978019.12459.P24.GZ43 DTG03978001.15 DTL03978003.1 2367.G22.GZ43 1505 DTP04070023.12540.H07.GZ43 DTG04070007.15 1506 DTP04084019.12542.D19.GZ43 DTG04084001.15 DTL04084001.1 1507 DTP04160016.12472.M22.GZ43 DTG04160003.15 DTL04160003.1 1508 DTP04302030.1361159 DTG04302002.15 DTL04302006.1 2483.007.GZ43 1509 DTP04378018.12368.O11.GZ43 DTG04378001.15 1510 DTP04403022.12506.M05.GZ43 DTG04403003.15 DTL04403004.1 1511 DTP04414024.12368.D20.GZ43 DTG04414005.15 DTL04414004.1 1512 DTP04660026.1346470 DTG04660003.16 DTL04660002.1 2507.C03.GZ43 1513 DTP04956063.12538.I17.GZ43 DTG04956020.16 DTL04956028.1 1514 DTP04970027.12365.F24.GZ43 DTG04970007.16 DTL04970008.1 1515 DTP05205016.1345370 DTG05205001.16 DTL05205002.1 1516 DTP05571019.12459.J12.GZ43 DTG05571004.17 DTL05571003.1 2555.J10.GZ43 1517 DTP05650017.12557.LO1.GZ43 DTG05650003.17 DTL05650004.1 1518 DTP05742038.12560.K10.GZ43 DTG05742002.17 DTL05742003.1 1519 DTP06137039.12565.B15.GZ43 DTG06137001.18 DTL06137003.1 1520 DTP06161023.1398171 DTG06161007.18 DTL06161006.1 2367.F06.GZ43 1521 DTP06706028.12467.D10.GZ43 DTG06706003.19 DTL06705001.1 1522 DTP06837030.12540.I10.GZ43 DTG06837002.19 DTL06837010.1 1523 DTP07040024.12504.E23.GZ43 DTG07040006.19 DTL07040004.1 1524 DTP07088018.1365908 DTG07088001.19 DTL07088004.1 2565.HO1.GZ43 1525 DTP07405053.12560.B 11.GZ43 DTG07405010.110 DTL07405034.1 1526 DTP07408029.12466.M02.GZ43 DTG07408005.110 DTL07408005.1 1527 DTP07498023.12506.K20.GZ43 DTG07498002.110 DTL07498007.1 1528 DTP07600019.12464.H17.GZ43 DTG07600001.110 DTL07600004.1 1529 DTP08005033.12475.N21.GZ43 DTG08005009.111 DTL08005010.1 Table 5 SEQ PROTEIN DBL TWIST
SEQ

pOLYNTD SEQ NAMEGENE CHROM

ID NAME LOCUS ID

1530 DTP08098029.12540.M18.GZ43 DTG08098001.111 DTL08098013.1 1531 DTP08167027.12542.F05.GZ43 DTG08167002.111 DTL08167003.1 1532 DTP08249031.12498.G15.GZ43 DTG08249008.111 DTL08249005.1 1533 DTP08499031.12540.A24.GZ43 DTG08499009.112 DTL08499012.1 1534 DTP08514031.12541.L12.GZ43 DTG08514006.112 DTL08514015.1 1535 DTP08527022.12489.F09.GZ43 DTG08527005.112 DTL08527008.1 1536 DTP08595029.12554.N09.GZ43 DTG08595003.112 DTL08595002.1 1537 DTP08711028.12540.C19.GZ43 DTG08711001.112 DTL08710003.1 1538 DTP08773029.12559.I12.GZ43 DTG08773008.112 DTL08773011.1 1539 DTP08874021.12537.P14.GZ43 DTG08874001.112 DTL08874009.1 1540 DTP09387027.12561.P19.GZ43 DTG09387001.114 DTL09387002.1 1541 DTP09396031.12489.M11.GZ43 DTG09396001.114 DTL09396016.1 1542 DTP09553036.12505.J22.GZ43 DTG09553007.114 DTL09553018.1 1543 DTP09604025.12483.J07.GZ43 DTG09604006.114 DTL09604010.1 1544 DTP09705042.12536.022.GZ43 DTG09705006.114 DTL09705005.1 1545 DTP09742018.12542.N21.GZ43 DTG09742002.115 DTL09742007.1 1546 DTP09753026.12464.L02.GZ43 DTG09753002.115 DTL09753011.1 1547 DTP09793028.12464.I04.GZ43 DTG09793004.115 DTL09793004.1 1548 DTP09796037.12366.L21.GZ43 DTG09796002.115 DTL09796021.1 1549 DTP10221025.12556.C19.GZ43 DTG10221004.116 DTL10221002.1 1550 DTP10360049.12475.M20.GZ43 DTG10360016.116 DTL10360003.1 1551 DTP10539025.12506.J20.GZ43 DTG10539005.117 DTL10539004.1 1552 DTP10564031.12475.H06.GZ43 DTG10564006.117 DTL10564006.1 1553 DTP10683050.12542.K21.GZ43 DTG10683007.117 DTL10683002.1 1554 DTP10819020.12474.I06.GZ43 DTG10819003.117 DTL10819002.1 1555 DTP11363036.12542.C20.GZ43 DTG11363008.119 DTL11363017.1 1556 DTP11479027.12506.G24.GZ43 DTG11479007.119 DTL11479006.1 366725 ~

1557 DTP11483021.12459.H09.GZ43 DTG11483001.119 DTL11483006.1 1558 DTP11548024.12565.C17.GZ43 DTG11548002.119 DTL11548003.1 1559 DTP11730026.12535.B09.GZ43 DTG11730004.120 DTL11730009.1 1560 DTP11791019.12506.E12.GZ43 DTG11791003.120 DTL11791005.1 1561 DTP11864045.12456.H07.GZ43 DTG11864011.121 DTL11864023.1 1562 DTP11902037.12490.B06.GZ43 DTG11902009.121 DTL11902002.1 1563 DTP11915026.12474.G17.GZ43 DTG11915002.121 DTL11915001.1 1564 DTP11966049.12457.L21.GZ43 DTG11966014.122 DTL11966006.1 1565 DTP12042036.12459.GO1.GZ43 DTG12042005.122 DTL12042001.1 1566 DTP12201071.12562.B09.GZ43 DTG12201018.1X DTL12201023.1 1567 DTP12470029.12489.A13.GZ43 DTG12470004.1X DTL1247001 362841 6.1 1568 DTP12550018.12504.GO1.GZ43 DTG12550003.1_ _ 365934 __ DTL12550005.1 ~ X

Table 6 cDNA cDNA SEQ PROTEINPROTEIN SEQ POLYNTD

SEQ ID NAME SEQ NAME SEQ ID POLYNTD SEQ NAME
ID

1386 DTT00087024.11478 DTP00087033.1963 2467.H18.GZ43 1386 DTT00087024.11478 DTP00087033.133 2505.B05.GZ43 1387 DTT00089020.11479 DTP00089029.1213 2367.115.GZ43 1388 DTT00171014.11480 DTP00171023.11006 2473.F14.GZ43 1388 DTT00171014.11480 DTP00171023.11122 2489.A03.GZ43 1389 DTT00514029.11481 DTP00514038.11113 2488.G02.GZ43 1390 DTT00740010.11482 DTP00740019.1952 2466.108.GZ43 1391 DTT00945030.11483 DTP00945039.1945 2466.D19.GZ43 1392 DTT01169022.11484 DTP01169031.1482 2540.117.GZ43 1392 DTT01169022.11484 DTP01169031.1914 2464.N05.GZ43 1393 DTT01178009.11485 DTP01178018.1113 2510.021.GZ43 1394 DTT01315010.11486 DTP01315019.11181 2496.F14.GZ43 1395 DTT01503016.11487 DTP01503025.1386 2538.M17.GZ43 1396 DTT01555018.11488 DTP01555027.1366 2538.C07.GZ43 1396 DTT01555018.11488 DTP01555027.1368 2538.D03.GZ43 1396 DTT01555018.11488 DTP01555027.1369 2538.D04.GZ43 1397 DTT01685047.11489 DTP01685056.11177 2496.C08.GZ43 1398 DTT01764019.11490 DTP01764028.1267 2535.C23.GZ43 1398 DTT01764019.11490 DTP01764028.1771 2456.D04.GZ43 1399 DTT01890015.11491 DTP01890024.11087 2482.J06.GZ43 1399 DTT01890015.11491 DTP01890024.11042 2475.B20.GZ43 1399 DTT01890015.11491 DTP01890024.11200 2497.L21.GZ43 1400 DTT02243008.11492 DTP02243017.11224 2562.G21.GZ43 1400 DTT02243008.11492 DTP02243017.11204 2497.P04.GZ43 1400 DTT02243008.11492 DTP02243017.11025 2474.J19.GZ43 1400 DTT02243008.11492 DTP02243017.11191 2497.D11.GZ43 1401 DTT02367007.11493 DTP02367016.1174 2366.P08.GZ43 1402 DTT02671007.11494 DTP02671016.1903 2464.H22.GZ43 1402 DTT02671007.11494 DTP02671016.11055 2480.G11.GZ43 1403 DTT02737017.11495 DTP02737026.1385 2538.M16.GZ43 1404 DTT02850005.11496 DTP02850014.1992 2472.G03.GZ43 1404 DTT02850005.11496 DTP02850014.11111 2488.FO6.GZ43 1404 DTT02850005.11496 DTP02850014.11039 2475.N08.GZ43 1405 DTT02966016.11497 DTP02966025.1103 2510.M14.GZ43 1406 DTT03037029.11498 DTP03037038.19 2504.D16.GZ43 1407 DTT03150008.11499 DTP03150017.1428 2565.G20.GZ43 1407 DTT03150008.11499 DTP03150017.1585 2555.112.GZ43 1407 DTT03150008.11499 DTP03150017.1235 2368.DOS.GZ43 1407 DTT03150008.11499 DTP03150017.11174 2491.P10.GZ43 1408 DTT03367008.11500 DTP03367017.1519 2506.E18.GZ43 1408 DTT03367008.11500 DTP03367017.1557 2542.P19.GZ43 1409 DTT03630013.11501 DTP03630022.1114 2510.022.GZ43 1410 DTT03881017.11502 DTP03881026.11251 2507.012.GZ43 1411 DTT03913023.11503 DTP03913032.1889 2459.P24.GZ43 1412 DTT03978010.11504 DTP03978019.1211 2367.G22.GZ43 1413 DTT04070014.11505 DTP04070023.1423 2565.D06.GZ43 1413 DTT04070014.11505 DTP04070023.1374 2538.F03.GZ43 1413 DTT04070014.11505 DTP04070023.117 2504.113.GZ43 1413 DTT04070014.11505 DTP04070023.1692 2559.K12.GZ43 1413 DTT04070014.11505 DTP04070023.143 2505.E15.GZ43 1413 DTT04070014.11505 DTP04070023.1750 2561.M09.GZ43 1413 DTT04070014.11505 DTP04070023.1463 2540.H07.GZ43 Table 6 cDNA cDNA SEQ PROTEINPROTEIN SEQ POLYNTD
SEQ NAME SEQ NAME SEQ ID POLYNTD SEQ NAME
ID ID

1413 DTT04070014.11505 DTP04070023.11069 2481.D13.GZ43 1414 DTT04084010.11506 DTP04084019.1543 2542.D19.GZ43 1415 DTT04160007.11507 DTP04160016.1999 2472.M22.GZ43 1416 DTT04302021.11508 DTP04302030.11106 2483.007.GZ43 1417 DTT04378009.11509 DTP04378018.1260 2368.011.GZ43 1418 DTT04403013.11510 DTP04403022.1531 2506.M05.GZ43 1419 DTT04414015.11511 DTP04414024.1236 2368.D20.GZ43 1420 DTT04660017.11512 DTP04660026.1334 2537.D11.GZ43 1420 DTT04660017.11512 DTP04660026.11244 370938 2507.C03.GZ43 1421 DTT04956054.11513 DTP04956063.1379 2538.117.GZ43 1422 DTT04970018.11514 DTP04970027.1363 2538.B03.GZ43 1422 DTT04970018.11514 DTP04970027.1259 2368.003.GZ43 1422 DTT04970018.11514 DTP04970027.11101 346717 1422 DTT04970018.11514 DTP04970027.1134 2483.K02.GZ43 2365.F24.GZ43 1423 DTT05205007.11515 DTP05205016.1880 2459.J12.GZ43 1424 DTT05571010.11516 DTP05571019.1586 2555.J10.GZ43 1425 DTT05650008.11517 DTP05650017.1644 373385 2557.L01.GZ43 1426 DTT05742029.11518 DTP05742038.1721 2560.K10.GZ43 1426 DTT05742029.11518 DTP05742038.1126 2365.D10.GZ43 1426 DTT05742029.11518 DTP05742038.1756 345308 1427 DTT06137030.11519 DTP06137039.1419 2561.119.GZ43 2565.B15.GZ43 1428 DTT06161014.11520 DTP06161023.1205 2367.F06.GZ43 1429 DTT06706019.11521 DTP06706028.1967 2467.D10.GZ43 1430 DTT06837021.11522 DTP06837030.1465 2540.110.GZ43 1431 DTT07040015.11523 DTP07040024.110 372209 1432 DTT07088009.11524 DTP07088018.1170 2504.E23.GZ43 2366.J06.GZ43 1432 DTT07088009.11524 DTP07088018.1429 2565.H01.GZ43 1433 DTT07182014.1 DTP07182023.1306 2536.G22.GZ43 1434 DTT07405044.11525 DTP07405053.1703 370637 1435 DTT07408020.11526 DTP07408029.1956 2560.B11.GZ43 2466.M02.GZ43 1436 DTT07498014.11527 DTP07498023.1529 2506.K20.GZ43 1437 DTT07600010.11528 DTP07600019.1902 2464.H17.GZ43 1438 DTT08005024.11529 DTP08005033.11046 357865 1439 DTT08098020.11530 DTP08098029.1485 2475.N21.GZ43 1440 DTT08167018.11531 DTP08167027.1152 362334 2540.M18.GZ43 2365.N12.GZ43 1440 DTT08167018.11531 DTP08167027.1544 2542.F05.GZ43 1441 DTT08249022.11532 DTP08249031.11235 372900 2498.G15.GZ43 1442 DTT08499022.11533 DTP08499031.1452 2540.A24.GZ43 1443 DTT08514022.11534 DTP08514031.1508 372031 2541.L12.GZ43 1444 DTT08527013.11535 DTP08527022.1109 2510.N14.GZ43 1444 DTT08527013.11535 DTP08527022.1394 369351 1444 DTT08527013.11535 DTP08527022.11128 2554.A16.GZ43 2489.F09.GZ43 1444 DTT08527013.11535 DTP08527022.1569 2555.F16.GZ43 1445 DTT08595020.11536 DTP08595029.1413 2554.N09.GZ43 1446 DTT08711019.11537 DTP08711028.1472 376168 2540.C19.GZ43 1447 DTT08773020.11538 DTP08773029.1687 2559.112.GZ43 1448 DTT08874012.11539 DTP08874021.1356 2537.P14.GZ43 1449 DTT09387018.11540 DTP09387027.1762 371229 1450 DTT09396022.11541 DTP09396031.11140 2561.P19.GZ43 2489.M11.GZ43 1451 DTT09553027.11542 DTP09553036.154 2505.J22.GZ43 1452 DTT09604016.11543 DTP09604025.11100 2483.J07.GZ43 1453 DTT09705033.11544 DTP09705042.1323 2536.022.GZ43 Table 6 cDNA cDNA SEQ PROTEINPROTEIN SEQ POLYNTD
SEQ NAME SEQ NAME SEQ ID POLYNTD SEQ NAME
ID ID

1454 DTT09742009.11545 DTP09742018.1766 2456.B12.GZ43 1454 DTT09742009.11545 DTP09742018.1563 2542.N21.GZ43 1455 DTT09753017.11546 DTP09753026.1910 2464.L02.GZ43 1456 DTT09793019.11547 DTP09793028.1904 2464.104.GZ43 1457 DTT09796028.11548 DTP09796037.1189 357876 2366.L21.GZ43 1458 DTT10221016.11549 DTP10221025.1592 2556.C19.GZ43 1459 DTT10360040.11550 DTP10360049.11045 2475.M20.GZ43 1460 DTT10539016.11551 DTP10539025.1527 2506.J20.GZ43 1461 DTT10564022.11552 DTP10564031.11035 366793 2475.H06.GZ43 1462 DTT10683041.11553 DTP10683050.1561 2542.K21.GZ43 1463 DTT10819011.11554 DTP10819020.1796 373036 2457.C19.GZ43 1463 DTT10819011.11554 DTP10819020.1143 2365.J14.GZ43 1463 DTT10819011.11554 DTP10819020.11023 345456 2474.106.GZ43 1464 DTT11363027.11555 DTP11363036.1540 2542.C20.GZ43 1465 DTT11479018.11556 DTP11479027.1521 2506.G24.GZ43 1466 DTT11483012.11557 DTP11483021.1877 2459.H09.GZ43 1467 DTT11548015.11558 DTP11548024.1422 357169 2565.C17.GZ43 1468 DTT11730017.11559 DTP11730026.1264 2535.B09.GZ43 1469 DTT11791010.11560 DTP11791019.1518 2506.E12.GZ43 1470 DTT11864036.11561 DTP11864045.1778 366665 1471 DTT11902028.11562 DTP11902037.11144 2456.H07.GZ43 2490.B06.GZ43 1472 DTT11915017.11563 DTP11915026.1.591 2556.C11.GZ43 1472 DTT11915017.11563 DTP11915026.11021 373602 2474.G17.GZ43 1472 DTT11915017.11563 DTP11915026.11163 2491.C13.GZ43 1473 DTT11966040.11564 DTP11966049.11216 363657 2562.E14.GZ43 1473 DTT11966040.11564 DTP11966049.1818 2457.L21.GZ43 1473 DTT11966040.11564 DTP11966049.1532 2506.M13.GZ43 1474 DTT12042027.11565 DTP12042036.1874 2459.G01.GZ43 1475 DTT12201062.11566 DTP12201071.1759 357137 2561.017.GZ43 1475 DTT12201062.11566 DTP12201071.11207 2562.B09.GZ43 1476 DTT12470020.11567 DTP12470029.11124 375496 1476 DTT12470020.11567 DTP12470029.1799 2489.A13.GZ43 1476 DTT12470020.11567 DTP12470029.1690 362841 2457.D12.GZ43 2559.J02.GZ43 1476 DTT12470020.11567 DTP12470029.1568 2555.E20.GZ43 1477 DTT12550009.11568 DTP12550018.112 2504.G01.GZ43 Table 7 SEQ ACCES- GENBANK

ID SEQ NAME SION GENBANK DESCRIPTION SCORE

gi~4835690~dbj~AP000321.1AP000321 Homo Sapiens genomic DNA, chromosome 21q22.1, D21S226-AML region, 6 2504.C08.GZ43 365845 AP000321clone: 82F5, com lete 1.6E-31 se uence gig 16267134~dbj ~AP00293 8.1 AP00293 8 Hoplostethus japonicus mitochondrial DNA, 7 2504.C11.GZ43 365848 AP002938complete genome 4.8E-58 gi) 1043 5445 ~dbj ~AK023496.1 Homo sapiens cDNA FLJ13434 fis, clone 9 2504.D16.GZ43 365877 AK023496PLACE1002578 0 gi~339767~gb~M80340.1HUMTNL12 Human transposon L1.1 with a base deletion relative to L1.2B resulting in a premature stop codon 2504.E23.GZ43 365908 M80340in t 6.1E-182 gig 14524175 ~gb~AE007289.1 Sinorhizobium meliloti plasmid pSymA

section 95 of 121 of the complete plasmid 11 2504.F20.GZ43 365929 AE007289se uence 2.1E-98 gi~12830519~emb~AJ312523.1GG0312523 Gorilla gorilla gorilla Xq13.3 chromosome 365994 AJ312523 non-codin se uence, isolate1.1E-44 17 2504.I13.GZ43 G167W

~ gig 12961941 ~gb~AF342020.1AF342020 Sclerotinia sclerotiorum strain LES-1 285 ribosomal RNA gene, partial sequence;

020 inter epic s acer 1.1E-90 31 2504.012.GZ43 366137 AF342 ___ gi~2072968~gb~U93571.1HSU93571 Human 33 2505.B05.GZ43 366202 ~ L1 element L1.24 p40 gene,1.1E-226 U93571 complete cds gi~15870107~emb~AJ325713.1HSA325713 Homo Sapiens genomic sequence 37 2505.C17.GZ43 366238 AJ325713surrounding NotI site, 1.4E-21 clone NB1-110S

gi~3413799~emb~AJ224335.1HSAJ4335 Homo sapien mRNA for putative ~ secretory AJ224335 rotein, hBET3 5.2E-71 40 2505.D03.GZ43 366248 gi~7416074 ~dbj ~AB030001.1 43 2505.E15.GZ43 366284 AB030001Homo sa iens gene for 8.1E-55 SGRF, com lete cds gig 13421186~gb~AE005683.1AE005683 Caulobacter crescentus section 9 of 359 of 46 2505.G16.GZ43 366333 AE005683the complete genome 3.6E-63 gi~8925326~gb~AF255613.1AF255613 Homo sapiens teratoma-associated tyrosine kinase (TAPK) gene, exons 1 through 6 and partial 48 2505.I04.GZ43 366369 AF255613cds 7.9E-73 gi~3598786~gb~AF053644.1HSCSE1G2 Homo Sapiens cellular apoptosis 63 2505.009.GZ43 366518 AF053644susceptibility protein 9.4E-45 (CSE1 gene, exon 2 gi~2224650~dbj~AB002353.1AB002353 Human mRNA for KIAA0355 gene, 72 2510.C10.GZ43 369083 AB002353com lete cds 1.4E-71 Table 7 SEQ ACCES- GENBANK

ID SEQ NAME SION GENBANK DESCRIPTION SCORE

,~,.~..~, gi~3603422~gb~AF084935.1AF084935 Homo Sapiens galactokinase (GALK1) gene, 78 2510.G06.GZ43 369175 AF084935partial cds 8.9E-24 gig 1043 6933 ~dbj ~AK024617.1 Homo Sapiens cDNA: FLJ20964 fis, clone 89 2510.J11.GZ43 369252 AK024617ADSH00902 0 gig 1043 5673 ~dbj ~AK023 677.1AK023 677 Homo Sapiens cDNA FLJ13615 fis, clone PLACE1010896, weakly similar to NUF1 102 2510.L21.GZ43 369310 PROTEIN 1.2E-90 gi~8515842~gb~AF271388.1AF271388 Homo Sapiens CMP-N-acetylneuraminic acid 109 2510.N14.GZ43~369351 synthase mRNA, com lete 0 AF271388 cds gi~4164598~gb~AF113169.1AF113169 Homo Sapiens glandular kallikrein enhancer region, 115 2510.023.GZ43 369384 com lete se uence 2.2E-39 gi~3560568~gb~AF069489.1HSPDE4A3 Homo Sapiens cAMP specific phosphodiesterase 4A variant pde46 124 2365.C20.GZ43 345294 PDE4A gene, exons 2 throu6.6E-24 AF069489 h 13 and gig 12849956~dbj ~AK012908.1 Mus musculus 10, 11 days embryo cDNA, RIKEN full-length enriched library, 134 2365.F24.GZ43 345370 clone:2810046L04, full 2.9E-224 gi~14124949~gb~BC007999.1BC007999 Homo Sapiens, hypothetical protein FLJ10759, clone MGC:15757 143 2365.J14.GZ43 345456 IMAGE:3357436, mRNA, com 4.4E-56 BC007999 lete cds gi~1483626~gb~U20391.1HSU20391 Human 152 2365.N12.GZ43 345550 folate receptor FOLR1) 3.9E-41 U20391 gene, com lete cds gi~5917586~dbj~AB025285.1AB025285 Homo Sapiens c-ERBB-2 gene, exons 1', 2', 162 2366.E03.GZ43 345647 3', 4' 4.3E-30 gi~338414~gb~M15885.1HUMSPP
Human prostate secreted seminal plasma protein 163 2366.J03.GZ43 345652 mRNA, com lete cds 1.1E-68 _ _ _........_.
gi~15080738~gb~AF326517.1AF326517............

Abies grandis pinene synthase gene, partial 170 2366.J06.GZ43 345700 cds 0 gi~967202~gb~U27333.1HSU27333 Human alpha (1,3) fucosyltransferase (FUT6) 182 2366.K13.GZ43 345813 mRNA, major transcri t 2.5E-44 U27333 I, complete cds gi~8705239~gb~AF272390.1AF272390 Homo Sapiens myosin 5c (MY05C) mRNA, 189 2366.L21.GZ43 345942 com fete cds 1.4E-290 gig 11932035 ~emb~AJ279823.1 Ascovirus SfAV 1b partial pol gene for DNA

195 2367.B10.GZ43 346028 olymerase, Pol2-Pol3-Poll1.4E-231 AJ279823 fragment Table 7 SEQ ACCES- GENBANK

ID SEQ NAME SION GENBANK DESCRIPTION SCORE

~. .._.~.m~~.._ W.. gi~i5779227~gb~BC014669.1BC014669 __.... - ..

Homo Sapiens, clone IMAGE:4849317, 198 2367.C12.GZ43 BC014669mRNA, partial cds 2.9E-57 gig 15459138~gb~AE008517.1AE008517 Streptococcus pneumoniae R6 section 133 200 2367.D18.GZ43 AE008517of 184 ofthe com lete genome1.4E-34 gig 15874882~emb~AJ330464.1HSA330464 Homo Sapiens genomic sequence 205 2367.F06.GZ43 AJ330464surroundin NotI site, clone3.1E-100 gi~14334803~gb~AY035075.1 Arabidopsis thaliana putative H+-transporting ATPase 206 2367.F13.GZ43 AY035075AT4g30190~A, com lete cds 4.1E-229 gig 10437854~dbj~AK025355.1AK025355 Homo Sapiens cDNA: FLJ21702 fis, clone 208 2367.G13.GZ43 AK025355COL09874 1.8E-58 gi~7020278~dbj~AK000293.1AK000293 Homo Sapiens cDNA FLJ20286 fis, clone 209 2367.G17.GZ43 AK000293HEP04358 4.4E-34 gi~6808332~emb~AL137592.1HSM802347 Homo Sapiens mRNA; cDNA

DKFZp434L0610 (from clone 210 2367.G20.GZ43 AL137592DKFZp434L0610); partial 1.6E-60 346158 cds gig 15930193~gb~BC015529.1BC015529 Homo Sapiens, Similar to ribose 5-phosphate isomerase A, clone MGC:9441 211 2367.G22.GZ43 BC015529IMAGE:3904718, mRNA, com 9.7E-60 gi) 12958747~gb~AF324172.1AF324172 Dictyophora indusiata strain internal transcribed spacer l, partial 213 2367.I15.GZ43 AF324172sequence; 5.8S ribo 4.8E-65 gi~2352833 ~gb~AF009251.1 Homo Sapiens putative chloride channel 217 2367.K24.GZ43 AF009251gene (CLCN6 , exon 6 3.8E-62 gig 13344845~gb~AF 178322.1AF

Schmidtea mediterranea cytochrome oxidase C subunit I (COI) gene, partial cds;

219 2367.M06.GZ43 AF178322mitochondria) gene 1.5E-43 gig 10439097~dbj ~AK026286.1 Homo Sapiens cDNA: FLJ22633 fis, clone 220 2367.M14.GZ43 AK026286HSI06502 1E-300 gig 14039926~gb~AF368920.1AF368920 Caenorhabditis elegans voltage-dependent calcium channel alphal3 subunit (cca-1) 221 2367.M16.GZ43 AF368920mRNA, com lete c 1.6E-83 gi~1508005~emb~Z78727.1HSPA15B9 H.sapiens flow-sorted chromosome 224 2367.N16.GZ43 278727 HindIII fragment, SC6 A15B91.3E-37 gi~7020278 ~dbj ~AK000293.1 Homo Sapiens cDNA FLJ20286 fis, clone 231 2368.B18.GZ43 AK000293HEP04358 5E-34 Table 7 SEQ ACCES- GENBANK

ID SEQ NAME SION GENBANK DESCRIPTION SCORE

_~_ ~ ~ ~_ ._ ._.. .__ . giI12214232~emb~AJ276936.1N1VIE276936_...___ __. .._ --Neisseria meningitidis partial tbpB gene for transferrin binding protein B subunit, allele 235 2368.D08.GZ43 346458 66, 0 gi~15546022~gb~AY042191.1 Mus musculus RF-amide G protein-coupled receptor 245 2368.I04.GZ43 346574 MrgAl mRNA, com lete cds 3.1E-26 gig 15718363~emb~AJ310931.1HSA310931 Homo Sapiens mRNA for myosin heavy 249 2368.K21.GZ43 346639 chain 7E-55 gig 10438161 ~dbj~AK025595.1AK025595 Homo Sapiens cDNA: FLJ21942 fis, clone 252 2368.M19.GZ43 346685 HEP04527 4.7E-21 _. . _..._.._ _. gi~12852104~dbj~AK014328.1AK014328 Mus musculus 14, 17 days embryo head cDNA, RIKEN full-length enriched library, 257 2368.N15.GZ43 346705 clone:3230401M21, 3.1E-103 gi~9864373 ~emb~AL391428.1 Human DNA sequence from clone RP 11-60P19 on chromosome 1, complete 258 2368.N23.GZ43 346713 se uence Homo sa iens 4.8E-28 gig 12849956~dbj ~AK012908.1AK012908 Mus musculus 10, 11 days embryo cDNA, RIKEN full-length enriched library, 259 2368.003.GZ43 346717 clone:2810046L04, full 2.1E-227 gi~5922722~gb~AF102129.1AF102129 Rattus norvegicus KPL2 (Kpl2) mRNA, complete 260 2368.O11.GZ43 346725 cds 2.5E-103 _..~_W..._..-_.r. __ _ gi~12656358~gb~AF292648.1AF292648 Mus musculus zinc forger 202 ml (Znf202) 264 2535.B09.GZ43 370120 mRNA 2E-39 AF292648 , c om 1e te cds _ _ _ _ gig 12018057~gb~AF307053.1AF307053 Thermococcus litoralis sugar kinase, trehalose/maltose binding protein (malE), 267 2535.C23.GZ43 370158 trehalose/maltose 0 gig 14486704~gb~AF367433.1AF367433 Lotus japonicus phosphatidylinositol transfer-like protein III (LjPLP-III) mRNA, 269 2535.F05.GZ43 370212 com lete cds 3.8E-38 gi~7019966~dbj~AK000099.1AK000099 Homo Sapiens cDNA FLJ20092 fis, clone 276 2535.L03.GZ43 370354 COL04215 7.1E-52 gig 14250051 ~gb~BC008425.1BC008425 Homo Sapiens, clone MGC:14582 280 2535.007.GZ43 370430 IMAGE:4246114, mRNA, com 3.8E-34 BC008425 lete cds gi~13129059~ref~NM 024074.1 Homo Sapiens hypothetical protein 282 2535.P02.GZ43 370449 MGC3169 , mRNA 2.4E-23 gig 13517433 ~gb~AF310311.
lAF310311 Homo Sapiens isolate Nigeria 9 membrane 292 2536.A22.GZ43 370493 protein CH1 gene, artial 0 AF310311 cds Table 7 SEQ ACCES- GENBANK

ID SEQ NAME SIGN GENBANK SCORE
DESCRIPTION

gi~2353128~gb~AF015148.1AF015148 Homo 297 2536.D17.GZ43 AF015148sa 1.6E-46 370560 iens clone HS19.2 Alu-Ya5 se uence gi~3228525~gb~AF045605.1AF045605 Homo Sapiens germline chromosome 11, l 1q13 303 2536.G05.GZ43 AF045605region 6.2E-77 gig ~dbj ~AK026490.1 Homo Sapiens cDNA:

fis, clone 305 2536.G21.GZ43 AK026490KAIA4417 3.5E-143 gi~13540758~re~NC_002707.1 Anguilla 306 2536.G22.GZ43 NC jaonica mitochondrion, 2.3E-39 370637 002707 ~complete genome , , "7019966~dbj ~AK000099.1 gi~AK000099 Homo Sapiens cDNA

fis, clone 309 2536.I05.GZ43 AK000099COL04215 3.4E-63 gi~6177784 ~dbj ~AB013897.1AB013897 310 2536.I15.GZ43 AB013897Homo S.lE-53 370678 sa iens mRNA
for HKRl, artial cds gig 10435386~dbj~AK023448.1AK023448 Homo Sapiens cDNA

fis, clone PLACE1001104, weakly similar to 313 2536.J11.GZ43 HEAVY
CHAIN, NON-MU

_ gi~551542~gb~U14573.1HSU14573 ***ALU

WARNING:
Human Alu-Sq subfamily 314 2536.K12.GZ43 U14573 consensus 1E-96 370723 se uence _. ...... gi~7022548~dbj~AK001347.1AK001347 Homo Sapiens cDNA

fis, clone 319 2536.N05.GZ43 AK001347NT2RP2000195 6.7E-43 gi~3021395~emb~Y15724.1HSSERCA1 Homo sapiens gene, exons 320 2536.N20.GZ43 Y15724 (and 1.9E-27 370803 joined CDS) gi~288876~emb~X69516.1HSFOLA

330 2537.B07.GZ43 X69516 H.sapiens 8E
370886 e -ne 2 for .
folate 6 rec 0 e for _ _ _ _ _ _ _ _ _ __ gi~13376633~re~NM _ 025080.1 _ _ Homo Sapiens hypothetical protein 334 2537.D11.GZ43 NM 025080FLJ22316 8.7E-289 370938 , mRNA

gi~187144~gb~L04193.1HUMLIMGP
Human lens membrane protein (mp 19) gene, exon 338 2537.G05.GZ43 L04193 11 7.4E-52 gig 1508005~emb~Z78727.1HSPA15B9 H.sapiens flow-sorted chromosome 341 2537.I03.GZ43 278727 HindIII 1.7E-37 371050 fragment, gig 15384818~emb~AL603947.
lUMA0006 Ustilago maydis gene for predicted 345 2537.K17.GZ43 AL603947la 9.3E-76 371112 smamembrane-ATPase _............_-_ _ gi~9858570~gb~AF242865.1AF24286254 Homo Sapiens coxsackie virus and adenovirus receptor (CXADR) gene, exon 350 2537.N23.GZ43 AF242865and 2.4E-30 371190 com fete cds gig 13874462~dbj~AB060827.1AB060827 Macaca fascicularis brain cDNA
clone:QtrA

352 2537.005.G243 AB06082710256, 2.2E-24 371196 full insert se uence Table 7 SEQ ACCES- GENBANK
ID SEQ NAME SION GENBANK DESCRIPTION SCORE

~_ . _.._ ._._____. ~...n_..~..giy10439307~dbj~AK026442.1AK026442__ __ -..

Homo Sapiens cDNA: FLJ22789 fis, clone 356 2537.P14.GZ43 AK026442KAIA2171 6.3E-256 gi~7022685 ~dbj ~AK001432.1 Homo Sapiens cDNA FLJ10570 fis, clone 361 2538.A10.GZ43 AK001432NT2RP2003117 _ 1.9E-52 gig 12851449~dbj ~AK013900.1 Mus musculus 12 days embryo head cDNA, RIKEN full-length enriched library, 363 2538.B03.GZ43 AK013900clone:3010026L22, fizl 1.2E-201 gig 10434673 ~dbj ~AK022973.1 Homo Sapiens cDNA FLJ12911 fis, clone NT2RP2004425, highly similar to Mus 366 2538.C07.GZ43 AK022973musculus axotro hin mR 0 gig 174891 ~gb~M87914.1HLTMALNE461 Human carcinoma cell-derived Alu RNA

367 2538.C14.GZ43 M87914 transcri t, clone NE461 2E-89 gig 10434673 ~dbj ~AK022973.1 Homo Sapiens cDNA FLJ12911 fis, clone NT2RP2004425, highly similar to Mus 368 2538.D03.GZ43 AK022973musculus axotro hin m 4.3E-_ _ gig 10434673 ~dbj ~AK022973.1AK022973__ _ Homo Sapiens cDNA FLJ12911 fis, clone NT2RP2004425, highly similar to Mus 369 2538.D04.GZ43 AK022973musculus axotro hin mR 1.3E-287 gi~3916231~gb~AF074397.1AF074397 Homo Sapiens anti-mullerian hormone type II

receptor (AMHR2) gene, promoter region 371 2538.EO1.GZ43 AF074397and artial cds 4E-40 gi~598203~gb~L34639.1HUMPECAM09 Homo Sapiens platelet/endothelial cell adhesion molecule-1 (PECAM-1) gene, 374 2538.F03.GZ43 L34639 exon 6 1.5E-43 gi~9651700~gb~AF220173.1AF22017252 Homo Sapiens acid ceramidase (ASAH) 375 2538.H02.GZ43 AF220173gene, exons 2 throu h 2.5E-39 gi~3319283~gb~AF050179.1AF050179 Homo Sapiens CENP-C binding protein (DAXX) 379 2538.I17.GZ43 AF050179mRNA, com lete cds 4.9E-41 gi~14334803~gb~AY035075.1 Arabidopsis thaliana putative H+-transporting ATPase 380 2538.J10.GZ43 AY035075(AT4g30190 mRNA, complete3.5E-245 371465 cds gig 10434332~dbj~AK022749.1AK022749 Homo sapiens cDNA FLJ12687 fis, clone NT2RM4002532, weakly similar to 381 2538.K17.GZ43 AK022749PROTEIN HOM1 1.5E-31 gig 14030638~gb~AF375410.1AF375410 Arabidopsis thaliana At2g43970/F6E13.10 385 2538.M16.GZ43 AF375410ene, com lete cds 1.9E-53 Table 7 SEQ ACCES- GENBANK

ID SEQ NAME~ SION I GENBANK DESCRIPTION SCORE

4 a ,._.,~~na~m r >~e~
_ gi~10437996~dbj~AK025473.1AK025473rv-..~. .....
, . __ s _-_ Homo Sapiens cDNA: FLJ21820 fis, clone 386 HEP01232 3.2E-282 2538.M17.GZ43 gig 10439097~dbj ~AK026286.1 Homo Sapiens cDNA: FLJ22633 fis, clone 2538.P16.GZ43 gi~7022509 ~dbj ~AK001324.1 Homo Sapiens cDNA FLJ10462 fis, clone NT2RP 1001494, weakly similar to MALE

2554.A06.GZ43 gi~8515842~gb~AF271388.1AF271388 Homo Sapiens CMP-N-acetylneuraminic acid 394 NA, com lete cds 0 2554.A16.GZ43 synthase mR

~~ _ _ gi~15215695~gb~AY050376.1 Arabidopsis thaliana AT3g16950/K14A17 7 mRNA, 406 com lete cds 8.8E-27 2554.I15.GZ43 gig 10433751 ~dbj~AK022368.1AK022368 Homo Sapiens cDNA FLJ12306 fis, clone 415 MAMMA1001907 6.7E-46 2554.P16.GZ43 gi~4884261 ~emb~AL050012.1HSM800354 Homo Sapiens mRNA; cDNA

DKFZp564K133 (from clone 418 DKFZp564K133 1E-44 2565.B13.GZ43 gi~15146287~gb~AY049285.1 Arabidopsis thaliana AT3g58570/F14P22-160 mRNA, 419 com lete cds 2.1E-62 2565.B15.GZ43 gi~341200~gb~M24543.1HUMPSANTIG

Human prostate-specific antigen (PA) gene, 422 com fete cds 2.5E-49 2565.C17.GZ43 gig 13095271 ~gb~AF331321.1AF331321 HIV 1 isolate T7C44 from the Netherlands nonfunctional pol polyprotein gene, partial 423 se uence 4.7E-30 2565.D06.GZ43 gig 12214232~emb~AJ276936.1NME276936 Neisseria meningitidis partial tbpB gene for transferrin binding protein B subunit, allele 428 66, 0 2565.G20.GZ43 giI15080738~gb~AF326517.1AF326517 Abies grandis pinene synthase gene, partial 429 cds 1E-300 2565.HOl.GZ43 gi~7023492~dbj ~AK001926.1 Homo Sapiens cDNA FLJ11064 fis, clone 433 PLACE1004824 8.9E-295 2565.I22.GZ43 gig 12275949~gb~AF275699.1AF275699 Unidentified Hailaer soda lake bacterium F16 16S ribosomal RNA
gene, partial 442 se uence 1.4E-21 2565.M14.GZ43 gig 104371 l8~dbj~AK024752.1AK024752 Homo Sapiens cDNA: FLJ21099 fis, clone 447 CAS04610 4.3E-51 2565.007.GZ43 Table 7 SEQ ACCES- GENBANK

ID SEQ NAME SIGN GENBANK DESCRIPTION SCORE

_. _ _ _ . _ . _ ~ _ gi~1217632~emb~Z69920.1HS91K3D
Human DNA sequence from cosmid 91K3, Huntington's Disease Region, chromosome 452 2540.A24.GZ43 269920 4p16.3 1.1E-41 gi~15155943~gb~AE008025.1AE008025 Agrobacterium tumefaciens strain C58 circular chromosome, section 83 of 254 of 463 2540.H07.GZ43 AE008025the com lete se ue 1.7E-40 gi~7020892~dbj~AK000658.1AK000658 Homo Sapiens cDNA FLJ20651 fis, clone 465 2540.I10.GZ43 AK000658KAT01814 1.3E-53 gi~14150816~gb~AF375597.1AF375596S2 Mus musculus medium and short chain L-3-hydroxyacyl-Coenzyme A
dehydrogenase 468 2540.M22.GZ43 AF375597(Mschad gene, exo 0 gi~4579750~dbj~AB019559.1AB019559 Sus scrofa mRNA for 130 kDa regulatory 472 2540.C19.GZ43 AB019559subunit of myosin phosphatase,3.1E-24 372074 partial cds gi~13891961~gb~AY016428.1 Plasmodium falciparum isolate Fas 30-6-7 apical membrane antigen-1 (AMA-1) gene, partial 477 2540.F15.GZ43 AY016428cds 2.2E-33 gi~15875595~emb~AJ331177.1HSA331177 Homo sapiens genomic sequence 485 2540.M18.GZ43 AJ331177surrounding NotI site, 7.7E-237 372313 clone NL1-ZF18RS

gi~13277537~gb~BC003673.1BC003673 Homo sapiens, protamine 1, clone MGC:12307 IMAGE:3935638, mRNA, 507 2541.L08.GZ43 BC003673complete cds 2.6E-53 gig 12055486~emb~AJ297708.1 Rattus norvegicus RT6 gene for T cell 508 2541.L12.GZ43 AJ297708differentiation marker 9.4E-45 372667 RT6.2, exons 1-8 gig 14973493 ~gb~AE007488.1 Streptococcus pneumoniae TIGR4 section 514 2506.C15.GZ43 AE007488171 of 194 of the com 1.4E-287 366620 fete enome gig 10437625 ~dbj ~AK025164.1 Homo Sapiens cDNA: FLJ21511 fis, clone 519 2506.E18.GZ43 AK025164COL05748 0 gi~13736961~gb~AY030962.1 HIV-1 isolate NC3964-1999 from USA pol polyprotein 521 2506.G24.GZ43 AY0309620l gene, artial cds 9.1E-233 gi~5453323~gb~AF152924.1AF152924 Mus musculus syntaxin4-interacting protein synip 527 2506.J20.GZ43 AF152924mRNA, com lete cds 2.3E-79 gi~7020080~dbj ~AK000169.1 Homo Sapiens cDNA FLJ20162 fis, clone 528 2506.J22.GZ43 AK000169COL09280 1.8E-99 Table 7 SEQ ACCES- GENBANK

ID SEQ NAME SION GENBANK DESCRIPTION SCORE

___ .._._ ~w ..,. _ - giI15023517~gb~AE007580.1AE007580_w..w~
~~ __ _ . _.__ ~.e~.

Clostridium acetobutylicum 531 2506.M05.GZ43 AE007580section 68 of 356 of the 2.1E-217 366850 complete genome gi~3142369~gb~AF035442.1AF035442 Homo Sapiens VAV-like protein mRNA, partial 534 2506.P07.GZ43 AF035442cds 1E-44 gig 14972724~gb~AE007424.1 Streptococcus pneumoniae TIGR4 section 540 2542.C20.GZ43 AE007424107 of 194 of the complete2.3E-42 372843 genome gig 14249906~gb~BC008333.1BC008333 Homo Sapiens, clone IMAGE:3506145, 543 2542.D19.GZ43 BC008333_mRNA, partial cds ~ 5.3E-284 gig 1043 6495 ~dbj ~AK024179.1 Homo Sapiens cDNA FLJ14117 fis, clone 544 2542.F05.GZ43 AK024179MAMMA1001785 2.4E-41 gig 10434673 ~dbj ~AK022973.1AK022973 Homo Sapiens cDNA FLJ12911 fis, clone NT2RP2004425, highly similar to Mus 553 2542.M09.GZ43 AK022973musculus axotro hin mR 5.8E-243 gig 10437625 ~dbj ~AK025164.1 Homo Sapiens cDNA: FLJ21511 fis, clone 557 2542.P19.GZ43 _ gig 10433 509 ~dbj (AK022173.1 Homo Sapiens cDNA FLJ12111 fis, clone 562 2542.M24.GZ43 AK022173MAMMA1000025 1.2E-284 gi~2582414~gb~AF025409.1AF025409 Homo Sapiens zinc transporter 4 (ZNT4) mRNA, 563 2542.N21.GZ43 AF025409com lete cds 2E-70 gig 11121002 ~emb~AL 157697.11 Human DNA sequence from clone RP5-1092C14 on chromosome 6, complete 567 2555.D22.GZ43 AL1576971se uq ence Homo sa iens 1.1E-87 gig 10439509~dbj~AK026618.1AK026618 Homo Sapiens cDNA: FLJ22965 fis, clone 568 2555.E20.GZ43 AK026618KAT10418 0 gi~8515842~gb~AF271388.1AF271388 Homo Sapiens CMP-N-acetylneuraminic acid 569 2555.F16.GZ43 AF271388synthase mRNA, complete 0 373295 cds gi~10439593~dbj~AK026686.1AK026686 Homo Sapiens cDNA: FLJ23033 fis, clone 574 2555.K17.GZ43 AK026686LNG02005 1.8E-23 gi~5081331 ~gb~AF087913.1AF087913 Human endogenous retrovirus HERV-P-578 2555.P22.GZ43 AF087913T47D 5.8E-74 gi~11497445~ref~NC 000957.1 Borrelia 579 2555.A11.GZ43 NC 000957burgdorferi plasmid 1p5, 1.3E-57 373170 com lete se uence gig 12214232~emb~AJ276936.1NME276936 Neisseria meningitidis partial tbpB gene for transferrin binding protein B subunit, allele 585 2555.I12.GZ43 AJ27693666, 1.6E-237 Table 7 SEQ ACCES- GENBANK

ID SEQ NAME SIGN GENBANK DESCRIPTION SCORE

__ ..___ ._. _..,._ .._.. , _ _. _._.....
..~ gi~i4524175~gb~AE007289.1AE007289~-...

Sinorhizobium meliloti plasmid pSymA

section 95 of 121 of the complete plasmid 589 2556.A02.GZ43 2E-55 se uence gig 15418981 ~gb~AY039252.1 Macaca mulatta immunoglobulin alpha heavy chain constant region (IgA) gene, IgA-C.II allele, 591 2556.C11.GZ43 3.1E-29 partial cds gig 10433275 (dbj ~AK021966.1 Homo Sapiens cDNA FLJ11904 fis, clone 602 2556.H15.GZ43 1.6E-70 gi~15721873~dbj~AB071392.1AB071392 Expression vector pAQ-EX 1 DNA, 620 1392 com fete 1.2E-25 sequence 2557.B22.GZ43 gig 10435737~dbj~AK023721.1AK023721 Homo Sapiens cDNA FLJ13659 fis, clone PLACE1011576, moderately similar to 627 2557.J14.GZ43 1.6E-209 Human Kru e1 related gi~6177784~dbj~AB013897.1AB013897 635 2557.N14.GZ43 1E-44 Homo sa iens mRNA for HKR1, artial cds gig 14595115 ~dbj ~AB064318.
l AB064318 Comamonas testosterone gene for 16S

648 ar 4.6E-28 teal s e ue nce 2558.B24.GZ43 rRNA, _ - .___.
_ _ _ ._~....~ - gi~337698~gb~M92069.1HUMRTVLC
_ Human retrovirus-like sequence-isoleucine c 657 2558.G07.GZ43 6.7E-46 (RTVL-Ic gene, Alu repeats gig 10435 860~dbj ~AK023 812.1 Homo Sapiens cDNA FLJ13750 fis, clone 661 2558.H17.GZ43 5.2E-31 gig 104353 86~dbj ~AK023448.1 Homo sapiens cDNA FLJ13386 fis, clone PLACE1001104, weakly similar to 662 2558.JO1.GZ43 4.8E-278 MYOSIN HEAVY
CHAIN, NON-MU

gi~551542~gb~U14573.1HSU14573 ***ALU

WARNING: Human Alu-Sq subfamily 666 2558.K02.GZ43 1.3E-62 consensus se uence gig 14039582~gb~AF338713.1AF338713 Casuarius casuarius mitochondrion, partial 683 2559.D05.GZ43 4E-297 genome gi~14486435~gb~AY036096.1 HIV-1 isolate L2Q2P from Belgium reverse transcriptase 687 2559.I12.GZ43 1.4E-41 (pol) gene, partial cds gig 10439509~dbj ~AK026618.1 Homo Sapiens cDNA: FLJ22965 fis, clone 690 2559.J02.GZ43 0 gi~2181853~emb~Z96776.1HS9QT023 H.sapiens telomeric DNA sequence, clone 692 2559.K12.GZ43 S.lE-52 9QTEL023, read 9 TEL00023.se Table 7 SEQ ACCES- GENBANK

ID SEQ NAME SION GENBANK DESCRIPTION SCORE

gig 14972746~gb~AE007426.1 Streptococcus pneumoniae TIGR4 section 694 2559.L09.GZ43 374968 109 of 194 of the com fete8.1E-21 AE007426 genome gig 15990852~emb~AJ414564.1HSA414564 Homo Sapiens mRNA for connexin40.1 696 2559.M21.GZ43 375004 (CX40.1 gene 9.2E-30 gi~6807822~emb~AL137330:1HSM802010 Homo Sapiens mRNA; cDNA

DKFZp434F0272 (from clone 698 2559.N13.GZ43 375020 DKFZp434F0272) 4.1E-47 gi~551536~gb~U14567.1HSU14567 ***ALU

WARNING: Human Alu-J subfamily 714 2560.HO1.GZ43 375248 consensus se uence 2.7E-42 gi~7770069~gb~AF178754.3AF178754 Homo Sapiens lithium-sensitive myo-inositol monophosphatase A1 (IMPA1) gene, 719 2560.K02.GZ43 375321 romoter region and 3.1E-51 AF178754.3 gig 12844057~dbj ~AK009327.
l AK009327 Mus musculus adult male tongue cDNA, RIKEN full-length enriched ~ library, A clone:2310012P17, full 6.3E-80 720 2560.K08.GZ43 375327 __ gig 13448249~gb~AF344987.1AF344987 Hepatitis C virus isolate RDpostSClc2 721 2560.K10.GZ43 375329 0l rotein ene, artial cds 1E-300 gi~15982643~gb~AY037285.1AY03728452 HIV-1 from Cameroon vpu protein (vpu) and envelope glycoprotein (env) genes, 729 2560.008.GZ43 375423 com lete cds; and 5.2E-54 - ._______ _..

gi~8714504~gb~AF035968.2AF035968 Homo sapiens integrin alpha 2 (ITGA2) gene, 732 2561.B03.GZ43 376258 ITGA2-1 allele, exons 6-9,3.9E-32 AF035968.2 and artial cds gi~483 5645 ~dbj ~AP000276.1 Homo Sapiens genomic DNA, chromosome 21q22.1, D21S226-AML region, 733 2561.B12.GZ43 376267 clone:55A9, com fete se 1.9E-27 AP000276 uence gi~2995716~gb~AF052684.1HSPRCAD2 Homo Sapiens protocadherin 43 gene, exon 750 2561.M09.GZ43 376528 2 4.1E-41 gi~4680674~gb~AF132952.1AF132952 Homo sapiens CGI-18 protein mRNA, complete 753 2561.E22.GZ43 376349 cds 3E-41 gi~551542~gb~U14573.1HSU14573 ***ALU

WARNING: Human Alu-Sq subfamily 754 2561.G20.GZ43 376395 consensus se uence 1.5E-71 gi~2995717~gb~AF052685.1HSPRCAD3 Homo Sapiens protocadherin 43 gene, exon 755 2561.H17.GZ43 376416 3, exon 4, and com lete 2.1E-24 AF052685 cds gig 13448249~gb~AF344987.1AF344987 Hepatitis C virus isolate RDpostSClc2 756 2561.I19.GZ43 376442 0l rotein gene, artial 3.2E-201 AF344987 cds Table 7 SEQ ACCES- GENBANK

ID SEQ NAME SION GENBANK DESCRIPTION SCORE

gi~ Sp8005~emb~Z78727.1HSPA15B9 H.sapiens flow-sorted chromosome 6 761 2561.P16.GZ43 376607 278727 HindIII fragment, 1.6E-37 SC6pA15B9 gi~2270915~gb~U66535.1HSITGBF07 Human beta4-integrin (ITGB4) gene, exons 762 2561.P19.GZ43 376610 U66535 19,20,21,22,23,24 8.6E-41 and 25 gi~6467463 ~gb~AF 167458.1 HSDSRPKR04 Homo Sapiens double stranded RNA

activated protein kinase (PKR) gene, intron 763 2561.P23.GZ43 376614 AF167458 1 1E-22 gig 12018057~gb~AF307053.1AF307053 Thermococcus litoralis sugar kinase, trehalose/maltose binding protein (malE), 771 2456.D04.GZ43 355904 AF307053 trehalose/maltose 0 gi~3123571 ~emb~AJ005821.1HSA5821 777 2456.H02.GZ43 355998 AJ005821 Homo sa iens mRNA 5.8E-37 for X-like 1 rotein gi~6425045~gb~AF188746.1AF188746 Homo Sapiens prostrate kallikrein 2 (KLK2) 788 2456.N23.GZ43 356163 AF188746 mRNA, complete 9.6E-63 cds gig 14039926~gb~AF368920.1AF368920 Caenorhabditis elegans voltage-dependent calcium channel alphal3 subunit (cca-1) 796 2457.C19.GZ43 356279 AF368920 mRNA, com fete 1E-47 c gig 10439509~dbj ~AK026618.1 AK026618 Homo Sapiens cDNA: FLJ22965 fis, clone 799 2457.D12.GZ43 356296 AK026618 KAT10418 0 gig 15023883 (gb~AE007614.1 AE007614 Clostridium acetobutylicum ATCC824 810 2457.H17.GZ43 356397 AE007614 section 102 of 9E-63 356 of the com lete genome gig 10439892 ~dbj ~AK026920.1 AK026920 Homo Sapiens cDNA: FLJ23267 fis, clone 823 2458.A10.GZ43 356618 AK026920 COL07266 6.2E-84 gi~10998295~dbj~AB050432.1AB050432 Macaca fascicularis brain cDNA, 827 2458.B23.GZ43 356655 AB050432 clone: n A-21861 4.3E-129 gi~2226003~gb~U49973.1HSU49973 Human Tiggerl transposable element, complete 829 2458.C06.GZ43 356662 U49973 consensus se uence 2E-24 gig 1043 5445 ~dbj ~AK023496.1 AK023496 Homo Sapiens cDNA FLJ13434 fis, clone 842 2458.I09.GZ43 356809 AK023496 PLACE1002578 2.4E-39 gi~6649934~gb~AF031077.1AF031077 Homo Sapiens chromosome X, cosmid 843 2458.I1O.GZ43 356810 AF031077 LLNLc110C1837, 1.3E-52 com lete se uence gig 10439451 (dbj~AK026569.1AK026569 Homo Sapiens cDNA: FLJ22916 fis, clone KAT06406, highly similar to HSCYCR

845 2458.I17.GZ43 356817 AK026569 Human mRNA for 1.8E-38 T-cell gi~6983939~gb~AF184614.1AF184614 Homo Sapiens p47-phox (NCF1) gene, complete 846 2458.I20.GZ43 356820 AF184614 cds 4.2E-33 Table 7 SEQ ACCES- GENBANK

ID SEQ NAME SIGN GENBANK DESCRIPTION SCORE

.~..
_....___ gi) 14161363 ~gb~AF367251.1 ......_ AF367251 ..

Helicobacter pylori strain cytotoxin associated protein A (cagA) gene, 855 co lete cds 2.2E-70 2458.N06.GZ43 gig 14150816~gb~AF375597.1AF37559652 Mus musculus medium and short chain L-3-hydroxyacyl-Coenzyme A
dehydrogenase 865 Mschad gene, exo 0 2459.B11.GZ43 gi~6647297~emb~X04803.2HSYUBG1 Homo 866 sa iens ubi uitin ene 6.4E-52 2459.C05.GZ43 X04803.2 gi) 10437672 ~dbj ~AK025207.1 Homo Sapiens cDNA: FLJ21554 fis, clone 2459.F20.GZ43 ' gi~9651056~dbj~AB046623.1AB046623 Macaca fascicularis brain cDNA, clone 877 ccE-10576 1.7E-35 2459.H09.GZ43 gi~4500067~emb~AL049301.1HSM800086 Homo Sapiens mRNA; cDNA

DKFZp564P073 (from clone 888 KFZp564P073 1.3E-31 2459.023.GZ43 D

_ gig 12857675 ~dbj (AKO
18110.1 AKO 18110 Mus musculus adult male medulla oblongata cDNA, RIKEN full-length enriched library, 889 clone:633040 1.5E-33 2459.P24.GZ43 gi~8176599~dbj~AB035344.1AB03534451 903 Homo sa iens TCL6 gene, 1.1E-127 2464.H22.GZ43 exon 1-lOb gi~10437578~dbj/AK025125.1AK025125 Homo Sapiens cDNA: FLJ21472 fis, clone 2464.I04.GZ43 gi~10438647~dbj~AK025966.1AK025966 Homo Sapiens cDNA: FLJ22313 fis, clone 905 HRC05216 2.8E-61 2464.I20.GZ43 gi~12656333~gb~AF287938.1AF287938 Guichenotia ledifolia NADH dehydrogenase subunit F (ndhF) gene, partial cds;

909 chloroplast ene for 8.3E-44 2464.K18.GZ43 ~ gi~5737754~gb~AF141308.1HSPMFG1 Homo Sapiens polyamine modulated factor-912 1 PMF1) gene, exon 1 9.9E-76 2464.L15.GZ43 gi~2995716~gb~AF052684.1HSPRCAD2 Homo Sapiens protocadherin 43 gene, exon 2464.P17.GZ43 gi~31870~emb~X02571.1HSGP5MOS
Human gene fragment related to oncogene c-mos 934 with Alu re eats locus 2.7E-48 2465.J19.GZ43 5, re ion NV-1 gig 12859761 ~dbj~AK019509.1AK019509 Mus musculus 0 day neonate skin cDNA, RIKEN full-length enriched library, 935 clone:4632435C11, full 2.5E-63 2465.K20.GZ43 Table 7 SEQ ACCES- GENBANK

ID SEQ NAME SION GENBANK DESCRIPTION SCORE

..__.. .gi1i2844057~dbj~AK009327.1AK00932~_ __.
_ ._.
.
._ .._ .
_ ..~.._.._ .
..._..

Mus musculus adult male tongue cDNA, RIKEN full-length enriched library, 937 clone:2310012P17, full 7.9E-73 2465.L06.GZ43 _ gig 10433611 ~dbj ~AK022253.1 Homo Sapiens cDNA FLJ12191 fis, clone 939 MAMMA1000843 1.4E-112 2465.M11.GZ43 gig 10434796~dbj~AK023055.1AK023055 Homo Sapiens cDNA FLJ12993 fis, clone 943 NT2RP3000197 7.5E-39 2466.B02.GZ43 gi~6177784~dbj~AB013897.1AB013897 4 Homo sa iens mRNA for 4.3E-53 2466.C15.GZ43 HKR1, partial cds _ gi~4884352~emb~AL050141.1HSM800441 Homo sapiens mRNA; cDNA

DKFZp5860031 (from clone 945 DKFZ 5860031 3.4E-110 2466.D19.GZ43 gi~6900103 ~emb~AJ271729.1 Homo Sapiens mRNA for glucose-regulated 952 rotein HSPAS gene 6.2E-72 2466.I08.GZ43 gi~16197970~gb~AY058527.1 Drosophila 953 melanogaster LD23445 full9.4E-40 2466.JO1.GZ43 length cDNA

gi~13375486~gb~AF331425.1AF331425 HIV

1 D311 from Australia envelope protein 954 env en 1.6E
2466.J24.GZ43 e, artial cds -____ _ _ _ _ gi~3123571 ~emb~AJ005821.1HSA5821_ 958 Homo Sapiens mRNA for 1.4E-34 2467.B24.GZ43 X-like 1 protein gi~2695679~gb~AF036235.1AF036235 Gorilla gorilla L1 retrotransposon LlGg-lA, 963 nce 2E-169 2467.H18.GZ43 com lete se ue~

.---gi~15277963~gb~BC012960.1BC012960 Mus musculus, ring finger protein 12, clone MGC:13712 IMAGE:4193003, mRNA, 964 com lete cds 8.7E-36 2467.A03.GZ43 gig 14318629 ~gb~BC009113.1 Homo Sapiens, clone MGC:18122 965 IMAGE:4153377, mRNA, com 4.1E-167 2467.A05.GZ43 fete cds gi~551542~gb~U14573.1HSU14573 ***ALU

WARNING: Human Alu-Sq subfamily 969 consensus se uence 2E-61 2467.GO1.GZ43 gi~4530440~gb~AF117756.1AF117756 Homo Sapiens thyroid hormone receptor-associated protein complex component 971 mRNA, com fete 6.8E-77 2467.N22.GZ43 gig 10436318~dbj ~AK024049.1 Homo Sapiens cDNA FLJ13987 fis, clone Y79AA1001963, weakly similar to 973 PUTATIVE PRE-MRNA SPLICING2.1E-47 2467.I12.GZ43 gi~7416074 (dbj ~AB030001.1 977 Homo sa iens gene for 7.2E-22 2467.K14.GZ43 SGRF, complete cds Table 7 SEQ ACCES- GENBANK

ID SEQ NAME SION GENBANK DESCRIPTION SCORE

gig 1043 S 386~dbj ~AK023448.1AK023448 Homo Sapiens cDNA FLJ13386 fis, clone PLACE1001104, weakly similar to 979 2467.N03.GZ43 360780 MYOSIN HEAVY CHAIN, NON-MU0 gi~7023502 ~dbj ~AK001931.1 Homo Sapiens cDNA FLJ11069 fis, clone PLACE1004930, highly similar to Homo 980 2467.N07.GZ43 360784 sa iens MDC-3.13 isofo 2.3E-54 gig 15159908~gb~AE008338.1AE008338 Agrobacterium tumefaciens strain C58 linear chromosome, section 142 of 187 of the 981 2467.N09.GZ43 360786 com lete sequen 3.7E-50 gi~339606~gb~K01921.1HUMTGNB
Human Asn-tRNA gene, clone pHt6-2, complete 986 2472.C18.GZ43 360915 sequence and flanks 3E-29 gi~12958576~gb~AF321082.1AF321082 HIV

1 isolate DGOB from France envelope 992 2472.G03.GZ43 360996 g1 co rotein env gene, S.lE-28 AF321082 com lete cds gig 12958808~gb~AF338299.1AF338299 Amazona ochrocephala auropalliata mitochondrial control region 1, partial 999 2472.M22.GZ43 361159 se uence 1.4E-145 gi~15874675~emb~AJ330257.1HSA330257 Homo sapiens genomic sequence 1002 2472.P22.GZ43 361231 surroundin NotI site, 1.1E-63 AJ330257 clone NLl-FA14R

gig 14573206~gb~AF306355.1AF306355 Homo Sapiens clone TF3.19 immunoglobulin heavy chain variable region 1005 2473.F08.GZ43 361361 mRNA, partial cds 3.2E-29 gig 11034759~dbj ~AB050477.1 1006 2473.F14.GZ43 361367 Homo sa iens NIBAN mRNA, 0 AB050477 com fete cds gi~15982934~gb~AF224341.1AF224341 Mus musculus thiamine transporter 1 (Slc19a2) 1011 2473.I08.GZ43 361433 gene, exons 1 through 8.7E-67 AF224341 6 and com fete cds gi~6979641~gb~AF203815.1AF203815 Homo 1015 2473.013.G243 361582 sec~uence 5.4E-44 AF203815 sa iens al hp a gene , gi~7020417~dbj ~AK000373.1 Homo Sapiens cDNA FLJ20366 fis, clone 61673 AK000373 HEP18008 5.6E-47 1018 2474.C08.GZ43 3 _ gi~2315862~gb~U75285.1HSU75285 Homo Sapiens apoptosis inhibitor survivin gene, 1021 2474.G17.GZ43 361778 com lete cds 1.1E-87 gi~1644298~emb~Z81315.1HSF62D4 Human DNA sequence from fosmid F62D4 on 1023 2474.I06.GZ43 361815 chromosome 22q12-qter 2.1E-67 gi~3712662~gb~AF029062.1AF029062 Homo Sapiens DEAD-box protein (BATI) gene, 1024 2474.J18.GZ43 361851 artial cds 1.2E-28 Table 7 SEQ ACCES- GENBANK

ID SEQ NAME SIGN GENBANK DESCRIPTION SCORE

gi~4884443 ~emb~AL050204.1 Homo Sapiens mRNA; cDNA

DKFZp586F1223 (from clone 1030 2474.P22.GZ43 AL050204DKFZp586F1223 8.9E-33 gi~5689800~emb~AL109666.1IR035907 Homo Sapiens mRNA full length insert 1031 2475.A05.GZ43 AL109666cDNA clone EUROIMAGE 359076.3E-43 gig 10435762~dbj~AK023739.1AK023739 Homo Sapiens cDNA FLJ13677 fis, clone 1032 2475.C18.GZ43 AK023739PLACE1011982 2.8E-180 a gi~10436527~dbj~AK024206.1AK024206 Homo Sapiens cDNA FLJ14144 fis, clone 1033 2475.E18.GZ43 AK024206MAMMA1002909 1.9E-21 _____..................................
gi~12657820~gb~AF322634.1AF32263451 Human herpesvirus 3 strain VZV-Iceland 1035 2475.H06.GZ43 AF322634g1 coprotein B gene, com 1.2E-173 362175 fete cds gi~3882436~gb~AF026853.1HSHADHSC

Homo Sapiens mitochondrial short-chain L-3 hydroxyacyl-CoA dehydrogenase 1036 2475.H13.GZ43 t AF026853HADHSC gene, nuclear _ 2.1E-30 gi~12847322~dbj~AK011295.1AK011295 Mus musculus 10 days embryo cDNA, RIKEN full-length enriched library, 2 AKO1 clone:2610002L04, full 1.1E-84 1 1295 ins 1039 2475.N08.GZ43 _ _ gig 10435902~dbj~AK023843.1AK023843 _ __ _ Homo Sapiens cDNA FLJ13781 fis, clone 1045 2475.M20.GZ43 AK023843PLACE4000465 8.8E-42 gi~255496~gb~S45332.1545332 erythropoietin receptor [human, placental, 1046 2475.N21.GZ43 545332 Genomic, 8647 nt] 1.4E-101 gi~603558~emb~X83497.1HSLTRERV9 H.sapiens DNA for ZNF80-linked 1055 2480.G11.GZ43 X83497 lon terminal re eat 6.1E-40 gig 12862447~dbj ~AB002070.1 Aspergillus clavatus gene for 185 rRNA, 1056 2480.H06.GZ43 AB002070artial sequence, strain:NRRL5.5E-28 gig 11121002 ~emb~AL 157697.11 Human DNA sequence from clone RPS-1092C14 on chromosome 6, complete 1061 2480.M20.GZ43 AL1576971se uence Homo Sapiens 9.3E-36 gi~7242950~dbj ~AB037719.1 Homo Sapiens mRNA for 1064 2480.P23.GZ43 AB037719rotein, partial cds 3.6E-35 gig 1043 5415 (dbj ~AK023471.1 Homo Sapiens cDNA FLJ13409 fis, clone 1065 2481.B06.GZ43 AK023471PLACE1001716 0 gi~2808416~emb~AL021306.

Human DNA sequence from clone CTB-1109B5 on chromosome 22 Contains a GSS, 1068 2481.D10.GZ43 AL021306com lete se uence [Homo 7E-52 Table 7 SEQ ACCES- GENBANK

ID SEQ NAME SION GENBANK DESCRIPTION SCORE

. , ._ . .. . . . _ . _ gi~28579~emb~X64467.1 _.. .
HSALADG ' . -. _. .. _._.
_ H.sapiens ALAD gene for porphobilinogen 1069 2481.D13.GZ43 358972 synthase 4.2E-53 gig 10439868 ~dbj ~AK026901.1 Homo Sapiens cDNA: FLJ23248 fis, clone 1075 2481.K12.GZ43 359139 COL03555 5.9E-52 gig 10434440~dbj ~AK022821.1 Homo sapiens cDNA FLJ12759 fis, clone 1083 2482.E17.GZ43 359384 NT2RP2001347 9.4E-35 gig 12852104~dbj ~AK014328.1 Mus musculus 14, 17 days embryo head cDNA, RIKEN full-length enriched library, 1084 2482.E20.GZ43 359387 clone:3230401M21, 5.2E-99 gi~15459095~gb~AE008514.1AE008514 Streptococcus pneumoniae R6 section 130 1091 2482.N09.GZ43 359592 of 184 of the co lete 6.9E-107 AE008514 enome gig 10434285 ~dbj ~AK022722.1 Homo sapiens cDNA FLJ12660 fis, clone NT2RM4002174, moderately similar to 1100 2483.J07.GZ43 359878 MRP PROTEIN 1E-300 -__.~.__~_ - gi~12849956~dbj~AK012908.1AK012908 Mus musculus 10, 11 days embryo cDNA, RIKEN full-length enriched library, 1101 2483.K02.GZ43 359897 clone:2810046L04, full 3.7E-189 _-_-_-..__~. ----- gi~12852104~dbj~AK014328.1AK014328 Mus musculus 14, 17 days embryo head cDNA, RIKEN full-length enriched library, 1106 2483.007.GZ43 359998 clone:3230401M21, 3.2E-103 gi~4589607~dbj~AB023199.1AB023199 Homo Sapiens mRNA for 1108 2488.C19.GZ43 362511 protein, complete cds 1.1E-50 gi~7022203 ~dbj ~AK001136.1 Homo Sapiens cDNA FLJ10274 fis, clone 1110 2488.E20.GZ43 362560 HEMBB1001169 1E-35 gig 12847322 (dbj ~AKO
l 1295.1 AKO 11295 Mus musculus 10 days embryo cDNA, RIKEN full-length enriched library, 1111 2488.F06.GZ43 362570 clone:2610002L04, full 8.1E-55 AK011295 ins gi~31481~emb~X15723.1HSFLTRIN
Human 1113 2488.G02.GZ43 362590 fur ene, exons 1 through 1.8E-85 gi~3882436~gb~AF026853.1HSHADHSC

Homo Sapiens mitochondrial short-chain L-3 hydroxyacyl-CoA dehydrogenase 1117 2488.K04.GZ43 362688 HADHSC ene, nuclear 2.1E-30 gig 11034759~dbj ~AB050477.1 1122 2489.A03.GZ43 362831 Homo sa iens NIBAN mRNA, 6.7E-46 AB050477 complete cds gi) 10439509~dbj ~AK026618.1 Homo Sapiens cDNA: FLJ22965 fis, clone 1124 2489.A13.GZ43 362841 KAT10418 1.8E-178 Table 7 SEQ ACCES- GENBANK

ID SEQ NAME SION GENBANK DESCRIPTION SCORE

_. --~~g1~34~83655~gb~AF086310.1~HL1MZD51F08~______ ~._.~
_.
...
~
_ .
_~.__~...
.

Homo Sapiens full length insert cDNA clone 1127 AF086310 ZD51F08 2.5E-79 2489.D18.GZ43 gi~8515842~gb~AF271388.IAF271388 Homo Sapiens CMP-N-acetylneuraminic acid 1128 AF271388 synthase mRNA, com lete 0 2489.F09.GZ43 cds~~~~~~

gig 1043 5762 ~dbj ~AK023739.1 Homo Sapiens cDNA FLJ13677 fis, clone 1129 AK023739 PLACE1011982 6.8E-209 2489.G05.GZ43 gi~15155994~gb~AE008029.1AE008029 Agrobacterium tumefaciens strain circular chromosome, section 87 of 254 of 1140 AE008029 the com lete se ue 4.2E-44 2489.M11.GZ43 gi~7023475 ~dbj ~AK001915.1 AK001915 Homo Sapiens cDNA FLJ11053 fis, clone 1144 AK001915 PLACE1004664 1.7E-43 2490.B06.GZ43 ~~ gi~3882436~gb~AF026853.1HSHADHSC

Homo Sapiens mitochondria) short-chain hydroxyacyl-C0A dehydrogenase 1155 AF026853 HADHS~gene, nuclear 2E-30 2490.J22.GZ43 gi~9622123~gb~AF167438.1AF167438 Homo Sapiens androgen-regulated short-chain dehydrogenase/reductase 1 (ARSDRl) 1160 AF167438 mRNA, com fete cds 8.8E-74 2490.N24.GZ43 gig 10433714~dbj ~AK02233 8. I

Homo Sapiens cDNA FLJ12276 fis, clone 1163 AK022338 MAMMA1001692 6.2E-30 2491.C13.GZ43 gig 12214232~emb~AJ276936.1NME276936 Neisseria meningitidis partial tbpB gene for transferrin binding protein B
subunit, allele 174 AJ276936 66, 0 2491.P10.GZ43 __ gig 15418751 ~gb~AY027632.1 Measles virus strain MVs/Masan.KOR/49.00/2 63976 AY027632 hems glutinin (H) mRNA, 7.8E-283 1175 com fete cds 2491.P20.GZ43 _ gi~2289943~gb~U67829.1HSU67829 __ Human 1177 U67829 rimary Alu transcript _ 3.6E-90 2496.C08.GZ43 gi~33945~emb~X16983.1HSINTAL4 Human 1181 X16983 mRNA for rote in al ha-4 4.7E-53 2496.F14.GZ43 subunit gi~13278716~gb~BC004138.1BC004138 Homo Sapiens, ribosomal protein L6, clone MGC:1635 IMAGE:2823733, mRNA, 1183 BC004138 com lete cds 8.3E-53 2496.I06.GZ43 gi~13376008~ref~NM_024711.1 Homo Sapiens hypothetical protein FLJ22690 1184 NM 024711 FLJ22690 , mRNA ).)E-28 2496.K15.GZ43 .________ _ - gi~15088516~gb~AF284421.1AF284421-Homo Sapiens complement factor 1192 AF284421 mRNA, com fete cds 4.1E-158 2497.E09.GZ43 gig 1027529~emb~Z56298.1HS l OC4R

H.sapiens CpG island DNA genomic Msel fragment, clone )0c4, reverse read 1195 256298 cpgl0c4.rtla 2.5E-42 2497.J05.GZ43 Table 7 SEQ ACCES- GENBANK

ID SEQ NAME SION GENBANK DESCRIPTION SCORE

.__ . gi~10435386~dbj~AK023448.1AIC023448 Homo Sapiens cDNA FLJ13386 fis, clone PLACE1001104, weakly similar to 11992497.L05.GZ43 AK023448MYOSIN HEAVY CHAIN, NON-MU0 gi~190813~gb~M64241.1HUMQM
Human Wilin's tumor-related protein (QM) mRNA, 12072562.B09.GZ43 M64241 complete cds 3.2E-52 gi~5106788~gb~AF083247.1AF083247 Homo 12102562.IO1.GZ43 AF083247sa iens MDG1 mRNA, com 2.4E-48 375656 lete cds gig 11066459~gb~AF223389.1AF223389 Homo Sapiens PCGEM1 gene, non-coding 12142562.OO1.GZ43 AF223389mRNA 8.7E-57 gig 10435378 ~dbj ~AK023442.
l AK023442 Homo sapiens cDNA FLJ13380 fis, clone 12172562.H11.GZ43 AK023442PLACE1001007 1.7E-64 gig 12656321 ~gb~AF287932.1AF287932 Rayleya bahiensis NADH
dehydrogenase subunit F (ndhF) gene, partial cds;

12182562.B24.GZ43 AF287932chloroplast gene for chl 1.8E-31 gi~13738569~gb~AY031766.1 HIV-1 isolate NC5203-1999 from USA pol polyprotein 12292498.A02.GZ43 AY031766(pol) gene, artial cds 1.3E-29 gi~6102936~emb~AL122114.1HSM801274 Homo Sapiens mRNA; cDNA

DKFZp434K0221 (from clone 12302498.A19.GZ43 AL122114DKFZp434K0221); partial 1E-59 364870 cds gi~184564~gb~M86752.1HUMIEF
Human transformation-sensitive protein (IEF SSP

12352498.G15.GZ43 M86752 3521 mRNA, com lete cds 3.4E-54 gig 15880072~emb~AJ335654.1HSA335654 Homo Sapiens genomic sequence 12382498.I17.GZ43 AJ335654surroundin NotI site, 4.3E-41 365060 clone NR5-IJ21R

gi~36129~emb~X15940.1HSRPL31 Human 12392498.K20.GZ43 X15940 mRNA for ribosomal protein1.7E-25 gi~6979641~gb~AF203815.1AF203815 Homo 12402498.M19.GZ43 AF203815sa iens al ha ene se uence4E-47 gig 15553753~gb~AF410975.1AF410975 Measles virus genotype D4 strain MVi/Montreal.CAN/12.89 hemagglutinin 12422498.P07.GZ43 AF410975ene, com fete cds 3.5E-29 gi~13376633~ref~NM 025080.1 Homo Sapiens hypothetical protein 12442507.C03.GZ43 NM 025080FLJ22316 , mRNA 1E-232 gig 184406~gb~M81806.1 Human housekeeping (Q1Z
7F5) gene, 12592511.J18.GZ43 M81806 exons 2 through 7, com 4.7E-34 369643 lete cds gig 10437268 ~dbj ~AK024860.1 Homo Sapiens cDNA: FLJ21207 fis, clone 12612499.A22.GZ43 AK024860COL00362 6.4E-49 Table 7 SEQ ACCES- GENBANK

ID SEQ NAME SION GENBANK DESCRIPTION SCORE

,... _..__ _ _... W . . .. g1i15874882~emb~AJ330464.1HSA330464..._ W
_ ... . ~ _ .~~..._..

Homo Sapiens genomic sequence 1263 2499.C09.GZ43 365292 surrounding NotI site, 3.3E-100 AJ330464 clone NRl-IL7C

gi~3882436~gb~AF026853.1HSHADHSC

Homo Sapiens mitochondrial short-chain L-3 hydroxyacyl-CoA dehydrogenase 1268 C1u1009284.1 AF026853 HADHSC gene, nuclear 1.3E-30 gi) 16304966~emb~AL590711.7AL590711 Human DNA sequence from clone RP11-284018 on chromosome 9, complete 1269 C1u1022935.2 AL590711.7 3.9E-118 sequence [Homo Sapiens]

gig 182743 ~gb~M87652.1 HUMFPRPR

Human formylpeptide receptor gene, 1270 C1u1037152.1 M87652 romoter re ion 1.1E-21 gig 10439509 ~dbj ~AK026618.1 Homo Sapiens cDNA: FLJ22965 fis, clone 1271 C1u13903.1 AK026618 KAT10418 1.5E-293 gi~13365953~dbj~AB056828.1AB056828 Macaca fascicularis brain cDNA clone:QflA

1272 C1u139979.2 AB056828 13447, full insert sequence1.4E-33 gi~4884443 ~emb~AL050204.1 Homo Sapiens mRNA; cDNA

DKFZp586F1223 (from clone 1274 C1u187860.2 AL050204 DKFZ 586F1223 4.7E-33 gi~7416074~dbj~AB030001.1AB030001 1275 C1u189993.1 AB030001 Homo Sapiens gene for SGRF,9.6E-87 com lete cds gi~3170173~gb~AF039687.1AF039687 Homo Sapiens antigen NY-CO-1 (NY-CO-1) 1276 C1u20975.1 AF039687 mRNA, com fete cds 2.7E-190 gig 11066459~gb~AF223389.1AF223389 Homo Sapiens PCGEM1 gene, non-coding 1278 C1u218833.1 AF223389 mRNA 1E-139 gig 1031576~emb~Z59663.1HS

H.sapiens CpG island DNA
genomic Msel fragment, clone 168f~, forward read 1279 C1u244504.2 259663 c 168f~3.ftla 7.5E-22 gig 12857525 ~dbj ZAKO
18003.1 AKO 18003 Mus musculus adult male thymus cDNA, RIKEN full-length enriched library, 1281 C1u376516.1 AK018003 clone:5830450H20, full 1.7E-63 gi~2072968~gb~U93571.1HSU93571 Human 1282 C1u376630.1 U93571 L1 element L1.24 p40 gene,8.7E-291 complete cds gig 10437268 ~dbj ~AK024860.1 Homo Sapiens cDNA: FLJ21207 fis, clone 1283 C1u377044.2 AK024860 COL00362 1.6E-49 gi) 13937991 (gb~BC007110.1BC007110 Homo Sapiens, clone MGC:14768 1284 C1u379689.1 BC007110 IMAGE:4291902, mRNA, com 0 lete cds Table 7 SEQ ACCES- GENBANK

ID SEQ NAME SION GENBANK DESCRIPTION SCORE

gi~12844769~dbj~AK009770.1AK009770w.._.
~~

Mus musculus adult male tongue cDNA, RIKEN full-length enriched library, 6 C1u387530.4 AK009770 clone:2310043C14, full 1.5E-80 _ gig 1043 5386~dbj ~AK023448.1AK023448 _ Homo Sapiens cDNA FLJ13386 fis, clone PLACE1001104, weakly similar to 1287 C1u388450.2 AK023448 MYOSIN HEAVY CHAIN, NON-MU0 gi~1508005~emb~Z78727.1HSPA15B9 H.sapiens llow-sorted chromosome 6 1288 C1u396325.1 278727 HindIII fragment, SC6pA15B91.2E-38 gi~12862672~dbj~AB038971.1AB03896557 Homo Sapiens CFLAR gene, exon 10, exon 1291 CIu400258.1 ~ AB038971 11 4E-74 gi~6715105~gb~AF170811.1AF170811 Homo 1293 C1u402591.3 AF170811 sa iens CaBP2 (CABP2 ene,7E-26 complete cds gig 12847570~dbj~AK011443.1AK011443 Mus musculus 10 days embryo cDNA, RIKEN full-length enriched library, 1295 C1u404081.2 AK011443 clone:2610018B07, full 5E-153 ins gig 16326128~dbj ~AB042029.1AB042029 Homo sapiens DEPC-1 mRNA
for prostate 1297 C1u41346.1 AB042029 cancer antigen-1, com 0 lete cds gi~7020278 (dbj ~AK000293.1 Homo Sapiens cDNA FLJ20286 fis, clone 1299 C1u416124.1 AK000293 HEP04358 3.3E-34 gig 140425 l4~dbj ~AK027667.1 Homo Sapiens cDNA FLJ14761 fis, clone 1300 C1u417672.1 AK027667 NT2RP3003302 1.6E-183 gi~9844925~gb~AF287270.1AF287270 Homo Sapiens mucolipin (MCOLN1) gene, 1301 C1u423664.1 AF287270 com lete cds 6.3E-34 gig 15559816~gb~BC014256.1BC014256 Homo Sapiens, Similar to guanine nucleotide binding protein (G protein), beta 1303 C1u442923.3 BC014256 0l a tide 2-like 1.5E-236 gi~7159715 ~emb~AL022342.6HS29M

Human DNA sequence from clone RP1-29M10 on chromosome 20, complete 1304 C1u446975.1 AL022342.6 1.8E-74 se uence Homo sa iens gig 12804410~gb~BC001607.1BC001607 Homo Sapiens, clone IMAGE:3543874, 1305 C1u449839.2 BC001607 mRNA, artial cds 1.9E-27 gi~255496~gb~S45332.1545332 erythropoietin receptor [human, placental, 1306 CIu449889.1 S45332 Genomic, 8647 nt 8E-101 gi~4038586~emb~AJ004862.1HSAJ4862 Homo Sapiens partial MUCSB
gene, exon 1-1307 C1u451707.2 AJ004862 29 4.7E-49 Table 7 SEQ ACCES- GENBANK

ID SEQ NAME SION GENBANK DESCRIPTION SCORE

..... giI10434673~dbj~AK022973.1AK022973 Homo sapiens cDNA FLJ12911 fis, clone NT2RP2004425, highly similar to Mus 1308 musculus axotrophin mR 1.7E-285 C1u454509.3 gig 1043 6049~dbj ~AK023951.1 Homo Sapiens cDNA FLJ13889 fis, clone 1310 THYR01001595 3.3E-27 C1u455862.1 gi~12849888~dbj~AK012865.1AK012865 Mus musculus 10, 11 days embryo cDNA, RIKEN full-length enriched library, 1311 clone:2810036K01, full 1.7E-57 C1u460493.1 l gi~11066459~gb~AF223389.1AF223389 Homo Sapiens PCGEM1 gene, ~ non-coding AF223389 mRNA 1.2E-116 C1u470032.1 1 gi~13938350~gb~BC007307.1BC007307 Homo sapiens, Similar to zinc forger protein 268, clone IMAGE:3352268, mRNA, partial 1317 cds 4.6E-56 C1u477271.1 gi~7020973~dbj~AK000713.1AK000713 Homo Sapiens cDNA FLJ20706 fis, clone C1u480410.1 ~

gi~9755121~gb~AF270579.1AF270579 Homo 1320 sa iens clone 18 tel 481c63.8E-29 C1u497138.1 se uence gi~2226003~gb~U49973.1HSU49973 Human Tiggerl transposable element, complete 1321 consensus se uence 1.4E-24 C1u498886.1 gig 13938610~gb~BC007458.1BC007458 Homo Sapiens, clone MGC:12217 1323 IMAGE:3828631, mRNA, com 0 C1u5013.2 lete cds gig 12224956~emb~AL512712.1HSM802915 Homo Sapiens mRNA; cDNA

DKFZp761 J 139 (from clone C1u5105.2 gi) 1043 5 860~dbj ~AK023 812.1 AK023 812 Homo Sapiens cDNA FLJ13750 fis, clone 1325 PLACE3000331 1.4E-32 C1u510539.2 gig 14270388 ~emb~AJ403947.1 Homo Sapiens partial SLC22A3 gene for 1326 organic cation trans orter4.4E-295 C1u514044.1 3, exon 2 gi~5579305~gb~AF093016.1AF093016 Homo 1329 sa iens 22k48 ene, 5'UTR 7.3E-67 C1u520370.1 gig 15028613 ~emb~AL 157362.1 Human DNA sequence from clone RP11-142D16 on chromosome 13q14.3-21.31, 1330 com fete se uence Homo 4.9E-23 C1u524917.1 gig 13874604~dbj~AB060919.1AB060919 Macaca fascicularis brain cDNA clone:QtrA

1331 14728, full insert se 1.5E-31 C1u528957.1 uence gi~3123571 ~emb~AJ005821.1HSA5821 1334 Homo sa iens mRNA for 3.5E-36 C1u540142.2 X-like 1 rotein Table 7 SEQ ACCES- GENBANK

ID SEQ NAME SION GENBANK DESCRIPTION SCORE

~_Tm _...... _.__..._ g1~352321rv7~gb~AF088011.1HUMYY75G10....._...
. ._ Homo Sapiens full length insert cDNA clone 1335 C1u540379.2 AF088011YY75G10 2.4E-49 gi~551540~gb~U14571.1HSU14571 ***ALU

WARNING: Human Alu-Sc subfamily 1336 C1u549507.1 U14571 consensus se uence 1.6E-48 gi~10280537~dbj~AB038163.1AB038163 Homo Sapiens NDUFV3 gene for mitochondrial NADH-Ubiquinone 1339 C1u556827.3 AB038163oxidoreductase, com fete 9.7E-22 cds gi~3108092~gb~AF061258.1AF061258 Homo 1340 CIu558569.2 AF061258Sapiens LIM protein mRNA,1E-300 com lete cds gig 10435902 ~dbj ~AK023 843.1 AK023 843 Homo Sapiens cDNA FLJ13781 fis, clone 1343 C1u570804.1 AK023843PLACE4000465 4.4E-42 gi~885681~gb~U18271.1HSTMP06 Human thymopoietin (TMPO) gene, partial exon 6, complete exon 7, partial exon 8, and partial 1344 C1u572170.2 U18271 cds for t 4.9E-57 gi~10803412~emb~AJ276804.1HSA276804 Homo Sapiens mRNA for protocadherin 1346 C1u587168.1 AJ276804(PCDHX gene 5.8E-69 gi~1613889~gb~U73166.1U73166 Homo Sapiens cosmid clone LUCA15 from 3p21.3, 1347 C1u588996.1 U73166 com fete se uence 9.3E-22 gig 11878341 ~gb~AF327178.1AF327178 Homo Sapiens clone 20pte1 cA35 21t7 1349 C1u598388.1 AF327178se uence 1.1E-26 gi~14388457~dbj~AB063021,1AB063021 Macaca fascicularis brain cDNA

1350 C1u604822.2 AB063021clone:QmoA-11389, full 2.6E-65 insert se uence gig 10433005 ~dbj ~AK021759.1 Homo Sapiens cDNA FLJ11697 fis, clone 1353 C1u627263.1 AK021759HEMBA1005035 5.7E-30 gig 11121002 ~emb~AL 157697.11 Human DNA sequence from clone RP5-1092C14 on chromosome 6, complete 1356 C1u641662.2 AL1576971se uence Homo Sapiens 7E-84 gig 10436287 ~dbj ~AK024029.1 Homo Sapiens cDNA FLJ13967 fis, clone Y79AA1001402, weakly similar to Homo 1358 C1u6712.1 AK024029sa iens araneo lash 0 gi~298606~gb~S56773.1556773 putative serine-threonine protein kinase {3' UTR, 1361 C1u685244.2 556773 Alu re eats human, Genomic,1.1E-35 1470 nt gi~559316~dbj~D28126.1HUMATPSAS

Human gene for ATP synthase alpha 1362 CIu691653.1 D28126 subunit, com fete cds 6.3E-37 exon 1 to 12 gig 15207866~dbj~AB070013.1AB070013 Macaca fascicularis testis cDNA clone:QtsA

1367 C1u709796.2 AB07001311243, full insert se 8.4E-118 uence Table 7 SEQ ACCES- GENBANK

ID SEQ NAME SION GENBANK DESCRIPTION SCORE

~., gi~8515842~gb~AF271388.1AF271388 Homo Sapiens CMP-N-acetylneuraminic acid 1369 AF271388synthase mRNA, complete 0 C1u727966.1 cds gig 13436241 (gb~BC004923.1BC004923 Homo Sapiens, clone IMAGE:3605104, 1372 BC004923mRNA, artial cds 4.1E-250 C1u756337.1 gi) 10434987~dbj~AK023179.1AK023179 Homo Sapiens cDNA FLJ13117 fis, clone 1376 AK023179NT2RP3002660 6.4E-33 C1u823296.3 gig 14041890~dbj~AK0273O1.1AK027301 Homo Sapiens cDNA FLJ14395 fis, clone HEMBA1003250, weakly similar to C1u830453.2 2 gi~4589607~dbj~AB023199.1AB023199 Homo sapiens mRNA for 1378 AB023199protein, com lete cds 3.3E-51 C1u839006.1 gi~6002309~emb~AL078632.6HSA255N20 Human DNA sequence from clone 255N20 on chromosome 22, complete sequence 1379 AL078632.6 4.2E-40 C1u847088.1 [Homo sa iens]

gi~1110571~gb~S79349.1579349 Homo Sapiens type 1 iodothyronine deiodinase 1380 579349 hdiol ene, partial cds 1.6E-48 C1u853371.2 gi~3882438~gb~AF026855.1HSHADHSC

Homo Sapiens mitochondrial short-chain L-3 hydroxyacyl-CoA dehydrogenase 1381 AF026855(HADHSC) gene, nuclear 1.1E-65 C1u88462.1 gig 10437753 ~dbj ~AK025271.1 Homo Sapiens cDNA: FLJ21618 fis, clone 1382 AK025271COL07487 8.2E-54 CIu935908.2 gi~2695679~gb~AF036235.1AF036235 Gorilla gorilla L1 retrotransposon LlGg-lA, 1386 AF036235complete se uence 0 DTT00087024.1 gig 12958747~gb~AF324172.1AF324172 Dictyophora indusiata strain ASI 32001 internal transcribed spacer 1, partial 1387 AF324172se uence; 5.8S ribo 1.1E-142 DTT00089020.1 gig 11034759 ~dbj ~AB050477.1 1388 AB050477Homo sa iens NIBAN mRNA, 0 DTT00171014.1 com lete cds gig 12805042/gb~BC001978.1BC001978 Homo Sapiens, clone IMAGE:3461487, 1389 BC001978mRNA, partial cds 6E-284 DTT00514029.1 gi~7229461~gb~AF216292.1AF216292 Homo Sapiens endoplasmic reticulum lumenal Ca2+ binding protein grp78 mRNA, 1390 AF216292com lete cds 9.5E-229 DTT00740010.1 gi~5834563~emb~AL117237.1HS328E191 Novel human gene mapping to chomosome DTT00945030.1 gi~33945~emb~X16983.1HSINTAL4 Human 1394 X16983 mRNA for integrin alpha-40 DTT01315010.1 subunit Table 7 SEQ ACCES- GENBANK

ID SEQ NAME SION GENBANK DESCRIPTION SCORE

_.. _ ~. _ .._. . gl~ 10437996~dbj ~AK025473.1AK025473_.. _._..
....

Homo Sapiens cDNA: FLJ21820 fis, clone 1395 DTT01503016.1 AK025473HEP01232 0 gi~15023874~gb~AE007613.1AE007613 Clostridium acetobutylicum 1396 DTT01555018.1 AE007613section 101 of 356 of the 0 complete genome gig 177005 ~gb~M54985.1 GIBBGLOETA

H.lar psi-eta beta-like globin pseudogene, 1397 DTT01685047.1 M54985 exon 1,2,3 6.8E-107 gig 12018057~gb~AF307053.1AF307053 Thermococcus litoralis sugar kinase, trehalose/maltose binding protein (malE), 1398 DTT01764019.1 AF307053trehalose/maltose 0 gi~7022920~dbj ~AK0015 80.1 AK001580 Homo Sapiens cDNA FLJ10718 fis, clone NT2RP3001096, weakly similar to Rattus 1401 DTT02367007.1 AK001580norve icus 1e recan 0 gig 14488027~gb~AF384048.1AF384048 Homo Sapiens interferon kappa precursor 1402 DTT02671007.1 AF384048ene, com fete cds 1.8E-170 gig 10197635 ~gb~AF 182418.1 Homo Sapiens MDS017 (MDS017) mRNA, 1403 DTT02737017.1 AF182418com fete cds 9E-207 gig 12847322~dbj ~AK011295.
l AK011295 Mus musculus 10 days embryo cDNA, RIKEN full-length enriched library, 1404 DTT02850005.1 AK011295clone:2610002L04, full 2.5E-141 ins gig 13 87905 5 ~gb~AE006916.1 Mycobacterium tuberculosis CDC1551, 1406 DTT03037029.1 AE006916section 2 of 280 of the 2.1E-129 complete genome gig 1580780~gb~M83822.1HUMCDC4REL

Human beige-like protein (BGL) mRNA, 1407 DTT03150008.1 M83822 artial cds 0 gi~15011903~ref~NM 012090.2 Homo NM-012090Sapiens actin cross-linking factor (ACF7), 1408 DTT03367008.1 .2 transcri t variant 1, mRNA0 gi~12857675~dbj~AKO18110.1AK018110 Mus musculus adult male medulla oblongata cDNA, RIKEN full-length enriched library, 1411 DTT03913023.1 AK018110clone:633040 2E-214 gig 15930193~gb~BC015529.1BC015529 Homo Sapiens, Similar to ribose 5-phosphate isomerase A, clone MGC:9441 1412 DTT03978010.1 BC015529IMAGE:3904718, mRNA, com 0 gi~893273~gb~L43411.1HiJM25DC1Z
Homo Sapiens (subclone 5-g5 from P 1 H25) DNA

1413 DTT04070014.1 L43411 se uence 4E-102 gi) 12240019~gb~AF259790.1AF259790 Desulfitobacterium Sp.

chlorophenol reductive dehalogenase (cprA) 1414 DTT04084010.1 AF259790gene, com fete cds 2.2E-288 Table 7 SEQ ACCES- GENBANK

ID SEQ NAME SION GENBANK DESCRIPTION SCORE

_._ _. ____._.gi~12958808~gb~AF338299.1AF338299~__..
,~4~ ~

Amazona ochrocephala auropalliata mitochondrial control region 1, partial 1415 DTT04160007.1 AF338299se uence 1.4E-181 gi~5922722~gb~AF102129.1AF102129 Rattus norvegicus KPL2 (Kpl2) mRNA, complete 1417 DTT04378009.1 AF102129cds 4.7E-146 gi~15023517~gb~AE007580.1AE007580 Clostridium acetobutylicum 1418 DTT04403013.1 AE007580section 68 of 356 of the 1.5E-199 com lete enome gi~13376631~ref~NM_025079.1 Homo Sapiens hypothetical protein 1420 DTT04660017.1 NM 025079FLJ23231 , mRNA 0 gi~3319283~gb~AF050179.1AF050179 Homo Sapiens CENP-C binding protein (DAXX) 1421 DTT04956054.1 AF050179mRNA, com lete cds 0 gig 12854041 ~dbj ZAKO
15 635.1 AKO 15635 Mus musculus adult male testis cDNA, RIKEN full-length enriched library, 1422 DTT04970018.1 AK015635clone:4930486L2_4, full 1.4E-84 gi~3327079~dbj~AB014533.1AB014533 Homo Sapiens mRNA for 1424 DTT05571010.1 AB014533protein, artial cds 1.8E-53 gig 13448249~gb~AF344987.1AF344987 Hepatitis C virus isolate RDpostSClc2 1426 DTT05742029.1 AF3449870l rotein gene, artial 0 cds gi~15146287~gb~AY049285.1 Arabidopsis thaliana AT3g58570/F14P22_160 mRNA, 1427 DTT06137030.1 AY049285com lete cds 2.2E-143 gig 15 874883 ~emb~AJ330465.1 Homo Sapiens genomic sequence 1428 DTT06161014.1 AJ330465surrounding NotI site, 2.5E-28 clone NRl-IM15C

gig 12407487~gb~AF226787.1AF226787 Syrrhopodon confertus ribulose-1,5-bisphosphate carboxylase large subunit 1429 DTT06706019 AF226787rbcL ene, artial cd 0 .1 _ gi~7020892 ~dbj ~AK000658.1AK000658 Homo sapiens cDNA FLJ20651 fis, clone 1430 DTT06837021.1 AK000658KAT01814 0 gi~3005557~gb~AF047347.1AF047347 Homo Sapiens adaptor protein X1 lalpha mRNA, 1431 DTT07040015.1 AF047347com fete cds 0 gig 15080738~gb~AF326517.1AF326517 Abies grandis pinene synthase gene, partial 1432 DTT07088009.1 AF326517cds 0 gi~9955412~dbj~AB035187.1AB035187 Homo Sapiens RHD gene, intron 1, complete 1433 DTT07182014.1 AB035187se uence 3.1E-84 gig 16267254~dbj~AP002946.1AP002946 Mastacembelus favus mitochondrial DNA, 1434 DTT07405044.1 AP002946com fete genome 0 Table 7 SEQ ACCES- GENBANK

ID SEQ NAME SION GENBANK DESCRIPTION SCORE

_... ~_..~ g1~15156405~gb~AE008061.1AE008061_ Agrobacterium tumefaciens strain C58 circular chromosome, section 119 of 254 of 1435 DTT07408020.1 AE008061the com lete se a 6.9E-245 gi~885679~gb~U18270.1HSTMP04 Human thymopoietin (TMPO) gene, exons 4 and 5, 1438 DTT08005024.1 U18270 and complete cds for thymoS.lE-108 oietin al ha gig 15021617~gb~AF387946.1AF387946 Homo Sapiens clone J102 melanocortin 1 1439 DTT08098020.1 AF387946receptor gene, romoter 0 region gi~11034852~ref~NM_020642.1 Homo Sapiens chromosome 11 open reading frame 1440 DTT08167018.1 NM 02064217 (Cllorfl7 , mRNA 1E-183 ' gi~184564~gb~M86752.1HUMIEF
Human transformation-sensitive protein (IEF SSP

1441 DTT08249022.1 M86752 3521 mRNA, com lete cds 0 gi~7023494~dbj ~AK001927.1AK001927 Homo Sapiens cDNA FLJ11065 fis, clone PLACE1004868, weakly similar to MALE

1443 DTT08514022.1 AK001927STERILITY PROTEIN 2 0 gi~8515842~gb~AF271388.1AF271388 Homo Sapiens CMP-N-acetylneuraminic acid 1444 DTT08527013.1 AF271388synthase mRNA, com fete 0 cds gig 177764~gb~L07758.1 1445 DTT08595020.1 L07758 Human IEF SSP 9502 mRNA, 0 complete cds gi~2443337~dbj~D87930.1D87930 Homo Sapiens mRNA for myosin phosphatase 1446 DTT08711019.1 D87930 tar et subunit 1 MYPT1 0 gi~37260~emb~X15187.1HSTRA1 Human tral mRNA for human homologue of marine 1447 DTT08773020.1 X15187 tumor re'ection anti en 6.8E-298 gig 10439307~dbj ~AK026442.1 Homo sapiens cDNA: FLJ22789 fis, clone 1448 DTT08874012.1 AK026442KAIA2171 0 gi~15186755~gb~AF273672.1AF273672 Mus musculus RANBP9 isoform 1 (Ranbp9) 1449 DTT09387018.1 AF273672mRNA, complete cds 0 gi~7021874~dbj ~AK000913.1 Homo Sapiens cDNA FLJ10051 fis, clone 1450 DTT09396022.1 AK000913HEMBA1001281 0 gig 10434285 ~dbj (AK022722.1 Homo sapiens cDNA FLJ12660 fis, clone NT2RM4002174, moderately similar to 1452 DTT09604016.1 AK022722MRP PROTEIN 2.2E-198 gi~2582414~gb~AF025409.1AF025409 Homo Sapiens zinc transporter 4 (ZNT4) mRNA, 1454 DTT09742009.1 AF025409com lete cds 0 gi~187280~gb~L03532.1HUMM4PR0 1455 DTT09753017.1 L03532 Human M4 rotein mRNA, complete5.7E-58 cds Table 7 SEQ ACCES- GENBANK

ID SEQ NAME SION GENBANK DESCRIPTION SCORE

~..... _......gii10437578~dbj~AK025125.1AK025125_.._..
. .... -...
.
_ .
.

Homo Sapiens cDNA: FLJ21472 ( fis, clone DTT09793019.1 gi~8705239~gb~AF272390.1AF272390 Homo Sapiens myosin 5c (MY05C) mRNA, 1457 AF272390com lete cds 0 DTT09796028.1 gi~6453351~emb~AJ133798.1HSA133798 1459 AJ133798Homo sa iens mRNA for 0 DTT10360040.1 co ine VI rotein gi~5453323~gb~AF152924.1AF152924 Mus musculus syntaxin4-interacting protein synip 1460 AF152924mRNA, com lete cds 2.6E-70 DTT10539016.1 gig 12657820~gb~AF322634.1AF32263451 Human herpesvirus 3 strain VZV-Iceland 1461 AF322634lyco rotein B gene, complete0 DTT10564022.1 cds gi~36114~emb~X69392.1HSRP26AA

1462 X69392 H.sa iens mRNA for ribosomal3E-250 DTT10683041.1 protein L26 gi~551537~gb~U14568.1HSU14568 ***ALU

WARNING: Human Alu-Sb subfamily 1463 U14568 consensus sequence 2.6E-93 DTT10819011.1 gi~10954043~gb~AF309561.1AF309561 Homo Sapiens KRAB zinc finger protein 1465 AF309561ZFQR mRNA, com lete cds 0 DTT11479018.1 gi~1616674~gb~U57053.1HSU57053 Human unconventional myosin-ID
(MYO1F) gene, 1466 U57053 artial cds 3.1E-245 DTT11483012.1 gi~35740~emb~X05332.1HSPSAR
Human DTT11548015.1 X05332 mRNA for rostate specific0 1467 ant~en r ~_ gi~551541~gb~U14572.1HSU14572 ***ALU

WARNING: Human Alu-Sp subfamily 1468 U14572 consensus se uence 4.7E-90 DTT11730017.1 gi~7023475 ~dbj ~AK001915.1 Homo Sapiens cDNA FLJ11053 fis, clone DTT11902028.1 gi~1724068~gb~U66062.1HSU66062 Human glp-1 receptor gene, promoter region and 1472 U66062 artial cds 5.9E-111 DTT11915017.1 gi) 189265 ~gb~M73791.1 HUMNOVGENE

1475 M73791 Human novel gene mRNA, 0 DTT12201062.1 com lete cds gig 10439509~dbj~AK026618.1AK026618 Homo Sapiens cDNA: FLJ22965 fis, clone DTT12470020.1 Table 8 SEQ SEQ NAME PFAM PFAM DESCRIPTION SCORE START END
ID ID

Ubiquitin-conjugating 7 2504.C11.GZ43 PF00179enz a 92.64 4 159 2504.E23.GZ43 PF01260AP endonuclease 88.28 222 481 365908 famil 1 Uncharacterized ACR, YggU

46 2505.G16.GZ43 PF02594famil COG1872 77.64 263 495 109 2510.N14.GZ43 PF02348C id 1 ltransferase187.84357 675 126 2365.D10.GZ43 PF01018GTP1/OBG famil 96.12 50 507 Cyclophilin type peptidyl-134 2365.F24.GZ43 PF00160rol 1 cis-traps 120.2 251 522 345370 isomerase 2366.L21.GZ43 PF00612IQ calinodulin-bindin~motif33.96 415 477 2366.L21.GZ43 PF00063M osin head motor207.128 369 345942 domain Cyclophilin type peptidyl-259 2368.003.GZ43 PF00160rol 1 cis-traps 120.2 242 5~3 346717 isomerase 267 2535.C23.GZ43 PF02114Phosducin 32 152 589 334 2537.D11.GZ43 PF00083Su ar and other 122.884 288 370938 traps orter 335 2537.D20.GZ43 PF00131Metallothionein 48.56 563 665 349 2537.N12.GZ43 PF01352KRAB box 123.24313 498 Cyclophilin type peptidyl-363 2538.B03.GZ43 PF00160rol 1 cis-traps 117.68320 591 371266 isomerase 391 2554.A06.GZ43 PF03015Male sterili rotein44.96 605 749 394 2554.A16.GZ43 PF02348C 'd 1 ltransferase195.48397 650 405 2554.I10.GZ43 PF03041lef 2 31.88 479 536 Ubiquinol-cytochrome C

reductase complex l4kD

419 2565.B15.GZ43 PF02271subunit 70.76 29 188 422 2565.C17.GZ43 PF00089T sin 45.28 5 110 482 2540.I17.GZ43 PF00023Ank re eat 75.44 444 542 NADH-ubiquinone/plastoquinone 507 2541.L08.GZ43 PF00499oxidoreductase 54.72 89 237 372663 chain 6 RNA recognition motif.

(a.k.a. RRM, RBD, or RNP

514 2506.C15.GZ43 PF00076domain 44.44 70 276 521 2506.G24.GZ43 PF00096Zinc fin er, C2H246.68 156 224 366725 a PDZ domain (Also known as 527 2506.J20.GZ43 PF00595DHR or GLGF . 34.16 290 502 543 2542.D19.GZ43 PF00098Zinc knuckle 46.68 224 276 563 2542.N21.GZ43 PF01545Cation efflux 42.24 191 325 373108 famil 569 2555.F16.GZ43 PF02348C id 1 ltransferase215.04357 713 Cytochrome c oxidase 716 2560.H21.GZ43 PF00510subunit III 37.28 224 436 721 2560.K10.GZ43 PF01018GTP1/OBG famil 104.5650 573 759 2561.017.GZ43 PF00826Ribosomal L10 79.88 46 180 766 2456.B 12.GZ43PF01545Cation efflux 34.16 102 236 355864 famil 771 2456.D04.GZ43 PF02114Phosducin 30.52 139 576 Uncharacterized ACR, YggU

813 2457.J23.GZ43 PF02594famil COG1872 77.64 189 421 818 2457.L21.GZ43 PF00023Ank re eat 38 208 306 Table 8 SEQ SEQ NAME PFAM ID PFAM DESCRIPTIONSCORE START END
ID

RNA recognition motif.

(a.k.a. RRM, RBD, or RNP

910 2464.L02.GZ43 PF00076 domain 34.84 244 350 914 2464.N05.GZ43 PF00023 Ank re eat 128.28491 589 Uncharacterized ACR, YggU

935 2465.K20.GZ43 PF02594 famil COG1872 77.64 210 442 952 2466.I08.GZ43 PF00012 Hs 70 rotein 120.9216 208 967 2467.D10.GZ43 PF00008 EGF-like domain 31.04 63 113 NADH-ubiquinone/plastoquinone 1002 2472.P22.GZ43 PF00499 oxidoreductase 64.72 81 209 361231 chain 6 1011 2473.I08.GZ43 PF00895 ATP s thase rotein66.88 5 148 1039 2475.N08.GZ43 PF00804 S taxin 53.08 226 601 1051 2480.D13.GZ43 PF03025 Pa illomavirus 33.56 583 749 1065 2481.B06.GZ43 PF00098 Zinc knuckle 35.88 79 133 4Fe-4S iron sulfur cluster binding proteins, NifH/frxC

1100 2483.J07.GZ43 PF00142 famil 32.8 211 288 Cyclophilin type peptidyl-1101 2483.K02.GZ43 PF00160 rol 1 cis-traps ~ X7.52244 516 359897 isomerase 1107 2488.B07.GZ43 PF01260 AP endonuclease 79.88 251 614 362475 famil 1 1128 2489.F09.GZ43 PF02348 C 'd 1 ltransferase174.36347 591 Cytochrome C oxidase subunit II, transmembrane 1183 2496.I06.GZ43 PF02790 domain 45.8 131 242 1207 2562.B09.GZ43 PF00826 Ribosomal L10 106.2849 341 1216 2562.E14.GZ43 PF00023 Ank re eat 87.04 230 328 Uncharacterized ACR, YggU

1225 2562.H18.GZ43 PF02594 famil COG1872 65.44 206 437 1244 2507.C03.GZ43 PF00083 Su ar and other 95.52 107 355 366992 traps orter Cyclophilin type peptidyl-1267 2499.I09.GZ43 PF00160 rol 1 cis-traps 43.24 139 238 365436 isomerase Table 9 SEQ PROTEIN SEQ
ID NAME PFAM PFAM DESCRIPTION SCORE START END
ID

tRNA synthetase 1481DTP00514038.1PF00587class II core 33.42 1 116 domain G, H, P, S and T

1482DTP00740019.1PF00012Hs 70 rotein 948.2227 564 1484DTP01169031.1PF00023Ank re eat 159.6682 114 1484DTP01169031.1PF00023Ank re eat 159.66181 213 1484DTP01169031.1PF00023Ank re eat 159.66148 180 1484DTPO 1169031.1PF00023Ank re eat 159.66115 147 1484DTPO 1169031.1PF00023Ank re eat 159.6682 114 1484DTP01169031.1PF00023Ank re eat 159.6649 81 1484DTP01169031.1PF00023Ank re eat 159.6616 48 1484DTP01169031.1PF00023Ank re eat 159.66181 213 1484DTP01169031.1PF00023Ank re eat 159.66115 147 1484DTP01169031.1PF00023Ank re eat 159.6649 81 1484DTP01169031.1PF00023Ank re eat 159.6616 48 1484DTP01169031.1PF00023Ank re eat 159.66148 180 1486DTP01315019.1PF01839FG-GAP re eat 255.09427 479 1486DTP01315019.1PF01839FG-GAP re eat 255.0949 111 1486DTP01315019.1PF01839FG-GAP re eat 255.09248 300 1486DTP01315019.1PF01839FG-GAP re eat 255.09303 362 1486DTP01315019.1PF01839FG-GAP re eat 255.09365 424 1495DTP02737026.1PF01423Sm rotein 31.6 19 66 1496DTP02850014.1PF00804S taxin 156.591 292 1496DTP02850014.1PF00804S taxin 156.591 292 1496DTP02850014.1PF00804S taxin 156.591 292 1510DTP04403022.1PF00400WD domain, G-beta 35.93 80 116 1510DTP04403022.1PF00400re eat 35.93 38 74 WD domain, G-beta re eat 1510DTP04403022.1PF00400WD domain, G-beta 35.93 1 33 re eat 1512DTP04660026.1PF00083Su ar and other 234.431 484 traps orter 1512DTP04660026.1PF00083Su ar and other 234.431 484 1518DTP05742038.1PF01018traps orter 133.76105 208 GTPl/OBG famil 1518DTP05742038.1PF01018GTPI/OBG famil 133.767 97 1518DTP05742038.1PF01018GTPl/OBG famil 133.76105 208 1518DTP05742038.1PF01018GTP1/OBG famil 133.767 97 1518DTP05742038.1PF01018GTP1/OBG famil 133.76105 208 1518DTP05742038.1PF01018GTP1/OBG famil 133.767 97 Ubiquinol-cytochrome 519 TP06137039.1F02271 reductase complex 41.38 54 l4kD
subunit 1521DTP06706028.1PF00054Laminin G domain 63.34 56 178 1521DTP06706028.1PF00054Laminin G domain 63.34 281 292 Phosphotyrosine 1523DTP07040024.1PF00640interaction 233.89461 618 domain PTB/PID .

PDZ domain (Also 1523DTP07040024.1PF00595known as 85.47 656 742 DHR or GLGF .

1532DTP08249031.1PF00515TPR Domain 115 4 37 1532DTP08249031.1PF00515TPR Domain 115 72 105 1532DTP08249031.1PF00515TPR Domain 115 38 71 1532DTP08249031.1PF00515TPR Domain 115 259 292 1532DTP08249031.1PF00515TPR Domain 115 300 333 1532DTP08249031.1PF00515TPR Domain 115 225 258 1535DTP08527022.1PF02348C id 1 Itransferase48.59 1 166 Table 9 SEQ PROTEIN
SEQ

ID NAME PFAM PFAM DESCRIPTION SCORE START END
ID

1535DTP08527022.1PF02348 C id 1 ltransferase48.59 1 166 1535DTP08527022.1PF02348 C id 1 ltransferase48.59 1 166 1535DTP08527022.1PF02348 C id 1 ltransferase48.59 1 166 1536DTP08595029.1PF00400 WD domain, G-beta 80.04 183 221 re eat 1536DTP08595029.1PF00400 WD domain, G-beta 80.04 236 273 re eat 1536DTP08595029.1PF00400 WD domain, G-beta 80.04 365 402 re eat 1536DTP08595029.1PF00400 WD domain, G-beta 80.04 279 316 re eat 1536DTP08595029.1PF00400 WD domain, G-beta 80.04 325 357 re eat 1537DTP08711028.1PF00023 Ank re eat 81.96 22 54 1537DTP08711028.1PF00023 Anlc re eat 81.96 55 87 1538DTP08773029.1PF00183 90 rotein 100.71 104 173 Hs 1540DTP09387027.1PF00069 _ 224.56 76 342 Protein kinase domain 1545DTP09742018.1PF01545 Cation efflux famil368.71 114 418 1545DTP09742018.1PF01545 Cation efflux famil368.71 114 418 - DTP09796037.1PF00612 IQ calinodulin-binding87.63 879 899 1548 motif 1548DTP09796037.1PF00612 IQ calmodulin-bindin87.63 856 876 motif 1548DTP09796037.1PF00612 IQ calmodulin-bindin87.63 831 851 motif 1548DTP09796037.1PF00612 I calmodulin-bindin87.63 808 828 motif 1548DTP09796037.1PF00612 IQ calmodulin-bindin87.63 780 800 motif 1548DTP09796037.1PF00612 IQ calmodulin-bindin87.63 757 777 motif 1548DTP09796037.1PF01843 DIL domain 125.23 1574 1679 1548DTP09796037.1PF00063 M osin head motor 1228.24 69 741 domain 1550DTP10360049.1PF00168 C2 domain 50.07 26 114 1550DTP10360049.1PF00168 C2 domain 50.07 228 315 PDZ domain (Also lrnown as 1551DTP10539025.1PF00595 DHR or GLGF . 32.34 5 84 1553DTP10683050.1PF00467 KOW motif 89.22 49 107 1556DTP11479027.1PF00096 Zinc fin er, C2H2 209.31 402 424 a 1556DTP11479027.1PF01352 KRAB box 134.58 8 70 1556DTP11479027.1PF00096 Zinc fm er, C2H2 209.31 374 396 a 1556DTP11479027.1PF00096 Zinc fm er, C2H2 209.31 346 368 a 1556DTP11479027.1PF00096 Zinc fm er, C2H2 209.31 318 340 a 1556DTP11479027.1PF00096 Zinc fin er, C2H2 209.31 290 312 a 1556DTP11479027.1PF00096 Zinc fin er, C2H2 209.31 262 284 a 1556DTP11479027.1PF00096 Zinc finger, C2H2 209.31 234 256 a 1556DTP11479027.1PF00096 Zinc fm er, C2H2 209.31 206 228 a 1557DTP11483021.1PF00063 M osin head motor 339.24 117 271 domain 1557DTP11483021.1PF00063 M osin head motor 339.24 34 115 domain 1558DTP11548024.1PF00089 T sin 272.53 25 253 1564DTP11966049.1PF00023 Ank re eat 165.68 49 81 1564DTP11966049.1PF00023 Ank re eat 165.68 148 180 1564DTP11966049.1PF00023 Ank re eat 165.68 181 214 1564DTP11966049.1PF00023 Ank re eat 165.68 148 180 1564DTP11966049.1PF00023 Ank re eat 165.68 115 147 1564DTP11966049.1PF00023 Ankre eat 165.68 82 114 1564DTP11966049.1PF00023 Ank re eat 165.68 49 81 1564DTP11966049.1PF00023 Ank re eat 165.68 181 214 1564DTP11966049.1PF00023 Ank re eat 165.68 181 214 1564DTP11966049.1PF00023 Ankre eat 165.68 16 48 1564DTP11966049.1PF00023 Ankre eat 165.68 115 147 1564DTP11966049.1PF00023 Ank re eat 165.68 82 114 1564DTP11966049.1PF00023 Ank repeat 165.68 ~ _ 16 ~ 48 Table 9 SEQ PROTEIN
ID SEQ PFAM PFAM DESCRIPTION SCORE START END
NAME ID

1564DTP11966049.1PF00023 Ankre eat 165.68148 180 1564DTP11966049.1PF00023 Ankre eat 165.68115 147 1564DTP11966049.1PF00023 Ankre eat 165.6882 114 1564DTP11966049.1PF00023 Ankre eat 165.6849 81 1564DTP 11966049.1PF00023 Ank re eat 165.6816 48 1566DTP12201071.1PF00826 Ribosomal L10 467.361 _176 1566DTP12201071.1PF00826 Ribosomal L10 ~ 467.36( 1 _ r w Q ~ m ~ r b , ~ V ~ .b U
. ~ . O
vID c~ .L,' c~ ~. v1 cdb O . y ~ c~
N .. y~
~ ~p ~ cti , P. ~ ~ ~~ O p ~ ' ~

. ~', O ~ ~,~ ~ F
V ~ ~

~ ~c4,-v> ~
~' ~ ~.~x . ~ w.~~ a. ~
~o z o ~
~
~
~
-o A~

c~

a z z z z a ~ z z z z ~

a a, M

,7a M O _ O
~ O

a Q, m b0 by bD
~

w z z z a o ~ .~

o .
O

c~
O ~ ~ ~
' ;, r., , 0 ~ b ~ N ~ b ~ U
~ ~
~ O

cd O. ~ ~
a ~c d .O O c~
.

~~ ~ ~ ~ ~~ 1 N~
v O ~ cdS~rO O t~i~ ~ 0 c~ ~ VI
a ~ ~ > ~ > > . fn ~ ~ ~ N O
~

W ~ ~ ~ ~ .'~~ ~ ~ In V ~ " V7 ~~"
. O

l . . ~

O

d b O O

b O

a !/~
O

v U v~ U

~, N

O

~"~ V'1 N N N
V

1 ,_, N

H b ~ 4~
y L, ~ ~ ~ O t~, U
~ ~ ~
~

O ~ ' O
~

V

p,,~~G~~ ~c~

a 'b o - o A~~ ~

~

a z z z a ~ z ~ z z z ~

a ' ;c C, ~ ~ ~ N 01 N

.-, O O
~~

a ~, ~, z ~, a 4 'C ~ . d . .

O -~ ~ b(1' ~ ~ ~1. c ..w P, P. ' U ~

p O .
~

~ O .d O ,~, O
p ~
, N
~

w ~~ cd'~ ~ N .~ ~*"~p~'~ U
~

n , W O
c , ~~ o s., inV ~ ~ ci~V.f".O~ ~~p n tiP.O~

0 0 0 ~~ ~ ~~ ~
f" S"

... . O
- . '~~~
. ~
~ ~
~ ' G3.f.3.c r c d dF
.
, O O

b H H ~ H

O V'1 O V1 V1 V1 V W l1 U

V ~ U y O

c ~
d P,~ ~ N
s..

E-~U v~~ C~ U

~.

t~ O\ N O
~O

O

N M M

U O ~' o~ ~ 3a ~

, ~, ~
~

~. o ~
~, ~

U p ~ ' fl ~
o b ~ ,~
a ., , x~. ~~;~b a~~

a ao 00 d0 A~a z z z ~, z z z z ~
a GL M O V~
;b ~ ~ ,~ .-.

~ z z , a f ~ 'g ~

O an o oo s~. .~. .d s~, A, ~, O ~y ~ ~ O .b O t3 p ~
~ fj p ~, , . . U
~ ~

~.' ~ ' N Cd ' ~ ~ ' U~~.,.,N
U ~' ~ CCS ~ y ~ >
w ~vy 0 .r . ~N w .~ O

a v N ~ v > O V ~ b v ~~ O
~ ~ V ~ O
~v w O ~ ~ ~ ~ ~ ' y Q.
n ~ ~ . O pQ, 1 ~ ~

' ~~ ~~. ~ s., ~~~.., ~ ~ O
> ~ ~

~ C]Uc~~~ ~~ ~ ~~ ~ ~ ~~ dm ~ ii ~~ c P

. . .

d 'b H ~ H

M ~!1 bD N

O U y 'd C~ N

C~ c~i y ~ ~ ~', O
i..a p p, v v O ~ 0 it ~

a: d E v '-~

N

N N

O

.fir ~O ~O ~f ~D

N N N
C~

<
H

b Vj ~ ~ ~ U

~~ z ~ ~~

~ ~
'~

b c ~ v ~ ~ o yo A ~ ' o ~ ~ ~ o 0 ~'o~
C7 y .3 V ~ o y ~ ~ ~ ~
x ~ ~. ~

p ~ ~

U E'~ .s"~..-~
b 'C Q"

O

V by by bD b0 by A~a z z z z z ~ ~ z z z z z a b N O N

w w ~ O ~ N O O

i'.

O O

z ~. ~ z z a ' ~ U ~ '" ~

n .b O. O O ~" ." p O c O ~ N O ~ O ~ 0 ~ U c,.., O

p O ~ ~ ~ ~v ~p ~ ~ y n o~
~

~ .n , ~ p , ~,~
U ~ '~
~

_~ ~ i~ ~ _D
w O U 0 ~ ~ O b ~ ~ ~ O
~ U

~ ~ . O .t", V b ~ .~, ~ U wt"~' O 'yO v~U O
~ O V~N U U ~ .

U N ~~ b i~ U . v, ,., ~ ~ ~'O
i~
v~

a > ~O > ~ >~ . ~ iG Q '~'~ .
y '~' '~" "~ ~ ~ .
'~' ~ ~ ' ~"
~

r ~ ~1. C~.~ W b ~ .
.. Q, ~ ~ t3. .

O ~

d b H H ~ H

vp N

~"

'b te te U R U o d v ', R
'.

G ~ b N N M M M

H

,~ 00 OO ~O 01 C~
N N N M M

on 4.
~

i . . U
U

. .
~

O ~ O U O O ~
O ''' O
.

V O ~ ~~ c~ ,~
c~

3 ~a'a~ ~ 'o~~o ~

E"'~i~.H ~ 1-~.~
a O Q.
. ~ U
~

rr"rn O O ~ O
y b 0~ W. i 4.

Aa z z ~ z ' ; a w w ~

~ z z z z z ~

, a b e ~ ~ ~ 0 ~ O 0 a 0 0 ~

~. z z a o ~ 0 0 o ~ ~. ~
~ ~.

O ~N Q,'UOf~.pO ~ ~1. ~ Q OO~

~ ~ v~ ~
p v~

c~ ~ , O ~

-. ~~ oz ~ o ~ o a~ ,~ .~ O ~ > ~' N
~ ~~ ~ o ~

V O N ~ ~ V V ~ ~ U ~ N V ~ ~
'~ N ~ cOn > ~ N
.~'~i v O <n v~~ n O O O ~ O ~
.~ O c~f w O V

' ' ~ U '~
O
~

H ~w ~ a~~ a~ ~ ~ U ~ ~ ~ a 3 ~.~ ~

o ' d b H H H H H

d V1 M O 00 N

~G ~ ~O

b O

O O O
U U U

O" O

v~ d o d U U
o sa ~i M

V1 ~O 01 01 M M M M

H

O ~
~
cd ~ +, U
~

+.~ O O 'p ~ ~ cue,~
c~ ~ O y ~' .b v 'c," ~n ...~,~ ~ cn .~'. V ~ ~, 3 U O

C ~~ ~~".'p ~~ p . _ . '~'UN
p ~p ~~ O
~

V ~ ~ b O S~. ~ V , 0 <n U '~ G~, ~ ~'.'3 p ~'-.
~ r, O
~

N ~ U 0 O cd ~ ~
W 'b ~ ~ U cd U 4 r .n .
-d ~' .~ O O ~' 'b ~

,~~, ~ U U
O ~ Z Z a a A

~ a w .a d ~ z z z ~ z a Q' y o 00 y b O

a ~.

a~
z a o~ yo ~ o'~ ~~~ o ~ ~ ~

, ; o ~ ~

o~ ~ ~ ~ ~~ o v~ ~ o ~ ~ ~

o ~ ~ ~
~

~ ~~ ~~ ~..o ~ ~ ~o ~o ~.

.

~ ~ s ~

.
, O
"

b a~ v~ M cV ~n .

b ~

O O

~ ~
O O

v~ d d M M ~!1 O

O
M

V'~ V1 V1 V1 >, o ~
~ ~ c~ ' ~ ~'~

iC~~ ~'~ ~ vl~y ~' Cl.~c ~
~ y. ~ U
, ~

b ~ cy00r O N ~~'~' ~ .t",0 U ~~ ~~H 'p Q yylj ~Y~ yL. , ~NO,~ O~ ~I~-~O~ yE.,~O
V ~ Oy a ~ o~ ,b ~~~~ .d ~~ ~ o~ >.b ..d,n~ 3 ~o .b dbt+..~~ ~b cdc~~b..r~ai.~ ~b cdU ~b.~cdc~

a an ou ' ' i a Ana z z o o >
> a ;
a a. w .

z z z z a C. oo N I~ N
~
;d o ~ o '~ ~ ~ o ~

z z ~, z a o o ~ ~w o 0~~ ~ ~ a. ~ Q..i .~

3 _ p ~ CIA _ ~
N

pp cd i N
cd 4, ~ .

OO~ '~ ~ ~U ~U U
~
O

V O~ O~. r ~
n , ~"~

a ~ b~ x0 y ~

~. Cd N V7 Y .~ it .~
. !/) ~ ~ ~ ~ VI
~

O

b O

~ "

O ~ .r ~ O
a U F
U

b U O

d U U d ~1 cn v b 'O ~D ~_' M V1 C~

V1 [~ 00 00 O

., ~ a ~ ~ y b o -d o 'n y ~ cant ~ ~ . '~,a' ~, ~ . ~ '~ v~ ~
o ~' ep . ~ ~ 'b ~ ~ ~ a~
E ~o"'a ;d°"~..,~~ ~>,~U o~~U~"~~~b o .~ ~ w o ~ ~ a~ w ~ ~ y ~ o ~ ~ ~ o ~ o o cv y a~ o ~ N a~ ~ p ~ .b a~ ~ ~ ~ ~ C
V ~ ~,~ ~ ~ a ~ ~ ~ °o~ ~ o-d a~ ° ~'o ~ ~~ o.~
W ~, s.. N p, ~ O ~ .~ N ~. 'U . U cd cd 3 ~ b c~ cd f'., ,~ U v~
C~ bD ~ N ~ ~ ~ N ~ N
O~ O'~ O~ 0,.~.
r~
i', y ~~~°z z z z z a N
V7 M ~, M
z ~ 0 0 0 ~, a m ,.O c~ ~ cG ~ cd o ~ a. ~ a. ~ ~ a, w ~, a y o a~ io.y o ~ o 0 0 '+, ~Q.O°P.~yP..~
O . ~ .y by cn O ,~ . s:. i..U.~ ~ . ~ O U
O ~ '~'' b .y ~ ~ .y ~'~ .y ~ cd O
U O U U U O U
r~'a~ W~O~~" ~ ~ r'~~~
M M N
~ e~ ~ C7 ~ ~ U
C7 c7 c7 c~
b H E~ H H Hr °' n, 0 00 00 0 N ~1 ~D vi N

..
C i"~ U U ~ ~ O
d '-' ~ o U a4 d ~ d o b vo 00 0~ 0 00 o°o o°o o°0 0 o°~

t~ o, o .~ 00 00 0o a\ ov o0 I~ I~ t~ t~ 00 E-~

O

b ~ V
d ~ 't"~' ~ v G

~, . c~ ~ N ~ cd '''"'~, c~ '> ~ ~' b C ~ O ~ 0 ~
~ ~ t ~

, O U~ ~ ~"c0~ ~~~U~~ ~~~U~ ~~O
i~

.
.

~b ~s w u, u.a~a,.~ w a.O
~ U

a ~

An a;a w a w a ~ a ~'~ o wa ~~~ z z z z z a b c~

d ~
a w w N w H ' ~

P~ P~ Pr P~ P~

a .

y ~ ~ ~~ o o ~ o O o ~ ~, p ~ ~ t'., O ~
p P ~ U
~

. O . . C ~ ~'O
'i' 'n '~~

Q ~N u ~

. ' ~

V ~U OU O U~ ~ UQ.U iny~.. O VQ, VU O
U

O O Vi O cn c~Vi cd~ c~ ~ O
a V~ ~ O r~O 7 ~ O
O a.~~ ~y ~ ~
~ U
~~ ~
O, ~ ~ /~
..~ ~
~ '' Y ~ 1r C!1 Vl y M
O

b a o0 N O O

b0 U

b i' ~ ~ ~ O
O

U O

U U ~O" ~ ~
o o U d ~ E~

Ov O_ ~_ N_ M_ O~ O1 01 01 O

N M
h o p~ 01 01 01 o 00 00 ~ 00 Op N

G7 .U '-~r~0 cd U

C

U ~ ~
a~ ' ~

.

b A ~

a o wa oo a, b ~ ~~ z a b a a .

y O .

C~ O
Y

("'~ ~ .
C~ ~~", Cd o ~

~l o ~o N

M
H

O

b O G
~

a b d a, C

a, H

Table 13 BREAST BREAST COLON COLON PROSTATEPROSTATE

SEQ PATIENTSPATIENT PATIENTS PATIENTSPATIENTSPATIENTS

ID CLONE ID >=2x S <=halfx >=2x <=halfx>=2x <=halfx 4 M00072944A:C07 35 8 M00072947B:G04 32.5 9 M00072947D:G05 27.5 15 M00072963B:G11 40 16 M00072967A:G07 25 18 M00072968A:F08 22.5 20 M00072968D:E05 32.5 21 M00072970C:B07 25 _ M00072971C:B07 22.5 28 M00072975A:D23.5 34 M00073001A:F07 27.5 38 M00073003A:E06 42.5 __ ~~

39 M00073003B:E10 27.5 ~~

42 M00073006A:H0823.5 43 M00073006C:D07 27.5 45 M00073009B:C08 32.5 52.4 48 M00073013A:D10 32.5 49 M00073013A:F10 20 50 M00073013C:B10 32.5 M w ~~~

52 M00073014D:F01_ 40 _ 54 _ 47.5 M00073015A:H06 61 M00073020C:F07 32.5 62 M00073020D:C06 37.5 63 M00073021C:E04 30 ~ ~

71 M00073030B:C02 _ __ __ 22.5 72 M00073030C:A02 20 ~

73 M00073036C:H10 25 86 M00073043D:H09 32.5 90 M00073044C:G12 32.5 94 M00073045C:E06 22.5 96 M00073045D:B04 30 105 M00073048C:B01 20 _ .,...........

107 M00073049A:H04 27.5 49.2 ~~

108 M00073049B:B03 40 31.7 23.5 109 M00073049B:B06 20 110 M00073049C:C09 20 136 M00073066C:D02 27.5 142 M00073070B:B06 32.5 146 M00073074D:A04 20 153 M00073086D:B05 _ 30 156 M00073091B:C04 20 163 M00073424D:C0352.9 171 M00073403C:C10 30 173 M00073403C:E1129.4 52.5 176 M00073412C:E07 30 177 M00073435C:E06 27.5 178 M00073412D:B07 35.3 42.5 189 M00073430C:B02 32.5 196 M00073442A:F07 25 197 M00073442B:D12 27.5 20.6 199 M00073446C:A03 22.5 Table 13 BREAST BREAST COLON COLON PROSTATEPROSTATE

SEQ PATIENTSPATIENTPATIENTSPATIENTSPATIENTSPATIENTS

ID CLONE ID >=2x S <=halfx>=2x <=halfx >=2x <=halfx 201M00073447D:F01. _ . _45 ___.. 38.1 .

204M00073453C:C0941.2 ~ _ ~ ~VT ~ ~~~~

212M00073469B:A09 27.5 _36.5 ~

216M00073474C:F08 30 22.2 220M00073484B:A05 23.5 30 22.2 228M00073497C:D03 29.4 30 233M00073513A:G0723.5 25.4 236M00073517A:A06 32.5 241M00073529A:F03 20 242M00073530B:A02 20 54.0 243M00073531B:H02 50.8 246M00073539C:H05 27.5 247M00073541B:C10 30 248M00073547B:F04__ 22.5 249M00073547C:D02 35 256M00073554B:D11 37.5 _ M00073568A:G06 32.5 264 ~

265M00073568C:G07 25 269M00073576B:E03 22.5 270M00073576C:C11 20 m~ ~m 273M00073580A:D08 32.5 280M00073598D:E11 40 284M00073601D:D08 32.5 _ 286M00073603B:C03 30 288M00073603C:C02 76.5 67.5 290M00073604B:B07 30 294M00073605B:F11 58.8 299M00073614C:F06 60 300M00073615D:E03 82.5 301M00073616A:F06 32.5 28.6 304M00073621D:A04 27.5 316M00073633D:A04 23.5 52.5 318M00073634C:H0823.5 85 39.7 319M00073635D:C10 35.3 323M00073638A:A12 47.5 ~~T

_ M00073639A:G08 27.5 _ _ 325 ~~~ ~~~~~
~~

340M00073651C:F0629.4 27.5 36.5 ____..__............_.__.__.__...._____ 342M00073652D:B11 64.7 70 343M00073655B:A04 37.5 353M00073669A:F04 20 354M00073669B:E1223.5 27.5 357M00073687A:D11 50 22.2 361M00073672D:E09 35 42.9 367M00073677B:F01 32.5 369M00073678B:H02 35 372M00073681A:F12 29.4 25.4 377M00073689C:C09 41.3 382M00073696C:D11 35.3 _ _ ~ ~~ ~~~~~~~~

384M00073697C:F11 29.4 _ 34.9 388M00073700B:D12 30 _ ~

390M00073708D:E10 23.8 Table 13 BREAST BREAST COLON COLON PROSTATEPROSTATE

SEQ PATIENTS PATIENTPATIENTS PATIENTSPATIENTSPATIENTS

ID CLONE ID >=2x S <=halfx >=2x <=halfx >=2x <=halfx 392-.M00073709B:F01_ _ _ . 25 ....._ ____..

394M00073709C:A02 22.5 398M00073713D:E07 27.5 399M00073715A:F05 20 31.7 400M00073715B:B06 ~.u 27.0 37.5 401M00073717C:A12 37.5 403M00073720D:H11 27.5 20.6 408M00073735C:E04 23.8 413M00073743C:F03 25 417M00073748B:F07 35 424M00073754B:D05 37.5 436M00073765A:E02 32.5 439M00073766B:B07 22.5 442M00073772B:E07 22.2 450M00073779B:B11 32.5 462M00073798A:H03 35 464M00073801B:A10 35 467M00073809C:E0923.5 45 25.4 469M00073813D:B06 27.0 470M00073814C:B04 71.4 473M00073790A:A12 36.5 480M00073799A:G02 37.5 481M00073799D:G04 30_ _ M00073813A:E06 32.5 487M00073813B:A01 30 493M00073822C:E02 35 494M00073824A:C04 38.1 ~

497M00073832A:A06 20 20.6 500M00073834A:H10 35 502M00073834D:H06 25 31.7 503M00073836D:E05 23.8 506M00073838B:F09 25 509M00073839A:D0523.5 47.5 41.3 513M00073850A:H09 54.0 532M00073867D:F10 36.5 533M00073871B:C12 32.5 534M00073872C:B09 22.5 ~

535M00073872D:B01 32.5 536M00073872D:E10 22.5 544M00073883B:D03 22.5 550M00073892B:F12 32.5 555M00073905B:A03 55.6 562M00073897B:B11___ _____ 30 564M00073899A:D06 32.5 _ __ __ ~~~~~

565M00073911B:G10 23.8 567M00073916A:B07 42.5 23.8 572M00073923C:A0429.4 22.5 575M00073931D:E02 27.5 577M00073936D:E05 25 579M00073908C:D09 40 27.0 599M00073944D:A07 27.5 Table 13 BREAST BREAST COLON COLON PROSTATE PROSTATE

SEQ PATIENTS PATIENT PATIENTSPATIENTS PATIENTSPATIENTS

ID CLONE ID >=2x S <=halfx >=2x <=halfx >=2x <=halfx 620M00073968B:B06 27.5 . 57.1 625M00073979C:G07 37.5 44.4 634M00073988D:F09 38.1 641M00073979B:B05 2_7.5 66.7 645M00073988C:G08_ 40_ ,~"

654M00074011D:C05 42.5 656M00074013C:C09 20 659M00074015A:C03 22.5 665M00074020D:G10 40 669M00074025A:F06 25 36.5 670M00074025B:A12 20.6 67 M00074026C:H09_ ~ 32.5 1 '~

_ M00074053C:E0530 "687 25.0 695M00074059B:G10 27.5 703M00074075B:A0927.5 706M00074079A:E07 42.5 31.7 708M00074084D:B04 33.3 710M00074085B:E06 23.8 ' ",~,~

712M00074087B:C09 28.6 ",~ '.~.W~H.""~'~
w "-713M00074087C:G05 23.8 717M00074089D:E03 20 54.0 720M00074093B:A0323.5 27.5 "~"" '~
~

_ M00074094B:F10~ 52.4 722 .

723M00074096D:G12 25.4 726M00074098C:B09 ~ 23.8 727M00074099C:B09 20 729M00074101D:D0735 730M00074102A:C04 37.5 733M00074107C:C08 35 741M00074131A:H09 37.5 27.0 742M00074132C:F10 32.5 22.2 747M00074138D:A08 45 22.2 w~ ~ m'~m _ M00074142B:C11 32.S

750M00074142D:A10 22.5 753M00074122A:B02 37.5 756M00074132A:E1122.5 757M00074132B:B07 35 20.6 758M00074134A:G11 27.5 759M00074149A:B1041.2 47.5 _ ' ~

762M00074153D:A05~ 3_7.5_ ~"~

765M00074157C:G08 25 767M00074158C:F12 37.5 769M00074159C:A05 25 777M00074174A:C02 27.5 27.0 782M00074177B:H08 35 785M00074179C:B01 27.5 28.6 787M00074184D:B01 37.5 28.6 789M00074191C:D08 57.1 790M00074192C:C10 33.3 793M00074198C:A1229.4 45 31.7 794M00074198D:D10 36.5 Table 13 BREAST BREAST COLON COLON PROSTATEPROSTATE

SEQ PATIENTS PATIENT PATIENTSPATIENTSPATIENTSPATIENTS

ID CLONE ID >=2x S <=halfx >=2x<=halfx >=2x <=halfx 800.M00074203D:F01 --..._ .. _~.40_.~ ~ _~._ ~ _ . e..

802 M00074206A:H12 40 22.2 ~

806 M00074208B:F09 2_2.5_ 41.3 811 M00074215A:F09 42.5 813 M00074216D:H03 35 819 M00074223B:D12 30 ~~

821 225A:H12 25 827 _ 30 _ M00074234A:C05 830 M00074234D:F12 37.5 834 M00074242D:F09 25 837 M00074247B:G11 27.5 839 M00074248C:E12 25.4 -.................

840 M00074249C:B11 27.5 846 M00074251C:E03 35 849 M00074253C:F03 32.5 850 M00074255B:A01 20 851 M00074258A:H12 32.5 861 M00074271B:E11 25 869 M00074280D:H03 20 31.7 870 M00074284B:B03 27.5 25.4 873 M00074288A:F11 45 20.6 874 M00074290A:G10 37.5 875 M00074290C:B05 20.6 ~. -_ 293D:B05 20 _ ~

_ _ 32.5 878 M00074293D:H07 882 M00074304B:C09 22.5 39.7 883 M00074304D:D07 _ 36.5 884 M00074306A:B09 27.5 ~~~~~~~~~~~~~~

886 M00074310D:D02 35 25.4 888 M00074315B:A03 22.5 892 M00074835A:H10 40 893 M00074835B:F12 22.5 895 M00074837A:E01 35 899 M00074843D:D02 25 65.1 900 M00074844B:B02 58.8 20 901 M00074844D:F09 30 20.6 905 M00074847B:G03 30 909 M00074852B:A02 37.5 912 M00074854A:C11 40 913 M00074855B:A05 27.5 917 M00074863D:F07 27.5 919 M00074317D:B08 20.6 920 M00074320C:A06 54.0 ~ ~

921 M00074865A:F05 20 50.8 923 M00074871C:G05 20 926 M00074879A:A02 35 22.2 930 M00074890A:E03 20 20.6 931 M00074895D:H12 20.6 934 M00074901C:E05 27.5 938 M00074905D:A01 35 30.2 941 M00074912B:A10 65.1 Table 13 BREAST BREAST COLON COLON PROSTATEPROSTATE

SEQ PATIENTSPATIENT PATIENTSPATIENTSPATIENTSPATIENTS

ID CLONE ID >=2x S <=halfx >=2x<=halfx >=2x <=halfx 943 M00074916A:H03 30 949 M00074927D:G09 22.5 954 M00074936B:E10 37.5 955 M00074939B:A06 32.5 959 M00074966D:E08 34.9 962 M00074974C:E11 22.2 964 M00074954A:H06 20 975 M00072985A:C12 20 981 M00072996B:A10 27.5 20.6 984 M00072997D:H06 40 20.6 986 M00074333D:A11 41.2 47.5 990 M00074343C:A03 30 _ ~~~~~~--~~r~~~~~~

998 M00074366A:H07 27.5 42.9 M ~11 ~~

1004 M00074392C:D02 32.5 1006 M00074417D:F07 23.5 67.5 1008 M00074406B:F10 27.5 1012 M00074391B:D02 27.5 1019 M00074461D:E04 47.5 25.4 1025 M00074488C:C08 32.5 1027 M00074501A:G07 49.2 1029 M00074515A:E02 25.4 1030 M00074515C:A11 32.5 1031 M00074516B:H03 23.8 1032 M00074525A:B05 20.6 1039 M00074561D:D12 30 28.6 1040 M00074566B:A04 35 1044 M00074555A:E10 27.5 1045 M00074561A:B09 40 _ ~ -~---- .......,.........,.._....~, ..............

1052 M00074582D:B09 25 .4 1057 M00074596D:B 20 22.2 1058 M00074606C:G0229.4 1064 M00074628C:D03 37.5 1067 M00074637A:C02 20 1068 M00074638D:C1229.4 35 1069 M00074639A:C08 30 1073 M00074662B:A05 35.3 1078 M00074676D:H07 22.5 1080 M00074681D:A02 32.5 1082 M00074699B:C03 32.5 1083 M00074701D:H09 25 1086 M00074713B:F02 20 39.7 1089 M00074723D:D05 27.5 1092 M00074740B:F06 27.5 1095 M00074752A:D08 32.5 20.6 1099 M00074765D:F06 40 1102 M00074773C:G03 20 1103 M00074774A:D03 31.7 1105 M00074780C:C02 20 1110 M00075000A:D06 32.5 1117 M00074800B:H01 35 1120 M00074825C:E06 30 Table 13 BREAST BREAST COLON COLON PROSTATEPROSTATE

SEQ PATIENTSPATIENTPATIENTS PATIENTSPATIENTS
PATIENTS

ID CLONE ID >=2x S <=haifx>=2x <=hatfx >=2x <=halfx 1122 _~ . _ ~. 30 ~..~.
M00075018A:G04 ....~

1134 32.5 M00075035C:C09 M00075045D:H03 1145 22.5 M00075153C:C11 M00075161A:E05 M00075152D:C06 1155 42.5 M00075160A:E04 1163 27.5 M00075174D:D06 1167 29.4 36.5 M00075199D:D11 M00075201D:A05 1169 35 20.6 M00075203A:G06 1179 41.2 37.5 28.6 M00075245A:A06 1189 34.9 M00075283A:F04 1198 25.0 62.5 M00075329B:E10 1203 22.5 M00075344D:A08 1224 27.5 M00075379A:E07 M00075383A:B11 M00075409A:E04 1235 35 20.6 M00075448B:G11 ~

1239 35.3 62.5 20.6 M00075460C:B06 - ....... .....

1245 32.5 M00075504B:A10 1250 32.5 M00075514A:G12 1266 20 20.6 M00075621A:F06 1386 23.5 1387 34.3 1388 23.5 67.5 1390 35.3 26.1 1400 32.5 - __._... -~- --1402 41.3 ~

1403 ~

_ 1404 30.0 28.6 1426 36.6 1427 42.9 38.2 1429 31.6 1434 55.0 1438 21.3 21.5 1439 30.0 . .~._. ._..~..w,w...~.~...__"._~._ -.~~_ ~..._.

1445 27.5 1447 29.4 32.6 1449 35.3 60.9 1461 29.4 1462 41.2 36.2 1463 27.5 1472 23.4 1474 37.5 1475 35.3 54.3 Table 15 CLONE ID ATCC# ES No. CLONE ID ATCC#
ES No.

ES 210 M00073054A:A06PTA-2376 ES 213 M00074100B:E01PTA-2379 ES 210 M00073054A:C10PTA-2376 ES 213 M00074101D:D07PTA-2379 ES 210 M00073054B:E07PTA-2376 ES 213 M00074102A:C04PTA-2379 ES 210 M00073054C:E02PTA-2376 ES 213 M00074105A:D02PTA-2379 ES 210 M00073055D:E11PTA-2376 ES 213 M00074106C:E03PTA-2379 ES 210 M00073056C:A09PTA-2376 ES 213 M00074107C:C08PTA-2379 ES 210 M00073056C:C12PTA-2376 ES 213 M00074111C:B02PTA-2379 ES 210 M00073057A:F09PTA-2376 ES 213 M00074111C:G11PTA-2379 ES 210 M00073057D:A12PTA-2376 ES 213 M00074116C:A03PTA-2379 ES 210 M00073060B:C06PTA-2376 ES 213 M00074120A:A12PTA-2379 ES 210 M00073061B:F10PTA-2376 ES 213 M00074123B:A03PTA-2379 ES 210 M00073061C:G08PTA-2376 ES 213 M00074123B:G07PTA-2379 ES 210 M00073062B:D09PTA-2376 ES 213 M00074130B:F06PTA-2379 ES 210 M00073062C:D09PTA-2376 ES 213 M00074131A:H09PTA-2379 ES 210 M00073064C:A11PTA-2376 ES 213 M00074132C:F10PTA-2379 ES 210 M00073064C:H09PTA-2376 ES 213 M00074135A:G09PTA-2379 ES 210 M00073064D:B11PTA-2376 ES 213 M00074135C:E09PTA-2379 ES 210 M00073065D:D11PTA-2376 ES 213 M00074137C:E05PTA-2379 ES 210 M00073066B:G03PTA-2376 ES 213 M00074138D:A01PTA-2379 ES 210 M00073066C:D02PTA-2376 ES 213 M00074138D:A08PTA-2379 ES 210 M00073067A:E09PTA-2376 ES 213 M00074138D:B07PTA-2379 ES 210 M00073067B:D04PTA-2376 ES 213 M00074142B:C11PTA-2379 ES 210 M00073067D:B02PTA-2376 ES 213 M00074142D:A10PTA-2379 ES 210 M00073069D:G03PTA-2376 ES 213 M00074148B:D09PTA-2379 ES 210 M00073070A:B12PTA-2376 ES 213 M00074108B:C04PTA-2379 ES 210 M00073070B:B06PTA-2376 ES 213 M00074122A:B02PTA-2379 ES 210 M00073071D:D02PTA-2376 ES 213 M00074126B:E12PTA-2379 ES 210 M00073072A:A10PTA-2376 ES 213 M00074128D:C09PTA-2379 ES 210 M00073074B:G04PTA-2376 ES 213 M00074132A:E11PTA-2379 ES 210 M00073074D:A04PTA-2376 ES 213 M00074132B:B07PTA-2379 ES 210 M00073078B:F08PTA-2376 ES 213 M00074134A:G11PTA-2379 ES 210 M00073080B:A07PTA-2376 ES 213 M00074149A:B10PTA-2379 ES 210 M00073081A:F08PTA-2376 ES 213 M00074149A:F12PTA-2379 ES 210 M00073081D:C07PTA-2376 ES 213 M00074153A:E07PTA-2379 ES 210 M00073084C:E02PTA-2376 ES 213 M00074153D:A05PTA-2379 ES 210 M00073085D:B01PTA-2376 ES 213 M00074154A:D03PTA-2379 ES 210 M00073086D:B05PTA-2376 ES 213 M00074155B:G09PTA-2379 ES 210 M00073088C:B04PTA-2376 ES 213 M00074157C:G08PTA-2379 ES 210 M00073088D:F07PTA-2376 ES 213 M00074157D:G05PTA-2379 ES 210 M00073091B:C04PTA-2376 ES 213 M00074158C:F12PTA-2379 ES 210 M00073091D:B06PTA-2376 ES 213 M00074158C:H10PTA-2379 ES 210 M00073092A:D03PTA-2376 ES 213 M00074159C:A05PTA-2379 ES 210 M00073092D:B03PTA-2376 ES 213 M00074160A:D12PTA-2379 ES 210 M00073094B:A01PTA-2376 ES 213 M00074161C:F04PTA-2379 ES 210 M00073412A:C03PTA-2376 ES 213 M00074162A:B03PTA-2379 ES 210 M00073408C:F06PTA-2376 ES 213 M00074165D:A11PTA-2379 Table 15 CLONE ID ATCC# ES No. CLONE ID ATCC#
ES No.

ES 210 M00073424D:C03PTA-2376 ES 213 M00074170A:D09PTA-2379 ES 210 M00073403B:F06PTA-2376 ES 213 M00074170D:F05PTA-2379 ES 210 M00073407A:E12PTA-2376 ES 213 M00074172B:D12PTA-2379 ES 210 M00073412A:H09PTA-2376 ES 213 M00074174A:C02PTA-2379 ES 210 M00073421C:B07PTA-2376 ES 213 M00074174C:C03PTA-2379 ES 210 M00073416B:F01PTA-2376 ES 213 M00074175D:E04PTA-2379 ES 210 M00073425A:G10PTA-2376 ES 213 M00074176A:A06PTA-2379 ES 210 M00073425A:H12PTA-2376 ES 213 M00074176A:B10PTA-2379 ES 210 M00073403C:C10PTA-2376 ES 213 M00074177B:H08PTA-2379 ES 210 M00073428D:H03PTA-2376 ES 213 M00074178B:G07PTA-2379 ES 210 M00073403C:E11PTA-2376 ES 213 M00074179A:A01PTA-2379 ES 210 M00073435B:E11PTA-2376 ES 213 M00074179C:B01PTA-2379 ES 210 M00073431A:G02PTA-2376 ES 213 M00074184D:A04PTA-2379 ES 210 M00073412C:E07PTA-2376 ES 213 M00074184D:B01PTA-2379 ES 210 M00073435C:E06PTA-2376 ES 213 M00074190B:F09PTA-2379 ES 210 M00073412D:B07PTA-2376 ES 213 M00074191C:D08PTA-2379 ES 210 M00073429B:H10PTA-2376 ES 213 M00074192C:C10PTA-2379 ES 210 M00073403C:H09PTA-2376 ES 213 M00074195D:B09PTA-2379 ES 210 M00073412D:E02PTA-2376 ES 213 M00074197C:A12PTA-2379 ES 210 M00073427B:C08PTA-2376 ES 213 M00074198C:A12PTA-2379 ES 210 M00073423C:E01PTA-2376 ES 213 M00074198D:D10PTA-2379 ES 210 M00073427B:E04PTA-2376 ES 213 M00074199A:C10PTA-2379 ES 210 M00073425D:F08PTA-2376 ES 213 M00074201A:F03PTA-2379 ES 210 M00073096B:A12PTA-2376 ES 213 M00074201C:E12PTA-2379 ES 210 M00073430C:A01PTA-2376 ES 213 M00074202A:A05PTA-2379 ES 210 M00073418B:B09PTA-2376 ES 213 M00074202B:D03PTA-2379 ES 210 M00073430C:B02PTA-2376 ES 213 M00074203D:F01PTA-2379 ES 210 M00073097C:A03PTA-2376 ES 213 M00074206A:G02PTA-2379 ES 210 M00073418B:H09PTA-2376 ES 213 M00074206A:H12PTA-2379 ES 210 M00073408A:D06PTA-2376 ES 213 M00074206B:F04PTA-2379 ES 210 M00073438A:A08PTA-2376 ES 213 M00074207D:E07PTA-2379 ES 210 M00073438A:B02PTA-2376 ES 213 M00074208B:B05PTA-2379 ES 210 M00073438D:G05PTA-2376 ES 213 M00074208B:F09PTA-2379 ES 210 M00073442A:F07PTA-2376 ES 213 M00074208D:E08PTA-2379 ES 210 M00073442B:D12PTA-2376 ES 213 M00074209D:H11PTA-2379 ES 210 M00073442D:E11PTA-2376 ES 213 M00074210B:G12PTA-2379 ES 210 M00073446C:A03PTA-2376 ES 213 M00074213A:C06PTA-2379 ES 210 M00073447B:A03PTA-2376 ES 213 M00074215A:F09PTA-2379 ES 210 M00073447D:F01PTA-2376 ES 213 M00074216C:C11PTA-2379 ES 210 M00073448B:F11PTA-2376 ES 213 M00074216D:H03PTA-2379 ES 210 M00073448B:F07PTA-2376 ES 213 M00074217A:H01PTA-2379 ES 210 M00073453C:C09PTA-2376 ES 213 M00074217C:B04PTA-2379 ES 210 M00073455C:G09PTA-2376 ES 213 M00074217C:C09PTA-2379 ES 210 M00073457A:G09PTA-2376 ES 213 M00074219D:F03PTA-2379 ES 210 M00073462C:H12PTA-2376 ES 213 M00074221B:F12PTA-2379 ES 210 M00073462D:D12PTA-2376 ES 213 M00074223B:D12PTA-2379 Table 15 CLONE ID ATCC# ES No. CLONE ID ATCC#
ES No.

ES 210 M00073464B:E01PTA-2376 ES 213 M00074224A:G06PTA-2379 ES 210 M00073464D:G12PTA-2376 ES 213 M00074225A:H12PTA-2379 ES 210 M00073465A:H08PTA-2376 ES 213 M00074226C:E06PTA-2379 ES 210 M00073469B:A09PTA-2376 ES 213 M00074230D:B05PTA-2379 ES 210 M00073469D:A06PTA-2376 ES 213 M00074231A:D10PTA-2379 ES 210 M00073470D:A01PTA-2376 ES 213 M00074231D:G11PTA-2379 ES 210 M00073474A:G11PTA-2376 ES 213 M00074232B:G06PTA-2379 ES 210 M00073474C:F08PTA-2376 ES 213 M00074234A:C05PTA-2379 ES 210 M00073475D:E05PTA-2376 ES 213 M00074234A:E07PTA-2379 ES 210 M00073478C:A07PTA-2376 ES 213 M00074234B:F07PTA-2379 ES 210 M00073483B:C07PTA-2376 ES 213 M00074234D:F12PTA-2379 ES 210 M00073484B:A05PTA-2376 ES 213 M00074235C:D06PTA-2379 ES 210 M00073484C:B04PTA-2376 ES 213 M00074236B:E06PTA-2379 ES 210 M00073486A:A12PTA-2376 ES 213 M00074236C:E11PTA-2379 ES 210 M00073487A:C07PTA-2376 ES 213 M00074242D:F09PTA-2379 ES 210 M00073489B:A07PTA-2376 ES 213 M00074243A:H08PTA-2379 ES 210 M00073493A:E12PTA-2376 ES 213 M00074243C:B06PTA-2379 ES 210 M00073493D:F05PTA-2376 ES 213 M00074244C:B11PTA-2379 ES 210 M00073495B:G11PTA-2376 ES 213 M00074247B:G11PTA-2379 ES 210 M00073497C:D03PTA-2376 ES 213 M00074247C:E02PTA-2379 ES 210 M00073504D:F03PTA-2376 ES 213 M00074248C:E12PTA-2379 ES 210 M00073505D:F01PTA-2376 ES 213 M00074249C:B11PTA-2379 ES 210 M00073509B:B11PTA-2376 ES 213 M00074249C:H08PTA-2379 ES 210 M00073509B:E03PTA-2376 ES 213 M00074250D:E06PTA-2379 ES 210 M00073513A:G07PTA-2376 ES 213 M00074260D:F06PTA-2379 ES 210 M00073513D:A11PTA-2376 ES 213 M00074251B:F08PTA-2379 ES 210 M00073515A:F09PTA-2376 ES 213 M00074251C:B06PTA-2379 ES 210 M00073517A:A06PTA-2376 ES 213 M00074251C:E03PTA-2379 ES 210 M00073517D:F11PTA-2376 ES 213 M00074251D:E03PTA-2379 ES 210 M00073520D:A04PTA-2376 ES 213 M00074252C:E02PTA-2379 ES 210 M00073524A:A03PTA-2376 ES 213 M00074253C:F03PTA-2379 ES 210 M00073524A:G05PTA-2376 ES 213 M00074255B:A01PTA-2379 ES 210 M00073529A:F03PTA-2376 ES 213 M00074258A:H12PTA-2379 ES 210 M00073530B:A02PTA-2376 ES 213 M00074258A:H09PTA-2379 ES 210 M00073531B:H02PTA-2376 ES 213 M00074259C:G08PTA-2379 ES 210 M00073531C:F12PTA-2376 ES 213 M00074260B:A11PTA-2379 ES 210 M00073537B:A12PTA-2376 ES 213 M00074265B:C07PTA-2379 ES 210 M00073539C:H05PTA-2376 ES 213 M00074266A:D01PTA-2379 ES 210 M00073541B:C10PTA-2376 ES 213 M00074267A:B04PTA-2379 ES 210 M00073547B:F04PTA-2376 ES 213 M00074268A:D08PTA-2379 ES 210 M00073547C:D02PTA-2376 ES 213 M00074268C:G03PTA-2379 ES 210 M00073549B:B03PTA-2376 ES 213 M00074270B:A01PTA-2379 ES 210 M00073551B:E10PTA-2376 ES 213 M00074271B:E11PTA-2379 ES 210 M00073552A:F06PTA-2376 ES 214 M00072971A:E04PTA-2380 ES 210 M00073554A:C01PTA-2376 ES 214 M00072971A:F11PTA-2380 ES 210 M00073554A:G04PTA-2376 ES 214 M00072971C:B07PTA-2380 Table 15 CLONE ID ATCC# ES No. CLONE ID ATCC#
ES No.

ES 210 M00073554B:A08PTA-2376 ES 214 M00072972A:C03PTA-2380 ES 210 M00073554B:D11PTA-2376 ES 214 M00072974A:A11PTA-2380 ES 210 M00073555A:B09PTA-2376 ES 214 M00072974D:B04PTA-2380 ES 210 M00073555D:B04PTA-2376 ES 214 M00072975A:D11PTA-2380 ES 210 M00073557A:A05PTA-2376 ES 214 M00072975A:E02PTA-2380 ES 210 M00073558A:A02PTA-2376 ES 214 M00072977A:F06PTA-2380 ES 210 M00073561C:A04PTA-2376 ES 214 M00072977B:C05PTA-2380 ES 210 M00073565D:E05PTA-2376 ES 214 M00072980B:C05PTA-2380 ES 210 M00073566A:G01PTA-2376 ES 214 M00072980B:G01PTA-2380 ES 210 M00073568A:G06PTA-2376 ES 214 M00073001A:F07PTA-2380 ES 210 M00073568C:G07PTA-2376 ES 214 M00073001B:E07PTA-2380 ES 210 M00073569A:H02PTA-2376 ES 214 M00073002B:B12PTA-2380 ES 210 M00073571A:F12PTA-2376 ES 214 M00073002D:B08PTA-2380 ES 210 M00073575B:H12PTA-2376 ES 214 M00073003A:E06PTA-2380 ES 210 M00073576B:E03PTA-2376 ES 214 M00073003B:E10PTA-2380 ES 210 M00073576C:C11PTA-2376 ES 214 M00073003B:H01PTA-2380 ES 210 M00073577B:D12PTA-2376 ES 214 M00073003C:C05PTA-2380 ES 210 M00073579B:A04PTA-2376 ES 214 M00073006A:H08PTA-2380 ES 210 M00073580A:D08PTA-2376 ES 214 M00073006C:D07PTA-2380 ES 210 M00073587D:E12PTA-2376 ES 214 M00073007D:E05PTA-2380 ES 210 M00073588B:H07PTA-2376 ES 214 M00073009B:C08PTA-2380 ES 210 M00073590C:F07PTA-2376 ES 214 M00073009D:A02PTA-2380 ES 210 M00073592B:D09PTA-2376 ES 214 M00073012A:C11PTA-2380 ES 210 M00073594B:B11PTA-2376 ES 214 M00073013A:D10PTA-2380 ES 210 M00073595D:A11PTA-2376 ES 214 M00073013A:F10PTA-2380 ES 210 M00073598D:E11PTA-2376 ES 214 M00073013C:B10PTA-2380 ES 210 M00073599C:E08PTA-2376 ES 214 M00073013C:G05PTA-2380 ES 210 M00073601A:B06PTA-2376 ES 214 M00073014D:F01PTA-2380 ES 210 M00073601A:F07PTA-2376 ES 214 M00073015A:E12PTA-2380 ES 210 M00073601D:D08PTA-2376 ES 214 M00073015A:H06PTA-2380 ES 210 M00073603A:F04PTA-2376 ES 214 M00073015B:A05PTA-2380 ES 210 M00073603B:C03PTA-2376 ES 214 M00073015C:E10PTA-2380 ES 210 M00073603C:A11PTA-2376 ES 214 M00073017A:D06PTA-2380 ES 210 M00073603C:C02PTA-2376 ES 214 M00073017A:F03PTA-2380 ES 210 M00073603D:E07PTA-2376 ES 214 M00073019A:H12PTA-2380 ES 210 M00073604B:B07PTA-2376 ES 214 M00073019B:B12PTA-2380 ES 210 M00073604B:H06PTA-2376 ES 214 M00073020C:F07PTA-2380 ES 210 M00073604C:H09PTA-2376 ES 214 M00073020D:C06PTA-2380 ES 210 M00073605B:F10PTA-2376 ES 214 M00073021C:E04PTA-2380 ES 210 M00073605B:F11PTA-2376 ES 214 M00073021D:C03PTA-2380 ES 210 M00073606D:F12PTA-2376 ES 214 M00073023A:D10PTA-2380 ES 210 M00073610A:F06PTA-2376 ES 214 M00073025A:E11PTA-2380 ES 210 M00073614B:A12PTA-2376 ES 214 M00073026B:F01PTA-2380 ES 210 M00073614B:G09PTA-2376 ES 214 M00073026D:G04PTA-2380 ES 210 M00073614C:F06PTA-2376 ES 214 M00073027B:H12PTA-2380 ES 210 M00073615D:E03PTA-2376 ES 214 M00073030A:G05PTA-2380 Table 15 CLONE ID ATCC# ES No. CLONE ID ATCC#
ES No.

ES 210 M00073616A:F06PTA-2376 ES 214 M00073030B:C02PTA-2380 ES 210 M00073617A:H04PTA-2376 ES 214 M00073030C:A02PTA-2380 ES 210 M00073620A:G05PTA-2376 ES 214 M00073036C:H10PTA-2380 ES 210 M00073621D:A04PTA-2376 ES 214 M00073037A:C06PTA-2380 ES 210 M00073621D:D02PTA-2376 ES 214 M00073037D:H02PTA-2380 ES 210 M00073621D:H05PTA-2376 ES 214 M00073038C:C07PTA-2380 ES 210 M00073623D:H10PTA-2376 ES 214 M00073038D:D12PTA-2380 ES 210 M00073625C:D09PTA-2376 ES 214 M00073038D:F10PTA-2380 ES 211 M00073626D:A01PTA-2377 ES 214 M00073039A:D09PTA-2380 ES 211 M00073628A:E03PTA-2377 ES 214 M00073039C:B10PTA-2380 ES 211 M00073630A:C03PTA-2377 ES 214 M00073040A:B02PTA-2380 ES 211 M00073630B:E09PTA-2377 ES 214 M00073040D:F05PTA-2380 ES 211 M00073630C:D02PTA-2377 ES 214 M00073043B:C10PTA-2380 ES 211 M00073632A:B12PTA-2377 ES 214 M00073043B:E08PTA-2380 ES 211 M00073632C:A03PTA-2377 ES 214 M00073043C:F04PTA-2380 ES 211 M00073633D:A04PTA-2377 ES 214 M00073043D:H09PTA-2380 ES 211 M00073633D:G04PTA-2377 ES 214 M00073044B:F08PTA-2380 ES 211 M00073634C:H08PTA-2377 ES 214 M00073044C:C12PTA-2380 ES 211 M00073635D:C10PTA-2377 ES 214 M00073044C:D08PTA-2380 ES 211 M00073636C:F03PTA-2377 ES 214 M00073044C:G12PTA-2380 ES 211 M00073637C:B01PTA-2377 ES 214 M00073044D:F08PTA-2380 ES 211 M00073637C:E04PTA-2377 ES 214 M00073045B:A03PTA-2380 ES 211 M00073638A:A12PTA-2377 ES 214 M00073045B:D06PTA-2380 ES 211 M00073638D:D10PTA-2377 ES 214 M00073045C:E06PTA-2380 ES 211 M00073639A:G08PTA-2377 ES 214 M00073045C:E07PTA-2380 ES 211 M00073639B:F02PTA-2377 ES 214 M00073045D:B04PTA-2380 ES 211 M00073634B:C12PTA-2377 ES 214 M00073046A:A05PTA-2380 ES 211 M00073640B:G08PTA-2377 ES 214 M00073046A:A06PTA-2380 ES 211.M00073640C:A03PTA-2377 ES 214 M00073046B:A12PTA-2380 ES 211 M00073640D:A11PTA-2377 ES 214 M00073046D:F04PTA-2380 ES 211 M00073640D:G07PTA-2377 ES 214 M00073047B:E10PTA-2380 ES 211 M00073641B:G07PTA-2377 ES 214 M00073047C:G01PTA-2380 ES 211 M00073641C:E04PTA-2377 ES 214 M00073048A:H05PTA-2380 ES 211 M00073643B:E11PTA-2377 ES 214 M00073048C:A11PTA-2380 ES 211 M00073644A:G12PTA-2377 ES 214 M00073048C:B01PTA-2380 ES 211 M00073646A:C01PTA-2377 ES 214 M00073048C:E11PTA-2380 ES 211 M00073647B:H07PTA-2377 ES 214 M00073049A:H04PTA-2380 ES 211 M00073649A:A03PTA-2377 ES 214 M00073049B:B03PTA-2380 ES 211 M00073649A:G08PTA-2377 ES 214 M00073049B:B06PTA-2380 ES 211 M00073651C:F06PTA-2377 ES 214 M00073049C:C09PTA-2380 ES 211 M00073651C:H07PTA-2377 ES 214 M00073049C:H07PTA-2380 ES 211 M00073652D:B11PTA-2377 ES 214 M00073050A:D09PTA-2380 ES 211 M00073655B:A04PTA-2377 ES 214 M00073051A:D07PTA-2380 ES 211 M00073657B:D05PTA-2377 ES 214 M00073051A:F12PTA-2380 ES 211 M00073659C:D03PTA-2377 ES 214 M00073051A:F07PTA-2380 ES 211 M00073663A:E02PTA-2377 ES 214 M00073052B:H12PTA-2380 Table 15 CLONE ID ATCC# ES No. CLONE ID ATCC#
ES No.

ES 211 M00073663D:G06PTA-2377 ES 214 M00074273B:B03PTA-2380 ES 211 M00073664A:E03PTA-2377 ES 214 M00074275A:B04PTA-2380 ES 211 M00073666B:B01PTA-2377 ES 214 M00074276A:A12PTA-2380 ES 211 M00073668A:H03PTA-2377 ES 214 M00074276A:E02PTA-2380 ES 211 M00073668B:A08PTA-2377 ES 214 M00074278B:D07PTA-2380 ES 211 M00073668D:D10PTA-2377 ES 214 M00074278D:E07PTA-2380 ES 211 M00073669A:F04PTA-2377 ES 214 M00074279C:C11PTA-2380 ES 211 M00073669B:E12PTA-2377 ES 214 M00074280D:H03PTA-2380 ES 211 M00073669D:G10PTA-2377 ES 214 M00074284B:B03PTA-2380 ES 211 M00073671B:D09PTA-2377 ES 214 M00074284C:B06PTA-2380 ES 211 M00073687A:D11PTA-2377 ES 214 M00074284C:E12PTA-2380 ES 211 M00073699C:E02PTA-2377 ES 214 M00074288A:F11PTA-2380 ES 211 M00073701D:G10PTA-2377 ES 214 M00074290A:G10PTA-2380 ES 211 M00073672D:B07PTA-2377 ES 214 M00074290C:B05PTA-2380 ES 211 M00073672D:E09PTA-2377 ES 214 M00074292D:B04PTA-2380 ES 211 M00073673A:D11PTA-2377 ES 214 M00074293D:B05PTA-2380 ES 211 M00073673D:H03PTA-2377 ES 214 M00074293D:H07PTA-2380 ES 211 M00073674D:F10PTA-2377 ES 214 M00074296C:G09PTA-2380 ES 211 M00073676A:G08PTA-2377 ES 214 M00074299B:F01PTA-2380 ES 211 M00073676D:H04PTA-2377 ES 214 M00074302D:G10PTA-2380 ES 211 M00073677B:F01PTA-2377 ES 214 M00074304B:C09PTA-2380 ES 211 M00073678B:E08PTA-2377 ES 214 M00074304D:D07PTA-2380 ES 211 M00073678B:H02PTA-2377 ES 214 M00074306A:B09PTA-2380 ES 211 M00073679A:D06PTA-2377 ES 214 M00074306B:H01PTA-2380 ES 211 M00073680D:F11PTA-2377 ES 214 M00074310D:D02PTA-2380 ES 211 M00073681A:F12PTA-2377 ES 214 M00074314A:C06PTA-2380 ES 211 M00073684B:F10PTA-2377 ES 214 M00074315B:A03PTA-2380 ES 211 M00073685A:F07PTA-2377 ES 214 M00074317C:C01PTA-2380 ES 211 M00073688C:A12PTA-2377 ES 214 M00074319C:H03PTA-2380 ES 211 M00073688D:C11PTA-2377 ES 214 M00074320C:B07PTA-2380 ES 211 M00073689C:C09PTA-2377 ES 214 M00074832B:E05PTA-2380 ES 211 M00073690B:G04PTA-2377 ES 214 M00074835A:H10PTA-2380 ES 211 M00073691A:G02PTA-2377 ES 214 M00074835B:F12PTA-2380 ES 211 M00073692D:H02PTA-2377 ES 214 M00074837A:B06PTA-2380 ES 211 M00073695C:D11PTA-2377 ES 214 M00074837A:E01PTA-2380 ES 211 M00073696C:D11PTA-2377 ES 214 M00074838B:E11PTA-2380 ES 211 M00073696D:A08PTA-2377 ES 214 M00074838D:B06PTA-2380 ES 211 M00073697C:F11PTA-2377 ES 214 M00074843A:C06PTA-2380 ES 211 M00073699B:D02PTA-2377 ES 214 M00074843A:F11PTA-2380 ES 211 M00073699B:D09PTA-2377 ES 214 M00074843D:D02PTA-2380 ES 211 M00073700A:C09PTA-2377 ES 214 M00074844B:B02PTA-2380 ES 211 M00073700B:D12PTA-2377 ES 214 M00074844D:F09PTA-2380 ES 211 M00073707B:G08PTA-2377 ES 214 M00074845A:D12PTA-2380 ES 211 M00073708D:E10PTA-2377 ES 214 M00074845B:F07PTA-2380 ES 211 M00073708D:F03PTA-2377 ES 214 M00074845D:D07PTA-2380 ES 211 M00073709B:F01PTA-2377 ES 214 M00074847B:G03PTA-2380 Table 15 CLONE ID ATCC# ES No. CLONE ID ATCC#
ES No.

ES 211 M00073709C:A01PTA-2377 ES 214 M00074847D:E07PTA-2380 ES 211 M00073709C:A02PTA-2377 ES 214 M00074849C:A04PTA-2380 ES 211 M00073710B:A09PTA-2377 ES 214 M00074852A:B01PTA-2380 ES 211 M00073710D:G06PTA-2377 ES 214 M00074852B:A02PTA-2380 ES 211 M00073711C:E12PTA-2377 ES 214 M00074852D:D08PTA-2380 ES 211 M00073713D:E07PTA-2377 ES 214 M00074853A:D05PTA-2380 ES 211 M00073715A:F05PTA-2377 ES 214 M00074854A:C11PTA-2380 ES 211 M00073715B:B06PTA-2377 ES 214 M00074855B:A05PTA-2380 ES 211 M00073717C:A12PTA-2377 ES 214 M00074857D:B02PTA-2380 ES 211 M00073718A:F11PTA-2377 ES 214 M00074858B:E05PTA-2380 ES 211 M00073720D:H11PTA-2377 ES 214 M00074861D:D01PTA-2380 ES 211 M00073724D:F04PTA-2377 ES 214 M00074863D:F07PTA-2380 ES 211 M00073732C:B09PTA-2377 ES 214 M00074864C:B09PTA-2380 ES 211 M00073733A:A05PTA-2377 ES 214 M00074317D:B08PTA-2380 ES 211 M00073733A:E03PTA-2377 ES 214 M00074320C:A06PTA-2380 ES 211 M00073735C:E04PTA-2377 ES 214 M00074865A:F05PTA-2380 ES 211 M00073737A:C12PTA-2377 ES 214 M00074869C:D04PTA-2380 ES 211 M00073739D:B04PTA-2377 ES 214 M00074871C:G05PTA-2380 ES 211 M00073740B:F08PTA-2377 ES 214 M00074874A:G07PTA-2380 ES 211 M00073741A:B01PTA-2377 ES 214 M00074875B:E08PTA-2380 ES 211 M00073741C:D05PTA-2377 ES 214 M00074879A:A02PTA-2380 ES 211 M00073743C:F03PTA-2377 ES 214 M00074879C:D02PTA-2380 ES 211 M00073746A:H03PTA-2377 ES 214 M00074884C:F10PTA-2380 ES 211 M00073748A:F09PTA-2377 ES 214 M00074887A:F03PTA-2380 ES 211 M00073748B:A12PTA-2377 ES 214 M00074890A:E03PTA-2380 ES 211 M00073748B:F07PTA-2377 ES 214 M00074895D:H12PTA-2380 ES 211 M00073750A:E08PTA-2377 ES 214 M00074898B:B01PTA-2380 ES 211 M00073750A:H08PTA-2377 ES 214 M00074900C:E10PTA-2380 ES 211 M00073750B:D05PTA-2377 ES 214 M00074901C:E05PTA-2380 ES 211 M00073750C:G06PTA-2377 ES 214 M00074903D:C04PTA-2380 ES 211 M00073751D:A06PTA-2377 ES 214 M00074904A:E11PTA-2380 ES 211 M00073753B:B05PTA-2377 ES 214 M00074904B:B07PTA-2380 ES 211 M00073754B:D05PTA-2377 ES 214 M00074905D:A01PTA-2380 ES 211 M00073754B:H02PTA-2377 ES 214 M00074906B:H12PTA-2380 ES 211 M00073754C:C01PTA-2377 ES 214 M00074906D:G02PTA-2380 ES 211 M00073758C:G03PTA-2377 ES 214 M00074912B:A10PTA-2380 ES 211 M00073760B:B11PTA-2377 ES 214 M00074912D:H08PTA-2380 ES 211 M00073760D:F04PTA-2377 ES 214 M00074916A:H03PTA-2380 ES 211 M00073762A:B09PTA-2377 ES 214 M00074919C:A08PTA-2380 ES 211 M00073762D:C02PTA-2377 ES 214 M00074921C:E05PTA-2380 ES 211 M00073763A:D06PTA-2377 ES 214 M00074922A:D06PTA-2380 ES 211 M00073764B:B09PTA-2377 ES 214 M00074927A:D02PTA-2380 ES 211 M00073764D:A07PTA-2377 ES 214 M00074927B:G08PTA-2380 ES 211 M00073764D:B12PTA-2377 ES 214 M00074927D:G09PTA-2380 ES 211 M00073765A:E02PTA-2377 ES 214 M00074929D:D04PTA-2380 ES 211 M00073765C:B01PTA-2377 ES 214 M00074930C:D11PTA-2380 Table 15 CLONE ID ATCC# ES No. CLONE ID ATCC#
ES No.

ES 211 M00073766A:B07PTA-2377 ES 214 M00074933A:D04PTA-2380 ES 211 M00073766B:B07PTA-2377 ES 214 M00074935A:C01PTA-2380 ES 211 M00073766B:C04PTA-2377 ES 214 M00074936B:E10PTA-2380 ES 211 M00073769D:G10PTA-2377 ES 214 M00074939B:A06PTA-2380 ES 211 M00073772B:E07PTA-2377 ES 214 M00074940C:H08PTA-2380 ES 211 M00073773A:F05PTA-2377 ES 215 M00074950A:D01PTA-2381 ES 211 M00073773A:G04PTA-2377 ES 215 M00074958D:H10PTA-2381 ES 211 M00073773B:A09PTA-2377 ES 215 M00074966D:E08PTA-2381 ES 211 M00073774C:G12PTA-2377 ES 215 M00074967B:A11PTA-2381 ES 211 M00073776C:F11PTA-2377 ES 215 M00074968D:A02PTA-2381 ES 211 M00073777A:A01PTA-2377 ES 215 M00074974C:E11PTA-2381 ES 211 M00073777A:H03PTA-2377 ES 215 M00074980D:E07PTA-2381 ES 211 M00073779B:B11PTA-2377 ES 215 M00074954A:H06PTA-2381 ES 211 M00073784A:A12PTA-2377 ES 215 M00074954B:E03PTA-2381 ES 211 M00073785C:A05PTA-2377 ES 215 M00074957D:F11PTA-2381 ES 211 M00073785D:D01PTA-2377 ES 215 M00074962B:F08PTA-2381 ES 211 M00073787D:H12PTA-2377 ES 215 M00074968A:D09PTA-2381 ES 211 M00073788C:A10PTA-2377 ES 215 M00074973A:H03PTA-2381 ES 211 M00073790C:E07PTA-2377 ES 215 M00072987B:A03PTA-2381 ES 211 M00073793C:E09PTA-2377 ES 215 M00072997B:H03PTA-2381 ES 211 M00073795A:F03PTA-2377 ES 215 M00072951C:C11PTA-2381 ES 211 M00073795B:B05PTA-2377 ES 215 M00072953B:G03PTA-2381 ES 211 M00073795B:B09PTA-2377 ES 215 M00072982D:B03PTA-2381 ES 211 M00073796A:C03PTA-2377 ES 215 M00072985A:C12PTA-2381 ES 211 M00073798A:H03PTA-2377 ES 215 M00072985B:D03PTA-2381 ES 211 M00073800D:F08PTA-2377 ES 215 M00072986A:C03PTA-2381 ES 211 M00073801B:A10PTA-2377 ES 215 M00072993B:D06PTA-2381 ES 211 M00073802D:B11PTA-2377 ES 215 M00072995C:D07PTA-2381 ES 211 M00073806D:C09PTA-2377 ES 215 M00072995D:C09PTA-2381 ES 211 M00073809C:E09PTA-2377 ES 215 M00072996B:A10PTA-2381 ES 211 M00073810C:F05PTA-2377 ES 215 M00072996C:C04PTA-2381 ES 211 M00073813D:B06PTA-2377 ES 215 M00072997D:F08PTA-2381 ES 211 M00073814C:B04PTA-2377 ES 215 M00072997D:H06PTA-2381 ES 211 M00073786D:B03PTA-2377 ES 215 M00074323D:F09PTA-2381 ES 211 M00073789C:B06PTA-2377 ES 215 M00074333D:A11PTA-2381 ES 211 M00073790A:A12PTA-2377 ES 215 M00074335A:H08PTA-2381 ES 211 M00073792B:A03PTA-2377 ES 215 M00074337A:G08PTA-2381 ES 211 M00073794B:G09PTA-2377 ES 215 M00074340B:D06PTA-2381 ES 211 M00073794D:G07PTA-2377 ES 215 M00074343C:A03PTA-2381 ES 211 M00073796A:D08PTA-2377 ES 215 M00074346A:H09PTA-2381 ES 211 M00073796B:A03PTA-2377 ES 215 M00074347B:F11PTA-2381 ES 211 M00073799A:A09PTA-2377 ES 215 M00074349A:E08PTA-2381 ES 211 M00073799A:G02PTA-2377 ES 215 M00074355D:H06PTA-2381 ES 211 M00073799D:G04PTA-2377 ES 215 M00074361C:B01PTA-2381 ES 211 M00073803B:B03PTA-2377 ES 215 M00074365A:E09PTA-2381 ES 211 M00073803B:C06PTA-2377 ES 215 M00074366A:D07PTA-2381 Table 15 CLONE ID ATCC# ES No. CLONE ID ATCC#
ES No.

ES 211 M00073810B:G10PTA-2377 ES 215 M00074366A:H07PTA-2381 ES 211 M00073810C:A06PTA-2377 ES 215 M00074370D:G09PTA-2381 ES 211 M00073813A:E06PTA-2377 ES 215 M00074375D:E05PTA-2381 ES 211 M00073813B:A01PTA-2377 ES 215 M00074382D:F04PTA-2381 ES 211 M00073815D:E02PTA-2377 ES 215 M00074384D:G07PTA-2381 ES 211 M00073818A:A06PTA-2377 ES 215 M00074388B:E07PTA-2381 ES 211 M00073819D:C11PTA-2377 ES 215 M00074392C:D02PTA-2381 ES 211 M00073821A:B10PTA-2377 ES 215 M00074405B:A04PTA-2381 ES 211 M00073821B:H03PTA-2377 ES 215 M00074417D:F07PTA-2381 ES 211 M00073822C:E02PTA-2377 ES 215 M00074392D:D01PTA-2381 ES 211 M00073824A:C04PTA-2377 ES 215 M00074406B:F10PTA-2381 ES 211 M00073826B:C01PTA-2377 ES 215 M00074430D:G09PTA-2381 ES 211 M00073831B:H09PTA-2377 ES 215 M00074395A:B11PTA-2381 ES 211 M00073832A:A06PTA-2377 ES 215 M00074404B:H01PTA-2381 ES 211 M00073832A:G01PTA-2377 ES 215 M00074391B:D02PTA-2381 ES 211 M00073832B:B05PTA-2377 ES 215 M00074390C:E04PTA-2381 ES 212 M00073834A:H10PTA-2378 ES 215 M00074411B:G07PTA-2381 ES 212 M00073834D:E07PTA-2378 ES 215 M00074415B:A01PTA-2381 ES 212 M00073834D:H06PTA-2378 ES 215 M00074453B:H03PTA-2381 ES 212 M00073836D:E05PTA-2378 ES 215 M00074453C:E09PTA-2381 ES 212 M00073837B:D12PTA-2378 ES 215 M00074454A:D08PTA-2381 ES 212 M00073838A:H07PTA-2378 ES 215 M00074461D:E04PTA-2381 ES 212 M00073838B:F09PTA-2378 ES 215 M00074463B:C03PTA-2381 ES 212 M00073838B:H06PTA-2378 ES 215 M00074468B:C03PTA-2381 ES 212 M00073838D:E01PTA-2378 ES 215 M00074473D:H09PTA-2381 ES 212 M00073839A:D05PTA-2378 ES 215 M00074474B:F02PTA-2381 ES 212 M00073840D:C08PTA-2378 ES 215 M00074488C:C10PTA-2381 ES 212 M00073841A:A03PTA-2378 ES 215 M00074488C:C08PTA-2381 ES 212 M00073845D:F05PTA-2378 ES 215 M00074492A:F11PTA-2381 ES 212 M00073850A:H09PTA-2378 ES 215 M00074501A:G07PTA-2381 ES 212 M00073850D:G04PTA-2378 ES 215 M00074502C:B08PTA-2381 ES 212 M00073851A:C05PTA-2378 ES 215 M00074515A:E02PTA-2381 ES 212 M00073851A:E04PTA-2378 ES 215 M00074515C:A11PTA-2381 ES 212 M00073853C:A01PTA-2378 ES 215 M00074516B:H03PTA-2381 ES 212 M00073854B:B04PTA-2378 ES 215 M00074525A:B05PTA-2381 ES 212 M00073854C:F08PTA-2378 ES 215 M00074533A:D07PTA-2381 ES 212 M00073857A:B12PTA-2378 ES 215 M00074539D:A10PTA-238.1 ES 212 M00073859A:C09PTA-2378 ES 215 M00074540B:H07PTA-2381 ES 212 M00073860B:F12PTA-2378 ES 215 M00074541D:E07PTA-2381 ES 212 M00073861D:A09PTA-2378 ES 215 M00074549B:A06PTA-2381 ES 212 M00073861D:D08PTA-2378 ES 215 M00074557A:G08PTA-2381 ES 212 M00073862B:D11PTA-2378 ES 215 M00074561D:D12PTA-2381 ES 212 M00073862D:F06PTA-2378 ES 215 M00074566B:A04PTA-2381 ES 212 M00073863B:G09PTA-2378 ES 215 M00074569D:D04PTA-2381 ES 212 M00073863C:D04PTA-2378 ES 215 M00074521D:F01PTA-2381 ES 212 M00073865B:G04PTA-2378 ES 215 M00074549C:H08PTA-2381 Table 15 CLONE ID ATCC# ES No. CLONE ID ATCC#
ES No.

ES 212 M00073866A:G07PTA-2378 ES 215 M00074555A:E10PTA-2381 ES 212 M00073867B:E01PTA-2378 ES 215 M00074561A:B09PTA-2381 ES 212 M00073867D:F10PTA-2378 ES 215 M00074565A:D08PTA-2381 ES 212 M00073871B:C12PTA-2378 ES 215 M00074571D:F02PTA-2381 ES 212 M00073872C:B09PTA-2378 ES 215 M00074573A:H02PTA-2381 ES 212 M00073872D:B01PTA-2378 ES 215 M00074577B:B12PTA-2381 ES 212 M00073872D:E10PTA-2378 ES 215 M00074577C:A05PTA-2381 ES 212 M00073873C:A06PTA-2378 ES 215 M00074582C:C02PTA-2381 ES 212 M00073875A:B03PTA-2378 ES 215 M00074582D:B09PTA-2381 ES 212 M00073875C:G02PTA-2378 ES 215 M00074584D:C01PTA-2381 ES 212 M00073878C:A03PTA-2378 ES 215 M00074588C:H06PTA-2381 ES 212 M00073879D:B08PTA-2378 ES 215 M00074589A:E10PTA-2381 ES 212 M00073880B:B02PTA-2378 ES 215 M00074593A:F05PTA-2381 ES 212 M00073880B:B09PTA-2378 ES 215 M00074596D:B12PTA-2381 ES 212 M00073883B:D03PTA-2378 ES 215 M00074606C:G02PTA-2381 ES 212 M00073883B:H03PTA-2378 ES 215 M00074607D:A12PTA-2381 ES 212 M00073886C:C12PTA-2378 ES 215 M00074613D:F0.1PTA-2381 ES 212 M00073889B:G08PTA-2378 ES 215 M00074614B:D10PTA-2381 ES 212 M00073891A:A06PTA-2378 ES 215 M00074625A:C12PTA-2381 ES 212 M00073892A:E02PTA-2378 ES 215 M00074628C:C11PTA-2381 ES 212 M00073892B:F12PTA-2378 ES 215 M00074628C:D03PTA-2381 ES 212 M00073893D:A04PTA-2378 ES 215 M00074633A:B09PTA-2381 ES 212 M00073895C:F02PTA-2378 ES 215 M00074636D:C01PTA-2381 ES 212 M00073896A:F07PTA-2378 ES 215 M00074637A:C02PTA-2381 ES 212 M00073899C:E12PTA-2378 ES 215 M00074638D:C12PTA-2381 ES 212 M00073905B:A03PTA-2378 ES 215 M00074639A:C08PTA-2381 ES 212 M00073905D:C11PTA-2378 ES 215 M00074640D:F07PTA-2381 ES 212 M00073907B:B06PTA-2378 ES 215 M00074645C:B07PTA-2381 ES 212 M00073884D:B06PTA-2378 ES 215 M00074654D:B05PTA-2381 ES 212 M00073888C:C10PTA-2378 ES 215 M00074662B:A05PTA-2381 ES 212 M00073891C:A12PTA-2378 ES 215 M00074662D:D01PTA-2381 ES 212 M00073893B:C08PTA-2378 ES 215 M00074664C:G09PTA-2381 ES 212 M00073897B:B11PTA-2378 ES 215 M00074668D:D04PTA-2381 ES 212 M00073899A:C02PTA-2378 ES 215 M00074674D:D02PTA-2381 ES 212 M00073899A:D06PTA-2378 ES 215 M00074676D:H07PTA-2381 ES 212 M00073911B:G10PTA-2378 ES 215 M00074681C:G11PTA-2381 ES 212 M00073912B:C04PTA-2378 ES 215 M00074681D:A02PTA-2381 ES 212 M00073916A:B07PTA-2378 ES 215 M00074687B:E01PTA-2381 ES 212 M00073917B:B07PTA-2378 ES 215 M00074699B:C03PTA-2381 ES 212 M00073918C:B03PTA-2378 ES 215 M00074701D:H09PTA-2381 ES 212 M00073921B:H12PTA-2378 ES 215 M00074702B:F12PTA-2381 ES 212 M00073922C:E02PTA-2378 ES 215 M00074702D:H05PTA-2381 ES 212 M00073923C:A04PTA-2378 ES 215 M00074713B:F02PTA-2381 ES 212 M00073924B:H03PTA-2378 ES 215 M00074716C:H07PTA-2381 ES 212 M00073927D:E09PTA-2378 ES 215 M00074723D:C06PTA-2381 ES 212 M00073931D:E02PTA-2378 ES 215 M00074723D:D05PTA-2381 Table 15 CLONE ID ATCC# ES No. CLONE ID ATCC#
ES No.

ES 212 M00073932D:G05PTA-2378 ES 215 M00074728C:B08PTA-2381 ES 212 M00073936D:E05PTA-2378 ES 215 M00074730B:A04PTA-2381 ES 212 M00073938B:D11PTA-2378 ES 215 M00074740B:F06PTA-2381 ES 212 M00073908C:D09PTA-2378 ES 215 M00074744B:B12PTA-2381 ES 212 M00073916C:H11PTA-2378 ES 215 M00074748C:G02PTA-2381 ES 212 M00073918A:F07PTA-2378 ES 215 M00074752A:D08PTA-2381 ES 212 M00073918A:G12PTA-2378 ES 215 M00074753C:E10PTA-2381 ES 212 M00073919C:B04PTA-2378 ES 215 M00074755A:B10PTA-2381 ES 212 M00073920D:F08PTA-2378 ES 215 M00074755A:E07PTA-2381 ES 212 M00073922D:G04PTA-2378 ES 215 M00074765D:F06PTA-2381 ES 212 M00073924C:G05PTA-2378 ES 215 M00074766C:F12PTA-2381 ES 212 M00073927C:B07PTA-2378 ES 215 M00074768C:A05PTA-2381 ES 212 M00073933B:B12PTA-2378 ES 215 M00074773C:G03PTA-2381 ES 212 M00073938B:F09PTA-2378 ES 215 M00074774A:D03PTA-2381 ES 212 M00073941B:A06PTA-2378 ES 215 M00074777A:E01PTA-2381 ES 212 M00073941D:H09PTA-2378 ES 215 M00074780C:C02PTA-2381 ES 212 M00073942B:C01PTA-2378 ES 215 M00074782A:E04PTA-2381 ES 212 M00073942C:E04PTA-2378 ES 215 M00074808B:H02PTA-2381 ES 212 M00073942D:D09PTA-2378 ES 215 M00074996C:D07PTA-2381 ES 212 M00073942D:G05PTA-2378 ES 215 M00074981C:C09PTA-2381 ES 212 M00073944A:E10PTA-2378 ES 215 M00075000A:D06PTA-2381 ES 212 M00073944A:H05PTA-2378 ES 215 M00074805A:C12PTA-2381 ES 212 M00073944C:H07PTA-2378 ES 215 M00074981D:A03PTA-2381 ES 212 M00073944D:A07PTA-2378 ES 215 M00074794C:H02PTA-2381 ES 212 M00073944D:E12PTA-2378 ES 215 M00074801C:E06PTA-2381 ES 212 M00073946D:F07PTA-2378 ES 215 M00074821B:B03PTA-2381 ES 212 M00073947C:B01PTA-2378 ES 215 M00074823A:E03PTA-2381 ES 212 M00073947C:E09PTA-2378 ES 215 M00074800B:H01PTA-2381 ES 212 M00073948A:G05PTA-2378 ES 215 M00074800D:G09PTA-2381 ES 212 M00073949A:C09PTA-2378 ES 215 M00074812A:F03PTA-2381 ES 212 M00073949D:C11PTA-2378 ES 215 M00074825C:E06PTA-2381 ES 212 M00073950C:A05PTA-2378 ES 215 M00074794A:G10PTA-2381 ES 212 M00073950D:H12PTA-2378 ES 215 M00075018A:G04PTA-2381 ES 212 M00073952A:G04PTA-2378 ES 215 M00075020D:B04PTA-2381 ES 212 M00073956D:F02PTA-2378 ES 215 M00075049A:C09PTA-2381 ES 212 M00073960A:B12PTA-2378 ES 215 M00075032A:F02PTA-2381 ES 212 M00073960B:A09PTA-2378 ES 215 M00075029B:E03PTA-2381 ES 212 M00073961B:G01PTA-2378 ES 215 M00075069C:C01PTA-2381 ES 212 M00073962D:E04PTA-2378 ES 215 M00075039A:E01PTA-2381 ES 212 M00073963A:G08PTA-2378 ES 215 M00075024C:G05PTA-2381 ES 212 M00073963B:F04PTA-2378 ES 215 M00075074D:G11PTA-2381 ES 212 M00073964B:H07PTA-2378 ES 215 M00075011A:C11PTA-2381 ES 212 M00073967A:A10PTA-2378 ES 215 M00075061A:B03PTA-2381 ES 212 M00073967C:A01PTA-2378 ES 215 M00075043B:H05PTA-2381 ES 212 M00073968B:B06PTA-2378 ES 215 M00075035C:C09PTA-2381 ES 212 M00073968D:F11PTA-2378 ES 215 M00075045D:H03PTA-2381 Table 15 CLONE ID ATCC# ES No. CLONE ID ATCC#
ES No.

ES 212 M00073970B:G01PTA-2378 ES 215 M00075078C:A07PTA-2381 ES 212 M00073977D:B10PTA-2378 ES 215 M00075075A:D12PTA-2381 ES 212 M00073978D:A02PTA-2378 ES 215 M00075077C:F09PTA-2381 ES 212 M00073979C:G07PTA-2378 ES 215 M00075026A:D11PTA-2381 ES 212 M00073981C:F08PTA-2378 ES 215 M00075044A:C10PTA-2381 ES 212 M00073983B:D03PTA-2378 ES 215 M00075075A:E09PTA-2381 ES 212 M00073983C:C07PTA-2378 ES 215 M00075020C:D12PTA-2381 ES 212 M00073984B:D04PTA-2378 ES 215 M00075117B:B06PTA-2381 ES 212 M00073984B:E01PTA-2378 ES 215 M00075114C:G11PTA-2381 ES 212 M00073985C:A05PTA-2378 ES 215 M00075153C:C11PTA-2381 ES 212 M00073987B:A09PTA-2378 ES 215 M00075161A:E05PTA-2381 ES 212 M00073988B:C08PTA-2378 ES 215 M00075126B:A06PTA-2381 ES 212 M00073988D:F09PTA-2378 ES 215 M00075126D:H07PTA-2381 ES 212 M00073993A:A05PTA-2378 ES 216 M00075092C:F04PTA-2382 ES 212 M00073965D:A12PTA-2378 ES 216 M00075110C:B03PTA-2382 ES 212 M00073966C:F08PTA-2378 ES 216 M00075132C:A03PTA-2382 ES 212 M00073968C:C09PTA-2378 ES 216 M00075152D:C06PTA-2382 ES 212 M00073968C:F02PTA-2378 ES 216 M00075125B:C07PTA-2382 ES 212 M00073975A:A12PTA-2378 ES 216 M00075132C:E07PTA-2382 ES 212 M00073979B:B05PTA-2378 ES 216 M00075160A:E04PTA-2382 ES 212 M00073979C:B01PTA-2378 ES 216 M00075149B:A01PTA-2382 ES 212 M00073982B:H01PTA-2378 ES 216 M00075120C:H04PTA-2382 ES 212 M00073986C:D07PTA-2378 ES 216 M00075093B:F10PTA-2382 ES 212 M00073988C:G08PTA-2378 ES 216 M00075102A:D02PTA-2382 ES 212 M00074000C:D06PTA-2378 ES 216 M00075090D:B07PTA-2382 ES 212 M00074003C:H06PTA-2378 ES 216 M00075161D:G06PTA-2382 ES 212 M00074004A:H01PTA-2378 ES 216 M00075165B:D04PTA-2382 ES 212 M00074004C:F03PTA-2378 ES 216 M00075174D:D06PTA-2382 ES 212 M00074006C:B12PTA-2378 ES 216 M00075180D:F05PTA-2382 ES 212 M00074007B:A02PTA-2378 ES 216 M00075181D:G10PTA-2382 ES 212 M00074010B:D07PTA-2378 ES 216 M00075189C:G05PTA-2382 ES 212 M00074011A:F08PTA-2378 ES 216 M00075199D:D11PTA-2382 ES 212 M00074011D:C05PTA-2378 ES 216 M00075201D:A05PTA-2382 ES 212 M00074013B:F07PTA-2378 ES 216 M00075203A:G06PTA-2382 ES 212 M00074013C:C09PTA-2378 ES 216 M00075211D:F09PTA-2382 ES 212 M00074014A:G03PTA-2378 ES 216 M00075221C:E02PTA-2382 ES 212 M00074014D:F04PTA-2378 ES 216 M00075228D:G09PTA-2382 ES 212 M00074015A:C03PTA-2378 ES 216 M00075232C:A06PTA-2382 ES 212 M00074017B:G10PTA-2378 ES 216 M00075232D:C06PTA-2382 ES 212 M00074017D:C01PTA-2378 ES 216 M00075234C:E06PTA-2382 ES 212 M00074019D:H05PTA-2378 ES 216 M00075239C:D06PTA-2382 ES 212 M00074020B:G11PTA-2378 ES 216 M00075242A:G04PTA-2382 ES 212 M00074020C:A05PTA-2378 ES 216 M00075243D:F04PTA-2382 ES 212 M00074020D:G10PTA-2378 ES 216 M00075245A:A06PTA-2382 ES 212 M00074021C:H07PTA-2378 ES 216 M00075249A:B08PTA-2382 ES 212 M00074022A:C06PTA-2378 ES 216 M00075252B:F10PTA-2382 Table 15 CLONE ID ATCC# ES No. CLONE ID ATCC#
ES No.

ES 212 M00074024B:G07PTA-2378 ES 216 M00075255A:G11PTA-2382 ES 212 M00074025A:F06PTA-2378 ES 216 M00075259C:G02PTA-2382 ES 212 M00074025B:A12PTA-2378 ES 216 M00075270D:A02PTA-2382 ES 212 M00074026C:H09PTA-2378 ES 216 M00075273C:E01PTA-2382 ES 212 M00074027D:B03PTA-2378 ES 216 M00075274B:F06PTA-2382 ES 212 M00074030D:A12PTA-2378 ES 216 M00075275B:H07PTA-2382 ES 212 M00074032B:H08PTA-2378 ES 216 M00075279C:E08PTA-2382 ES 212 M00074032C:E02PTA-2378 ES 216 M00075283A:F04PTA-2382 ES 212 M00074032C:H07PTA-2378 ES 216 M00075302B:C07PTA-2382 ES 212 M00074036B:C08PTA-2378 ES 216 M00075305C:C07PTA-2382 ES 212 M00074036D:B05PTA-2378 ES 216 M00075309C:A06PTA-2382 ES 212 M00074037A:B03PTA-2378 ES 216 M00075323B:B12PTA-2382 ES 212 M00074038A:G08PTA-2378 ES 216 M00075324B:C10PTA-2382 ES 212 M00074038C:B08PTA-2378 ES 216 M00075324D:E02PTA-2382 ES 212 M00074040A:B06PTA-2378 ES 216 M00075326C:B01PTA-2382 ES 212 M00074043C:A05PTA-2378 ES 216 M00075326D:A09PTA-2382 ES 212 M00074050B:H07PTA-2378 ES 216 M00075329B:E10PTA-2382 ES 212 M00074051C:F05PTA-2378 ES 216 M00075330D:F11PTA-2382 ES 212 M00074052C:E03PTA-2378 ES 216 M00075333D:B07PTA-2382 ES 212 M00074053C:E05PTA-2378 ES 216 M00075333D:D10PTA-2382 ES 212 M00074053C:G11PTA-2378 ES 216 M00075336B:B04PTA-2382 ES 212 M00074053D:D05PTA-2378 ES 216 M00075344D:A08PTA-2382 ES 212 M00074054C:B04PTA-2378 ES 216 M00075347D:D01PTA-2382 ES 212 M00074055A:G08PTA-2378 ES 216 M00075354A:D11PTA-2382 ES 213 M00072942B:E02PTA-2379 ES 216 M00075354A:G12PTA-2382 ES 213 M00072942D:F07PTA-2379 ES 216 M00075354C:B12PTA-2382 ES 213 M00072943B:E04PTA-2379 ES 216 M00075360D:D04PTA-2382 ES 213 M00072944A:C07PTA-2379 ES 216 M00075365B:B06PTA-2382 ES 213 M00072944A:E06PTA-2379 ES 216 M00075384A:B03PTA-2382 ES 213 M00072944C:C02PTA-2379 ES 216 M00075389B:C06PTA-2382 ES 213 M00072944D:C08PTA-2379 ES 216 M00075391D:D07PTA-2382 ES 213 M00072947B:G04PTA-2379 ES 216 M00075402A:F01PTA-2382 ES 213 M00072947D:G05PTA-2379 ES 216 M00075405B:C07PTA-2382 ES 213 M00072950A:A06PTA-2379 ES 216 M00075405D:A10PTA-2382 ES 213 M00072961A:G04PTA-2379 ES 216 M00075365D:B08PTA-2382 ES 213 M00072961B:G10PTA-2379 ES 216 M00075380D:F06PTA-2382 ES 213 M00072961C:B06PTA-2379 ES 216 M00075356D:C03PTA-2382 ES 213 M00072962A:B05PTA-2379 ES 216 M00075352D:F09PTA-2382 ES 213 M00072963B:G11PTA-2379 ES 216 M00075359D:E09PTA-2382 ES 213 M00072967A:G07PTA-2379 ES 216 M00075365D:H01PTA-2382 ES 213 M00072967B:G06PTA-2379 ES 216 M00075373C:B09PTA-2382 ES 213 M00072968A:F08PTA-2379 ES 216 M00075378B:C07PTA-2382 ES 213 M00072968D:A06PTA-2379 ES 216 M00075379A:E07PTA-2382 ES 213 M00072968D:E05PTA-2379 ES 216 M00075383A:B11PTA-2382 ES 213 M00072970C:B07PTA-2379 ES 216 M00075407A:B05PTA-2382 ES 213 M00074057A:B12PTA-2379 ES 216 M00075409A:E04PTA-2382 Table 15 CLONE ID ATCC# ES No. CLONE ID ATCC#
ES No.

ES 213 M00074058A:H02PTA-2379 ES 216 M00075409B:G12PTA-2382 ES 213 M00074058B:A10PTA-2379 ES 216 M00075416C:B02PTA-2382 ES 213 M00074059B:G10PTA-2379 ES 216 M00075458B:F09PTA-2382 ES 213 M00074060D:A10PTA-2379 ES 216 M00075464C:A07PTA-2382 ES 213 M00074061B:E01PTA-2379 ES 216 M00075458C:F01PTA-2382 ES 213 M00074063A:B03PTA-2379 ES 216 M00075463C:E07PTA-2382 ES 213 M00074063A:D09PTA-2379 ES 216 M00075464C:C04PTA-2382 ES 213 M00074063B:B12PTA-2379 ES 216 M00075448B:G11PTA-2382 ES 213 M00074069D:C11PTA-2379 ES 216 M00075434A:D06PTA-2382 ES 213 M00074070D:G05PTA-2379 ES 216 M00075457C:A06PTA-2382 ES 213 M00074075B:A09PTA-2379 ES 216 M00075454C:D06PTA-2382 ES 213 M00074075C:H04PTA-2379 ES 216 M00075460C:B06PTA-2382 ES 213 M00074076B:F04PTA-2379 ES 216 M00075459A:C02PTA-2382 ES 213 M00074079A:E07PTA-2379 ES 216 M00075414A:D10PTA-2382 ES 213 M00074084C:E01PTA-2379 ES 216 M00075433A:C06PTA-2382 ES 213 M00074084D:B04PTA-2379 ES 216 M00075505B:A04PTA-2382 ES 213 M00074085A:H10PTA-2379 ES 216 M00075474D:B07PTA-2382 ES 213 M00074085B:E06PTA-2379 ES 216 M00075504B:A10PTA-2382 ES 213 M00074085D:E08PTA-2379 ES 216 M00075473C:E08PTA-2382 ES 213 M00074087B:C09PTA-2379 ES 216 M00075499A:H02PTA-2382 ES 213 M00074087C:G05PTA-2379 ES 216 M00075495D:D11PTA-2382 ES 213 M00074088B:A03PTA-2379 ES 216 M00075496D:G05PTA-2382 ES 213 M00074088C:E07PTA-2379 ES 216 M00075514A:G12PTA-2382 ES 213 M00074089A:B09PTA-2379 ES 216 M00075495B:C12PTA-2382 ES 213 M00074089D:E03PTA-2379 ES 216 M00075497D:H03PTA-2382 ES 213 M00074090A:E09PTA-2379 ES 216 M00075529A:A02PTA-2382 ES 213 M00074093A:A06PTA-2379 ES 216 M00075538C:E03PTA-2382 ES 213 M00074093B:A03PTA-2379 ES 216 M00075544A:C03PTA-2382 ES 213 M00074093B:C07PTA-2379 ES 216 M00075598B:A09PTA-2382 ES 213 M00074094B:F10PTA-2379 ES 216 M00075521B:E11PTA-2382 ES 213 M00074096D:G12PTA-2379 ES 216 M00075597C:G01PTA-2382 ES 213 M00074097A:F10PTA-2379 ES 216 M00075584D:B05PTA-2382 ES 213 M00074097C:B09PTA-2379 ES 216 M00075590B:G04PTA-2382 ES 213 M00074098C:B09PTA-2379 ES 216 M00075603D:D09PTA-2382 ES 213 M00074099C:B09PTA-2379 ES 216 M00075607B:D05PTA-2382 ES 216 M00075609A:H06PTA-2382 ES 216 M00075613D:F01PTA-2382 ES 216 M00075619C:D08PTA-2382 ES 216 M00075621A:F06PTA-2382 ES 216 M00075639A:D12PTA-2382

Claims (26)

We Claim:

1. An isolated polynucleotide comprising a nucleotide sequence which hybridizes under stringent conditions to a sequence selected from the group consisting of SEQ
ID NOS: 1-1477.

2. An isolated polynucleotide comprising at least 15 contiguous nucleotides of a nucleotide sequence having at least 90% sequence identity to a sequence selected from the group consisting of:
SEQ ID NOS:1-1477, a degenerate variant of SEQ ID NOS:1-1477, an antisense of SEQ ID NOS:1-1477, and a complement of SEQ ID NOS:1-1477.

3. An isolated polynucleotide comprising at least 15 contiguous nucleotides of a nucleotide sequence selected from the group consisting of SEQ ID NOS:1-1477, a degenerate variant of SEQ
ID NOS:1-1477, an antisense of SEQ ID NOS:1-1477, and a complement of SEQ ID
NOS:1-1477.

4. The isolated polynucleotide of claim 3, wherein the polynucleotide comprises at least 100 contiguous nucleotides of the nucleotide sequence.

5. The isolated polynucleotide of claim 3, wherein the polynucleotide comprises at least 200 contiguous nucleotides of the selected nucleotide sequence.

6. An isolated polynucleotide comprising a nucleotide sequence of at least 90%
sequence identity to a sequence selected from the group consisting of: SEQ ID NOS:1-1477, a degenerate variant of SEQ ID NOS:1-1477, an antisense of SEQ ID NOS:1-1477, and a complement of SEQ ID
NOS:1-1477.

7. The isolated polynucleotide of claim 6, wherein the polynucleotide comprises a nucleotide sequence of at least 95% sequence identity to the selected nucleotide sequence.

8. The isolated polynucleotide of claim 6, wherein the polynucleotide comprises a nucleotide sequence that is identical to the selected nucleotide sequence.

9. A polynucleotide comprising a nucleotide sequence of an insert contained in a clone deposited as ATCC Accession No. PTA-2918.

10. An isolated cDNA obtained by the process of amplification using a polynucleotide comprising at least 15 contiguous nucleotides of a nucleotide sequence of a sequence selected from the group consisting of SEQ ID NOS:1-1477.

11. The isolated cDNA of claim 10, wherein the polynucleotide comprises at least 25 contiguous nucleotides of the selected nucleotide sequence.

12. The isolated cDNA of claim 10, wherein the polynucleotide comprises at least 100 contiguous nucleotides of the selected nucleotide sequence.

13. The isolated cDNA of claims 10, 11, or 12, wherein amplification is by polymerase chain reaction (PCR) amplification.

14. An isolated recombinant host cell containing the polynucleotide according to claims 1, 2, 3,6,9,or 10.

15. An isolated vector comprising the polynucleotide according to claims 1, 2, 3, 6, 9, or 10.

16. A method for producing a polypeptide, the method comprising the steps of:
culturing a recombinant host cell containing the polynucleotide according to claims 1, 2, 3, 6, 9, or 10., said culturing being under conditions suitable for the expression of an encoded polypeptide;
and recovering the polypeptide from the host cell culture.

17. An isolated polypeptide encoded by the polynucleotide according to claims 1, 2, 3, 6, 9, or 10.

18. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:1478-1568.

19. An antibody that specifically binds the polypeptide of claim 17 or 18.

20. A method of detecting differentially expressed genes correlated with a cancerous state of a mammalian cell, the method comprising the step of:
detecting at least one differentially expressed gene product in a test sample derived from a cell suspected of being cancerous, where the gene product is encoded by a gene comprising an identifying sequence of at least one of SEQ ID NOS:1-1477;
wherein detection of the differentially expressed gene product is correlated with a cancerous state of the cell from which the test sample was derived.

21. A method of detecting differentially expressed genes correlated with a cancerous state of a mammalian cell, the method comprising the step of:
detecting at least one differentially expressed gene product in a test sample derived from a cell suspected of being cancerous, where the gene product comprises an amino acid sequence selected from the group consisting of SEQ ID NOS:1478-1568;
wherein detection of the differentially expressed gene product is correlated with a cancerous state of the cell from which the test sample was derived.

22. A library of polynucleotides, wherein at least one of the polynucleotides comprises the sequence information of the polynucleotide according to claims 1, 2, 3, 6, 9, or 10.

23. The library of claim 22, wherein the library is provided on a nucleic acid array.

24. The library of claim 22, wherein the library is provided in a computer-readable format.

25. A method of inhibiting tumor growth by modulating expression of a gene product, the gene product being encoded by a gene identified by a sequence selected from the group consisting of SEQ ID NOS:1-1477.

26. A method of inhibiting tumor growth by modulating expression of a gene product, the gene product comprising an amino acid sequence selected from the group consisting of SEQ ID
NOS:1478-1568.